{"meta":{"query_hash":"edc9517c5bb8","filters":{"venue":"Clinical Genitourinary Cancer"},"cohort_total":239,"direct_labels_cover":0,"predictions_cover":239,"exported":239,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/edc9517c5bb8","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Genitourinary+Cancer"},"results":[{"id":"W1965322951","doi":"10.1016/j.clgc.2014.06.004","title":"Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University","funders":"","keywords":"Medicine; Perioperative; Urothelial carcinoma; Salvage therapy; Oncology; Chemotherapy; Internal medicine; Urology; Surgery; Bladder cancer; Cancer","score_opus":0.0770716121855227,"score_gpt":0.4207425315289896,"score_spread":0.3436709193434669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965322951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227893,0.00057860446,0.00032877133,0.00037269492,0.00027501304,0.0059097307,0.00020416596,0.000008141982,0.00004395722],"genre_scores_gemma":[0.99393415,0.0013766206,0.0029793745,0.0001891522,0.0004263513,0.0009461035,0.000009662957,0.00004914474,0.00008945702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823874,0.0001863655,0.00086395175,0.0003517633,0.00013805907,0.00022114564],"domain_scores_gemma":[0.9978792,0.0007944732,0.00044931323,0.00039309502,0.0004041589,0.0000797335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003940233,0.0002260906,0.0007853176,0.000046082274,0.0000711247,0.00000531333,0.0001616221,0.0001474369,0.000035084402],"category_scores_gemma":[0.0002588408,0.00013922506,0.0004665486,0.0001569056,0.00022277738,0.0000633518,0.000023751454,0.0001250265,1.3863192e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12699795,0.0016963251,0.661353,0.00006190278,0.0002485287,6.250284e-8,0.00047600808,0.000019367344,0.0048779394,0.0000084949,0.00007989347,0.20418054],"study_design_scores_gemma":[0.120267995,0.010522221,0.8610246,0.00009120577,0.00006631179,6.3580205e-7,0.00001946623,0.000059320482,0.007482773,0.00012987637,0.00021777558,0.000117786076],"about_ca_topic_score_codex":0.000082782564,"about_ca_topic_score_gemma":0.000007509478,"teacher_disagreement_score":0.20406274,"about_ca_system_score_codex":0.00007262229,"about_ca_system_score_gemma":0.00054160185,"threshold_uncertainty_score":0.5677433},"labels":[],"label_agreement":null},{"id":"W1966303504","doi":"10.3816/cgc.2008.n.008","title":"Quality of Life, Morbidity, and Mortality Results of a Prospective Phase II Study of Intermittent Androgen Suppression for Men with Evidence of Prostate-Specific Antigen Relapse After Radiation Therapy for Locally Advanced Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; Sunnybrook Health Science Centre; Vancouver General Hospital","funders":"Health Canada; Abbott Laboratories","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Internal medicine; Radiation therapy; Population; Androgen suppression; Prospective cohort study; Prostate; Androgen deprivation therapy; Oncology; Urology; Cancer","score_opus":0.11971463573603029,"score_gpt":0.44189972567344477,"score_spread":0.32218508993741446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966303504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721583,0.016809193,0.000027761109,0.00020461762,0.00013577602,0.009158875,0.00148463,0.000012839651,0.0000080165455],"genre_scores_gemma":[0.9493833,0.046446484,0.00042613797,0.00003214181,0.000107241074,0.003475757,0.000040226496,0.00003398083,0.0000547227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664074,0.00017266216,0.001813894,0.0006907688,0.00043124403,0.00025067394],"domain_scores_gemma":[0.9962654,0.0005074346,0.0014365223,0.00052740163,0.0010827126,0.00018050232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075249374,0.000279232,0.001260304,0.00007981724,0.000076905126,0.0000035030437,0.00011407913,0.000104929175,0.000010091889],"category_scores_gemma":[0.00021036947,0.00019631865,0.00021958414,0.00020376741,0.00043790144,0.00019265192,0.000089094094,0.00013904677,4.4035453e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20111822,0.008801575,0.7482692,0.00081237394,0.0008090495,0.000014569199,0.0037483927,0.00009711599,0.0040598586,0.000001061436,0.00035453515,0.031914044],"study_design_scores_gemma":[0.052771855,0.06045811,0.83744705,0.0012430388,0.00022035195,0.0000017516143,0.00044420102,0.00008804516,0.046964765,0.000034173136,0.00013754403,0.00018909879],"about_ca_topic_score_codex":0.0005048935,"about_ca_topic_score_gemma":0.00011694024,"teacher_disagreement_score":0.14834635,"about_ca_system_score_codex":0.00011860281,"about_ca_system_score_gemma":0.000640677,"threshold_uncertainty_score":0.8005642},"labels":[],"label_agreement":null},{"id":"W1972744500","doi":"10.3816/cgc.2006.n.004","title":"The Role of Bisphosphonates in the Treatment of Prostate Cancer: Recommendations from an Expert Panel","year":2006,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec","funders":"","keywords":"Medicine; Prostate cancer; Zoledronic acid; Androgen deprivation therapy; Cancer; Oncology; Bisphosphonate; Prostate; Internal medicine; Bone metastasis; Osteoporosis","score_opus":0.1543635953746926,"score_gpt":0.48967063138232564,"score_spread":0.335307036007633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972744500","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009157628,0.98586416,6.118997e-8,0.0010949135,0.0006111635,0.0020782107,0.000988383,0.000013641006,0.00019183797],"genre_scores_gemma":[0.00084678543,0.9947245,0.00009535015,0.00016491783,0.0004362724,0.0023245981,0.00064221513,0.000046774334,0.00071860134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99672604,0.0005061998,0.0017280082,0.00045360863,0.00024308679,0.00034308658],"domain_scores_gemma":[0.9967643,0.0014052266,0.00079477724,0.0007871653,0.00009711947,0.0001513818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028240026,0.0003702893,0.0017493762,0.00006249564,0.000116170755,0.000010090879,0.00026059343,0.000287016,0.00008890645],"category_scores_gemma":[0.000030561943,0.00017647324,0.0005910303,0.00029183974,0.00021317978,0.000037426165,0.0000290152,0.00034447954,0.000007056027],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026765495,0.0024873486,0.011804247,0.00041541012,0.00035344102,0.00002724782,0.00029737662,6.283475e-7,1.5315062e-7,0.00000301697,0.0012133638,0.9831301],"study_design_scores_gemma":[0.0014757217,0.001637701,0.0049418067,0.0026943884,0.00093671266,0.0000049825667,0.0001769702,0.0000073355445,0.000009257671,0.00008759785,0.98789,0.00013754505],"about_ca_topic_score_codex":0.026415117,"about_ca_topic_score_gemma":0.0033864225,"teacher_disagreement_score":0.98667663,"about_ca_system_score_codex":0.0002944206,"about_ca_system_score_gemma":0.001243939,"threshold_uncertainty_score":0.9800681},"labels":[],"label_agreement":null},{"id":"W1976575396","doi":"10.1016/j.clgc.2014.06.015","title":"Dosing Patterns, Toxicity, and Outcomes in Patients Treated With First-Line Sunitinib for Advanced Renal Cell Carcinoma in Community-Based Practices","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Canadian Centre for Applied Research in Cancer Control","keywords":"Sunitinib; Medicine; Dosing; Renal cell carcinoma; Toxicity; Oncology; Internal medicine; Carcinoma; Pharmacology","score_opus":0.06840083324777685,"score_gpt":0.36831609110235947,"score_spread":0.2999152578545826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976575396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722373,0.0001663947,0.000031825122,0.0008222478,0.000091936985,0.001348856,0.00006777902,0.000030618303,0.00021658053],"genre_scores_gemma":[0.99718237,0.00009392474,0.0009614562,0.00094061374,0.0001282518,0.00028749337,0.0002371964,0.000054774457,0.00011394919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975629,0.0005335121,0.0007866637,0.00045557608,0.00025016986,0.0004111956],"domain_scores_gemma":[0.9960611,0.00254672,0.0005095881,0.0004943248,0.00015520214,0.00023307683],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006407933,0.00033285972,0.0008134721,0.00018724789,0.00012704541,0.000023648558,0.00014235928,0.00017098838,0.00001751392],"category_scores_gemma":[0.00037529616,0.000252324,0.00012451618,0.00018302856,0.00012559294,0.00013099099,0.000085236126,0.00064382283,0.0000018661694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061687166,0.003508485,0.9831811,0.0005469907,0.000035695004,0.00007748909,0.00009834709,0.00020389735,0.00009159283,4.2262778e-7,0.00003238909,0.0060548354],"study_design_scores_gemma":[0.030009078,0.010869211,0.9539433,0.00045306145,0.00017084822,0.000003590068,0.00007243836,0.00044991382,0.0033437547,0.000007925401,0.00041010338,0.0002667773],"about_ca_topic_score_codex":0.0009931329,"about_ca_topic_score_gemma":0.00288482,"teacher_disagreement_score":0.02923784,"about_ca_system_score_codex":0.00022228189,"about_ca_system_score_gemma":0.0001516826,"threshold_uncertainty_score":0.9999929},"labels":[],"label_agreement":null},{"id":"W1979333574","doi":"10.1016/j.clgc.2013.04.025","title":"Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Pazopanib; Docetaxel; Oncology; Chemotherapy; Metastatic Urothelial Carcinoma; Response Evaluation Criteria in Solid Tumors; Context (archaeology); Cyclophosphamide; Gemcitabine; Progressive disease; Cancer; Bladder cancer; Sunitinib; Urothelial carcinoma","score_opus":0.06850117939776647,"score_gpt":0.40310533449699604,"score_spread":0.3346041550992296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979333574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895731,0.00020598422,0.0002995578,0.0012923247,0.00022304033,0.008151122,0.0001865901,0.000030448015,0.00003783118],"genre_scores_gemma":[0.99141663,0.00012002988,0.0040631616,0.00089366134,0.00046461198,0.0025232385,0.000019463003,0.00007786453,0.00042132253],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979548,0.00020207273,0.0007683108,0.00051005365,0.0001758982,0.00038890785],"domain_scores_gemma":[0.9979451,0.0006228615,0.00022404146,0.0005305638,0.00038735254,0.0002901275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003701682,0.00027840675,0.00069136254,0.0001433529,0.000060657243,0.000013647215,0.00016973782,0.0001484306,0.0005492959],"category_scores_gemma":[0.00018580774,0.0001955927,0.0003007175,0.00030251208,0.00007987015,0.00011915345,0.000025098927,0.00019193791,0.0000093541985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48761746,0.0018166179,0.40940684,0.000016947735,0.00020304606,0.0000013470352,0.00013766643,0.00005228169,0.0025292353,2.2334709e-7,0.00088261295,0.09733571],"study_design_scores_gemma":[0.12769412,0.039374616,0.83132434,0.000067001296,0.000046055262,9.913953e-7,0.000008544874,0.000013461948,0.00084061414,0.000034506746,0.0004168029,0.00017895714],"about_ca_topic_score_codex":0.00011454824,"about_ca_topic_score_gemma":0.000012297691,"teacher_disagreement_score":0.4219175,"about_ca_system_score_codex":0.00028237712,"about_ca_system_score_gemma":0.0010216356,"threshold_uncertainty_score":0.79760385},"labels":[],"label_agreement":null},{"id":"W1985598595","doi":"10.1016/j.clgc.2013.07.004","title":"Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma","year":2013,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"Bayer HealthCare","keywords":"Medicine; Clinical trial; Renal cell carcinoma; Intensive care medicine; Clinical study design; Disease; Targeted therapy; Identification (biology); Medical physics; Oncology; Cancer; Internal medicine","score_opus":0.5976262395296403,"score_gpt":0.5387439501577905,"score_spread":0.058882289371849805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985598595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00062591565,0.9833547,0.00038253152,0.00066116673,0.0022097218,0.012369147,0.00027293508,0.00002073375,0.000103151164],"genre_scores_gemma":[0.00064143934,0.97767156,0.010096688,0.0003172476,0.0052496376,0.0045841685,0.0000895505,0.000119265365,0.0012304117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98286444,0.007585465,0.007653122,0.00096244033,0.0004261326,0.00050842954],"domain_scores_gemma":[0.931533,0.06378943,0.0026969044,0.0012264707,0.00037805014,0.00037615333],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.012238835,0.0007216516,0.008228475,0.00022233727,0.00010648099,0.00003396967,0.00034926838,0.0007653204,0.0007093378],"category_scores_gemma":[0.0054476727,0.00038798564,0.0043852325,0.00031655686,0.00041138695,0.000057192334,0.00013130924,0.0014993205,0.000059484275],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079724885,0.0016073083,0.00047472445,0.011835312,0.0018827105,0.00042179582,0.00004427861,0.000053047876,0.0000035765293,0.000021932845,0.065595195,0.91726285],"study_design_scores_gemma":[0.0076958407,0.0045908997,0.001305038,0.0045683365,0.025834754,0.00017421167,0.00009591006,0.00022819215,0.000029375129,0.00022033822,0.9546264,0.0006307127],"about_ca_topic_score_codex":0.000056193778,"about_ca_topic_score_gemma":0.0000134562,"teacher_disagreement_score":0.9166322,"about_ca_system_score_codex":0.00024276151,"about_ca_system_score_gemma":0.004225829,"threshold_uncertainty_score":0.9998572},"labels":[],"label_agreement":null},{"id":"W1985605203","doi":"10.1016/j.clgc.2014.10.005","title":"Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Docetaxel; Medicine; Taxane; Paclitaxel; Oncology; Internal medicine; Clinical endpoint; Clinical trial; Chemotherapy; Salvage therapy; Cancer; Breast cancer","score_opus":0.2056236045651798,"score_gpt":0.5066562109203223,"score_spread":0.3010326063551425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985605203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87734824,0.00573439,0.07751198,0.017616708,0.0039769365,0.014360239,0.0017287241,0.00024357869,0.0014792064],"genre_scores_gemma":[0.8947084,0.0014275217,0.078053646,0.0035438163,0.014866034,0.004575061,0.0001146182,0.00013387475,0.0025770497],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965035,0.00035887063,0.0014528765,0.00097100146,0.00020518617,0.0005086186],"domain_scores_gemma":[0.98994905,0.007836021,0.000524386,0.0006405724,0.00057281624,0.0004771865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017351568,0.00033847484,0.001023151,0.000055170905,0.0003629002,0.000056639077,0.00022805537,0.00033734125,0.000021495023],"category_scores_gemma":[0.0036365318,0.00029451487,0.0005051198,0.00012512879,0.0004122035,0.00019781137,0.00007815518,0.00034422093,0.000008644203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37655523,0.0021033008,0.31356537,0.000514252,0.00114888,0.0000130119115,0.00008853995,0.00001872657,0.00023981048,0.00045673508,0.028431768,0.27686438],"study_design_scores_gemma":[0.14257382,0.012194663,0.32425463,0.00008601786,0.0016093757,0.000013188202,0.00002069643,0.00007497018,0.00018643473,0.0026241567,0.5158929,0.00046911862],"about_ca_topic_score_codex":0.000022794286,"about_ca_topic_score_gemma":0.000011289851,"teacher_disagreement_score":0.48746118,"about_ca_system_score_codex":0.00009443983,"about_ca_system_score_gemma":0.0006248746,"threshold_uncertainty_score":0.9999507},"labels":[],"label_agreement":null},{"id":"W1985646974","doi":"10.1016/j.clgc.2013.04.012","title":"Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; BC Cancer Agency; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Renal cell carcinoma; Sunitinib; Temsirolimus; Radiosurgery; Brain metastasis; Internal medicine; Targeted therapy; Bevacizumab; Oncology; Sorafenib; Radiation therapy; Pazopanib; Cancer; Metastasis; Chemotherapy; Hepatocellular carcinoma","score_opus":0.05796752178198649,"score_gpt":0.3139130408923284,"score_spread":0.2559455191103419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985646974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98085314,0.00087464927,0.0003513026,0.0011047446,0.00020205093,0.0040349187,0.012449237,0.000042986932,0.00008697451],"genre_scores_gemma":[0.98086786,0.000063106534,0.009534719,0.0005512536,0.0002239735,0.00069302536,0.007528374,0.00011249788,0.00042515816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954081,0.000649841,0.0013091357,0.0010532084,0.0009691167,0.00061059726],"domain_scores_gemma":[0.9918978,0.004794167,0.0009974467,0.0009550422,0.00091336784,0.00044214958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005970719,0.0006858925,0.0012326929,0.00012716778,0.00017588837,0.00006379332,0.00041104588,0.00007659427,0.00047742468],"category_scores_gemma":[0.0003475285,0.00033458177,0.00032494462,0.0003705645,0.00056112226,0.00024243456,0.00010004432,0.00042587204,0.000008810686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028137313,0.00693999,0.94931054,0.0001466773,0.003312265,0.000351912,0.0003689331,0.00019088594,0.00079292135,0.000004256228,0.008523236,0.0019210716],"study_design_scores_gemma":[0.052977834,0.020334013,0.90446764,0.00023105736,0.004406128,0.000014805229,0.0009329402,0.0003678899,0.013398471,0.000017515034,0.002195191,0.00065651024],"about_ca_topic_score_codex":0.0034618638,"about_ca_topic_score_gemma":0.00028184312,"teacher_disagreement_score":0.044842895,"about_ca_system_score_codex":0.00010990128,"about_ca_system_score_gemma":0.0007702209,"threshold_uncertainty_score":0.9999106},"labels":[],"label_agreement":null},{"id":"W1989955619","doi":"10.1016/j.clgc.2014.09.004","title":"Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Salvage therapy; Urothelial carcinoma; Systemic therapy; End point; Oncology; Internal medicine; Urology; Cancer; Bladder cancer; Chemotherapy","score_opus":0.051355639782387635,"score_gpt":0.3699060234366396,"score_spread":0.3185503836542519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989955619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480665,0.00042882908,0.000049349786,0.0005303077,0.0016621238,0.0018172086,0.00017855687,0.00007121401,0.00045574695],"genre_scores_gemma":[0.9934671,0.00032276026,0.00020758373,0.003042888,0.0018021573,0.0004999836,0.00008189914,0.00009205166,0.00048359553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683034,0.00071682944,0.00092141586,0.0007135903,0.0003140997,0.0005037086],"domain_scores_gemma":[0.99788755,0.0007390732,0.00021670666,0.000606837,0.00017621253,0.000373627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011382184,0.00032445125,0.0007547658,0.0001457426,0.00009454666,0.000026978716,0.00023847984,0.00021958821,0.0002347163],"category_scores_gemma":[0.00043579025,0.00027056577,0.00029496805,0.00013664705,0.00014610062,0.00013173909,0.000066686785,0.00036808208,0.000055357443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061507735,0.0014532739,0.80329794,0.00013975789,0.00014309259,0.000065084976,0.0006213927,0.000007029986,0.0018045168,0.0000071664767,0.00094554055,0.13000748],"study_design_scores_gemma":[0.023207802,0.013104041,0.9557191,0.00029783844,0.00010381447,0.000017162905,0.00007984071,0.00022295958,0.00038324625,0.00016062074,0.0063970326,0.00030651223],"about_ca_topic_score_codex":0.00022469359,"about_ca_topic_score_gemma":0.000049049737,"teacher_disagreement_score":0.1524212,"about_ca_system_score_codex":0.00029251652,"about_ca_system_score_gemma":0.00040268645,"threshold_uncertainty_score":0.99997467},"labels":[],"label_agreement":null},{"id":"W2020496374","doi":"10.1016/j.clgc.2014.02.009","title":"Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Oncology; Targeted therapy; Internal medicine; Population; Kidney cancer; Cancer; Environmental health","score_opus":0.0668936906804395,"score_gpt":0.36309174508875747,"score_spread":0.296198054408318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020496374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951216,0.0020915398,0.00006278725,0.0005218263,0.00025786925,0.0015796177,0.000016893127,0.000013043967,0.00033484152],"genre_scores_gemma":[0.99734145,0.00014489373,0.0011990049,0.00046215503,0.00038175864,0.0002742259,0.00008437673,0.00002780244,0.00008433789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978686,0.0003797392,0.0008585436,0.0003407202,0.0002992272,0.00025316654],"domain_scores_gemma":[0.99800754,0.0010459649,0.00028294767,0.00045290834,0.000109268054,0.000101369376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057918014,0.0001861059,0.0005002774,0.000080516475,0.000046554695,0.0000073681754,0.00013743923,0.00008433568,0.000056923396],"category_scores_gemma":[0.00015130099,0.00011518638,0.00035733814,0.00017834736,0.00006968618,0.00003553245,0.00002135513,0.00021421965,0.000004784599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0136796385,0.006500014,0.49511096,0.000384199,0.0002921411,0.00013414447,0.0013083763,0.0009330408,0.006087905,0.00004693384,0.004153071,0.4713696],"study_design_scores_gemma":[0.0092471,0.012836659,0.9679394,0.00005421415,0.00019658914,0.000009080855,0.000085325526,0.0005344488,0.006288897,0.00016220359,0.0025052344,0.00014088862],"about_ca_topic_score_codex":0.00022100398,"about_ca_topic_score_gemma":0.000018505674,"teacher_disagreement_score":0.47282842,"about_ca_system_score_codex":0.00007587193,"about_ca_system_score_gemma":0.000104193794,"threshold_uncertainty_score":0.46971646},"labels":[],"label_agreement":null},{"id":"W2021770899","doi":"10.1016/j.clgc.2014.11.001","title":"First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Centre for Applied Research in Cancer Control; GlaxoSmithKline","keywords":"Pazopanib; Medicine; Temsirolimus; Everolimus; Internal medicine; Oncology; Adverse effect; Renal cell carcinoma; Cohort; Nausea; Clinical trial; Sunitinib; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","score_opus":0.04026818035067124,"score_gpt":0.31459013582231826,"score_spread":0.274321955471647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021770899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977513,0.00059770315,0.000024813357,0.00014860244,0.00019570818,0.0010235849,0.000118029144,0.000016868651,0.00012339753],"genre_scores_gemma":[0.9970628,0.0002308227,0.0019668438,0.0001959315,0.00016645098,0.00008402896,0.0001548288,0.00005225822,0.00008601279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968322,0.0008953365,0.0011401821,0.0004275694,0.00033226304,0.00037244274],"domain_scores_gemma":[0.9974535,0.0008385017,0.0006438521,0.000551782,0.00023985049,0.0002725199],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064781756,0.0003237322,0.0010420923,0.00011919474,0.00008423901,0.00000761958,0.00014830244,0.0002581188,0.000049219005],"category_scores_gemma":[0.00014208797,0.0002511272,0.00018552344,0.00020661831,0.00044227435,0.00013114035,0.00013870747,0.0007032632,8.057058e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071376585,0.002542272,0.9775511,0.00021022564,0.00008695455,0.00006971582,0.00029161214,0.0003145976,0.005080335,2.3673279e-7,0.00035604864,0.006359227],"study_design_scores_gemma":[0.019328747,0.015326403,0.9329115,0.0002217022,0.00013508454,0.0000049283854,0.000059433412,0.00022109025,0.030243311,0.000007189405,0.001316435,0.00022418323],"about_ca_topic_score_codex":0.0012635781,"about_ca_topic_score_gemma":0.00043399577,"teacher_disagreement_score":0.044639625,"about_ca_system_score_codex":0.00019519163,"about_ca_system_score_gemma":0.0002141083,"threshold_uncertainty_score":0.9999941},"labels":[],"label_agreement":null},{"id":"W2023072606","doi":"10.1016/j.clgc.2014.06.001","title":"A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"National Cancer Institute","keywords":"Bicalutamide; Medicine; Pazopanib; Prostate cancer; Castration; Oncology; Internal medicine; Cancer; Urology; Androgen receptor; Hormone","score_opus":0.06198738149956967,"score_gpt":0.42551997177265527,"score_spread":0.3635325902730856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023072606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959179,0.0003214248,0.0000042853953,0.00038371392,0.00013620265,0.0029233843,0.000081633385,0.00003839581,0.00019304745],"genre_scores_gemma":[0.995867,0.00026919137,0.000253132,0.00014926445,0.00027251986,0.0007325342,0.000036832873,0.00006137684,0.0023581486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969422,0.00022620705,0.00087157305,0.0006910508,0.00075530325,0.0005136563],"domain_scores_gemma":[0.9982117,0.0001707451,0.00029907012,0.0005222373,0.0004482597,0.00034801097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039232045,0.0003300668,0.0009160474,0.00016896524,0.00013403501,0.000018103467,0.00016420886,0.00011121685,0.00022579118],"category_scores_gemma":[0.000073968426,0.00018160668,0.00007508462,0.0005832936,0.00033353263,0.00013846827,0.00009117014,0.00049117254,0.000003801319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09307196,0.017837575,0.86398995,0.00017111399,0.00037144206,0.00019486794,0.00079823454,0.000075869626,0.00021493924,9.35102e-7,0.00024395304,0.023029154],"study_design_scores_gemma":[0.09618953,0.12949301,0.77035254,0.00074212806,0.0004183785,0.000004279672,0.0005793668,0.00025161853,0.00038217095,0.0000054183192,0.0012409032,0.00034064206],"about_ca_topic_score_codex":0.0009801262,"about_ca_topic_score_gemma":0.0034815639,"teacher_disagreement_score":0.111655444,"about_ca_system_score_codex":0.00022137426,"about_ca_system_score_gemma":0.0011419232,"threshold_uncertainty_score":0.74057055},"labels":[],"label_agreement":null},{"id":"W2027791854","doi":"10.1016/j.clgc.2014.12.003","title":"Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Hormonal therapy; Population; Androgen; Cancer; Hormone","score_opus":0.0790272422180056,"score_gpt":0.3952314846535048,"score_spread":0.3162042424354992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027791854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413,0.0009959644,0.00003766916,0.0003739452,0.00021733629,0.004134408,0.000034975423,0.000048060294,0.000027611666],"genre_scores_gemma":[0.9970732,0.00015737022,0.00025144388,0.00052958366,0.00022910057,0.0014689751,0.00012119302,0.000050277362,0.00011886009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706924,0.00044556466,0.0006218083,0.0006779331,0.0007819003,0.0004035326],"domain_scores_gemma":[0.99849856,0.0001360969,0.00011737111,0.0006557015,0.0002944154,0.00029785614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008364745,0.00026000498,0.0007302879,0.00016799514,0.000091179216,0.000025979245,0.00012913645,0.00006784769,0.00008276176],"category_scores_gemma":[0.00009257941,0.00017966024,0.00021320871,0.0005543695,0.000047739617,0.00009912392,0.00004541059,0.00027203973,0.000008818384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004300094,0.002109808,0.951999,0.00005850916,0.0009162946,0.00004922246,0.00017659354,0.0020918695,0.000010364262,3.1670984e-7,0.000052534484,0.038235378],"study_design_scores_gemma":[0.01929229,0.0034687808,0.9755042,0.000118648546,0.0002931555,2.3374801e-7,0.00005164575,0.00021797167,0.00014017955,0.000010745942,0.0006798153,0.0002223391],"about_ca_topic_score_codex":0.0010576559,"about_ca_topic_score_gemma":0.0004961451,"teacher_disagreement_score":0.038013037,"about_ca_system_score_codex":0.0003278998,"about_ca_system_score_gemma":0.0003777874,"threshold_uncertainty_score":0.73263323},"labels":[],"label_agreement":null},{"id":"W2029168581","doi":"10.1016/j.clgc.2013.09.002","title":"Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma","year":2013,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Clinical endpoint; Oncology; Urothelial carcinoma; Internal medicine; Overall survival; Primary (astronomy); Urothelial cancer; Carcinoma; Second line; First line; Cancer; Clinical trial; Bladder cancer","score_opus":0.1740494188975193,"score_gpt":0.4790419817274608,"score_spread":0.3049925628299415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029168581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034207214,0.93851817,0.000018747129,0.0030751538,0.0037136532,0.017547484,0.0009011645,0.000070121605,0.0019482689],"genre_scores_gemma":[0.0016463047,0.96916366,0.00040096045,0.0027650537,0.0060040723,0.006134432,0.00012812042,0.00025913387,0.013498257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99419904,0.000904976,0.0017485458,0.001241086,0.0011227474,0.0007836062],"domain_scores_gemma":[0.9937988,0.0018147747,0.00088710565,0.0024311205,0.00040888385,0.0006593063],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013039083,0.001017358,0.00336084,0.00010774004,0.00027236663,0.00004973504,0.0013803667,0.0005624021,0.0020459222],"category_scores_gemma":[0.00059024576,0.0004944724,0.0021574742,0.00038773683,0.0003375541,0.00011556341,0.00054790615,0.0011417232,0.00014779223],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067218407,0.0008983829,0.00017277582,0.0023865413,0.0014026146,0.000039562277,0.00013319177,0.0000018622744,0.000025873034,0.0000054538955,0.017475924,0.97073597],"study_design_scores_gemma":[0.009012163,0.008136624,0.0036863831,0.002850068,0.0024841405,0.000038958467,0.00002608805,0.0000048807765,0.00025083817,0.00024250061,0.9727343,0.000533077],"about_ca_topic_score_codex":0.00036570913,"about_ca_topic_score_gemma":0.000061705025,"teacher_disagreement_score":0.9702029,"about_ca_system_score_codex":0.0004093046,"about_ca_system_score_gemma":0.0059670825,"threshold_uncertainty_score":0.9997507},"labels":[],"label_agreement":null},{"id":"W2030980371","doi":"10.3816/cgc.2006.n.043","title":"A Randomized Phase III Study of Neoadjuvant Hormonal Therapy in Patients with Localized Prostate Cancer","year":2006,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hormonal therapy; Radiation therapy; Randomized controlled trial; Prostate cancer; Oncology; Prostate; Neoadjuvant therapy; Hormone therapy; Internal medicine; Bicalutamide; Cancer; Urology; Breast cancer","score_opus":0.03350345570443808,"score_gpt":0.37200553265588315,"score_spread":0.3385020769514451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030980371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98665917,0.006633224,0.0000039413335,0.0003944427,0.00028109518,0.00574566,0.00009905265,0.00003329748,0.00015013988],"genre_scores_gemma":[0.99044305,0.00569831,0.00009194342,0.00032469747,0.0003008407,0.0027516454,0.000073054296,0.00004850116,0.0002679738],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996806,0.00029103376,0.0013957612,0.0005971273,0.00051286485,0.00039717206],"domain_scores_gemma":[0.99838334,0.00027647126,0.00046800036,0.00039170144,0.00030332454,0.00017714045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046323022,0.00034259097,0.0016943323,0.0001256717,0.000050840197,0.000012452799,0.0001118633,0.00010472491,0.00022538182],"category_scores_gemma":[0.000025996538,0.00021425053,0.00025867572,0.00033621505,0.00028513666,0.000084994965,0.00004831683,0.0003020103,0.000002704387],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37636712,0.019766113,0.5640318,0.000025999976,0.00053400896,0.00015481749,0.0002220875,0.00015716032,0.000008980679,0.0000018130687,0.00056555495,0.038164552],"study_design_scores_gemma":[0.65572214,0.010727028,0.33160734,0.00021977654,0.00033100462,9.960304e-7,0.00007311183,0.00008320918,0.00014666413,0.000028118457,0.0008671989,0.00019337707],"about_ca_topic_score_codex":0.0029754739,"about_ca_topic_score_gemma":0.00036196396,"teacher_disagreement_score":0.27935505,"about_ca_system_score_codex":0.00021366801,"about_ca_system_score_gemma":0.0004299494,"threshold_uncertainty_score":0.8736883},"labels":[],"label_agreement":null},{"id":"W2032147926","doi":"10.3816/cgc.2007.n.022","title":"Continuing Benefit of Zoledronic Acid in Preventing Skeletal Complications in Patients with Bone Metastases","year":2007,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Hôpital Notre-Dame; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Zoledronic acid; Medicine; Placebo; Prostate cancer; Internal medicine; Incidence (geometry); Surgery; Urology; Cancer; Pathology","score_opus":0.032306235641630716,"score_gpt":0.3783189155830735,"score_spread":0.3460126799414428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032147926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99696374,0.0016668865,0.000019438954,0.00014386512,0.00009669708,0.0006918099,0.000029891107,0.000015656891,0.000372033],"genre_scores_gemma":[0.9980548,0.00013200201,0.0013246319,0.00016556386,0.00005599521,0.000053501626,0.000055251803,0.00001976957,0.00013849296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998107,0.00004759394,0.0009735208,0.00029578348,0.00020243812,0.00037361798],"domain_scores_gemma":[0.99900615,0.00018545694,0.00026735748,0.0002568889,0.000103772894,0.00018039125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048823026,0.00013778167,0.00050950516,0.00014474607,0.000026599584,0.0000027636734,0.000061126506,0.00008796608,0.000045666304],"category_scores_gemma":[0.00006168302,0.00011445095,0.00009649178,0.00030362367,0.00009133508,0.00006843544,0.00004261996,0.00030677384,0.000007019717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008201736,0.0017801895,0.9180233,0.00008244718,0.000048359976,0.00004962441,0.000044168686,0.00000888108,0.0000214627,0.000008288031,0.000015586316,0.07909755],"study_design_scores_gemma":[0.008150409,0.00086645794,0.98965555,0.00047414555,0.000083839725,0.0000041884587,0.000028880673,0.000019067413,0.00014612239,0.000022622715,0.00045321125,0.000095475145],"about_ca_topic_score_codex":0.00024693474,"about_ca_topic_score_gemma":0.00082653406,"teacher_disagreement_score":0.079002075,"about_ca_system_score_codex":0.000113266404,"about_ca_system_score_gemma":0.00011952904,"threshold_uncertainty_score":0.46671745},"labels":[],"label_agreement":null},{"id":"W2032898069","doi":"10.1016/j.clgc.2014.03.016","title":"Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma","year":2014,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Accrual; Oncology; Salvage therapy; Metastatic Urothelial Carcinoma; Internal medicine; Urothelial carcinoma; Disease; Intensive care medicine; Chemotherapy; Cancer; Bladder cancer","score_opus":0.1872850933706951,"score_gpt":0.47635958257400335,"score_spread":0.28907448920330825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032898069","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034070401,0.98284245,0.00018782819,0.00012315923,0.002107217,0.01088814,0.0003143793,0.00003123084,0.00009856498],"genre_scores_gemma":[0.0019306717,0.9903871,0.0006119541,0.0004004105,0.0030077328,0.003284843,0.00003130039,0.00010609348,0.00023990274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962497,0.0005806787,0.0016648489,0.00081587234,0.00031811107,0.0003707904],"domain_scores_gemma":[0.9948084,0.0030960247,0.00075165747,0.00093569705,0.00018000667,0.00022822809],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083678064,0.0005517175,0.0029140506,0.000063575935,0.00012641991,0.00001568307,0.00024371798,0.0004570643,0.000085412554],"category_scores_gemma":[0.00030901926,0.00030598155,0.001418136,0.00014421975,0.00036612063,0.000033891807,0.00009162995,0.00051134324,0.0000056202757],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038771532,0.0005082739,0.00007802631,0.0026590142,0.0007032274,0.000009156049,0.000035868226,0.0000016820171,0.0000011156073,0.0000026570563,0.0015373142,0.9556921],"study_design_scores_gemma":[0.036138523,0.013497051,0.00021694899,0.0017287038,0.0021270593,0.000015035293,0.000011490685,0.000010688429,0.000021017395,0.000060787126,0.9458752,0.00029747383],"about_ca_topic_score_codex":0.00005032815,"about_ca_topic_score_gemma":0.0000031881175,"teacher_disagreement_score":0.9553947,"about_ca_system_score_codex":0.000118800075,"about_ca_system_score_gemma":0.0013559563,"threshold_uncertainty_score":0.9999392},"labels":[],"label_agreement":null},{"id":"W2033476800","doi":"10.1016/j.clgc.2014.03.005","title":"Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Ontario Clinical Oncology Group","funders":"Pfizer","keywords":"Medicine; Docetaxel; Prostate cancer; Neutrophil to lymphocyte ratio; Internal medicine; Oncology; Proportional hazards model; Clinical endpoint; Urology; Gastroenterology; Prostate-specific antigen; Cancer; Lymphocyte; Clinical trial","score_opus":0.031524767388623295,"score_gpt":0.37021621365111523,"score_spread":0.3386914462624919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033476800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501884,0.00070963404,0.000013193236,0.0011857707,0.00022185242,0.0021978996,0.000087939385,0.000031673626,0.0005331708],"genre_scores_gemma":[0.99728817,0.0001892469,0.0005429053,0.00041079085,0.00031618017,0.00088204345,0.0000092852415,0.00005098321,0.00031036846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972715,0.00039080184,0.00095727976,0.00049163273,0.00046381357,0.00042502157],"domain_scores_gemma":[0.9980709,0.00032445494,0.0003627922,0.0006160638,0.00029736667,0.0003284095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005930499,0.00029387372,0.0006226605,0.00011853495,0.00008410824,0.00002296458,0.00024945821,0.000085542684,0.00015109597],"category_scores_gemma":[0.00035373162,0.00017484618,0.00030497691,0.0005971873,0.00030646802,0.00009682626,0.00010152984,0.0002871854,0.00001034625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007959066,0.00048591246,0.97469026,0.00029272275,0.00050284213,0.00011057986,0.00021051234,0.0025402894,0.004335121,0.0000123530135,0.001344416,0.0075159557],"study_design_scores_gemma":[0.0042293263,0.001526135,0.9894281,0.0006882525,0.0004932521,0.000014269654,0.000054796295,0.0017986601,0.0011302487,0.000040533232,0.00037002994,0.00022638432],"about_ca_topic_score_codex":0.00045079595,"about_ca_topic_score_gemma":0.00026842285,"teacher_disagreement_score":0.014737882,"about_ca_system_score_codex":0.00040659623,"about_ca_system_score_gemma":0.0019266604,"threshold_uncertainty_score":0.713002},"labels":[],"label_agreement":null},{"id":"W2034053985","doi":"10.1016/j.clgc.2013.07.010","title":"Population-Based Referrals for Adjuvant Radiotherapy After Radical Prostatectomy in Men With Prostate Cancer: Impact of Randomized Trials","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Randomized controlled trial; Radiation therapy; Oncology; Adjuvant radiotherapy; Urology; Population; Prostate; Adjuvant; Cancer; Internal medicine","score_opus":0.06761566883305067,"score_gpt":0.4357410631022356,"score_spread":0.3681253942691849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034053985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968175,0.014841486,0.000056057073,0.0028398903,0.00019752175,0.013408109,0.0003855518,0.000043065644,0.000053331903],"genre_scores_gemma":[0.9584982,0.010186504,0.002261033,0.0005862359,0.0005104026,0.027439801,0.00014064935,0.00008190797,0.000295266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99542075,0.00074163766,0.002290562,0.0006465699,0.000362944,0.0005375571],"domain_scores_gemma":[0.9955899,0.00239809,0.00084802747,0.0004395693,0.00036293367,0.00036145234],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021101786,0.00042102102,0.0036755581,0.00019223227,0.000042363536,0.000029836146,0.000112306996,0.00020381849,0.0010785388],"category_scores_gemma":[0.0005266083,0.00024043267,0.0011891838,0.00027748296,0.00027963275,0.00014953018,0.000019471661,0.00027894898,0.0000033025353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32403293,0.0010974965,0.63634884,0.00029269024,0.001392045,0.000044242894,0.00011945999,0.0008099889,0.00016350969,0.0000026291696,0.0024532187,0.03324292],"study_design_scores_gemma":[0.31519797,0.0040766927,0.67465526,0.001190672,0.00074749254,0.000003946537,0.000018026358,0.0023785874,0.00071234646,0.00020305318,0.00048591607,0.0003300672],"about_ca_topic_score_codex":0.0042682476,"about_ca_topic_score_gemma":0.00008732929,"teacher_disagreement_score":0.038306374,"about_ca_system_score_codex":0.0007264154,"about_ca_system_score_gemma":0.0012728607,"threshold_uncertainty_score":0.9998346},"labels":[],"label_agreement":null},{"id":"W2037252326","doi":"10.1016/j.clgc.2013.05.004","title":"Luteinizing Hormone–Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects","year":2013,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Luteinizing hormone; Hormone; Adverse effect; Hormone receptor; Internal medicine; Oncology; Bioinformatics; Physiology; Cancer; Breast cancer","score_opus":0.1516322326945628,"score_gpt":0.454092749034244,"score_spread":0.3024605163396812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037252326","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007335266,0.98656166,0.00005452326,0.00012859759,0.0011977146,0.0041062804,0.0001783734,0.00007367971,0.00036391776],"genre_scores_gemma":[0.0018714651,0.98756045,0.0017799243,0.000058045294,0.0042528394,0.0013737349,0.000084129984,0.00012505581,0.0028943692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994917,0.0003880394,0.0021243729,0.0013996616,0.00048478655,0.00068618706],"domain_scores_gemma":[0.9955847,0.0011740113,0.0012965429,0.0008576021,0.00073530717,0.00035181138],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059093896,0.00080490607,0.004267783,0.00017710378,0.00022557727,0.000017786257,0.00041355775,0.0006844145,0.00003502126],"category_scores_gemma":[0.0011945973,0.00055956957,0.0017234817,0.0003555983,0.00074302993,0.00013626208,0.00040024405,0.0011387309,0.00007468786],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085263664,0.0006347804,0.00008654744,0.064032845,0.001954774,0.00013304075,0.000052066367,0.0000013929279,0.00022892798,0.000012436071,0.0054142457,0.9265963],"study_design_scores_gemma":[0.0032122706,0.005578747,0.009178168,0.03031866,0.01032495,0.00012348981,0.00011453876,0.000018868639,0.000046472986,0.000096493546,0.9398257,0.0011616022],"about_ca_topic_score_codex":0.00005547433,"about_ca_topic_score_gemma":0.0000010871988,"teacher_disagreement_score":0.93441147,"about_ca_system_score_codex":0.00021138099,"about_ca_system_score_gemma":0.0009785396,"threshold_uncertainty_score":0.9996856},"labels":[],"label_agreement":null},{"id":"W2039105660","doi":"10.1016/j.clgc.2015.02.008","title":"Persistent, Unexplained Leukocytosis Is a Paraneoplastic Syndrome Associated With a Poor Prognosis in Patients With Urothelial Carcinoma","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Hematological disorders and diagnostics","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Leukocytosis; Urothelial carcinoma; Internal medicine; Carcinoma; Oncology; Pathology; Cancer; Bladder cancer","score_opus":0.06281715259500498,"score_gpt":0.3149987794033473,"score_spread":0.25218162680834233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039105660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963829,0.00029613488,0.000009530413,0.0014218953,0.00015185452,0.001116357,0.000089062145,0.000069366,0.0004629321],"genre_scores_gemma":[0.9971796,0.000041776566,0.00020486463,0.0018106531,0.000083949235,0.0002769174,0.00006587753,0.00005017098,0.00028617142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746585,0.00015507523,0.00064919953,0.0006021427,0.0005773204,0.00055043196],"domain_scores_gemma":[0.998043,0.000539193,0.00019881467,0.00023679719,0.00035740784,0.0006247805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023122919,0.0003262239,0.00089160237,0.000106018255,0.0000623235,0.000023185909,0.00014564327,0.00028123386,0.00014737294],"category_scores_gemma":[0.001145358,0.0002151506,0.00019950428,0.0004947693,0.0002548892,0.000079842546,0.00006714069,0.00046355877,0.000046081455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062047634,0.0031192626,0.9860262,0.000061248276,0.00024977094,0.0013401543,0.00014066284,0.000049281454,5.86992e-7,0.0000023501248,0.0024913577,0.00031435714],"study_design_scores_gemma":[0.019672401,0.017886672,0.96015036,0.0005246904,0.0005082316,0.00005506115,0.00019713619,0.00038639747,0.000012321393,0.000014264711,0.00023148784,0.00036095706],"about_ca_topic_score_codex":0.000110713656,"about_ca_topic_score_gemma":0.000081003156,"teacher_disagreement_score":0.025875825,"about_ca_system_score_codex":0.00021632727,"about_ca_system_score_gemma":0.0006410109,"threshold_uncertainty_score":0.8773587},"labels":[],"label_agreement":null},{"id":"W2044493544","doi":"10.1016/j.clgc.2015.02.001","title":"Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bladder cancer; Internal medicine; Cystectomy; Neutrophil to lymphocyte ratio; Oncology; Pathological; Gastroenterology; Stage (stratigraphy); Neoadjuvant therapy; Chemotherapy; Cisplatin; Retrospective cohort study; Lymphocyte; Urology; Cancer; Breast cancer","score_opus":0.040634914403198726,"score_gpt":0.348950956030141,"score_spread":0.30831604162694226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044493544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259925,0.0012992362,0.000007814817,0.0040705656,0.0004656025,0.0013214663,0.000054880013,0.00006950777,0.0001117005],"genre_scores_gemma":[0.9898544,0.00070705585,0.0010422801,0.006983047,0.00059702114,0.00052150484,0.000013892463,0.00006201511,0.00021878489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972059,0.000413443,0.00068528304,0.0007638311,0.00045910128,0.0004724418],"domain_scores_gemma":[0.9978304,0.0002974132,0.00016466042,0.00047634658,0.00037161255,0.0008596014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007032025,0.00032968045,0.000620712,0.00015112014,0.00006298418,0.00002715988,0.00016412628,0.00025732417,0.0001558211],"category_scores_gemma":[0.00049647427,0.00024766763,0.00011451371,0.00032882232,0.00032234984,0.00011228085,0.0001535295,0.00033384855,0.00002650224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061754692,0.0007586353,0.8979869,0.000038359674,0.00013501607,0.0007749103,0.00034358626,0.000052058174,0.0003204205,0.0000010975391,0.0031978635,0.034636453],"study_design_scores_gemma":[0.015981128,0.0030484013,0.9743498,0.0002273865,0.00012619232,0.000008557724,0.00010615616,0.000045428722,0.00025809553,0.000018609699,0.0054908693,0.00033938154],"about_ca_topic_score_codex":0.000038170045,"about_ca_topic_score_gemma":0.000033702956,"teacher_disagreement_score":0.076362886,"about_ca_system_score_codex":0.00043884912,"about_ca_system_score_gemma":0.0011296058,"threshold_uncertainty_score":0.99999756},"labels":[],"label_agreement":null},{"id":"W2046474914","doi":"10.1016/j.clgc.2014.03.003","title":"First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute; Genentech; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Renal cell carcinoma; Oncology; Cancer research; Cell culture; Internal medicine; Biology","score_opus":0.059614904111763366,"score_gpt":0.3511681714682748,"score_spread":0.29155326735651144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046474914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921418,0.0012496697,0.0014937081,0.0015650173,0.00039340183,0.0007759619,0.001974742,0.000018012282,0.00038770348],"genre_scores_gemma":[0.9893421,0.0002648239,0.0062560043,0.0008407349,0.0005473983,0.00012728108,0.0023590932,0.000056212637,0.0002063638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99397796,0.0013291956,0.002293771,0.0009587431,0.0009895645,0.00045077334],"domain_scores_gemma":[0.9936332,0.0027890436,0.0014037876,0.0012740525,0.00052192586,0.00037798582],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019468947,0.00046163172,0.001434738,0.00044365507,0.000077133416,0.000026802652,0.0003975271,0.00013060652,0.0011233939],"category_scores_gemma":[0.0005922998,0.00034763664,0.00067001506,0.0006605319,0.00030519467,0.00032970548,0.00024628377,0.0006839843,0.000014012222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055954377,0.006018207,0.95861095,0.00040178912,0.0017445865,0.0017965824,0.0009725753,0.007242524,0.015531153,0.000015055289,0.0011102872,0.00096087344],"study_design_scores_gemma":[0.00979065,0.0031834207,0.88141793,0.00018032655,0.011307569,0.00004146884,0.0008967756,0.015966477,0.07553651,0.00007592275,0.0011610736,0.0004418946],"about_ca_topic_score_codex":0.007024009,"about_ca_topic_score_gemma":0.0018506948,"teacher_disagreement_score":0.07719302,"about_ca_system_score_codex":0.0002690036,"about_ca_system_score_gemma":0.0004472887,"threshold_uncertainty_score":0.99989754},"labels":[],"label_agreement":null},{"id":"W2054379162","doi":"10.1016/j.clgc.2012.12.007","title":"Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Urothelial carcinoma; Oncology; Cisplatin; Urothelial cancer; Pooled analysis; Internal medicine; Metastatic Urothelial Carcinoma; Carcinoma; Bladder cancer; Cancer; Chemotherapy; Meta-analysis","score_opus":0.20872856748471622,"score_gpt":0.5079691153930224,"score_spread":0.2992405479083061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054379162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989268,0.0023685023,0.000388868,0.002295799,0.0010077162,0.0035915433,0.00064668345,0.000046957804,0.0003859293],"genre_scores_gemma":[0.97960603,0.0011559656,0.0022562714,0.0013643614,0.0017572546,0.0020075275,0.00026299345,0.000059410413,0.011530169],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99602693,0.00032484654,0.0020589356,0.0006622451,0.00052508863,0.00040192343],"domain_scores_gemma":[0.99586856,0.0018227266,0.00079813966,0.0005017058,0.00068976136,0.00031911867],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013067378,0.0003488386,0.00191987,0.00023131832,0.00018159786,0.000018389186,0.0001906381,0.00022485323,0.0102331955],"category_scores_gemma":[0.0013036758,0.00024382945,0.00148746,0.00055625814,0.0001690904,0.00012918968,0.00006324659,0.00022917005,0.000029116161],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10077761,0.010308095,0.04314208,0.0002547468,0.021066895,0.000058512753,0.00042321617,0.00051893445,0.020954408,0.00002497614,0.009297425,0.7931731],"study_design_scores_gemma":[0.41303918,0.1938029,0.23459679,0.0007540936,0.056593798,0.000042219246,0.00050263735,0.039498482,0.02239716,0.0019403261,0.034973815,0.0018585998],"about_ca_topic_score_codex":0.00030592,"about_ca_topic_score_gemma":0.000035664594,"teacher_disagreement_score":0.7913145,"about_ca_system_score_codex":0.00014399922,"about_ca_system_score_gemma":0.0012684915,"threshold_uncertainty_score":0.99430764},"labels":[],"label_agreement":null},{"id":"W2066355838","doi":"10.1016/j.clgc.2013.12.003","title":"A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Baker Hughes (Canada); Western University; Alberta Cancer Foundation; Sunnybrook Health Science Centre","funders":"","keywords":"Sunitinib; Medicine; Temsirolimus; Hazard ratio; Everolimus; Renal cell carcinoma; Internal medicine; Oncology; Confidence interval; Population; Clear cell renal cell carcinoma; Urology; Gastroenterology; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","score_opus":0.124437901460307,"score_gpt":0.39399840166557637,"score_spread":0.26956050020526934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066355838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880512,0.010747535,0.000021701015,0.00021108553,0.00015496307,0.00046349133,0.0000230317,0.000012127337,0.00031490406],"genre_scores_gemma":[0.9965908,0.00063752354,0.0020976365,0.00029512675,0.00014669108,0.00006161928,0.000043076703,0.000023976278,0.00010353843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763787,0.00039833502,0.0010735141,0.00033281292,0.00034238986,0.0002150877],"domain_scores_gemma":[0.9983401,0.0005388475,0.0004154172,0.00041907487,0.00014562624,0.00014095461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054716325,0.00019208423,0.00085748936,0.00013580188,0.000017894161,0.0000026845821,0.000127416,0.000092454,0.00036339505],"category_scores_gemma":[0.000093618604,0.00014553884,0.00033452173,0.00028324092,0.0001131994,0.000038504775,0.00002411019,0.00019915626,0.0000053038066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011363816,0.0009800387,0.9727981,0.0004674624,0.000057731242,0.00007315067,0.000060996026,0.00066747324,0.012309739,0.000007750924,0.000105725114,0.011335456],"study_design_scores_gemma":[0.0043365248,0.0032118428,0.937866,0.00020072787,0.00013675011,0.0000037527952,0.000021400232,0.00086524914,0.052934334,0.00011751359,0.00017628519,0.0001296712],"about_ca_topic_score_codex":0.0011559974,"about_ca_topic_score_gemma":0.000064255124,"teacher_disagreement_score":0.040624596,"about_ca_system_score_codex":0.00009571388,"about_ca_system_score_gemma":0.0003728432,"threshold_uncertainty_score":0.5934902},"labels":[],"label_agreement":null},{"id":"W2076483997","doi":"10.1016/j.clgc.2014.03.009","title":"Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency; McMaster University","funders":"","keywords":"Medicine; Chemoradiotherapy; Internal medicine; Radiation therapy; Oncology; Stage (stratigraphy); Mucositis; Proportional hazards model; Chemotherapy","score_opus":0.03276988785044034,"score_gpt":0.3731778031250632,"score_spread":0.3404079152746229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076483997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98264873,0.0048248167,0.0008940681,0.0013436112,0.00062737055,0.0017144318,0.00006213491,0.00009067964,0.0077941683],"genre_scores_gemma":[0.98821706,0.00005288157,0.001280412,0.0038200037,0.0019058693,0.00049149734,0.00005360403,0.00006554613,0.0041131545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979739,0.00007357367,0.00058290974,0.0005650572,0.00026045262,0.0005440749],"domain_scores_gemma":[0.9977599,0.00036277264,0.0001759887,0.00044998468,0.00024705357,0.0010043492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026342,0.00026438874,0.00061495043,0.00004399209,0.00011441289,0.000012584309,0.00015129798,0.0001472014,0.00024900035],"category_scores_gemma":[0.00010437547,0.00020354897,0.00024682208,0.00011520006,0.00015955672,0.000058408303,0.000029528745,0.00028121856,0.000043393848],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037359167,0.005807827,0.3934849,0.0058834227,0.000056113116,0.00030416553,0.00030847004,0.00034499634,0.001741244,0.00007385753,0.1137108,0.44092503],"study_design_scores_gemma":[0.11616011,0.048484657,0.38736513,0.00013478029,0.0010830847,0.00010773875,0.00038284107,0.013976046,0.00657849,0.00021875316,0.42372677,0.0017816],"about_ca_topic_score_codex":0.000029943994,"about_ca_topic_score_gemma":0.000009706989,"teacher_disagreement_score":0.43914345,"about_ca_system_score_codex":0.00010669814,"about_ca_system_score_gemma":0.00078877114,"threshold_uncertainty_score":0.8300486},"labels":[],"label_agreement":null},{"id":"W2077860755","doi":"10.3816/cgc.2009.n.035","title":"Tolerance of Sunitinib in Dialyzed Patients With Metastatic Renal Cell Carcinoma","year":2009,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Foothills Medical Centre","funders":"","keywords":"Sunitinib; Medicine; Renal cell carcinoma; Hemodialysis; Dialysis; Peritoneal dialysis; Internal medicine; Toxicity; Oncology; Urology","score_opus":0.042401785770641985,"score_gpt":0.3333178607955501,"score_spread":0.2909160750249081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077860755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945952,0.001195786,0.00000816119,0.0002697492,0.0001493298,0.00073653477,0.000030159756,0.000019312754,0.0029957648],"genre_scores_gemma":[0.99715257,0.0001251554,0.0013774175,0.00047935912,0.00022225399,0.0000470783,0.000045099612,0.000026253269,0.0005248092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775314,0.00017146266,0.0008818479,0.00043819417,0.00040305068,0.00035230396],"domain_scores_gemma":[0.99858534,0.00021697985,0.00027616715,0.0004596584,0.00021097345,0.00025086117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022242231,0.0002511693,0.00080170255,0.00012794229,0.000028105573,0.000005844226,0.00013273618,0.00008761568,0.00016751395],"category_scores_gemma":[0.000052388856,0.00018492632,0.00020680865,0.0003300763,0.0001343077,0.000073163494,0.000030521405,0.0003478689,0.0000136712315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053722155,0.0032092354,0.97255695,0.000118463315,0.0000557485,0.000708549,0.00012127357,0.00011394818,0.00081010384,0.000003554503,0.0004570878,0.016472846],"study_design_scores_gemma":[0.011552768,0.005508992,0.97608674,0.00015857724,0.00023762038,0.000007324202,0.000025512636,0.000041239055,0.0057931435,0.0000289564,0.00037162963,0.00018748439],"about_ca_topic_score_codex":0.00009242103,"about_ca_topic_score_gemma":0.000023396782,"teacher_disagreement_score":0.016285364,"about_ca_system_score_codex":0.00013004536,"about_ca_system_score_gemma":0.00030487223,"threshold_uncertainty_score":0.75410765},"labels":[],"label_agreement":null},{"id":"W2079168970","doi":"10.1016/j.clgc.2014.09.003","title":"Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; London Health Sciences Centre; University of Toronto; Western University; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Dana-Farber/Harvard Cancer Center","keywords":"Medicine; Renal cell carcinoma; Term (time); Oncology; Internal medicine; Carcinoma; Database","score_opus":0.0563195451303097,"score_gpt":0.32547690014645964,"score_spread":0.26915735501614996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079168970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960192,0.001079442,0.000056335346,0.0003198315,0.00024899558,0.0005038489,0.0014895815,0.000017557115,0.00026524527],"genre_scores_gemma":[0.99657035,0.00095367443,0.000542596,0.00015387437,0.00041247308,0.000036381,0.0010268668,0.00003709571,0.00026669848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974187,0.00029387747,0.0011203204,0.00051330304,0.000430483,0.0002233242],"domain_scores_gemma":[0.99687296,0.0013786253,0.00052622706,0.0007253609,0.00029773655,0.0001990913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050047913,0.00028075578,0.00075773813,0.00006311188,0.00004700362,0.000014700508,0.0002487409,0.00008574922,0.00015374948],"category_scores_gemma":[0.00016415083,0.0001676447,0.00016325979,0.00011859477,0.0005254864,0.000065569475,0.00012282497,0.00028779428,0.0000028891507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072015324,0.0006510193,0.97147334,0.00010783208,0.00059433794,0.00031521416,0.00025984528,0.0000026140135,0.013359721,0.0000015279619,0.0002047632,0.0058282414],"study_design_scores_gemma":[0.004649748,0.001824995,0.9681935,0.00021893269,0.00088311825,0.000027099737,0.000073216936,0.00013520653,0.023704255,0.0000026218358,0.0001248015,0.00016254302],"about_ca_topic_score_codex":0.0007064999,"about_ca_topic_score_gemma":0.00016143227,"teacher_disagreement_score":0.010344533,"about_ca_system_score_codex":0.00005299162,"about_ca_system_score_gemma":0.00018955514,"threshold_uncertainty_score":0.68363523},"labels":[],"label_agreement":null},{"id":"W2080771641","doi":"10.1016/j.clgc.2013.04.008","title":"Use of a Clinical Assistant to Screen Patients With Genitourinary Cancer to Encourage Entry into Clinical Trials and Use of Supportive Medication: A Pilot Project at a Canadian Cancer Center","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"Sanofi","keywords":"Medicine; Clinical trial; Prostate cancer; Retrospective cohort study; Psychological intervention; Cancer; Referral; Genitourinary system; Prospective cohort study; Internal medicine; Family medicine; Nursing","score_opus":0.2792360679714213,"score_gpt":0.49305666692671674,"score_spread":0.21382059895529543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080771641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98314595,0.0006583778,0.000014801498,0.0063138665,0.0013621992,0.0063830446,0.0020085694,0.000036620982,0.00007655924],"genre_scores_gemma":[0.9771894,0.004859757,0.00466569,0.0079476135,0.001229099,0.0019295074,0.00019653668,0.000111187364,0.0018712124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9898934,0.0016351521,0.0052239997,0.0013631077,0.0009180865,0.000966248],"domain_scores_gemma":[0.9894469,0.0027881193,0.0017381323,0.0010130401,0.0013154533,0.0036983588],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024020756,0.0005804648,0.0029713353,0.00037666466,0.00017562402,0.000038125352,0.00027680577,0.0005202755,0.0010452946],"category_scores_gemma":[0.0036474306,0.00041684162,0.0005192596,0.00055797165,0.00060359004,0.00035062153,0.00034078094,0.0008288585,0.00004167355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015234395,0.0027620422,0.84391737,0.00021604114,0.001124091,0.0001595696,0.00024545702,0.0000045124975,0.000013325755,0.0000011327609,0.057374597,0.07894746],"study_design_scores_gemma":[0.009975839,0.010468868,0.92870647,0.0010721168,0.0008611853,0.000012579584,0.000054609227,0.000049126404,0.000034015084,0.000004855469,0.04836849,0.0003918386],"about_ca_topic_score_codex":0.3130229,"about_ca_topic_score_gemma":0.15667297,"teacher_disagreement_score":0.15634993,"about_ca_system_score_codex":0.00063282845,"about_ca_system_score_gemma":0.005921621,"threshold_uncertainty_score":0.99986786},"labels":[],"label_agreement":null},{"id":"W2093356247","doi":"10.1016/j.clgc.2014.08.011","title":"Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; Queen Elizabeth II Health Sciences Centre; Western University; Sunnybrook Health Science Centre; University of Toronto; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Carcinoma; Internal medicine; Sarcomatoid carcinoma; Database; Pathology","score_opus":0.06455312898978038,"score_gpt":0.3293076878502526,"score_spread":0.2647545588604722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093356247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127793,0.0009794733,0.00017126245,0.0009168462,0.00080293685,0.0010844873,0.0025813773,0.000039336966,0.0021463537],"genre_scores_gemma":[0.98995286,0.00006307546,0.005447974,0.0010180713,0.0006630015,0.000111283945,0.0015458252,0.000085006395,0.0011128816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99426264,0.00065499,0.0022165095,0.0010522689,0.0012547366,0.00055886334],"domain_scores_gemma":[0.99387234,0.0024378172,0.0010849955,0.0015710248,0.00053874915,0.00049507554],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010192245,0.00056132156,0.001191404,0.00013353415,0.00013775218,0.000037615217,0.0006928504,0.00010553155,0.0004197979],"category_scores_gemma":[0.00045787287,0.0003462357,0.0004898558,0.00026476354,0.0005111782,0.00016516977,0.00036877903,0.00074863475,0.000080202524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008447281,0.0024282672,0.97635764,0.0001613157,0.00042437474,0.0004948349,0.00019256951,0.00009893164,0.001365573,0.000007655027,0.008667351,0.0013541917],"study_design_scores_gemma":[0.02385223,0.002930057,0.9488514,0.00012080597,0.0019998965,0.00002138943,0.000147804,0.00053479814,0.015162383,0.000037239082,0.005891917,0.00045007016],"about_ca_topic_score_codex":0.0011544031,"about_ca_topic_score_gemma":0.00011730612,"teacher_disagreement_score":0.027506243,"about_ca_system_score_codex":0.00022934125,"about_ca_system_score_gemma":0.00047595365,"threshold_uncertainty_score":0.99989897},"labels":[],"label_agreement":null},{"id":"W2093984374","doi":"10.1016/j.clgc.2014.03.006","title":"Metastatic Large-Cell Neuroendocrine Prostate Carcinoma: Successful Treatment With Androgen Deprivation Therapy","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Prostate; Neuroendocrine differentiation; Context (archaeology); Adenocarcinoma; Neuroendocrine tumors; Oncology; Small-cell carcinoma; Internal medicine; Androgen; Carcinoma; Cancer research; Cancer; Pathology; Hormone; Biology","score_opus":0.06053790294127071,"score_gpt":0.37806420833724846,"score_spread":0.31752630539597776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093984374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898118,0.0047115926,0.00009590904,0.0023498475,0.0002404631,0.0014564856,0.000052857456,0.00009237532,0.0011886938],"genre_scores_gemma":[0.9802332,0.011453355,0.00050200976,0.0007523729,0.0006253214,0.00053247414,0.0001395672,0.00007156017,0.0056901425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975366,0.00025655367,0.0005211335,0.00066596654,0.00039383728,0.0006258961],"domain_scores_gemma":[0.99843633,0.00023591344,0.00016817133,0.0005602837,0.00019610398,0.00040320586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002410428,0.00034209562,0.0006252141,0.00010858369,0.00016683248,0.00003653565,0.00013617796,0.00004676312,0.00025031136],"category_scores_gemma":[0.00002617213,0.00020790203,0.00021326206,0.00029647877,0.00016664008,0.0001245697,0.00005799745,0.00028477615,0.000055743956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061684903,0.003067941,0.8995698,0.00012016492,0.00034016385,0.0011403767,0.00011428033,0.000022870157,0.000611667,0.000007833848,0.00087112986,0.087965265],"study_design_scores_gemma":[0.11932063,0.05422996,0.47363663,0.00019964919,0.0011731545,0.00041320312,0.0002732855,0.0031107212,0.054918792,0.00024089638,0.29137418,0.0011088892],"about_ca_topic_score_codex":0.00012531421,"about_ca_topic_score_gemma":0.000037538637,"teacher_disagreement_score":0.42593318,"about_ca_system_score_codex":0.00018820411,"about_ca_system_score_gemma":0.00045861478,"threshold_uncertainty_score":0.8477999},"labels":[],"label_agreement":null},{"id":"W2128675949","doi":"10.1016/j.clgc.2013.04.020","title":"Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"Cancer Institute NSW; Sanofi","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Chemotherapy; Internal medicine; Cancer","score_opus":0.04536099101820812,"score_gpt":0.3538127279444684,"score_spread":0.30845173692626027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128675949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988673,0.0018110243,0.000009227566,0.002310066,0.00021357005,0.006364104,0.00015336373,0.00020821171,0.0002574785],"genre_scores_gemma":[0.9883021,0.00033824088,0.0016145819,0.0015232536,0.00035268933,0.006934751,0.00010782055,0.00014404551,0.00068251253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99574065,0.00031738007,0.0013305395,0.0010398293,0.0006963648,0.0008752322],"domain_scores_gemma":[0.9970225,0.0005715075,0.0004673345,0.0006426714,0.00061082176,0.00068513385],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030026934,0.00063657074,0.0009911279,0.00026315523,0.00013254468,0.00011012685,0.0002617951,0.00022185744,0.0020710165],"category_scores_gemma":[0.00041667736,0.00047475702,0.00030047866,0.00080528227,0.0005251326,0.00027753983,0.000046163885,0.0006057388,0.00014493254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055161035,0.001646777,0.9712969,0.00073887914,0.00061113946,0.0011849302,0.0001236522,0.00007437752,0.0020958616,0.0000029934818,0.0009011133,0.015807249],"study_design_scores_gemma":[0.010128621,0.0023803567,0.9803461,0.0016445983,0.0006285302,0.000031437892,0.00010410502,0.0011033015,0.0021795202,0.00004895552,0.0007873572,0.00061713735],"about_ca_topic_score_codex":0.00068395765,"about_ca_topic_score_gemma":0.00029665217,"teacher_disagreement_score":0.015190112,"about_ca_system_score_codex":0.00039074564,"about_ca_system_score_gemma":0.0023657477,"threshold_uncertainty_score":0.9997704},"labels":[],"label_agreement":null},{"id":"W2137336295","doi":"10.1016/j.clgc.2012.06.004","title":"Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Neutropenia; Internal medicine; Oncology; Hazard ratio; Proportional hazards model; Placebo; Chemotherapy; Cancer; Confidence interval; Pathology","score_opus":0.05422431967467393,"score_gpt":0.4329186536417635,"score_spread":0.37869433396708957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137336295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98240983,0.0069985297,0.0000603729,0.0058094584,0.00038451032,0.0032839556,0.00019237296,0.000044326836,0.0008166369],"genre_scores_gemma":[0.9823891,0.0033156518,0.0014135123,0.0012622883,0.0009069364,0.0027005733,0.00010650876,0.00009470133,0.0078107156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733114,0.00017124553,0.0006710154,0.0005328463,0.00043135116,0.00086237455],"domain_scores_gemma":[0.99857605,0.00019447005,0.00020114261,0.00031177947,0.00023342695,0.0004831621],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006147377,0.00034523167,0.0006391817,0.00014921922,0.0001239964,0.00003732304,0.00014995816,0.00010316809,0.0010446653],"category_scores_gemma":[0.000027273236,0.00024041334,0.00023373101,0.0003439611,0.00024242444,0.00022719344,0.000032395037,0.00042537166,0.000027096574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23875478,0.00787095,0.56359935,0.0016829527,0.0036542022,0.0016501232,0.00077806873,0.0016179503,0.06496951,0.000027552436,0.013172157,0.102222435],"study_design_scores_gemma":[0.12773395,0.0077451896,0.78386366,0.00096719654,0.0022825282,0.00010702426,0.0005721413,0.013576565,0.0166576,0.00011175257,0.04494587,0.0014365342],"about_ca_topic_score_codex":0.00036130231,"about_ca_topic_score_gemma":0.00011145192,"teacher_disagreement_score":0.22026432,"about_ca_system_score_codex":0.0004224423,"about_ca_system_score_gemma":0.0014836555,"threshold_uncertainty_score":0.9998685},"labels":[],"label_agreement":null},{"id":"W2158732258","doi":"10.1016/j.clgc.2013.07.013","title":"Periprostatic Adipose Tissue and Prostate Cancer Progression: New Insights into the Tumor Microenvironment","year":2013,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Malignancy; Cancer; Tumor progression; Adipose tissue; Prostate; Obesity; Tumor microenvironment; Insulin resistance; Oncology; Internal medicine; Cancer research; Bioinformatics; Biology","score_opus":0.03440061590890456,"score_gpt":0.379315280825505,"score_spread":0.3449146649166004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158732258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004015968,0.98322654,0.0000049384525,0.00035797516,0.009684846,0.0025618544,0.00006335513,0.000019509991,0.00006499199],"genre_scores_gemma":[0.000022663906,0.948333,0.0003700935,0.0007569552,0.035505466,0.0022634638,0.00013583132,0.0001305868,0.012481884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964128,0.0004076546,0.0011457241,0.0012244193,0.00027178985,0.00053760025],"domain_scores_gemma":[0.99777734,0.00007767336,0.00064661,0.00092674507,0.000070332266,0.0005012767],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002432928,0.00073386624,0.0014254443,0.00005222103,0.00024656343,0.00009627305,0.0005643442,0.00046059096,0.00024109319],"category_scores_gemma":[0.00006418692,0.00045365264,0.0004575536,0.00013903454,0.00058702886,0.000012554072,0.00064769195,0.00066911627,0.00006448728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006554848,0.00009032253,0.000052787058,0.0018882869,0.00029321844,0.0000031327431,0.00018794919,0.0000016567433,0.0002511404,0.000001499956,0.10743734,0.8897271],"study_design_scores_gemma":[0.00063579873,0.00044818688,0.00012608571,0.0021670193,0.0008551806,0.00003356142,0.000037619408,0.00000169151,0.000093001756,0.000022573695,0.9949631,0.00061615015],"about_ca_topic_score_codex":0.00026871252,"about_ca_topic_score_gemma":0.0001444631,"teacher_disagreement_score":0.889111,"about_ca_system_score_codex":0.00008985589,"about_ca_system_score_gemma":0.0013534853,"threshold_uncertainty_score":0.9997915},"labels":[],"label_agreement":null},{"id":"W2159738538","doi":"10.1016/j.clgc.2014.08.010","title":"Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Cisplatin; Hazard ratio; Perioperative; Internal medicine; Proportional hazards model; Gemcitabine; Chemotherapy; Oncology; Confidence interval; Anemia; Urology; Gastroenterology; Surgery","score_opus":0.05456261629408484,"score_gpt":0.37659038282777574,"score_spread":0.3220277665336909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159738538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809811,0.005472964,0.002893723,0.003441279,0.0014468189,0.004264902,0.00034537722,0.00017526391,0.000978534],"genre_scores_gemma":[0.97338647,0.0012417373,0.00380969,0.012302659,0.0033689798,0.004022796,0.000117278316,0.0001822959,0.0015680977],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99636894,0.0002675605,0.0010716469,0.0011065626,0.00046967238,0.0007156336],"domain_scores_gemma":[0.9969178,0.00096281973,0.0002955507,0.0009083911,0.00044049308,0.00047496037],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004419055,0.0006724637,0.0011507544,0.00011678153,0.0002939215,0.000048844304,0.00027238936,0.00036511585,0.0013163328],"category_scores_gemma":[0.00018302164,0.00051002647,0.00083613524,0.00023317226,0.0003080262,0.000100702426,0.000033089895,0.00048587416,0.000050555114],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09658166,0.004137147,0.33704746,0.00034760294,0.00070922764,0.00016219067,0.00042719068,0.0014702594,0.0019209677,0.000017526338,0.001996417,0.55518234],"study_design_scores_gemma":[0.15243211,0.05113437,0.419318,0.0007831271,0.00081748376,0.000024068371,0.000054048276,0.017825767,0.028731994,0.00022516008,0.32658845,0.0020654253],"about_ca_topic_score_codex":0.00007211825,"about_ca_topic_score_gemma":0.00005391915,"teacher_disagreement_score":0.5531169,"about_ca_system_score_codex":0.0002085764,"about_ca_system_score_gemma":0.0010581277,"threshold_uncertainty_score":0.9997351},"labels":[],"label_agreement":null},{"id":"W2167903555","doi":"10.1016/j.clgc.2013.11.017","title":"Extensive Necrotizing Fasciitis Associated With Sunitinib Therapy","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Foothills Medical Centre; University of Calgary; Island Health; University of Toronto","funders":"","keywords":"Sunitinib; Medicine; Tyrosine-kinase inhibitor; Renal cell carcinoma; Angiogenesis; Fasciitis; GiST; Toxicity; Internal medicine; Vascular endothelial growth factor; Oncology; Cancer research; Stromal cell; Cancer; VEGF receptors; Surgery","score_opus":0.07610663729308634,"score_gpt":0.36627617883622204,"score_spread":0.2901695415431357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167903555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881688,0.0015837253,0.000047050984,0.003951496,0.00046359052,0.0011739326,0.000018000517,0.00025001747,0.004343425],"genre_scores_gemma":[0.9811123,0.0030328163,0.0007139449,0.009366159,0.0010863189,0.0002043972,0.000036730904,0.000113987,0.0043333187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974597,0.00021644271,0.00071131263,0.0006130592,0.0004184268,0.00058103865],"domain_scores_gemma":[0.9973045,0.0007187596,0.00030178452,0.0005707661,0.0006651293,0.00043909057],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034681632,0.00034237315,0.00075797533,0.000085881475,0.00015507346,0.000045681885,0.00015796306,0.00040457989,0.0037997353],"category_scores_gemma":[0.00040647294,0.00025969002,0.00029989795,0.00040974162,0.00038993874,0.00017300752,0.000059443297,0.0010001246,0.0002292795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034530354,0.004082446,0.45813778,0.00007951954,0.0036292556,0.0027534575,0.000964035,0.00009267995,0.023804836,0.000020679197,0.09934347,0.4036388],"study_design_scores_gemma":[0.01391399,0.003298597,0.9525674,0.00075369654,0.00020295235,0.00023025971,0.0002942822,0.00030226648,0.0068754964,0.00026308044,0.020552525,0.0007454405],"about_ca_topic_score_codex":0.00024893918,"about_ca_topic_score_gemma":0.000032702043,"teacher_disagreement_score":0.49442962,"about_ca_system_score_codex":0.00017348593,"about_ca_system_score_gemma":0.000343128,"threshold_uncertainty_score":0.9999855},"labels":[],"label_agreement":null},{"id":"W2196142402","doi":"10.1016/j.clgc.2015.10.005","title":"Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Hazard ratio; Cisplatin; Chemotherapy; Oncology; Internal medicine; Regimen; Proportional hazards model; Chemotherapy regimen; Perioperative; Confidence interval; Retrospective cohort study; Surgery","score_opus":0.09136507234050824,"score_gpt":0.3933785982598038,"score_spread":0.3020135259192956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2196142402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98714334,0.0010285603,0.0009831135,0.0019443973,0.0010134458,0.0041716634,0.0003015159,0.00016832026,0.003245644],"genre_scores_gemma":[0.982722,0.00025981772,0.0065448633,0.0017858675,0.0023090665,0.0017686625,0.0002240863,0.00020128003,0.0041843583],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99646014,0.0001174984,0.0009940286,0.0010885892,0.0005591967,0.00078053505],"domain_scores_gemma":[0.9967642,0.00057327206,0.0003527766,0.00076964346,0.0007046457,0.000835493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003458149,0.0006962333,0.0012430425,0.000114402355,0.00024871668,0.00004674284,0.00025260285,0.00034769689,0.00040078745],"category_scores_gemma":[0.00021702732,0.0005209302,0.00044234126,0.00037175874,0.00031867906,0.00016104389,0.00004541176,0.00048207736,0.000051282015],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3947639,0.004647872,0.41763473,0.00063266675,0.0023159457,0.0008754712,0.0018566471,0.0049043223,0.0013112744,0.000019156074,0.009416546,0.16162148],"study_design_scores_gemma":[0.5362134,0.1455278,0.15191555,0.0016602491,0.0046703927,0.00013607541,0.0007757619,0.024614494,0.031212268,0.00006772013,0.099824175,0.0033820958],"about_ca_topic_score_codex":0.0002541286,"about_ca_topic_score_gemma":0.00025304372,"teacher_disagreement_score":0.26571918,"about_ca_system_score_codex":0.000524632,"about_ca_system_score_gemma":0.0020308092,"threshold_uncertainty_score":0.9997242},"labels":[],"label_agreement":null},{"id":"W2198033618","doi":"10.1016/j.clgc.2015.12.023","title":"Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute","keywords":"Prostate cancer; Medicine; Androgen receptor; Prostate; Cancer; Cancer research; Androgen deprivation therapy; Oncology; Androgen; Adenocarcinoma; Internal medicine; Hormone","score_opus":0.12458159150662867,"score_gpt":0.45912500398680195,"score_spread":0.3345434124801733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2198033618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851264,0.0071963714,0.0000055303344,0.0046209395,0.0007909575,0.0016234394,0.0003698856,0.00009949332,0.0001669974],"genre_scores_gemma":[0.99394673,0.0014167671,0.00049845944,0.0006131251,0.0008187268,0.0005507743,0.000052509233,0.000084269814,0.0020186075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99602735,0.00068473927,0.0010389221,0.00087436364,0.00060037454,0.00077427336],"domain_scores_gemma":[0.99694294,0.00034575997,0.00020036023,0.0005883366,0.00065345713,0.0012691317],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000821309,0.0003678103,0.0008788811,0.0003580384,0.00007275043,0.000025852556,0.0002393442,0.0001360747,0.0001266938],"category_scores_gemma":[0.00067192176,0.00030519592,0.00021003361,0.0007618983,0.0003599082,0.00019558304,0.00027760735,0.00065159786,0.000016674896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38152105,0.0023301798,0.41269648,0.0009479265,0.00038474944,0.112890124,0.016168172,0.000795414,0.020462181,0.000007662256,0.004961106,0.04683497],"study_design_scores_gemma":[0.18412295,0.15134145,0.45063522,0.0056530354,0.0020128707,0.012493389,0.038077507,0.0059702075,0.07019989,0.000106626816,0.075184084,0.004202752],"about_ca_topic_score_codex":0.0016877502,"about_ca_topic_score_gemma":0.00036499006,"teacher_disagreement_score":0.19739808,"about_ca_system_score_codex":0.0006718378,"about_ca_system_score_gemma":0.002551776,"threshold_uncertainty_score":0.99994004},"labels":[],"label_agreement":null},{"id":"W2212423693","doi":"10.1016/j.clgc.2015.12.026","title":"Desmoplastic Small Round Cell Tumor Presenting as an Isolated Testicular Mass in an Adult With Multiple Previous Malignancies","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Desmoplastic small-round-cell tumor; Testicular cancer; Pathology; Oncology; Internal medicine; Cancer research; Cancer; Immunohistochemistry","score_opus":0.07605188571086151,"score_gpt":0.3530543778406104,"score_spread":0.27700249212974887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2212423693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595773,0.0022399472,0.00004860584,0.00019513133,0.00026727878,0.00088338566,0.000014924795,0.000103455364,0.00028955017],"genre_scores_gemma":[0.9938092,0.00016548859,0.0041217096,0.000670681,0.0004885976,0.00035674075,0.000047997844,0.000069507754,0.00027007973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975258,0.000247599,0.00068391487,0.0007110236,0.00031322465,0.0005184417],"domain_scores_gemma":[0.9976557,0.00047315448,0.00021300075,0.0005609361,0.00038309125,0.0007141326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029176916,0.0003264427,0.0006151759,0.00008868599,0.00007154808,0.000054743356,0.0001763628,0.00015055771,0.00004979024],"category_scores_gemma":[0.0004929041,0.00024502006,0.00011565619,0.0002518325,0.00013996882,0.0001916203,0.00006997004,0.0003757297,0.000052641226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014579841,0.0037857126,0.9854171,0.000084101055,0.000091579976,0.0067807077,0.00022047869,0.0005308831,0.0002866363,0.0000027697538,0.00010318422,0.0012388078],"study_design_scores_gemma":[0.012827203,0.007592835,0.96173924,0.00052226544,0.00068025483,0.0003347684,0.0007042603,0.013292864,0.001214122,0.00009101298,0.00047622508,0.00052497594],"about_ca_topic_score_codex":0.0006441812,"about_ca_topic_score_gemma":0.000551068,"teacher_disagreement_score":0.023677941,"about_ca_system_score_codex":0.0001830346,"about_ca_system_score_gemma":0.0005164979,"threshold_uncertainty_score":0.99916285},"labels":[],"label_agreement":null},{"id":"W2214412695","doi":"10.1016/j.clgc.2015.12.007","title":"Hematologic Parameters to Predict Small Renal Mass Biopsy Pathology","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Renal mass; Renal pathology; Pathology; Biopsy; Hematologic Neoplasms; Hematologic malignancy; Internal medicine; Kidney; Cancer; Nephrectomy","score_opus":0.1399516400823857,"score_gpt":0.3901498421154825,"score_spread":0.2501982020330968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2214412695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897561,0.0010972252,0.00036787524,0.0032135274,0.0020809886,0.000870331,0.0000501805,0.0002527613,0.0023110153],"genre_scores_gemma":[0.9421985,0.00021209438,0.047441144,0.006520994,0.0016647493,0.00072318653,0.000042883035,0.00008547461,0.001110971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695647,0.00034506197,0.0009493678,0.0007838725,0.00035549162,0.00060975226],"domain_scores_gemma":[0.99713176,0.00027176715,0.00019793598,0.0007583551,0.00028562165,0.0013545835],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009974755,0.00031275302,0.0007236833,0.00015273802,0.000065299384,0.000020389743,0.0003303676,0.00040775447,0.0001855335],"category_scores_gemma":[0.0011875749,0.0002633056,0.00036713973,0.0003197398,0.00037842142,0.00005374441,0.00023715691,0.00045715927,0.00041384806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051742857,0.00059872057,0.9171392,0.00013481102,0.0003751771,0.008302183,0.00010035064,0.000051186653,0.001335148,0.000016764121,0.053113066,0.01365914],"study_design_scores_gemma":[0.016897785,0.009062487,0.8639515,0.00097472104,0.0019840314,0.0029473442,0.0006882711,0.0008753888,0.0075149424,0.002388512,0.09064489,0.0020701168],"about_ca_topic_score_codex":0.000013031382,"about_ca_topic_score_gemma":0.0000034857126,"teacher_disagreement_score":0.053187653,"about_ca_system_score_codex":0.00019862448,"about_ca_system_score_gemma":0.00057650334,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W2216703724","doi":"10.1016/j.clgc.2015.10.011","title":"Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal","funders":"","keywords":"Medicine; Ethnic group; Charlson comorbidity index; Socioeconomic status; Comorbidity; Subgroup analysis; Epidemiology; Internal medicine; Surveillance, Epidemiology, and End Results; Population; African american; Cancer; Demography; Gerontology; Cancer registry; Confidence interval","score_opus":0.19242303712189826,"score_gpt":0.4041198364005924,"score_spread":0.21169679927869414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216703724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98304224,0.00498194,0.000023053475,0.0026287723,0.0002489869,0.00058634364,0.000010985262,0.00001600535,0.008461678],"genre_scores_gemma":[0.99305844,0.0023998509,0.002035756,0.0006845202,0.00033888425,0.00021301898,0.000014170043,0.000016559907,0.0012387707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831134,0.0002558867,0.00057970727,0.000295012,0.00031955141,0.00023852476],"domain_scores_gemma":[0.9990346,0.00021070559,0.00011650489,0.0003846838,0.00011068598,0.00014286427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006941571,0.00016713154,0.00041562004,0.00007031278,0.000033888602,0.000011430881,0.00018795233,0.00009654302,0.00004016573],"category_scores_gemma":[0.000029203706,0.00010318774,0.00022235585,0.00024214403,0.0002874614,0.00004191738,0.00009294937,0.0003172051,0.000013257922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014126572,0.0013364139,0.9787948,0.00023248604,0.00047978095,0.0014689751,0.000630024,0.00012025201,0.000038984814,0.00030197276,0.00567831,0.009505309],"study_design_scores_gemma":[0.0042267228,0.0019267653,0.9831063,0.00030828558,0.0004012259,0.000037061945,0.0018642218,0.00008835087,0.00031966905,0.0006120876,0.006933963,0.00017534042],"about_ca_topic_score_codex":0.00017698103,"about_ca_topic_score_gemma":0.00006889312,"teacher_disagreement_score":0.010016235,"about_ca_system_score_codex":0.0000978124,"about_ca_system_score_gemma":0.00016644967,"threshold_uncertainty_score":0.4207874},"labels":[],"label_agreement":null},{"id":"W2397377428","doi":"10.1016/j.clgc.2016.05.003","title":"Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis","year":2016,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Carboplatin; Gemcitabine; Internal medicine; Docetaxel; Oncology; Taxane; Meta-analysis; Paclitaxel; Chemotherapy; Cisplatin; Cancer; Urology; Breast cancer","score_opus":0.17177038917727194,"score_gpt":0.4438781869271826,"score_spread":0.2721077977499107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397377428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002518247,0.99102557,0.000016938335,0.0007451625,0.00006203452,0.0069045573,0.0008984261,0.000010500689,0.00008499875],"genre_scores_gemma":[0.0045507653,0.9925375,0.00015629262,0.0005535299,0.00016230857,0.0012763212,0.000034633773,0.000069129484,0.00065951014],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99348354,0.001321019,0.0036423367,0.00073703896,0.00048705764,0.00032899712],"domain_scores_gemma":[0.9935032,0.0032272974,0.0019194856,0.0010302515,0.00015842219,0.00016133887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021278744,0.0006777315,0.012997672,0.0002548932,0.000054512788,0.000010506513,0.0003134234,0.00022469419,0.0004722992],"category_scores_gemma":[0.000725271,0.00028910625,0.0021190392,0.00092030474,0.00027167614,0.00004632898,0.0001545301,0.00048289206,0.0000040563705],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006513204,0.00041505782,0.00018731847,0.8797908,0.10153593,0.00017922126,0.00016222506,0.000002130741,1.2282973e-7,0.0000035334829,0.000093343006,0.016979024],"study_design_scores_gemma":[0.0038694867,0.00094474043,0.00040467622,0.052723214,0.9342286,0.00014532435,0.000025901618,0.0000073102833,5.238576e-7,0.0000049764863,0.007330911,0.00031433286],"about_ca_topic_score_codex":0.00025020342,"about_ca_topic_score_gemma":0.0001844651,"teacher_disagreement_score":0.8326927,"about_ca_system_score_codex":0.000108671185,"about_ca_system_score_gemma":0.00066766574,"threshold_uncertainty_score":0.99995613},"labels":[],"label_agreement":null},{"id":"W2401517553","doi":"10.1016/j.clgc.2016.05.019","title":"Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Papillary renal cell carcinomas; Leiomyomatosis; Fumarase; Germline mutation; Cancer research; Tyrosine kinase; Renal cell carcinoma; Metastasis; Pathogenesis; Tyrosine-kinase inhibitor; Germline; Pathology; Internal medicine; Carcinoma; Oncology; Cancer; Mutation; Receptor; Gene; Biology; Genetics","score_opus":0.049069436257547165,"score_gpt":0.33576451621007697,"score_spread":0.2866950799525298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401517553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939998,0.0014666916,0.000038848666,0.002906131,0.0005045535,0.0006551365,0.000059483307,0.000030796935,0.00033856975],"genre_scores_gemma":[0.9971583,0.00031822533,0.00052891375,0.00041337594,0.00038609226,0.00007432485,0.000029958137,0.00004419332,0.0010466233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762917,0.00038342527,0.0008187236,0.0005293044,0.00032183775,0.00031757227],"domain_scores_gemma":[0.9984631,0.00028040673,0.00017851534,0.000506805,0.00023844371,0.00033272908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005227985,0.00023137944,0.00052181416,0.00020760487,0.000050386705,0.000004327498,0.000072801944,0.00017957597,0.00040845084],"category_scores_gemma":[0.00027063102,0.00016818084,0.00021250475,0.0004307649,0.00012445716,0.00006191594,0.00014179196,0.00021007565,0.00007963231],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022463169,0.0007350491,0.041915666,0.0000744576,0.000027741278,0.0009960834,0.000072620984,0.000028106579,0.9250375,0.0000027725814,0.002481608,0.006165208],"study_design_scores_gemma":[0.0044443654,0.009373518,0.4507689,0.00046162854,0.000092432325,0.00004076281,0.000025841078,0.000010615669,0.5293796,0.00002060577,0.0051543615,0.0002273564],"about_ca_topic_score_codex":0.000074088864,"about_ca_topic_score_gemma":0.000013066731,"teacher_disagreement_score":0.40885323,"about_ca_system_score_codex":0.00041298103,"about_ca_system_score_gemma":0.0002824161,"threshold_uncertainty_score":0.68582153},"labels":[],"label_agreement":null},{"id":"W2404852579","doi":"10.1016/j.clgc.2016.05.009","title":"Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Bone metastasis; Docetaxel; Radiology; Metastasis; Lesion; Nuclear medicine; Proportional hazards model; Cancer; Confidence interval; Internal medicine; Surgery","score_opus":0.14115413462752094,"score_gpt":0.4419744133769954,"score_spread":0.3008202787494745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404852579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98543704,0.0065868595,0.00020316926,0.0057657184,0.00026171675,0.0012402674,0.00037595202,0.000030269943,0.000099040946],"genre_scores_gemma":[0.9897851,0.0052416027,0.0031308495,0.00025171437,0.00017627484,0.0004694058,0.000028620243,0.00003213539,0.0008843404],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973972,0.00022656588,0.0010198208,0.0005427293,0.00041127956,0.00040241855],"domain_scores_gemma":[0.9983622,0.00038198355,0.00022129253,0.000308505,0.00035900698,0.00036703498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070487044,0.0002446873,0.0008168074,0.00041126268,0.000058571448,0.000020181358,0.00007687217,0.00008629858,0.00015822588],"category_scores_gemma":[0.00014566004,0.0001532283,0.00018202647,0.0007456885,0.00035085666,0.00016488247,0.00008358477,0.00023017073,0.0000048767242],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011305489,0.0016653867,0.29042247,0.000683118,0.0009298175,0.00085449044,0.0007908939,0.000067697125,0.3172906,0.000078854544,0.0029208204,0.37299034],"study_design_scores_gemma":[0.011941883,0.0035013608,0.9368254,0.002439271,0.00057378213,0.00003487568,0.0005402251,0.0002120858,0.040148098,0.0002558879,0.0030638939,0.00046325417],"about_ca_topic_score_codex":0.00063858996,"about_ca_topic_score_gemma":0.001202917,"teacher_disagreement_score":0.6464029,"about_ca_system_score_codex":0.00019206046,"about_ca_system_score_gemma":0.000560952,"threshold_uncertainty_score":0.6248469},"labels":[],"label_agreement":null},{"id":"W2469882367","doi":"10.1016/j.clgc.2016.05.001","title":"Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Taxane; Carboplatin; Salvage therapy; Hazard ratio; Internal medicine; Oncology; Cisplatin; Chemotherapy; Confidence interval; Gemcitabine; Surgery; Urology; Cancer; Breast cancer","score_opus":0.07187810949543827,"score_gpt":0.4065238027753753,"score_spread":0.33464569327993704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469882367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99458987,0.0007206689,0.00007340581,0.0002074061,0.00078183564,0.0025636714,0.0007151786,0.00005933748,0.00028863712],"genre_scores_gemma":[0.9960834,0.00082652614,0.00030855316,0.0002470091,0.0008993703,0.00072386937,0.00003225266,0.00008600512,0.0007930402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997768,0.00012522242,0.0008076892,0.00058967766,0.00028739526,0.00042205222],"domain_scores_gemma":[0.9978212,0.0007416833,0.00035286794,0.0005682555,0.00024381968,0.0002721523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014357868,0.0003793332,0.000836659,0.00009688538,0.000081961596,0.0000069917496,0.00013346909,0.00018691833,0.00021665815],"category_scores_gemma":[0.00013351828,0.0002075723,0.0008523785,0.00011003832,0.00010998957,0.000064563,0.000017485072,0.00010381099,0.000020023443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019401124,0.001881745,0.6077642,0.00005662228,0.0003919299,0.000014918697,0.000066454195,0.000024072431,0.005383405,9.054181e-7,0.00036606786,0.36464855],"study_design_scores_gemma":[0.05938547,0.040656075,0.8852199,0.0007632095,0.00023584494,0.0000041453927,0.000008152303,0.000030010004,0.012373757,0.000017002229,0.001018666,0.00028777064],"about_ca_topic_score_codex":0.00011573788,"about_ca_topic_score_gemma":0.000008852787,"teacher_disagreement_score":0.36436078,"about_ca_system_score_codex":0.0008068689,"about_ca_system_score_gemma":0.00094200735,"threshold_uncertainty_score":0.8464553},"labels":[],"label_agreement":null},{"id":"W2479114272","doi":"10.1016/j.clgc.2016.07.023","title":"A Statistical Approach to Determine the Optimal Duration of Post-Treatment Follow-Up: Application to Metastatic Nonseminomatous Germ Cell Tumors","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Agence Nationale de la Recherche","keywords":"Medicine; Confidence interval; Testicular cancer; Germ cell tumors; Statistical significance; Surgery; Cure rate; Internal medicine; Cancer; Oncology; Chemotherapy","score_opus":0.0460010595576425,"score_gpt":0.36150168405096955,"score_spread":0.31550062449332705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2479114272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772148,0.00032901866,0.018626517,0.0011860405,0.00014157117,0.001852713,0.00040806137,0.00003733001,0.00020395387],"genre_scores_gemma":[0.9841941,0.000065747736,0.013023681,0.00049816683,0.00022045974,0.0010199236,0.000071190036,0.000034188088,0.0008725653],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981252,0.00011483176,0.0007103138,0.00048237623,0.00028554222,0.0002817305],"domain_scores_gemma":[0.9979949,0.0005756054,0.00020410662,0.00055704947,0.00018605038,0.00048227617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016556242,0.00023103839,0.0004716462,0.000061020623,0.0000695498,0.000011431671,0.00012878068,0.00005379954,0.00007030287],"category_scores_gemma":[0.00030578134,0.00011973616,0.00022544498,0.00016084798,0.00009903092,0.00003923996,0.000071290946,0.0000639035,0.00011877879],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008987483,0.01128403,0.2199263,0.000335015,0.0011271897,0.00055834436,0.00066652446,0.00036942115,0.02021276,0.00014027985,0.0030036469,0.733389],"study_design_scores_gemma":[0.0111251455,0.011587443,0.95799106,0.00023391804,0.0027994276,0.00019489112,0.00026703184,0.0017613788,0.0077240425,0.0000637259,0.0056956047,0.0005563389],"about_ca_topic_score_codex":0.00013023717,"about_ca_topic_score_gemma":0.00001477395,"teacher_disagreement_score":0.73806477,"about_ca_system_score_codex":0.00017570623,"about_ca_system_score_gemma":0.00033381436,"threshold_uncertainty_score":0.4882699},"labels":[],"label_agreement":null},{"id":"W2481386596","doi":"10.1016/j.clgc.2016.06.008","title":"Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Metformin; Propensity score matching; Hazard ratio; Internal medicine; Confidence interval; Proportional hazards model; Retrospective cohort study; Diabetes mellitus; Cancer; Kidney cancer; Nephrectomy; Renal cell carcinoma; Population; Kidney disease; Oncology; Surgery; Kidney; Endocrinology","score_opus":0.04497834636614622,"score_gpt":0.3087816892335585,"score_spread":0.26380334286741225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2481386596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833946,0.01550263,0.000021471034,0.0001072012,0.00029486726,0.0003607302,0.00029158528,0.000011459322,0.000015447862],"genre_scores_gemma":[0.9697062,0.026893811,0.0001443485,0.0019627612,0.00033652716,0.00021765815,0.000048959973,0.000035787023,0.0006539633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980064,0.00015273484,0.00048625798,0.0007113241,0.00021243308,0.00043085066],"domain_scores_gemma":[0.9987165,0.000066751345,0.00019152803,0.0005022765,0.00019869368,0.00032430538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028717867,0.00027140556,0.0006460866,0.00009933973,0.000056809244,0.000031425454,0.00019669865,0.000201756,0.00013734023],"category_scores_gemma":[0.00027716463,0.00015957121,0.00019557083,0.00026695823,0.00023947573,0.000032122993,0.00018141614,0.00013632904,0.00000288108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036730146,0.00020405275,0.9263444,0.0000196667,0.0007685247,0.0000029139583,0.000009197864,0.000007693803,0.00028083564,9.112723e-7,0.0009827206,0.0710118],"study_design_scores_gemma":[0.00293399,0.00035495588,0.9559142,0.000064332206,0.00042509998,7.428802e-8,0.000002460933,0.000005570863,0.001486217,0.0000070878928,0.03848234,0.0003236696],"about_ca_topic_score_codex":0.00011559885,"about_ca_topic_score_gemma":0.00053769146,"teacher_disagreement_score":0.07068813,"about_ca_system_score_codex":0.000041143074,"about_ca_system_score_gemma":0.0002370823,"threshold_uncertainty_score":0.6507125},"labels":[],"label_agreement":null},{"id":"W2488303827","doi":"10.1016/j.clgc.2016.07.018","title":"A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer","year":2016,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Public Health; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Taxane; myalgia; Prostate cancer; Incidence (geometry); Internal medicine; Cabazitaxel; Cancer; Clinical trial; Oncology; Chemotherapy; Observational study; Breast cancer; Androgen deprivation therapy","score_opus":0.0528981432978041,"score_gpt":0.4295533392958634,"score_spread":0.3766551959980593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488303827","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014478608,0.9632827,0.000012442066,0.00041901495,0.0008864976,0.01900285,0.001895489,0.000018992976,0.0000034023287],"genre_scores_gemma":[0.0004098007,0.986256,0.000094070085,0.0008369484,0.00025067432,0.011171384,0.00009625441,0.0001000064,0.0007848502],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9953942,0.0009673436,0.0022204483,0.00070756976,0.00027316035,0.0004372798],"domain_scores_gemma":[0.9917677,0.004593951,0.0026256498,0.0005748802,0.00026324173,0.00017459766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001872828,0.00057436613,0.004418647,0.000117878786,0.00008447766,0.000008949368,0.00032209427,0.00036259816,0.00008571693],"category_scores_gemma":[0.0015135229,0.00030197957,0.001240811,0.0003131311,0.0002026094,0.000051233823,0.00007320615,0.00042779912,0.0000012240296],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044684223,0.00033382737,0.021191537,0.7518571,0.0015508794,0.000008627671,0.000027246131,2.3038884e-7,2.9365742e-7,1.7623664e-7,0.0017239406,0.22285928],"study_design_scores_gemma":[0.0058196117,0.002303604,0.0030035574,0.90201426,0.012621767,0.000008484024,0.0000044968406,0.0000111325635,0.0000036725548,0.0000075676594,0.07379684,0.00040503684],"about_ca_topic_score_codex":0.00010889815,"about_ca_topic_score_gemma":0.000052661362,"teacher_disagreement_score":0.22245423,"about_ca_system_score_codex":0.0005602708,"about_ca_system_score_gemma":0.0012410145,"threshold_uncertainty_score":0.99994326},"labels":[],"label_agreement":null},{"id":"W2500670690","doi":"10.1016/j.clgc.2016.07.022","title":"A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Germ cell tumors; Etoposide; Oncology; Concordance; Internal medicine; Proportional hazards model; Cisplatin; Chemotherapy","score_opus":0.031256571530880475,"score_gpt":0.3418429633400645,"score_spread":0.310586391809184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2500670690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955468,0.0030325672,0.000027538139,0.00036810295,0.00020540724,0.00047056095,0.00012228116,0.000049082173,0.00017766168],"genre_scores_gemma":[0.9957572,0.002931926,0.00024809438,0.00009338745,0.00022933769,0.00009342677,0.000015288142,0.000026129297,0.0006051635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862343,0.00010971483,0.0005513558,0.00035807272,0.00015869382,0.00019870368],"domain_scores_gemma":[0.99829215,0.0006084306,0.00036942368,0.00030520433,0.00011812868,0.0003066862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015205491,0.00015654208,0.00036962447,0.00005586663,0.000037458787,0.0000059297677,0.00006741954,0.0001009074,0.00008514853],"category_scores_gemma":[0.0006171258,0.000097510645,0.00015601024,0.0000939054,0.00024709763,0.000045628738,0.00005915994,0.000114979215,0.000032359352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046338284,0.00069872226,0.893607,0.00010560721,0.00009304213,0.00018333351,0.000023052955,1.6241863e-7,0.0010303641,0.0000020340212,0.00041790993,0.10337538],"study_design_scores_gemma":[0.0030584617,0.0010573309,0.99323094,0.00041458628,0.0005274591,0.00003451616,0.000026153612,0.000055877612,0.0010190674,0.000059601105,0.00039957635,0.00011643658],"about_ca_topic_score_codex":0.000033149903,"about_ca_topic_score_gemma":0.0000040079913,"teacher_disagreement_score":0.10325895,"about_ca_system_score_codex":0.000049002214,"about_ca_system_score_gemma":0.00023844164,"threshold_uncertainty_score":0.39763686},"labels":[],"label_agreement":null},{"id":"W2522935852","doi":"10.1016/j.clgc.2016.08.012","title":"Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"American Society for Radiation Oncology; Prostate Cancer Foundation","keywords":"Prostatectomy; Medicine; Prostate cancer; Radiation therapy; Cost effectiveness; Oncology; Adjuvant therapy; Internal medicine; Cancer; Intensive care medicine","score_opus":0.1608032523094253,"score_gpt":0.4728689907432387,"score_spread":0.31206573843381336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522935852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747157,0.0036077271,0.00027561994,0.002725818,0.0017930174,0.014661611,0.0021024244,0.000024772218,0.000093325565],"genre_scores_gemma":[0.9452398,0.006784729,0.0015820387,0.0012456771,0.0008194366,0.042874757,0.00004535138,0.0000957139,0.0013125228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975464,0.00016884641,0.00083381264,0.0006850153,0.00028638318,0.00047954684],"domain_scores_gemma":[0.9963494,0.0012240832,0.0005381023,0.0010442258,0.0005578688,0.00028635422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009268586,0.00031269953,0.0007524147,0.0000665546,0.00041636988,0.00007885239,0.00038586545,0.00018956924,0.00007436558],"category_scores_gemma":[0.00062652264,0.00020195273,0.00060062745,0.00011060794,0.00023477868,0.0001391101,0.00016614376,0.00018956958,0.0000058215564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015054093,0.00050515577,0.6766243,0.0001205591,0.00054680737,0.0000066396783,0.00029725392,0.000051429088,0.0009797068,0.000007235149,0.00417216,0.30163464],"study_design_scores_gemma":[0.013973826,0.0016711287,0.8278657,0.00061571744,0.0003002835,0.000001380225,0.000016322192,0.00003134993,0.008714296,0.0002765148,0.14632033,0.0002131489],"about_ca_topic_score_codex":0.00026242514,"about_ca_topic_score_gemma":0.00012514231,"teacher_disagreement_score":0.3014215,"about_ca_system_score_codex":0.00046976117,"about_ca_system_score_gemma":0.00095704774,"threshold_uncertainty_score":0.8235394},"labels":[],"label_agreement":null},{"id":"W2562774782","doi":"10.1016/j.clgc.2016.12.014","title":"Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Metastatic Urothelial Carcinoma; Chemotherapy; Univariate analysis; Performance status; Multivariate analysis; Oncology; Proportional hazards model; Gastroenterology; Toxicity; Adverse effect; Cancer; Urothelial carcinoma; Bladder cancer","score_opus":0.054823167612941544,"score_gpt":0.3807051565461041,"score_spread":0.32588198893316256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562774782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434,0.0025572113,0.000032632382,0.0008747044,0.0003183611,0.000905668,0.00057473924,0.00003275013,0.00036396057],"genre_scores_gemma":[0.9896762,0.0007719822,0.00031080897,0.0012713661,0.0003996857,0.00018752391,0.0000502646,0.00006385789,0.007268325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997011,0.00018309205,0.0012175741,0.0007106165,0.00043768177,0.00044002253],"domain_scores_gemma":[0.99785197,0.00044079483,0.00038977183,0.00061118376,0.0004661232,0.00024015909],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003260626,0.00040068722,0.0016914849,0.00037274265,0.00004474126,0.0000066749376,0.00017656389,0.00013243864,0.008430994],"category_scores_gemma":[0.00010187106,0.00023174516,0.0004753022,0.0008204513,0.0003328353,0.00012206059,0.00006755413,0.00022931841,0.000025288959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009786718,0.00320181,0.94552094,0.00021946266,0.012289775,0.0001356247,0.00034707677,0.000021093736,0.0005326566,0.000002763303,0.0014603836,0.026481675],"study_design_scores_gemma":[0.031984627,0.0041821077,0.9524791,0.00023803143,0.005621738,0.000002870591,0.000087603534,0.000036783567,0.0030430749,0.000040809628,0.0019493271,0.0003339001],"about_ca_topic_score_codex":0.00006422687,"about_ca_topic_score_gemma":0.0005912899,"teacher_disagreement_score":0.026147775,"about_ca_system_score_codex":0.0002222136,"about_ca_system_score_gemma":0.00041677183,"threshold_uncertainty_score":0.99247545},"labels":[],"label_agreement":null},{"id":"W2565985412","doi":"10.1016/j.clgc.2016.12.025","title":"Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Institute for Clinical Evaluative Sciences","keywords":"Medicine; Gemcitabine; Bladder cancer; Carboplatin; Regimen; Internal medicine; Oncology; Vinblastine; Population; Chemotherapy; Cancer registry; Cancer; Cisplatin","score_opus":0.08039182811776317,"score_gpt":0.4279513018811414,"score_spread":0.3475594737633782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565985412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98195,0.0028230473,0.000030447107,0.013285697,0.00039688495,0.0012087001,0.00015855841,0.000023764767,0.00012292276],"genre_scores_gemma":[0.9689504,0.02098934,0.0003828093,0.0041440357,0.0012617721,0.0012344815,0.000016713919,0.00003334478,0.002987117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868345,0.00008856455,0.00041705728,0.00038946318,0.00015457216,0.00026686979],"domain_scores_gemma":[0.9990758,0.00041664444,0.00010430451,0.00024123277,0.000058879603,0.00010317874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015013733,0.00021615179,0.00044821153,0.00004363912,0.00007629507,0.000012211261,0.000076857184,0.0001202622,0.00014455638],"category_scores_gemma":[0.000029214048,0.00010170741,0.0002110772,0.000074465715,0.00009063217,0.000068916896,0.000015740008,0.000079007645,0.000004198035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010845722,0.0004081967,0.7630975,0.000013169032,0.00035789577,0.000013844676,0.00018412757,0.0000020303148,0.00011707784,0.000014709972,0.0008903217,0.23381655],"study_design_scores_gemma":[0.010766165,0.0015620592,0.97588116,0.00007732974,0.0002376395,0.0000032465966,0.00004481542,0.000038007634,0.00023512055,0.00030251988,0.0107040405,0.00014790618],"about_ca_topic_score_codex":0.0011208488,"about_ca_topic_score_gemma":0.0004920364,"teacher_disagreement_score":0.23366866,"about_ca_system_score_codex":0.0002643499,"about_ca_system_score_gemma":0.00016007612,"threshold_uncertainty_score":0.41475078},"labels":[],"label_agreement":null},{"id":"W2573089847","doi":"10.1016/j.clgc.2017.01.005","title":"Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of British Columbia; BC Cancer Agency; Dalhousie University","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Oncology; Toxicity; VEGF receptors; Internal medicine; Targeted therapy; Second-line therapy; Cancer; Chemotherapy","score_opus":0.11363597456475641,"score_gpt":0.4247044064405806,"score_spread":0.3110684318758242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573089847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98919773,0.006861031,0.000014498227,0.00076493545,0.0008815595,0.0018088188,0.00006306502,0.000026101892,0.0003822391],"genre_scores_gemma":[0.9955446,0.00046169566,0.0021778543,0.00010696675,0.00041735935,0.00039816592,0.0000311756,0.00005375511,0.00080843223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773514,0.00018736292,0.0007805831,0.00055390876,0.0003115043,0.00043151996],"domain_scores_gemma":[0.99735445,0.00081236725,0.000660364,0.00084381574,0.00013017231,0.00019884498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060458423,0.00033993088,0.0011029075,0.00010530275,0.00014830286,0.000030877298,0.00030021407,0.00014759916,0.00014198013],"category_scores_gemma":[0.00023589031,0.0002330613,0.000551932,0.00007133629,0.00026935065,0.0001475517,0.00011495439,0.00031974557,0.0000031307854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015916541,0.001992561,0.8867404,0.00035858806,0.00046599988,0.00029614833,0.00042839095,0.000010220948,0.032118827,0.000004572861,0.0003480892,0.061319645],"study_design_scores_gemma":[0.019548142,0.0066205617,0.86002743,0.00016378827,0.00020106886,0.000003277634,0.00010560859,0.00010300202,0.11251773,0.000052642623,0.00043889383,0.00021784533],"about_ca_topic_score_codex":0.00006876545,"about_ca_topic_score_gemma":0.00017862063,"teacher_disagreement_score":0.0803989,"about_ca_system_score_codex":0.00012879069,"about_ca_system_score_gemma":0.00025499123,"threshold_uncertainty_score":0.9503964},"labels":[],"label_agreement":null},{"id":"W2585144179","doi":"10.1016/j.clgc.2017.01.016","title":"Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Saskatchewan Cancer Agency; Pfizer","keywords":"Medicine; Sunitinib; Dosing; Discontinuation; Renal cell carcinoma; Regimen; Internal medicine; Oncology; Adverse effect; Population; Renal function; Urology","score_opus":0.08856902812750578,"score_gpt":0.4031532497966694,"score_spread":0.3145842216691636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585144179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525124,0.00041062164,0.00001778019,0.00081192685,0.00034930464,0.00264499,0.00015849939,0.000021797192,0.0003338441],"genre_scores_gemma":[0.99634105,0.000012629544,0.0011722018,0.00016414793,0.0003675677,0.00036402058,0.00005294696,0.000042802512,0.0014826424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788046,0.00017956713,0.00082509214,0.00050183554,0.00032891167,0.00028414032],"domain_scores_gemma":[0.9972524,0.0007943744,0.0006205077,0.00081944955,0.00024638238,0.00026688215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000586693,0.00026284,0.0008781948,0.00008689148,0.00026243215,0.00002959754,0.00018386803,0.000073213756,0.000037681748],"category_scores_gemma":[0.00041316226,0.00020263436,0.00031266152,0.00004242988,0.00015494057,0.00007679876,0.00010264342,0.00020670852,0.0000027256865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019449792,0.0018964766,0.99065554,0.00021635802,0.0001691375,0.00021376919,0.0001016105,0.000009245586,0.00013149172,0.0000060423104,0.00053433795,0.0041210093],"study_design_scores_gemma":[0.0125877755,0.0032640118,0.98123884,0.00006530042,0.0011152719,0.0000048127845,0.00014274445,0.00010868142,0.0011107629,0.00004127459,0.00013518006,0.00018532749],"about_ca_topic_score_codex":0.0019801657,"about_ca_topic_score_gemma":0.00062645826,"teacher_disagreement_score":0.010642796,"about_ca_system_score_codex":0.00015729299,"about_ca_system_score_gemma":0.0004493188,"threshold_uncertainty_score":0.8263189},"labels":[],"label_agreement":null},{"id":"W2592873754","doi":"10.1016/j.clgc.2017.02.002","title":"Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Chemotherapy; Internal medicine; Perioperative; Oncology; Lymph node; Stage (stratigraphy); Proportional hazards model; Penile cancer; Retrospective cohort study; Surgery; Cancer","score_opus":0.03055347263178582,"score_gpt":0.39558978975928033,"score_spread":0.3650363171274945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592873754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654096,0.00028722992,0.0000069864445,0.0003879563,0.00023644991,0.0009775844,0.00021655018,0.000010183199,0.0013360921],"genre_scores_gemma":[0.99736124,0.000042546213,0.0009280928,0.0006035291,0.00012268191,0.000047407495,0.00005002994,0.000027635477,0.00081684144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665856,0.00017433568,0.0018209264,0.0005949211,0.0003977942,0.00035348363],"domain_scores_gemma":[0.99654436,0.00039766278,0.0009260287,0.0010822787,0.00055966113,0.00048999797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004914752,0.00025236708,0.001356791,0.00013753482,0.00008470465,0.000009547992,0.00029114683,0.00019303475,0.00012644379],"category_scores_gemma":[0.00072512677,0.00018053052,0.00057725626,0.00019428383,0.0005021889,0.00012339215,0.000101458936,0.00039217793,0.0000069052835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04043075,0.0050009824,0.9502493,0.00020692275,0.00010410943,0.00004574609,0.00016188415,0.000053338248,0.0000074789896,4.6898984e-7,0.00008893956,0.0036500932],"study_design_scores_gemma":[0.048564985,0.0042249076,0.9457689,0.000029760062,0.0006262291,1.601908e-7,0.000114715054,0.0002631978,0.00009307903,0.0000012045948,0.00014275522,0.0001700861],"about_ca_topic_score_codex":0.00047535723,"about_ca_topic_score_gemma":0.0003083039,"teacher_disagreement_score":0.008134235,"about_ca_system_score_codex":0.000060129918,"about_ca_system_score_gemma":0.00059278094,"threshold_uncertainty_score":0.7361821},"labels":[],"label_agreement":null},{"id":"W2602722441","doi":"10.1016/j.clgc.2017.03.007","title":"Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non–muscle-invasive Bladder Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology","keywords":"Medicine; Bladder cancer; Neutrophil to lymphocyte ratio; Lymphocyte; Oncology; Internal medicine; Primary (astronomy); Cancer; Immunology; Pathology","score_opus":0.0354414923943765,"score_gpt":0.3702700535807678,"score_spread":0.3348285611863913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602722441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98865587,0.0032889633,0.00000558345,0.0016115697,0.0011758399,0.0017584475,0.00009826135,0.00005056169,0.00335492],"genre_scores_gemma":[0.9916063,0.002658068,0.0007088201,0.0016454844,0.0017306866,0.0010648664,0.000018658011,0.00008086423,0.0004862786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674326,0.00014196629,0.0012253243,0.00080339675,0.00049406145,0.0005919854],"domain_scores_gemma":[0.99678856,0.00034429604,0.00060682266,0.0013281613,0.0003821574,0.0005499886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049320917,0.0003670529,0.0009303907,0.000195886,0.0001991544,0.000044606193,0.0006248878,0.00032196176,0.00037105213],"category_scores_gemma":[0.00083696406,0.00034386347,0.0004013834,0.00020099107,0.0005220711,0.00021788722,0.00048650065,0.00043673432,0.000072275885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024559908,0.00073366356,0.92048347,0.0004179595,0.00034709918,0.0005164912,0.00015352917,0.0000691113,0.0117789805,0.000004878748,0.0022260123,0.060812835],"study_design_scores_gemma":[0.003977201,0.00056528323,0.985813,0.0010124665,0.00039922143,0.000008142059,0.000066150606,0.00022367343,0.0045944997,0.0000613175,0.002918629,0.00036038356],"about_ca_topic_score_codex":0.00028691484,"about_ca_topic_score_gemma":0.00015091902,"teacher_disagreement_score":0.06532958,"about_ca_system_score_codex":0.00041608553,"about_ca_system_score_gemma":0.0022761342,"threshold_uncertainty_score":0.99990135},"labels":[],"label_agreement":null},{"id":"W2606962296","doi":"10.1016/j.clgc.2017.04.006","title":"Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Confidence interval; Prostatectomy; Incidence (geometry); Internal medicine; Proportional hazards model; Oncology; Epidemiology; Surveillance, Epidemiology, and End Results; Confounding; Cancer; Cancer registry","score_opus":0.09925951799187302,"score_gpt":0.4456136316898717,"score_spread":0.34635411369799873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606962296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94860417,0.034644745,0.000014342208,0.0127522405,0.0005875159,0.001238893,0.0015000141,0.000047343354,0.00061073876],"genre_scores_gemma":[0.93372023,0.057607792,0.0001221432,0.0015108708,0.00046359957,0.0005786834,0.000077502424,0.00004459674,0.0058745686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684614,0.00018210783,0.0009847531,0.000849714,0.0005963521,0.0005409449],"domain_scores_gemma":[0.99669856,0.00040983193,0.00069097686,0.0012495487,0.000406316,0.0005447396],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046952465,0.0003724441,0.0016552063,0.00021921755,0.0003143169,0.000062985455,0.00040724775,0.00009334178,0.00029749543],"category_scores_gemma":[0.00028703362,0.00027048113,0.00045910562,0.0002673801,0.001016043,0.00039294738,0.0004387182,0.00058127457,0.0000050998797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036413968,0.00042305086,0.95694935,0.00037830803,0.0034516994,0.0012087122,0.000055026518,0.00002283741,0.0011628515,0.0000021356714,0.004506909,0.028197728],"study_design_scores_gemma":[0.0097881565,0.0005957565,0.97932065,0.0002681703,0.0022923066,0.000014124742,0.000030511452,0.00046627346,0.00070997607,0.000016536884,0.0062217284,0.00027580291],"about_ca_topic_score_codex":0.004968067,"about_ca_topic_score_gemma":0.00032993226,"teacher_disagreement_score":0.027921924,"about_ca_system_score_codex":0.0001748531,"about_ca_system_score_gemma":0.0014330237,"threshold_uncertainty_score":0.9999747},"labels":[],"label_agreement":null},{"id":"W2612397142","doi":"10.1016/j.clgc.2017.05.014","title":"Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institutes of Health; National Cancer Institute; Sanofi; Abbott Laboratories","keywords":"Medicine; Prostate cancer; Docetaxel; Hazard ratio; Internal medicine; Oncology; Confidence interval; Proportional hazards model; Response Evaluation Criteria in Solid Tumors; Enzalutamide; Prostate-specific antigen; Cancer; Progressive disease; Disease","score_opus":0.11292832206148902,"score_gpt":0.43059886480570775,"score_spread":0.31767054274421874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612397142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933554,0.00019402133,3.4267674e-7,0.002929856,0.00014473297,0.0019544405,0.00012487512,0.000009092479,0.0012872248],"genre_scores_gemma":[0.99266946,0.00074261293,0.0000364448,0.000023481121,0.00013734029,0.0003002739,0.000019551915,0.00002499419,0.00604586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787974,0.0003463229,0.00045958054,0.00034788126,0.00071884907,0.00024760867],"domain_scores_gemma":[0.9978631,0.00027330135,0.0007875027,0.0005647504,0.00042674347,0.00008456068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087173405,0.00018149042,0.0005741583,0.00008125007,0.00015329283,0.000025776524,0.00018486493,0.00006549146,0.000044521286],"category_scores_gemma":[0.00017789761,0.00009606101,0.000072126735,0.0002322159,0.00020546645,0.00008986868,0.00004920823,0.00028404375,0.000001097368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012120571,0.0014013469,0.9783807,0.00012506309,0.00062247936,0.00008441102,0.00058868335,0.00012576107,0.0021419323,0.0000025877823,0.00017063053,0.0042358395],"study_design_scores_gemma":[0.010551974,0.0055781673,0.9630605,0.00056659593,0.0004557405,0.0000011602681,0.000747675,0.000027998209,0.018767765,0.0000069763714,0.0001189009,0.00011652494],"about_ca_topic_score_codex":0.0024706263,"about_ca_topic_score_gemma":0.0069134138,"teacher_disagreement_score":0.01662583,"about_ca_system_score_codex":0.0003816394,"about_ca_system_score_gemma":0.000613737,"threshold_uncertainty_score":0.39172542},"labels":[],"label_agreement":null},{"id":"W2613354668","doi":"10.1016/j.clgc.2017.05.007","title":"Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Cystectomy; Cystoprostatectomy; Radiation therapy; Surgery; Genitourinary system; Urology; Urinary diversion; Internal medicine; Bladder cancer; Cancer","score_opus":0.09100725329578864,"score_gpt":0.43840633249904226,"score_spread":0.34739907920325364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613354668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931526,0.0007635227,0.00023458661,0.0010632093,0.0015015845,0.0015341288,0.00007762458,0.000041301533,0.0016314494],"genre_scores_gemma":[0.9926571,0.00040742164,0.0018213722,0.00095313846,0.0015259514,0.00024311291,0.0000029477421,0.000030492578,0.0023584187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981233,0.00007643093,0.0005874494,0.00056228833,0.00036467134,0.00028589647],"domain_scores_gemma":[0.99830186,0.000040380488,0.00024497253,0.00089166325,0.00021326779,0.00030784906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023850585,0.00024270528,0.00074421475,0.000064176544,0.0003115442,0.000025885678,0.00030445933,0.00012073786,0.00043781844],"category_scores_gemma":[0.00016815668,0.00019031146,0.0002958613,0.000093160765,0.00031311504,0.00011259229,0.00010019192,0.00030818026,0.000026496591],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018018276,0.0023228577,0.96785825,0.00003510986,0.0005735568,0.0002561949,0.00045301716,0.000046562473,0.00033036043,0.0000108490185,0.0010621598,0.02524924],"study_design_scores_gemma":[0.008895718,0.0033433968,0.9822665,0.00012378064,0.00019624476,0.000014316674,0.00010944787,0.00009461262,0.0002484443,0.000015442554,0.0045098416,0.00018226034],"about_ca_topic_score_codex":0.0006591408,"about_ca_topic_score_gemma":0.000253725,"teacher_disagreement_score":0.025066981,"about_ca_system_score_codex":0.00020385813,"about_ca_system_score_gemma":0.0005224203,"threshold_uncertainty_score":0.7760676},"labels":[],"label_agreement":null},{"id":"W2613761563","doi":"10.1016/j.clgc.2017.05.006","title":"Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Interquartile range; Medicine; Cystectomy; Quartile; Odds ratio; Confidence interval; Bladder cancer; Internal medicine; Surgery; Cancer","score_opus":0.11917036530780481,"score_gpt":0.4432306947105458,"score_spread":0.324060329402741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613761563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957494,0.00026541113,0.00018611184,0.0014601575,0.00041045013,0.0011544257,0.0005229877,0.000024778135,0.00022624864],"genre_scores_gemma":[0.9961558,0.00011121585,0.0004434213,0.0001355228,0.0002093286,0.0003593032,0.000008852224,0.000010719332,0.0025658635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981306,0.00018473262,0.0005478115,0.00049236143,0.00041957488,0.00022488787],"domain_scores_gemma":[0.99853,0.00019664304,0.00025563687,0.00058097596,0.00015165289,0.00028514324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045584622,0.00023028982,0.0008150451,0.00002827321,0.00019780766,0.000026056014,0.00010327411,0.00010709901,0.000080994214],"category_scores_gemma":[0.0002924329,0.00014286145,0.00016776688,0.000043882308,0.0002348602,0.000087659115,0.00007575516,0.00015333814,0.000010058709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050487006,0.0029199957,0.97882396,0.00004537497,0.00086040585,0.000095841395,0.00024115642,0.0000022696831,0.000012715197,0.000002935821,0.000026192085,0.011920436],"study_design_scores_gemma":[0.013281378,0.0024525279,0.9801716,0.000051056442,0.0004228868,0.0000020859304,0.00010360979,0.000005205921,0.000047076726,0.0000035001551,0.0033125551,0.00014650862],"about_ca_topic_score_codex":0.0014637684,"about_ca_topic_score_gemma":0.0033662922,"teacher_disagreement_score":0.011773927,"about_ca_system_score_codex":0.00043264267,"about_ca_system_score_gemma":0.0003542747,"threshold_uncertainty_score":0.5825721},"labels":[],"label_agreement":null},{"id":"W2659875471","doi":"10.1016/j.clgc.2017.06.004","title":"Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Astellas Pharma; Sanofi","keywords":"Medicine; Prostate cancer; Internal medicine; Androgen receptor; Docetaxel; Hazard ratio; Androgen deprivation therapy; Prostate-specific antigen; Oncology; Taxane; Enzalutamide; Cancer; Breast cancer; Confidence interval","score_opus":0.062336598362176865,"score_gpt":0.3819573128623433,"score_spread":0.31962071450016644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2659875471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209297,0.0020762556,6.358897e-7,0.0027169923,0.00025144863,0.0019862384,0.0008095447,0.000020819569,0.000045113407],"genre_scores_gemma":[0.9707943,0.02741355,0.0005452679,0.0001778345,0.00015928426,0.00043437566,0.00025626906,0.00006321005,0.00015590858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969233,0.00058295194,0.0010381516,0.00043374926,0.0005614144,0.00046042012],"domain_scores_gemma":[0.99668705,0.0007981732,0.00089999946,0.0009363334,0.0005077441,0.00017066565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011054078,0.0004045645,0.0010228807,0.00013713293,0.00041219394,0.00006177773,0.00038903486,0.00013419762,0.00026922964],"category_scores_gemma":[0.00018115484,0.00024223348,0.00018254365,0.00027233272,0.0006341599,0.00022027557,0.000088963105,0.00073045125,0.0000010417834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025350256,0.0011361528,0.9405163,0.0002038188,0.0009800553,0.000023645418,0.0021225295,0.0000036065226,0.00089410134,6.8277836e-7,0.0001874286,0.028581439],"study_design_scores_gemma":[0.01868363,0.0030517273,0.9723783,0.00040842846,0.00012108814,6.9593773e-7,0.00042762456,0.000021037302,0.0033252032,0.000012812262,0.0013125158,0.0002569139],"about_ca_topic_score_codex":0.001796805,"about_ca_topic_score_gemma":0.0024213106,"teacher_disagreement_score":0.031862043,"about_ca_system_score_codex":0.0001597031,"about_ca_system_score_gemma":0.00039872635,"threshold_uncertainty_score":0.98779947},"labels":[],"label_agreement":null},{"id":"W2719550704","doi":"10.1016/j.clgc.2017.06.003","title":"Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology","keywords":"Medicine; Proportional hazards model; Lymphovascular invasion; Hazard ratio; Thrombocytosis; Stage (stratigraphy); Internal medicine; T-stage; Cohort; Oncology; Urology; Lymph node; Carcinoma; Cancer; Metastasis; Confidence interval; Platelet","score_opus":0.048477951581277025,"score_gpt":0.3851021898531702,"score_spread":0.33662423827189314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2719550704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377096,0.0013313865,0.000005931563,0.0006972965,0.00050216814,0.0013084552,0.00011287529,0.000027519172,0.002243438],"genre_scores_gemma":[0.9974455,0.00066593563,0.0005741948,0.00019475944,0.00063586095,0.00030213728,0.000007648609,0.000037001544,0.00013691623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978655,0.0002137529,0.0007609121,0.00055315666,0.00029021045,0.00031644295],"domain_scores_gemma":[0.9982285,0.0003487104,0.00033602427,0.00063885143,0.00018380205,0.0002641347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000497931,0.00024229914,0.00068059383,0.000095001276,0.00016622008,0.000030727122,0.00024847512,0.00024595586,0.00013425549],"category_scores_gemma":[0.001053094,0.00020592517,0.00022084662,0.00006812149,0.00092909974,0.00021374138,0.00022946551,0.00040604282,0.0000066288158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022245443,0.0008162925,0.9900165,0.00023359609,0.00019873734,0.00026034642,0.0003270735,0.000004064482,0.00046224936,0.000021389946,0.000279519,0.0051556593],"study_design_scores_gemma":[0.0036036535,0.0012604857,0.99059516,0.00049623265,0.00038410787,0.00002172944,0.00012256695,0.000742295,0.0023117617,0.00010137475,0.00016446039,0.00019618469],"about_ca_topic_score_codex":0.00009391123,"about_ca_topic_score_gemma":0.000010210417,"teacher_disagreement_score":0.004959475,"about_ca_system_score_codex":0.0000931986,"about_ca_system_score_gemma":0.00052380876,"threshold_uncertainty_score":0.8397385},"labels":[],"label_agreement":null},{"id":"W2737333498","doi":"10.1016/j.clgc.2017.07.014","title":"Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Proportional hazards model; Hazard ratio; Internal medicine; Progression-free survival; Oncology; Chemotherapy; Univariate analysis; Urology; Cancer; Confidence interval; Gastroenterology; Multivariate analysis; Androgen deprivation therapy","score_opus":0.12033434774859395,"score_gpt":0.44305116817026297,"score_spread":0.32271682042166905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737333498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98452955,0.0026173885,0.00019073446,0.005705785,0.00027157107,0.0058469935,0.00053567,0.000087891065,0.00021443033],"genre_scores_gemma":[0.97921723,0.0033107598,0.002294669,0.00017919274,0.00043583763,0.0055764,0.00012468128,0.0001325139,0.008728719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633604,0.00013761266,0.00093615934,0.0009801596,0.00068895007,0.0009210878],"domain_scores_gemma":[0.99710757,0.00026059354,0.0005346541,0.0011371736,0.00050789956,0.00045211005],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006911991,0.0005064047,0.0010858185,0.000146127,0.00043621834,0.00016120893,0.00048864196,0.00019582095,0.00007770105],"category_scores_gemma":[0.0002358612,0.00034018722,0.0002134719,0.00020309455,0.0006623845,0.00033970366,0.00015893261,0.00054661196,0.0000051650727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07903076,0.0023561853,0.8510568,0.0012540385,0.0014913005,0.001191712,0.000893244,0.0034616613,0.0025379984,0.000011298098,0.0015365246,0.055178456],"study_design_scores_gemma":[0.080648616,0.006325891,0.78969634,0.0023288939,0.0009292516,0.000027162458,0.00025440034,0.1150468,0.002707904,0.00045482768,0.00063064566,0.0009492688],"about_ca_topic_score_codex":0.0005666442,"about_ca_topic_score_gemma":0.0018729909,"teacher_disagreement_score":0.11158513,"about_ca_system_score_codex":0.00050556555,"about_ca_system_score_gemma":0.0023411498,"threshold_uncertainty_score":0.999905},"labels":[],"label_agreement":null},{"id":"W2737755444","doi":"10.1016/j.clgc.2017.07.018","title":"Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Positron emission tomography; Confidence interval; Odds ratio; Bladder cancer; Magnetic resonance imaging; Stage (stratigraphy); Logistic regression; Radiology; Nuclear medicine; Cancer; Computed tomography; Internal medicine","score_opus":0.03682113614610499,"score_gpt":0.3799245230723125,"score_spread":0.3431033869262075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737755444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935812,0.0035914592,0.000021511285,0.00021185332,0.00050526985,0.0013526188,0.00051140203,0.000042309755,0.00018242003],"genre_scores_gemma":[0.9965666,0.0019519916,0.0002328109,0.00021583564,0.00052912626,0.00026404054,0.00011062484,0.000059594175,0.00006940912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824375,0.000065111104,0.00056137564,0.00058293727,0.00019377966,0.000353049],"domain_scores_gemma":[0.9981862,0.00017865389,0.00051297026,0.00047991314,0.0002700048,0.00037227632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015397914,0.00032268124,0.0006440522,0.00015179791,0.00027840032,0.000052141408,0.00019153194,0.000043903594,0.00012755941],"category_scores_gemma":[0.00006084014,0.00024156416,0.00033634185,0.00008914762,0.0001984286,0.00027133027,0.000087204135,0.00016781826,0.0000012022768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034975652,0.00055449246,0.9685047,0.00014536409,0.0006638706,0.000060253264,0.000032218748,0.000019603227,0.00023838789,0.0000017141525,0.0015411127,0.024740681],"study_design_scores_gemma":[0.01209804,0.002021805,0.9795496,0.00047258422,0.000786322,0.000018831568,0.000018008679,0.0017233654,0.002403449,0.00003103062,0.00060035556,0.00027659253],"about_ca_topic_score_codex":0.0014882559,"about_ca_topic_score_gemma":0.00009287165,"teacher_disagreement_score":0.02446409,"about_ca_system_score_codex":0.00015383337,"about_ca_system_score_gemma":0.00048415601,"threshold_uncertainty_score":0.98507005},"labels":[],"label_agreement":null},{"id":"W2742727144","doi":"10.1016/j.clgc.2017.07.026","title":"Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Prostate Cancer Foundation","keywords":"Medicine; Prostatectomy; Prostate cancer; Prostate-specific antigen; Proportional hazards model; Univariate analysis; Confidence interval; Stage (stratigraphy); Urology; Internal medicine; Oncology; Surgery; Cancer; Multivariate analysis","score_opus":0.07020088189698086,"score_gpt":0.42518401383945753,"score_spread":0.35498313194247666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742727144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913798,0.0037825527,0.00007364911,0.00079175516,0.001148974,0.0017224693,0.0009650935,0.000042903062,0.000092793125],"genre_scores_gemma":[0.99209774,0.0052875336,0.000284195,0.00010783297,0.0007665231,0.0011175652,0.0001440717,0.000028053146,0.00016650515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980616,0.00005951079,0.0007237717,0.00058324315,0.00027000107,0.00030185422],"domain_scores_gemma":[0.9975961,0.0002147095,0.0007296311,0.0008327249,0.00021424657,0.00041258064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020306754,0.00023557141,0.00044924373,0.000050492934,0.00029304958,0.00005091635,0.000166723,0.00012034258,0.000035055567],"category_scores_gemma":[0.0006684721,0.00017303629,0.0003387305,0.00005309147,0.00043409705,0.0002579879,0.00010066423,0.00015983605,0.0000042492175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0115576945,0.0011865349,0.8784686,0.0001575081,0.0001121804,0.00019168663,0.00026896608,0.000005541747,0.00011111761,0.0000013315688,0.0002607766,0.10767808],"study_design_scores_gemma":[0.0068664677,0.0023446009,0.9806902,0.0007406265,0.00035482622,0.0000021568346,0.000023203633,0.00004299354,0.0063111987,0.000019694819,0.0024132836,0.00019079198],"about_ca_topic_score_codex":0.00005889817,"about_ca_topic_score_gemma":0.0000173001,"teacher_disagreement_score":0.10748729,"about_ca_system_score_codex":0.00019607891,"about_ca_system_score_gemma":0.0003059247,"threshold_uncertainty_score":0.70562154},"labels":[],"label_agreement":null},{"id":"W2748271565","doi":"10.1016/j.clgc.2017.07.001","title":"Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Bladder cancer; Internal medicine; Proportional hazards model; Lymph node; Oncology; Tissue microarray; Cystectomy; Stage (stratigraphy); Cancer; Confidence interval; Cadherin; Biomarker; Survival analysis; Cell","score_opus":0.037392255950071576,"score_gpt":0.36233653435889096,"score_spread":0.3249442784088194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748271565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949428,0.001360225,0.0000015675511,0.00027546711,0.00039126616,0.0009240136,0.00007674423,0.000019920639,0.0020080372],"genre_scores_gemma":[0.9970656,0.0009792452,0.00025593114,0.00023582984,0.00047332648,0.00033005176,0.000014839459,0.000044129676,0.0006010228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829525,0.00006260214,0.0005265404,0.00046004582,0.00033981088,0.0003157551],"domain_scores_gemma":[0.9984176,0.00010927237,0.00037094846,0.0006771954,0.00021141759,0.0002135299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104763414,0.00022898792,0.0005708994,0.00006060528,0.000110021,0.000017609154,0.00024181863,0.00016836249,0.000503162],"category_scores_gemma":[0.0001624805,0.00016311741,0.00013075482,0.00007532642,0.00026807628,0.000163149,0.00013869694,0.000319437,0.000015544407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028339634,0.001210196,0.97089463,0.00008128222,0.00017746603,0.000050426348,0.00011685628,0.0000118468815,0.0004722942,0.0000010088569,0.00045893804,0.023691095],"study_design_scores_gemma":[0.008106521,0.001793857,0.9838522,0.0008419682,0.00020872275,0.0000011878702,0.00004816033,0.000007654277,0.0038636788,0.000045340963,0.0010487447,0.00018194209],"about_ca_topic_score_codex":0.00060804165,"about_ca_topic_score_gemma":0.000333376,"teacher_disagreement_score":0.023509152,"about_ca_system_score_codex":0.00010084936,"about_ca_system_score_gemma":0.0005694832,"threshold_uncertainty_score":0.6651735},"labels":[],"label_agreement":null},{"id":"W2748372943","doi":"10.1016/j.clgc.2017.08.002","title":"External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population-based Study","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Prostatectomy; Prostate cancer; Interquartile range; Stage (stratigraphy); Cohort; Lymph node; Prostate-specific antigen; Population; Dissection (medical); Lymphadenectomy; Urology; Prostate; Cancer; Radiology; Oncology; Surgery; Internal medicine","score_opus":0.11332004871470644,"score_gpt":0.43751846598963035,"score_spread":0.32419841727492393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748372943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926549,0.00077539467,0.00003606563,0.0023589765,0.001238484,0.002647504,0.00023222693,0.000023269897,0.00003317623],"genre_scores_gemma":[0.99657166,0.00033558105,0.0002910288,0.00037159186,0.0006515545,0.0014392787,0.00002094292,0.000027521397,0.00029085137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983568,0.000096846954,0.0006098564,0.00042000844,0.00027511388,0.00024136023],"domain_scores_gemma":[0.99805194,0.00017874847,0.0006666027,0.00075636647,0.00023839409,0.00010795689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041610093,0.00017887328,0.00044125153,0.00003319525,0.00038083625,0.000041755873,0.00024521342,0.000073585135,0.000065256136],"category_scores_gemma":[0.00022671252,0.00011475012,0.00029013044,0.000055975484,0.000111747184,0.00008946902,0.000102149024,0.00018285889,0.0000015663709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008415535,0.0010129536,0.9545043,0.00011553127,0.000100954094,0.000036836882,0.0000937583,0.000303571,0.00012286365,0.0000030124888,0.00016088846,0.042703744],"study_design_scores_gemma":[0.0053264736,0.0015101471,0.98919594,0.00045133368,0.00038731055,0.0000014460352,0.000051810417,0.00023628639,0.0022913704,0.00013163974,0.0002929777,0.000123242],"about_ca_topic_score_codex":0.00068634615,"about_ca_topic_score_gemma":0.00009959644,"teacher_disagreement_score":0.0425805,"about_ca_system_score_codex":0.00019733315,"about_ca_system_score_gemma":0.000414546,"threshold_uncertainty_score":0.4679374},"labels":[],"label_agreement":null},{"id":"W2750977739","doi":"10.1016/j.clgc.2017.08.008","title":"Shrinking Hepatic Hemangiomas in a Patient Treated for Metastatic Germ Cell Tumor","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Etoposide; Germ cell tumors; Bleomycin; Cisplatin; Oncology; Internal medicine; Chemotherapy; Germinoma; Seminoma; Testicular cancer; Germ cell","score_opus":0.07880990781772557,"score_gpt":0.41848480532497623,"score_spread":0.33967489750725066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750977739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949338,0.0025425483,0.000020726808,0.00033472918,0.00035354026,0.0011798873,0.000068698646,0.0000395113,0.00052658713],"genre_scores_gemma":[0.9965803,0.0001569317,0.0015358179,0.0003818299,0.00024916863,0.0005458587,0.000037232854,0.00004212726,0.0004707429],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983758,0.000060177586,0.00059123355,0.00043680755,0.00018488268,0.00035112276],"domain_scores_gemma":[0.9983482,0.0002655369,0.00038049155,0.0006389975,0.00008464194,0.00028212633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014806121,0.00021406068,0.00054850697,0.00006553267,0.00017017774,0.000038665097,0.00014228148,0.000054479548,0.00009460621],"category_scores_gemma":[0.00040898594,0.00016929097,0.00040692638,0.000057185436,0.000100703175,0.000075657976,0.00008942862,0.00013756688,0.000029427576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009884961,0.0026564496,0.9478536,0.00030386733,0.00025021532,0.0038581097,0.000055772987,0.000017820905,0.000108330474,0.0000060464627,0.00049720844,0.043404076],"study_design_scores_gemma":[0.010402292,0.002323034,0.97979015,0.0004608301,0.0011798154,0.00004859901,0.000044803845,0.0017029304,0.0008841518,0.00032523222,0.0025397916,0.000298384],"about_ca_topic_score_codex":0.0002785589,"about_ca_topic_score_gemma":0.00006779988,"teacher_disagreement_score":0.04310569,"about_ca_system_score_codex":0.00011876507,"about_ca_system_score_gemma":0.00023281205,"threshold_uncertainty_score":0.6903485},"labels":[],"label_agreement":null},{"id":"W2751039941","doi":"10.1016/j.clgc.2017.08.019","title":"Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Genitourinary system; Oncology; Internal medicine; Clinical trial; Randomized controlled trial","score_opus":0.6998276852707463,"score_gpt":0.6579835191735466,"score_spread":0.041844166097199764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751039941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93813485,0.014645669,0.00007380127,0.03315762,0.0024765274,0.004913399,0.00009373536,0.00011351699,0.0063908543],"genre_scores_gemma":[0.9603916,0.02167612,0.0011267677,0.0036040752,0.0047367685,0.00081125443,0.000052372394,0.00012434625,0.007476736],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9748427,0.010275945,0.009961373,0.0019945058,0.0016214462,0.0013040256],"domain_scores_gemma":[0.8886763,0.102925256,0.0028698093,0.0034458875,0.00091774965,0.0011650374],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.11389129,0.0007428604,0.007271207,0.0004760733,0.00057879963,0.00020058158,0.001818119,0.0022581837,0.0010888135],"category_scores_gemma":[0.14011836,0.0005701152,0.002650299,0.00038246892,0.0045346497,0.00050459447,0.0014804775,0.007789188,0.00009930105],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43047833,0.010586223,0.48464417,0.00038611595,0.0016470209,0.0056741126,0.0002888544,0.000009580659,0.00047755273,0.0006699296,0.012336539,0.05280156],"study_design_scores_gemma":[0.77251446,0.007823919,0.17184299,0.0036743337,0.0008122267,0.000055475368,0.00044011202,0.0011268086,0.00048561642,0.02362022,0.016364213,0.0012396191],"about_ca_topic_score_codex":0.0011420919,"about_ca_topic_score_gemma":0.001144928,"teacher_disagreement_score":0.34203613,"about_ca_system_score_codex":0.00018738478,"about_ca_system_score_gemma":0.004288394,"threshold_uncertainty_score":0.99982435},"labels":[],"label_agreement":null},{"id":"W2751103497","doi":"10.1016/j.clgc.2017.09.003","title":"Identifying Psychosocial Distress and Stressors Using Distress-screening Instruments in Patients With Localized and Advanced Penile Cancer","year":2017,"lang":"en","type":"letter","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Psychosocial; Penile cancer; Distress; Cancer; Quality of life (healthcare); Prostate cancer; Psychosexual development; Psychiatry; Clinical psychology; Internal medicine; Psychology","score_opus":0.07036041780127776,"score_gpt":0.4219131222647663,"score_spread":0.3515527044634885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751103497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799115,0.0043999646,0.000007044045,0.011392086,0.0011991801,0.0013042341,0.0015995789,0.00003789773,0.0001485142],"genre_scores_gemma":[0.9628677,0.0010133368,0.00074170256,0.02913197,0.004026875,0.00026081858,0.00096767134,0.00015552458,0.0008344346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996032,0.00018453844,0.001014184,0.0012076128,0.00068916945,0.0008725102],"domain_scores_gemma":[0.99757814,0.00015906525,0.0007801874,0.00062614045,0.0001815295,0.00067495304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001582964,0.00062163314,0.0012587373,0.000161336,0.00038927473,0.000121923506,0.00025606633,0.0007838941,0.00013097204],"category_scores_gemma":[0.00014938497,0.00054016744,0.00017755358,0.00012849228,0.00058796274,0.0002845026,0.00027272917,0.001991237,0.0000022072084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004666474,0.00027846693,0.91945815,0.0020660716,0.00010814592,0.00072534475,0.000057249097,0.000009999983,0.0000011113963,1.6804303e-7,0.01048939,0.06213941],"study_design_scores_gemma":[0.019571371,0.00065133034,0.9424737,0.0029704974,0.00075863936,0.000010931743,0.000056413515,0.00016775375,0.0000030359422,0.000039247276,0.032475054,0.0008220437],"about_ca_topic_score_codex":0.0010582358,"about_ca_topic_score_gemma":0.000247097,"teacher_disagreement_score":0.06131737,"about_ca_system_score_codex":0.0002308838,"about_ca_system_score_gemma":0.000430422,"threshold_uncertainty_score":0.99970496},"labels":[],"label_agreement":null},{"id":"W2751215168","doi":"10.1016/j.clgc.2017.08.005","title":"Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Biochemical recurrence; Internal medicine; Gynecology; Cancer","score_opus":0.17808546896709068,"score_gpt":0.47745107562301586,"score_spread":0.29936560665592515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751215168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737444,0.0005163142,0.000002934137,0.0010885224,0.00007018826,0.010751322,0.000108637505,0.000043752145,0.013673925],"genre_scores_gemma":[0.99388903,0.00026653355,0.00015743854,0.00010267282,0.00026141043,0.004901547,0.000042227646,0.000049755086,0.00032938682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760425,0.00031014945,0.000897202,0.00056909927,0.00029622644,0.00032307356],"domain_scores_gemma":[0.9978469,0.00019195607,0.0007050944,0.0008109618,0.00017689484,0.000268197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004767888,0.00027216552,0.0010843878,0.00006451551,0.00011947368,0.000030643925,0.00026174507,0.00010568887,0.00006631649],"category_scores_gemma":[0.0001332181,0.00019129511,0.0001544733,0.00010462106,0.000613093,0.0001408592,0.00012295286,0.00038551952,0.000010791192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066607455,0.0022943628,0.9625258,0.00016418169,0.00017731257,0.0007977773,0.000120184435,0.000007853197,0.000121238,0.000004618297,0.0022427116,0.024883227],"study_design_scores_gemma":[0.013195018,0.0039988044,0.96564865,0.0010289464,0.00004801411,0.000008648487,0.000084473555,0.00006312624,0.0056371316,0.00000815847,0.0100703975,0.00020865367],"about_ca_topic_score_codex":0.00044743056,"about_ca_topic_score_gemma":0.00011820714,"teacher_disagreement_score":0.024674574,"about_ca_system_score_codex":0.0001736976,"about_ca_system_score_gemma":0.0005003059,"threshold_uncertainty_score":0.7800788},"labels":[],"label_agreement":null},{"id":"W2751687881","doi":"10.1016/j.clgc.2017.08.020","title":"The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Bayer HealthCare","keywords":"Medicine; Radium-223; Enzalutamide; Prostate cancer; Docetaxel; Radium; Oncology; Abiraterone; Internal medicine; Abiraterone acetate; Cancer; Bone metastasis; Androgen deprivation therapy","score_opus":0.3042373536338288,"score_gpt":0.49066077146474124,"score_spread":0.18642341783091243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751687881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739953,0.014323621,0.0000012534994,0.0086534945,0.00072644075,0.0012537953,0.0001760194,0.000017634004,0.00085241144],"genre_scores_gemma":[0.97028637,0.01869947,0.00015533829,0.00018974638,0.00035169424,0.00040498795,0.000019331826,0.000031221753,0.0098618595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977352,0.00019832738,0.000880814,0.0003904638,0.0003945681,0.00040060916],"domain_scores_gemma":[0.99762446,0.0006181337,0.0004451425,0.000830508,0.00025431582,0.00022746164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070397544,0.00020056312,0.00055183365,0.000065857705,0.00036937222,0.000100339814,0.00029070114,0.00008781503,0.000080464626],"category_scores_gemma":[0.00043022115,0.00012212085,0.00021499628,0.00011825317,0.00085226464,0.00027734187,0.00013278291,0.00045429048,0.000009059701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012685209,0.0010200466,0.9045857,0.0003005631,0.0006994213,0.0014292728,0.0002892675,0.00004149875,0.003595638,0.000049534978,0.016021682,0.059282172],"study_design_scores_gemma":[0.009296214,0.0010887174,0.93027395,0.0005578618,0.00015742463,0.0000094548695,0.00019568461,0.00025841477,0.0027498018,0.00017027189,0.055019733,0.0002224533],"about_ca_topic_score_codex":0.002956824,"about_ca_topic_score_gemma":0.00116982,"teacher_disagreement_score":0.05905972,"about_ca_system_score_codex":0.00016668734,"about_ca_system_score_gemma":0.0016966091,"threshold_uncertainty_score":0.49799436},"labels":[],"label_agreement":null},{"id":"W2753069614","doi":"10.1016/j.clgc.2017.08.011","title":"Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université de Sherbrooke; McGill University","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Prostate cancer; Cancer; Radiation therapy; Prostate; Oncology; Surgery; Internal medicine","score_opus":0.1549085546321779,"score_gpt":0.4554041013892394,"score_spread":0.3004955467570615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753069614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864375,0.009603001,0.0000070635033,0.002579536,0.0001394255,0.00078434544,0.00023608947,0.000004984272,0.00020806956],"genre_scores_gemma":[0.9691923,0.029848127,0.00005629072,0.00013483013,0.00011268328,0.00053740223,0.00008124734,0.000012807455,0.000024285771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982872,0.00018016106,0.00080424314,0.00032570012,0.00022019932,0.00018247079],"domain_scores_gemma":[0.9978536,0.00084301183,0.0006878912,0.0004505869,0.000078643956,0.0000862711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036837315,0.00014921837,0.00063054665,0.00007327136,0.00009862468,0.000014106602,0.00013157331,0.00009000122,0.000032362113],"category_scores_gemma":[0.00010214362,0.000105592655,0.00012457144,0.000090827045,0.00038711532,0.000093102906,0.000052606792,0.00022032818,0.000002010628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062338205,0.0010648789,0.8898278,0.000041131894,0.00019478955,0.000028659158,0.0006322116,0.00019646522,0.00003816756,0.000009412742,0.00047039866,0.106872685],"study_design_scores_gemma":[0.0030376203,0.00031512658,0.99327016,0.0004204482,0.00023776802,0.0000018330618,0.000335078,0.0009427877,0.00070259755,0.0002886461,0.00035993606,0.00008801098],"about_ca_topic_score_codex":0.013799547,"about_ca_topic_score_gemma":0.00096789736,"teacher_disagreement_score":0.10678468,"about_ca_system_score_codex":0.00020317985,"about_ca_system_score_gemma":0.00033499845,"threshold_uncertainty_score":0.99276763},"labels":[],"label_agreement":null},{"id":"W2753901771","doi":"10.1016/j.clgc.2017.08.012","title":"Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre","funders":"Sanofi","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Internal medicine; Bleomycin; Chemotherapy; Odds ratio; Pneumonitis; Chemotherapy regimen; Germ cell tumors; Adverse effect; Asymptomatic; Risk factor; Regimen; Gastroenterology; Oncology; Surgery; Lung","score_opus":0.0646788704708834,"score_gpt":0.4267789825561201,"score_spread":0.36210011208523674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753901771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99508446,0.00023110355,0.0000010538629,0.0003403826,0.00042516473,0.00067781506,0.0001788274,0.000041383013,0.0030197878],"genre_scores_gemma":[0.9977747,0.00038309497,0.000038603743,0.0002540669,0.0008326385,0.00004720627,0.000021380905,0.000061525054,0.00058674417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975844,0.00012615781,0.0009328646,0.0005591181,0.0003228797,0.00047456453],"domain_scores_gemma":[0.99774563,0.00023867292,0.0005967935,0.0008519468,0.00021028561,0.00035666462],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023353288,0.00034705707,0.0009477939,0.00013323464,0.00017415303,0.000035110963,0.0003179972,0.00026689662,0.00046356753],"category_scores_gemma":[0.00026462492,0.0002824819,0.00078032614,0.00010706445,0.00019069655,0.00013277416,0.00009439146,0.00059646246,0.000028246912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011530744,0.0014717125,0.94340664,0.00017893397,0.00013309854,0.0007679848,0.00008212594,0.0000711039,0.02663511,0.0000015292575,0.00024997425,0.015471068],"study_design_scores_gemma":[0.0041425787,0.012116886,0.97824067,0.0008816624,0.00009495042,0.000012070949,0.000018524364,0.0007821834,0.0033500735,0.000018100689,0.00006129638,0.00028102513],"about_ca_topic_score_codex":0.0020695832,"about_ca_topic_score_gemma":0.000025878102,"teacher_disagreement_score":0.034834035,"about_ca_system_score_codex":0.0003079522,"about_ca_system_score_gemma":0.0004658225,"threshold_uncertainty_score":0.99996275},"labels":[],"label_agreement":null},{"id":"W2761290291","doi":"10.1016/j.clgc.2017.09.011","title":"Analysis of Suicide Risk in Patients with Penile Cancer and Review of the Literature","year":2017,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Penile cancer; Penectomy; Cancer; Population; Surveillance, Epidemiology, and End Results; Epidemiology; Depression (economics); Internal medicine; Surgery; Psychiatry; Cancer registry","score_opus":0.09241422617241636,"score_gpt":0.479554176809179,"score_spread":0.38713995063676265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761290291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025635766,0.97064954,3.4577557e-8,0.000079510755,0.00023294837,0.0016045069,0.0016399955,0.000004030123,0.0001536959],"genre_scores_gemma":[0.0052201147,0.993359,0.00001744969,0.00036518762,0.00019669493,0.00018344766,0.0001742498,0.000028674964,0.00045515774],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970272,0.00034729234,0.001519848,0.00048006777,0.00037497564,0.00025062595],"domain_scores_gemma":[0.9961032,0.000282182,0.0018360228,0.0011026596,0.0003560364,0.00031986792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050818536,0.00032288072,0.0034947002,0.00019630094,0.0000575706,0.000006810847,0.00029452046,0.0002909653,0.00014235154],"category_scores_gemma":[0.0006125737,0.00016832628,0.0010704462,0.00087511126,0.0002604871,0.000044257937,0.00014892871,0.00080247887,0.0000013326024],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023022993,0.00023083603,0.4329021,0.13273086,0.000411953,0.000011906921,0.000009607967,4.0770652e-7,1.1506679e-9,1.6927014e-7,0.00045230694,0.43301964],"study_design_scores_gemma":[0.00113583,0.00033891195,0.60480607,0.1553022,0.026533965,0.0000013139628,0.0000016719837,0.0000015244993,3.585498e-8,0.0000018484999,0.21170278,0.00017384999],"about_ca_topic_score_codex":0.0003363292,"about_ca_topic_score_gemma":0.00018594618,"teacher_disagreement_score":0.4328458,"about_ca_system_score_codex":0.00008655909,"about_ca_system_score_gemma":0.0016324508,"threshold_uncertainty_score":0.68641466},"labels":[],"label_agreement":null},{"id":"W2767182382","doi":"10.1016/j.clgc.2017.10.012","title":"Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Metastatic Urothelial Carcinoma; Chemotherapy; Internal medicine; Oncology; Bone metastasis; Retrospective cohort study; Proportional hazards model; Metastasis; Cancer; Urothelial carcinoma; Bladder cancer","score_opus":0.038967938103646564,"score_gpt":0.3499311026994399,"score_spread":0.3109631645957933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767182382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249035,0.00027097476,0.000001526965,0.001662378,0.0009321292,0.0014349753,0.00024463868,0.000022144417,0.0029408634],"genre_scores_gemma":[0.99586827,0.00008154255,0.000120615645,0.001206301,0.0019677458,0.0001586068,0.00006284245,0.00004996333,0.0004841306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761903,0.00020801228,0.000658372,0.00054443895,0.00059368345,0.00037644902],"domain_scores_gemma":[0.9982304,0.00016623717,0.00038956062,0.0008832326,0.000118877535,0.00021167581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021765496,0.00031063388,0.00061425386,0.00008582011,0.0003323985,0.000063552936,0.00017608973,0.000084545034,0.00039583212],"category_scores_gemma":[0.00020333086,0.00018384334,0.00023120188,0.00009928185,0.00020468472,0.00015131172,0.0000991603,0.00042198444,0.00010727961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009731598,0.0017342619,0.90414286,0.00002188298,0.00022508916,0.00038224328,0.00016836113,0.000018415403,0.0000028619959,0.00003247766,0.0010391001,0.08250084],"study_design_scores_gemma":[0.01094155,0.0060082413,0.9786664,0.00013748588,0.00048746876,0.00001327509,0.000031501913,0.000010065938,0.000073730895,0.00021841923,0.0031976146,0.00021422164],"about_ca_topic_score_codex":0.002626493,"about_ca_topic_score_gemma":0.0009973086,"teacher_disagreement_score":0.08228662,"about_ca_system_score_codex":0.00020440189,"about_ca_system_score_gemma":0.00036580666,"threshold_uncertainty_score":0.74969137},"labels":[],"label_agreement":null},{"id":"W2767678806","doi":"10.1016/j.clgc.2017.10.015","title":"Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Proportional hazards model; Prostatectomy; Biochemical recurrence; Internal medicine; Urology; Oncology; Cumulative incidence; Cumulative dose; Metastasis; Cancer; Surgery; Cohort; Confidence interval","score_opus":0.04245840618537775,"score_gpt":0.40280566478281105,"score_spread":0.3603472585974333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767678806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990556,0.002780849,0.0000021769517,0.0006209746,0.00052737177,0.0049347985,0.00040316297,0.000034444092,0.00014023708],"genre_scores_gemma":[0.9922501,0.0029187393,0.00011444937,0.00013221677,0.00035006664,0.0038969216,0.00014559907,0.00005177522,0.00014011792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746835,0.00018349239,0.0008582518,0.0006717171,0.0003436154,0.0004745571],"domain_scores_gemma":[0.99759495,0.0005812682,0.00078917574,0.0005210613,0.0002674097,0.00024612085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047437596,0.0003652097,0.001077631,0.00010212607,0.00019318321,0.000032124462,0.00018448677,0.00020129234,0.000058590504],"category_scores_gemma":[0.00032161045,0.0002399605,0.0002578875,0.00013344525,0.00036981594,0.00017077634,0.0000787602,0.0003605254,0.0000018513539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013343835,0.0011670156,0.809272,0.00034368018,0.0003814928,0.00006921768,0.00012543432,0.00007355261,0.000013863465,0.000002307429,0.00041557194,0.17479205],"study_design_scores_gemma":[0.033633377,0.022661457,0.93676054,0.001116665,0.0005068297,0.0000011859609,0.00001071719,0.00013629305,0.0027776195,0.000016118542,0.0021268697,0.00025231513],"about_ca_topic_score_codex":0.0002892506,"about_ca_topic_score_gemma":0.000086383196,"teacher_disagreement_score":0.17453973,"about_ca_system_score_codex":0.00061095424,"about_ca_system_score_gemma":0.0004318136,"threshold_uncertainty_score":0.9785305},"labels":[],"label_agreement":null},{"id":"W2773593291","doi":"10.1016/j.clgc.2017.11.004","title":"Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Multidisciplinary approach; Medicine; Bladder cancer; Family medicine; Nursing; Cancer; Internal medicine","score_opus":0.05583987742814905,"score_gpt":0.38280239173580316,"score_spread":0.3269625143076541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773593291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174815,0.002688664,0.0000024082024,0.0005389279,0.00081411604,0.0011350546,0.00057252304,0.00002834281,0.002471787],"genre_scores_gemma":[0.9968022,0.0011126995,0.00010922983,0.0003062009,0.00063747907,0.00028108826,0.00007677017,0.00006661791,0.0006076739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977738,0.0000883702,0.0007294199,0.0006357738,0.0004076833,0.00036495063],"domain_scores_gemma":[0.9977549,0.000114605486,0.00049600116,0.0009857826,0.00037360075,0.00027514013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010782285,0.00032681145,0.0008127743,0.000092952934,0.00017231093,0.000019943345,0.00031980147,0.00021701759,0.00030690865],"category_scores_gemma":[0.00006762976,0.00024490338,0.00024140727,0.00007286314,0.00029373914,0.00021397087,0.00022239161,0.0004158979,0.000010276083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035995955,0.0011987457,0.9704541,0.00027836394,0.00034472308,0.000238257,0.000494351,0.00001220204,0.000023142362,5.712318e-7,0.0005630368,0.02279292],"study_design_scores_gemma":[0.01645248,0.002791184,0.97779506,0.0009621286,0.000246002,0.0000011761786,0.00036706193,0.000004719783,0.00040951403,0.000007262595,0.0006925005,0.0002709083],"about_ca_topic_score_codex":0.002175798,"about_ca_topic_score_gemma":0.0010635222,"teacher_disagreement_score":0.022522012,"about_ca_system_score_codex":0.00018843479,"about_ca_system_score_gemma":0.0011088494,"threshold_uncertainty_score":0.99868697},"labels":[],"label_agreement":null},{"id":"W2776594178","doi":"10.1016/j.clgc.2017.12.012","title":"Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone acetate; Docetaxel; Androgen deprivation therapy; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.18384847412308658,"score_gpt":0.4752861645697759,"score_spread":0.2914376904466893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776594178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96454674,0.011281667,0.00023052655,0.0074311034,0.0010862076,0.009951117,0.0053834086,0.0000732263,0.000016028884],"genre_scores_gemma":[0.88440925,0.08449872,0.0063492535,0.00096724887,0.0009909776,0.012460842,0.00032089333,0.00020477129,0.009798069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99365604,0.00032072223,0.0027345119,0.0013949125,0.00075430307,0.0011395187],"domain_scores_gemma":[0.9929104,0.0019328399,0.0016972951,0.001205221,0.0016439839,0.0006102656],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018160907,0.0008010984,0.002559407,0.00017456849,0.00064088195,0.00015207235,0.00045433006,0.00025663787,0.0002542386],"category_scores_gemma":[0.0011426677,0.0004955778,0.00095062633,0.00026036237,0.0010336739,0.0005652482,0.00019010899,0.0005547305,0.000008889376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34922627,0.003997463,0.46510112,0.0023361382,0.011273024,0.0010349585,0.001332468,0.000307356,0.004420817,0.000007880941,0.0038099037,0.15715262],"study_design_scores_gemma":[0.096350566,0.018457023,0.83598095,0.0013967174,0.0049614594,0.00004275777,0.0005370554,0.0022613662,0.01984339,0.0005196092,0.01814885,0.0015002597],"about_ca_topic_score_codex":0.00092492206,"about_ca_topic_score_gemma":0.00435623,"teacher_disagreement_score":0.37087983,"about_ca_system_score_codex":0.0003590053,"about_ca_system_score_gemma":0.002318997,"threshold_uncertainty_score":0.9997496},"labels":[],"label_agreement":null},{"id":"W2777354357","doi":"10.1016/j.clgc.2017.12.009","title":"Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Neutrophil to lymphocyte ratio; Internal medicine; Urothelial cancer; Proportional hazards model; Cancer; Mean time between failures; Hazard ratio; Lymphocyte; Gastroenterology; Oncology; Urology; Bladder cancer; Confidence interval","score_opus":0.03096370431593965,"score_gpt":0.3955360637080628,"score_spread":0.3645723593921232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777354357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874372,0.0019451389,9.0947947e-7,0.0055710636,0.0007833201,0.0010914877,0.000054709173,0.000025364809,0.0030908193],"genre_scores_gemma":[0.9913805,0.004427373,0.00036727823,0.0010937491,0.0006991016,0.0006385511,0.0000018626869,0.00003554496,0.0013560351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980805,0.00013844969,0.0007839584,0.00042824264,0.00026859652,0.0003002577],"domain_scores_gemma":[0.9980372,0.0003341379,0.00035629602,0.0008929904,0.00013274173,0.0002465885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005494072,0.00021362909,0.00073926634,0.000097418,0.00018102746,0.000030411109,0.00036358493,0.00010646873,0.00010785],"category_scores_gemma":[0.00046456332,0.0001456093,0.00023330303,0.00010126405,0.0006879789,0.00010994728,0.00030764355,0.00022864682,0.000009366895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009451651,0.00015812622,0.9126808,0.0000618257,0.00016874069,0.000058284313,0.000107319065,0.000025673975,0.0009094128,0.00013458308,0.0002037272,0.07603984],"study_design_scores_gemma":[0.009889487,0.00016024288,0.9794471,0.00022559466,0.00018184114,0.0000020425707,0.0000538224,0.00023219187,0.0020833788,0.00028817556,0.007263384,0.00017273982],"about_ca_topic_score_codex":0.0011763021,"about_ca_topic_score_gemma":0.0007966977,"teacher_disagreement_score":0.0758671,"about_ca_system_score_codex":0.00014966603,"about_ca_system_score_gemma":0.00047824226,"threshold_uncertainty_score":0.59377754},"labels":[],"label_agreement":null},{"id":"W2778808609","doi":"10.1016/j.clgc.2017.12.006","title":"Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies","year":2017,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Prednisone; Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Placebo; Randomized controlled trial; Abiraterone acetate; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.25017454742995576,"score_gpt":0.539170911552819,"score_spread":0.2889963641228633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778808609","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1924544,0.8031826,1.4385452e-7,0.00011202829,0.00026229298,0.0030487804,0.0008281352,0.0000131858,0.00009841545],"genre_scores_gemma":[0.04495706,0.95114386,0.000039860068,0.000015775082,0.00011957337,0.001549812,0.00009648926,0.000051174608,0.0020263954],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9954272,0.00077237317,0.001953882,0.0008278485,0.0005987439,0.0004199342],"domain_scores_gemma":[0.995137,0.0022255175,0.0014139467,0.00071599457,0.0003214577,0.00018609996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012105507,0.0006271382,0.006764534,0.00074810325,0.00010282424,0.000026432452,0.00022226102,0.0002123074,0.000039270428],"category_scores_gemma":[0.0007039268,0.0003795496,0.0011610325,0.00062181125,0.0008537866,0.000084067375,0.00017449028,0.0005529789,0.0000015482345],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063977875,0.0013026571,0.07086273,0.052720632,0.05257499,0.00057232653,0.0006844396,0.000034479606,0.000037247744,0.0000049259943,0.00013608491,0.8146717],"study_design_scores_gemma":[0.04371081,0.07979033,0.23821199,0.17083828,0.40523446,0.00003412724,0.0014958088,0.00010973332,0.00202674,0.00011024548,0.05541321,0.003024265],"about_ca_topic_score_codex":0.00031381287,"about_ca_topic_score_gemma":0.00042222845,"teacher_disagreement_score":0.8116474,"about_ca_system_score_codex":0.00066374405,"about_ca_system_score_gemma":0.0010281918,"threshold_uncertainty_score":0.99986565},"labels":[],"label_agreement":null},{"id":"W2781546173","doi":"10.1016/j.clgc.2017.12.016","title":"Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Epidemiology; Population; Hazard ratio; Odds ratio; Logistic regression; Internal medicine; Cancer; Confidence interval; Environmental health","score_opus":0.07452605924954833,"score_gpt":0.39969779965112495,"score_spread":0.3251717404015766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781546173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969669,0.00023708286,0.00016528735,0.00038675696,0.00049886573,0.0005441176,0.00037705767,0.000044472596,0.00077944744],"genre_scores_gemma":[0.9924995,0.00007122522,0.0011303341,0.00082634075,0.0019037819,0.00036488628,0.00023916454,0.000052822597,0.0029119926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801517,0.000050849998,0.00053534715,0.00058321346,0.0003109614,0.0005044539],"domain_scores_gemma":[0.9989254,0.00008294361,0.00015725898,0.00035741634,0.00025365228,0.00022333277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018108207,0.00025176234,0.0006582995,0.00046691703,0.00012227223,0.000017780823,0.000112636124,0.00015967456,0.0008941916],"category_scores_gemma":[0.00003233303,0.0001949492,0.00029479768,0.0010948409,0.000092228045,0.00009543336,0.000045785484,0.00018689186,0.000011668514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037568458,0.00055272947,0.96474695,0.000021319553,0.0013749198,0.000010066325,0.00012265715,0.00004148652,0.0000014324701,0.000005250589,0.0005791873,0.028787151],"study_design_scores_gemma":[0.008297633,0.001898197,0.98598903,0.00006319581,0.0018923017,6.175486e-7,0.000032416487,0.00028036765,0.00004015644,0.00002011598,0.0012505666,0.0002353798],"about_ca_topic_score_codex":0.0011912179,"about_ca_topic_score_gemma":0.0018403252,"teacher_disagreement_score":0.028551772,"about_ca_system_score_codex":0.0002485525,"about_ca_system_score_gemma":0.00020229677,"threshold_uncertainty_score":0.9790771},"labels":[],"label_agreement":null},{"id":"W2789859592","doi":"10.1016/j.clgc.2018.01.011","title":"Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Testicular cancer; Framingham Risk Score; Cisplatin; Internal medicine; Oncology; Disease; Cancer; Chemotherapy","score_opus":0.02383816253581744,"score_gpt":0.30989196123904555,"score_spread":0.2860537987032281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789859592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988526,0.0032768992,0.005682758,0.00034278884,0.0005984721,0.0012715918,0.00010527388,0.0000829968,0.000113252514],"genre_scores_gemma":[0.99478894,0.0005639395,0.0002688674,0.0009187298,0.0027689943,0.00050546194,0.000014981707,0.00007317294,0.00009689057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743974,0.0002444938,0.00068028097,0.0006514263,0.0006617781,0.00032226392],"domain_scores_gemma":[0.99753416,0.00021499465,0.00037705625,0.0011868869,0.00040425555,0.0002826744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071426225,0.00027806405,0.0005899827,0.000056464774,0.00018355965,0.000015845559,0.0002205424,0.00027297068,0.000087355416],"category_scores_gemma":[0.0003068096,0.00021295066,0.0009940305,0.0003774815,0.0006871928,0.0000799346,0.000063611114,0.0005348802,0.0000045851766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007439789,0.00021012222,0.92822605,0.00014238957,0.0006801562,0.000009597657,0.0001562119,0.0031720418,0.0023385447,8.419648e-7,0.000045064982,0.06427501],"study_design_scores_gemma":[0.0021264444,0.00018116193,0.9224104,0.00046662326,0.001190213,0.0000021603705,0.000022787519,0.05328452,0.018897617,0.00012259364,0.0010546996,0.00024076652],"about_ca_topic_score_codex":0.0013421995,"about_ca_topic_score_gemma":0.00018484358,"teacher_disagreement_score":0.064034246,"about_ca_system_score_codex":0.00015286493,"about_ca_system_score_gemma":0.00044450993,"threshold_uncertainty_score":0.86838764},"labels":[],"label_agreement":null},{"id":"W2791728754","doi":"10.1016/j.clgc.2018.02.005","title":"Revisiting the Prognostic Heterogeneity of AJCC Stage IV Carcinomas of the Upper Urinary Tract","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; AJCC staging system; Hazard ratio; Proportional hazards model; Stage (stratigraphy); Renal pelvis; Oncology; Confidence interval; Cancer staging; Cancer; Surveillance, Epidemiology, and End Results; Cancer registry; Survival analysis; Internal medicine; Urinary system; Staging system","score_opus":0.08032134750045948,"score_gpt":0.3931273802920347,"score_spread":0.3128060327915752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791728754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904408,0.0036980282,0.000007297833,0.0015424142,0.0007705072,0.0008188272,0.00009831437,0.000021916065,0.0026019006],"genre_scores_gemma":[0.994766,0.0004500458,0.000121888836,0.00068718893,0.0026830954,0.00006497762,0.0000038500984,0.000035214707,0.0011877278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978191,0.00029528377,0.0008271793,0.00037230938,0.00038054684,0.00030555323],"domain_scores_gemma":[0.9979787,0.00039130074,0.0003889272,0.0008456014,0.00026297584,0.000132501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004874067,0.00021350636,0.00053500145,0.000031829233,0.00015657232,0.000006995403,0.00033385726,0.0001355974,0.00040374845],"category_scores_gemma":[0.00024272788,0.000113737144,0.00051282684,0.0002435101,0.0007702496,0.00005399,0.00019406286,0.0003742377,0.000015249839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065303507,0.0006033378,0.9855209,0.00019751459,0.00022877291,0.000036094043,0.00015563345,0.0000030433657,0.0008516975,0.00000966075,0.00033385574,0.011406471],"study_design_scores_gemma":[0.0015158542,0.0018152925,0.98305535,0.000326324,0.00047503837,0.00006293013,0.00009264629,0.00004663434,0.006464445,0.000027348271,0.0060044415,0.00011370784],"about_ca_topic_score_codex":0.00015975421,"about_ca_topic_score_gemma":0.000007001342,"teacher_disagreement_score":0.011292763,"about_ca_system_score_codex":0.00006227242,"about_ca_system_score_gemma":0.00044609953,"threshold_uncertainty_score":0.46380663},"labels":[],"label_agreement":null},{"id":"W2793249623","doi":"10.1016/j.clgc.2018.01.003","title":"Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature","year":2018,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Sunitinib; Pazopanib; Renal cell carcinoma; Sorafenib; Adjuvant therapy; Nephrectomy; Oncology; Kidney cancer; Internal medicine; Adjuvant; Bevacizumab; Placebo; Tyrosine-kinase inhibitor; Cancer; Kidney; Chemotherapy; Pathology; Hepatocellular carcinoma; Alternative medicine","score_opus":0.09971389070820243,"score_gpt":0.4146607554077169,"score_spread":0.3149468646995145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793249623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004011459,0.99048793,2.9492432e-7,0.00032866502,0.00091799157,0.003283865,0.00017872888,0.000016686385,0.00077439495],"genre_scores_gemma":[0.00034209725,0.9935192,0.00027746428,0.00085625396,0.001199912,0.00060719345,0.000112211885,0.00011281853,0.0029728364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940773,0.0012923097,0.0026734658,0.0009016618,0.000590045,0.00046518233],"domain_scores_gemma":[0.99572825,0.0006427013,0.001326922,0.0017939229,0.00027556694,0.00023260579],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010495795,0.00075557496,0.0045635146,0.00018149937,0.000050449245,0.000014084813,0.0006085621,0.0004996492,0.00030343985],"category_scores_gemma":[0.00024519712,0.00039112914,0.0027767566,0.0010646534,0.00040716396,0.000048575912,0.00032108714,0.0014648646,0.000063157255],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014562526,0.001000407,0.0013449491,0.40327156,0.00044555578,0.0009644825,0.00012830569,1.088278e-7,0.0000024489273,0.0000010821941,0.01891075,0.5737847],"study_design_scores_gemma":[0.0009236753,0.000794356,0.0021984084,0.31333852,0.0034412348,0.00016660508,0.000008411039,4.5975406e-7,0.0000105996105,0.0000100447205,0.67882943,0.0002782139],"about_ca_topic_score_codex":0.000032763743,"about_ca_topic_score_gemma":0.000011880544,"teacher_disagreement_score":0.6599187,"about_ca_system_score_codex":0.00036346252,"about_ca_system_score_gemma":0.0016281593,"threshold_uncertainty_score":0.9998541},"labels":[],"label_agreement":null},{"id":"W2796329816","doi":"10.1016/j.clgc.2018.03.016","title":"Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"National Cancer Institute","keywords":"Medicine; Nomogram; Oncology; Docetaxel; Internal medicine; Pazopanib; Sunitinib; Confidence interval; Carboplatin; Renal cell carcinoma; Urology; Chemotherapy; Cisplatin","score_opus":0.18361739499181,"score_gpt":0.45337110015947707,"score_spread":0.26975370516766706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796329816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917793,0.001159922,0.00027108865,0.0029600316,0.0010774075,0.001965871,0.00018123382,0.000011186816,0.00059394154],"genre_scores_gemma":[0.9931731,0.00037944913,0.0010321435,0.0027438877,0.0016270853,0.00026926716,0.0000108163695,0.000042472468,0.00072175806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979397,0.00018816767,0.00083582196,0.0003342336,0.00037899413,0.0003230715],"domain_scores_gemma":[0.9981312,0.0006603353,0.0002176931,0.000661102,0.00020201707,0.00012762393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078919734,0.00021510333,0.000638574,0.000054713597,0.00007328524,0.000012466537,0.0004430365,0.00008437277,0.000287398],"category_scores_gemma":[0.00011522605,0.00012195033,0.0003802188,0.00033558064,0.00024119327,0.000043177657,0.0000583848,0.0002707306,0.000009530578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018533496,0.0036140864,0.5824702,0.0002869378,0.0016093864,0.00007073682,0.005738864,0.000067656176,0.0035295652,0.00020785262,0.016080465,0.36779076],"study_design_scores_gemma":[0.010607479,0.0077782795,0.9427561,0.00020735421,0.00049914746,0.00001221335,0.0005041412,0.000079586345,0.0049538333,0.00060553005,0.031778593,0.00021771234],"about_ca_topic_score_codex":0.0015448643,"about_ca_topic_score_gemma":0.0004152816,"teacher_disagreement_score":0.36757305,"about_ca_system_score_codex":0.000055656343,"about_ca_system_score_gemma":0.0005428051,"threshold_uncertainty_score":0.49729902},"labels":[],"label_agreement":null},{"id":"W2800033280","doi":"10.1016/j.clgc.2018.04.003","title":"Two Cases of Arterioureteral Fistula in the Setting of Previous Radiation Therapy and Indwelling Ureteral Stents: Results of Endovascular Management","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Infectious Aortic and Vascular Conditions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Urinary Fistula; Radiology; Fistula; Surgery","score_opus":0.05202607944733138,"score_gpt":0.37306959088257374,"score_spread":0.32104351143524235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800033280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713707,0.0014641837,0.000065084096,0.00014870227,0.00016841353,0.0005577156,0.000025564197,0.0000062652043,0.00042698818],"genre_scores_gemma":[0.9962321,0.0027050867,0.00041504408,0.00021713291,0.00034389517,0.000032410248,0.00001843633,0.000009669181,0.000026207887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845976,0.0002210737,0.00078543235,0.00019646512,0.00020206526,0.00013523312],"domain_scores_gemma":[0.9990541,0.00021313134,0.0002949853,0.0002985505,0.000103275255,0.00003598072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007658431,0.000100433754,0.0003485523,0.00008267259,0.000041277894,0.0000046379687,0.00007560489,0.00005984009,0.000024656063],"category_scores_gemma":[0.0000830787,0.00007179505,0.00019117379,0.00016185395,0.0001974654,0.000043867967,0.000032022977,0.00014386653,5.50863e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024285296,0.0010833459,0.78554034,0.00053653726,0.001367498,0.00018752714,0.004765645,0.0000974694,0.001207591,0.000100356454,0.0004708186,0.20221435],"study_design_scores_gemma":[0.008697437,0.0023297204,0.9844228,0.00045587608,0.00032370462,0.000087612156,0.0003663684,0.0005726876,0.0013761026,0.000097694756,0.0011515461,0.00011845291],"about_ca_topic_score_codex":0.00022326065,"about_ca_topic_score_gemma":0.000034670877,"teacher_disagreement_score":0.2020959,"about_ca_system_score_codex":0.000017994314,"about_ca_system_score_gemma":0.000039922958,"threshold_uncertainty_score":0.29277173},"labels":[],"label_agreement":null},{"id":"W2805011737","doi":"10.1016/j.clgc.2018.03.003","title":"Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Nephrectomy; Interquartile range; Renal cell carcinoma; Proportional hazards model; Disease; Retrospective cohort study; Regimen; Internal medicine; Cancer; Localized disease; Surgery; Urology; Oncology; Kidney; Prostate cancer","score_opus":0.019548714726438352,"score_gpt":0.3043169565525032,"score_spread":0.2847682418260648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805011737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99409175,0.002847804,0.0000029510861,0.00018242966,0.0007253125,0.0015092635,0.00022664884,0.000013072193,0.0004007829],"genre_scores_gemma":[0.9981374,0.00018364473,0.00005471577,0.000056674515,0.00074327656,0.00034440096,0.000022431072,0.000035727866,0.00042171087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970375,0.00042616043,0.0008439958,0.0006390091,0.00065629976,0.00039704278],"domain_scores_gemma":[0.9976036,0.000504851,0.0003087533,0.0008045184,0.00034519317,0.000433106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004908815,0.00032333343,0.00075697515,0.00011261521,0.00004253334,0.000006711034,0.00029926363,0.000102931794,0.0005587773],"category_scores_gemma":[0.00011279103,0.00019005133,0.00021752571,0.00051661633,0.00059616263,0.00006160238,0.00016232306,0.00035103087,0.000058564485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0246371,0.00056690397,0.96510386,0.00018570968,0.00006558818,0.00006599963,0.00011224465,0.000023107546,0.00008981046,1.3137092e-7,0.0014098859,0.0077396496],"study_design_scores_gemma":[0.004131201,0.011768862,0.9780891,0.00055866514,0.00029837393,5.724159e-7,0.0000053856484,0.000015054565,0.0037043132,0.0000014313292,0.0012416493,0.00018536873],"about_ca_topic_score_codex":0.00014338868,"about_ca_topic_score_gemma":0.00004722821,"teacher_disagreement_score":0.020505898,"about_ca_system_score_codex":0.0002067626,"about_ca_system_score_gemma":0.00036836517,"threshold_uncertainty_score":0.77500683},"labels":[],"label_agreement":null},{"id":"W2807085990","doi":"10.1016/j.clgc.2018.05.016","title":"Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cancer; Prostate cancer; Prostate; Oncology; Internal medicine","score_opus":0.17179034212278158,"score_gpt":0.4655013243474023,"score_spread":0.2937109822246208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807085990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96314436,0.032149475,0.0000033075014,0.00095768424,0.0012042995,0.0015556492,0.00031298932,0.00003977437,0.00063245423],"genre_scores_gemma":[0.9803288,0.016456122,0.00006171768,0.00030326872,0.0010725426,0.0006876449,0.00010069215,0.00004335836,0.00094583456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721575,0.0002679207,0.0008755827,0.000641684,0.0005347462,0.00046432408],"domain_scores_gemma":[0.997829,0.00018534625,0.00034049564,0.0004576605,0.0008968635,0.0002905985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000548085,0.0002741245,0.00075788837,0.0001730864,0.00008722047,0.00001421075,0.00017692092,0.00016762874,0.00040775648],"category_scores_gemma":[0.00010890537,0.00021457284,0.00016694357,0.00083992333,0.0007098803,0.00018846637,0.00011832114,0.0003868063,0.000021151489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00342701,0.0015172067,0.95548385,0.0005354507,0.00030880448,0.00008179426,0.00025560663,0.0000149976095,0.0007277947,0.000005008306,0.011721029,0.025921462],"study_design_scores_gemma":[0.0074458322,0.0021626183,0.9635458,0.0011198196,0.00012459682,0.0000010096713,0.00008536743,0.00006990397,0.012493788,0.00003804021,0.012668442,0.00024479],"about_ca_topic_score_codex":0.001741633,"about_ca_topic_score_gemma":0.00069888,"teacher_disagreement_score":0.025676673,"about_ca_system_score_codex":0.00038811722,"about_ca_system_score_gemma":0.0015867748,"threshold_uncertainty_score":0.8750026},"labels":[],"label_agreement":null},{"id":"W2859836197","doi":"10.1016/j.clgc.2018.07.002","title":"Prognostic Value of Serum Cholinesterase in Non–muscle-invasive Bladder Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Bladder cancer; Cholinesterase; Internal medicine; Oncology; Cancer; Urology","score_opus":0.06080499678222432,"score_gpt":0.4219349544516621,"score_spread":0.3611299576694378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2859836197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457884,0.0015649971,0.000007263507,0.0012977957,0.0011657242,0.000784682,0.00019900047,0.000036745976,0.0003649354],"genre_scores_gemma":[0.9872273,0.002164215,0.00012462283,0.0046720626,0.004728768,0.00022056501,0.000020581887,0.00005581403,0.0007860305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997431,0.0001708534,0.0010027095,0.0006643489,0.00030776768,0.0004233419],"domain_scores_gemma":[0.9979774,0.00041429413,0.00024416155,0.00051352393,0.00048875867,0.00036187045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021392522,0.00030290376,0.00070980855,0.0001586644,0.000060475213,0.00001303652,0.00018040351,0.0001796385,0.0007768415],"category_scores_gemma":[0.00051387865,0.000254322,0.00029989114,0.0004587684,0.00040998988,0.00013448746,0.00012350213,0.00038269506,0.000049154747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090387586,0.0014616044,0.96860933,0.00025982037,0.00015311281,0.00049885485,0.00023732986,0.000076169104,0.008627379,0.0000041855,0.0031185953,0.016049769],"study_design_scores_gemma":[0.0035476463,0.001131559,0.97745603,0.00075626635,0.0003024687,0.000016071224,0.000055177574,0.0004021276,0.014610685,0.000021609876,0.0014315356,0.00026882812],"about_ca_topic_score_codex":0.0001333255,"about_ca_topic_score_gemma":0.00029636253,"teacher_disagreement_score":0.01578094,"about_ca_system_score_codex":0.00006717817,"about_ca_system_score_gemma":0.00078722724,"threshold_uncertainty_score":0.9999909},"labels":[],"label_agreement":null},{"id":"W2884972285","doi":"10.1016/j.clgc.2018.07.007","title":"Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Proportional hazards model; Internal medicine; Androgen deprivation therapy; Docetaxel; Survival analysis; Prostate; Prostate-specific antigen; Progression-free survival; Performance status; Cancer; Overall survival","score_opus":0.06612133646766608,"score_gpt":0.4508892951953859,"score_spread":0.38476795872771985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884972285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873231,0.0033698147,0.000017620365,0.00091755134,0.00027564296,0.0069904067,0.00057404675,0.0000130775325,0.00051873154],"genre_scores_gemma":[0.9891386,0.0076204822,0.00006197116,0.00009753866,0.00024882454,0.0012390336,0.00003602595,0.000026984186,0.0015305534],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955275,0.0010827249,0.0020014646,0.00042382983,0.00059788657,0.0003665811],"domain_scores_gemma":[0.99252445,0.004751286,0.001150764,0.00057513715,0.0007929959,0.0002053905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016867664,0.00035455037,0.005509307,0.0003651011,0.00007237926,0.0000069580533,0.00014769411,0.00011252596,0.00065363524],"category_scores_gemma":[0.0006487573,0.00015360242,0.0039568576,0.00070334156,0.0019136838,0.000043637905,0.000058527465,0.00026211716,0.0000039818788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89805204,0.0023024892,0.010058329,0.000033412158,0.07361093,0.00004599806,0.00065868685,0.00009233148,0.0004638919,0.000008945254,0.00025422865,0.014418706],"study_design_scores_gemma":[0.88425606,0.019785002,0.068421476,0.000091172784,0.02226311,0.000001361254,0.00022935725,0.0014437694,0.003305846,0.00003158887,0.000028474007,0.00014280666],"about_ca_topic_score_codex":0.0014676956,"about_ca_topic_score_gemma":0.00010331458,"teacher_disagreement_score":0.058363147,"about_ca_system_score_codex":0.00034391848,"about_ca_system_score_gemma":0.0019702204,"threshold_uncertainty_score":0.7156848},"labels":[],"label_agreement":null},{"id":"W2890747191","doi":"10.1016/j.clgc.2018.09.006","title":"Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Kidney cancer; Carcinoma; Targeted therapy; Cancer","score_opus":0.05160311231907259,"score_gpt":0.32438790381401117,"score_spread":0.27278479149493856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890747191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642897,0.00054337276,0.0000025929025,0.00025311887,0.00010876664,0.0013966588,0.00007670857,0.00007081315,0.0011189802],"genre_scores_gemma":[0.99720114,0.000073999145,0.00044209583,0.0005034698,0.00025850945,0.00038792062,0.00012494119,0.00009026031,0.0009176503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969743,0.00034688396,0.00069964613,0.00079222623,0.0005809671,0.0006060034],"domain_scores_gemma":[0.9980117,0.00030037886,0.00041614092,0.00039478624,0.0005670419,0.000309933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023891134,0.0004560977,0.00087720813,0.00019569919,0.00012229335,0.000024322071,0.00014838549,0.00017120341,0.00045354854],"category_scores_gemma":[0.0000694334,0.00029282997,0.00018221742,0.00075637724,0.00042585548,0.00014201047,0.00005995079,0.00051681895,0.000020776273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007650085,0.0026496793,0.9803512,0.000039018134,0.00083405565,0.0010243455,0.0009952978,0.0000041974236,0.00019962912,1.8342972e-7,0.0006254781,0.0056268233],"study_design_scores_gemma":[0.011981767,0.014338944,0.95049447,0.00036275215,0.000904236,0.000013346412,0.00023015654,0.00006408035,0.021046843,0.0000060120433,0.0002050888,0.000352327],"about_ca_topic_score_codex":0.0003793227,"about_ca_topic_score_gemma":0.00025418325,"teacher_disagreement_score":0.029856762,"about_ca_system_score_codex":0.0005437219,"about_ca_system_score_gemma":0.00041426296,"threshold_uncertainty_score":0.9999524},"labels":[],"label_agreement":null},{"id":"W2891104247","doi":"10.1016/j.clgc.2018.09.008","title":"Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Cystectomy; Nomogram; Bladder cancer; Proportional hazards model; Retrospective cohort study; Concordance; Perioperative; Lymph node; Cumulative incidence; Stage (stratigraphy); Confidence interval; Cancer; Hazard ratio; Urology; Internal medicine; Oncology; Cohort; Surgery","score_opus":0.03668717770792943,"score_gpt":0.3472813592159894,"score_spread":0.31059418150805995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891104247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958397,0.00048405532,0.00028302832,0.00022354983,0.0007774071,0.0019147582,0.00032266474,0.000026992666,0.00012784246],"genre_scores_gemma":[0.99037325,0.0001842683,0.0049699517,0.0006559306,0.0013393358,0.002169318,0.000074329786,0.000043663294,0.00018993451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766856,0.00006257711,0.000845524,0.000609242,0.00042854954,0.0003855374],"domain_scores_gemma":[0.99867564,0.00016484255,0.00023788422,0.000287272,0.00043664043,0.00019770219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016080386,0.00027078242,0.00054146996,0.000112011694,0.00008124171,0.000007165317,0.0001235238,0.00020115037,0.00042147143],"category_scores_gemma":[0.00007214728,0.00020511923,0.00015204695,0.0002500386,0.00042852154,0.00010985485,0.00007299419,0.00024742566,0.000008869964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015537905,0.0015283644,0.9104586,0.00021833369,0.00055324467,0.000027859767,0.0007463251,0.000004176527,0.00006725926,0.0000023750656,0.0013821607,0.06947337],"study_design_scores_gemma":[0.013404365,0.0032114224,0.9708613,0.00088545075,0.0002781378,0.0000030401786,0.000048003112,0.00003062382,0.00086204347,0.000024586749,0.010153415,0.00023758433],"about_ca_topic_score_codex":0.000027789572,"about_ca_topic_score_gemma":0.00014689102,"teacher_disagreement_score":0.06923579,"about_ca_system_score_codex":0.00026120726,"about_ca_system_score_gemma":0.0016005641,"threshold_uncertainty_score":0.83645195},"labels":[],"label_agreement":null},{"id":"W2891539948","doi":"10.1016/j.clgc.2018.09.005","title":"Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"Kidney Cancer Association; National Cancer Institute; Conquer Cancer Foundation; National Institutes of Health; Cancer Prevention and Research Institute of Texas; Johnson Foundation","keywords":"Medicine; Sickle cell trait; Clinical trial; Renal cell carcinoma; Disease; Dosing; Internal medicine; Chemotherapy; Intensive care medicine; Oncology; Nephrectomy; Kidney","score_opus":0.13382681391219975,"score_gpt":0.4528119512202993,"score_spread":0.3189851373080996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891539948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871459,0.00017748098,0.000025276526,0.005989288,0.0014605962,0.0038026338,0.00015648082,0.00004766903,0.0011946653],"genre_scores_gemma":[0.9890189,0.00080621097,0.002461629,0.0028391255,0.0027783709,0.0011153537,0.0002663362,0.00004779757,0.00066626794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695504,0.00046271714,0.0010642176,0.0008437905,0.0003055348,0.0003686944],"domain_scores_gemma":[0.9967461,0.0014603968,0.0002918413,0.0008309661,0.00033953082,0.00033111952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010644273,0.00029267496,0.0005796902,0.00006408162,0.00028399564,0.00003805802,0.00018868198,0.00018271356,0.0005780833],"category_scores_gemma":[0.0003419523,0.00017296146,0.00028708047,0.00017551174,0.0005844448,0.00006934868,0.00015514642,0.0003613298,0.00003093784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0951363,0.0034307183,0.71719754,0.00004640101,0.00066247076,0.000041438627,0.000027791122,1.4264498e-7,0.000001323937,0.000037036116,0.1445611,0.038857754],"study_design_scores_gemma":[0.052429616,0.022518476,0.8401195,0.00012988882,0.0009056616,0.0000038082278,0.000031692998,0.00003993117,0.000078724464,0.00015332473,0.08336587,0.00022353],"about_ca_topic_score_codex":0.000024186056,"about_ca_topic_score_gemma":0.000028860397,"teacher_disagreement_score":0.12292194,"about_ca_system_score_codex":0.00012632587,"about_ca_system_score_gemma":0.00014769501,"threshold_uncertainty_score":0.7053163},"labels":[],"label_agreement":null},{"id":"W2893134098","doi":"10.1016/j.clgc.2018.09.016","title":"Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Metformin; Docetaxel; Prostate cancer; Internal medicine; Oncology; Prednisone; Diabetes mellitus; Proportional hazards model; Cancer; Endocrinology; Insulin","score_opus":0.03945590755046969,"score_gpt":0.3818552045301798,"score_spread":0.3423992969797101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893134098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815127,0.017004242,0.0000033804617,0.000026787413,0.000080052756,0.0004431471,0.00089334237,0.0000048889306,0.000031455435],"genre_scores_gemma":[0.99491674,0.0045135054,0.000034414214,0.00009876057,0.00014925707,0.00013550685,0.000067474626,0.000023439281,0.00006087751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998228,0.00012621871,0.0007052425,0.00038786465,0.00029150437,0.00026115097],"domain_scores_gemma":[0.99759835,0.00012116098,0.0007249671,0.0005430966,0.00093048555,0.00008192883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024055957,0.0002606139,0.0008957201,0.00008712966,0.000063747386,0.000006537952,0.00021164918,0.000091899165,0.000112654474],"category_scores_gemma":[0.00008589828,0.00013019364,0.00036326764,0.0004684699,0.000749219,0.000008600329,0.000054128275,0.000095368334,3.3593827e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004697825,0.0009059988,0.9574262,0.000037572325,0.018657895,7.6693567e-7,0.00011003387,0.00032690258,0.004886087,0.0000029183975,0.00031879728,0.012629024],"study_design_scores_gemma":[0.0050971243,0.0077457577,0.95589393,0.000074570184,0.00397834,2.5621786e-8,0.00007184271,0.00005463888,0.026594717,0.000008569342,0.00026722855,0.00021323067],"about_ca_topic_score_codex":0.00022121794,"about_ca_topic_score_gemma":0.0010237416,"teacher_disagreement_score":0.02170863,"about_ca_system_score_codex":0.000028046234,"about_ca_system_score_gemma":0.00027988866,"threshold_uncertainty_score":0.53091425},"labels":[],"label_agreement":null},{"id":"W2893828074","doi":"10.1016/j.clgc.2018.09.011","title":"Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Logistic regression; Prostate cancer; Epidemiology; Internal medicine; Population; Prostate-specific antigen; Demography; Stage (stratigraphy); Cancer; Gynecology; Environmental health","score_opus":0.04762448794292119,"score_gpt":0.41928996364143567,"score_spread":0.3716654756985145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893828074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941916,0.0004718239,0.000017273305,0.0005951686,0.00038870363,0.003599953,0.0006626537,0.000030128696,0.000042706408],"genre_scores_gemma":[0.9934936,0.0011140886,0.0005765637,0.00028062044,0.00039217478,0.0036277056,0.0002718635,0.000042110714,0.0002012778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754465,0.00029258122,0.0009393582,0.00064039405,0.00020172376,0.0003812972],"domain_scores_gemma":[0.9983302,0.00042222434,0.00047547993,0.00033314704,0.00026026438,0.00017869024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040503195,0.00029461514,0.0008726196,0.00016325625,0.00009141795,0.000014519917,0.00009439863,0.00004273696,0.0001102665],"category_scores_gemma":[0.0000541635,0.00023414532,0.00029582303,0.0004287695,0.00019452334,0.000056879224,0.000047668338,0.000103186925,0.0000035032654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014024333,0.0039395443,0.87285554,0.00011516364,0.0009596596,0.00006609288,0.00015150882,0.00022358281,0.000007038928,0.0000016952991,0.00011818481,0.10753765],"study_design_scores_gemma":[0.014576759,0.009219111,0.97297627,0.00026620168,0.0003751127,0.000001114166,0.00018519488,0.00069872243,0.00033270626,0.000015966441,0.0011418475,0.00021098243],"about_ca_topic_score_codex":0.011677815,"about_ca_topic_score_gemma":0.024070013,"teacher_disagreement_score":0.107326664,"about_ca_system_score_codex":0.000966345,"about_ca_system_score_gemma":0.00037020343,"threshold_uncertainty_score":0.9949035},"labels":[],"label_agreement":null},{"id":"W2894543473","doi":"10.1016/j.clgc.2018.09.017","title":"Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Urology; Cohort; Internal medicine; Oncology; Chemotherapy; Population; Cancer","score_opus":0.05022373847367602,"score_gpt":0.4042056028138359,"score_spread":0.3539818643401599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894543473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134064,0.0015265311,0.000011550292,0.0005961241,0.0013461107,0.00091167405,0.000059535072,0.000040850682,0.004166983],"genre_scores_gemma":[0.9949753,0.00064263004,0.00025546466,0.00065245014,0.0020852468,0.0001364592,0.000011562524,0.00006906413,0.0011718109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974152,0.0003802916,0.00085243635,0.000548636,0.00036823298,0.00043520643],"domain_scores_gemma":[0.9985129,0.00043283435,0.00017706961,0.0005167362,0.000114397546,0.00024601753],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064377405,0.00033022795,0.0010535063,0.00014263602,0.000050290953,0.000007820177,0.00018743589,0.00016604483,0.0014737796],"category_scores_gemma":[0.0001015157,0.0002500701,0.00044197906,0.00030935963,0.0004108527,0.00008543627,0.00005534928,0.00038700202,0.00008460207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010174835,0.0022715754,0.9533392,0.00019194212,0.00026473796,0.00042904157,0.00016951494,0.0000014254582,0.0011448134,0.000004127881,0.0006438654,0.03136493],"study_design_scores_gemma":[0.01617157,0.019715004,0.94634706,0.00017146613,0.00037088039,0.000105488354,0.000033144235,0.00006863474,0.011575352,0.000054306936,0.0051308987,0.0002562103],"about_ca_topic_score_codex":0.00034219256,"about_ca_topic_score_gemma":0.000014708328,"teacher_disagreement_score":0.031108718,"about_ca_system_score_codex":0.00012565272,"about_ca_system_score_gemma":0.00043454397,"threshold_uncertainty_score":0.9999952},"labels":[],"label_agreement":null},{"id":"W2894922686","doi":"10.1016/j.clgc.2018.09.021","title":"Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Gemcitabine; Cisplatin; Chemoradiotherapy; Radiation therapy; Chemotherapy; Confidence interval; Oncology; Stage (stratigraphy); Internal medicine; Urology; External beam radiotherapy; Cancer; Surgery; Brachytherapy","score_opus":0.028054779955515932,"score_gpt":0.3492026512342951,"score_spread":0.3211478712787792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894922686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311244,0.0013206667,0.000045433135,0.0016761052,0.0009860656,0.0015275521,0.00009842964,0.00010085696,0.0011324597],"genre_scores_gemma":[0.98466736,0.0020863113,0.0014292105,0.006811699,0.0028817672,0.00045881694,0.00004851468,0.00018403358,0.0014322953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965005,0.00011309304,0.0009168274,0.0010296995,0.0006075245,0.00083235995],"domain_scores_gemma":[0.99799824,0.00012661645,0.00030835957,0.00074741663,0.00035854787,0.00046079454],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022550265,0.0005737341,0.0011395392,0.00017686347,0.00015151691,0.000037386875,0.00027665732,0.00026514,0.0025020542],"category_scores_gemma":[0.000044488857,0.00043083527,0.00027329702,0.0005412389,0.000543398,0.00020654195,0.00006908279,0.0005822254,0.000077505116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037084718,0.0017514831,0.827162,0.00008421729,0.0009971574,0.00012272722,0.0008203254,0.000018736215,0.00012340529,0.0000020699179,0.0022834186,0.16292596],"study_design_scores_gemma":[0.022880148,0.005968084,0.96126294,0.00048179107,0.00037500454,0.000007983104,0.000092854476,0.00009120435,0.0011986464,0.000058413247,0.007078167,0.0005047768],"about_ca_topic_score_codex":0.0006516395,"about_ca_topic_score_gemma":0.0011075985,"teacher_disagreement_score":0.16242118,"about_ca_system_score_codex":0.0004544057,"about_ca_system_score_gemma":0.0008907141,"threshold_uncertainty_score":0.99981433},"labels":[],"label_agreement":null},{"id":"W2895612504","doi":"10.1016/j.clgc.2018.09.024","title":"Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Stage (stratigraphy); Proportional hazards model; Incidence (geometry); Epidemiology; Hazard ratio; Urology; Internal medicine; Surgical margin; Mortality rate; Propensity score matching; Cancer; Demography; Oncology; Confidence interval","score_opus":0.03634812508401912,"score_gpt":0.38369164269377554,"score_spread":0.3473435176097564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895612504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868188,0.0037389842,0.000008460756,0.0010747396,0.00074661855,0.0050405124,0.0023394574,0.00005493496,0.00017748155],"genre_scores_gemma":[0.980882,0.013420371,0.00018878651,0.00065437105,0.0011712644,0.0030737137,0.00021664494,0.000098104254,0.00029478414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960379,0.0003233155,0.0012825452,0.0012206612,0.00044575,0.0006898503],"domain_scores_gemma":[0.99584377,0.0017175777,0.00057386735,0.0005512805,0.0007103335,0.00060316426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006498461,0.00058993394,0.0015726156,0.000082073646,0.00022849374,0.000026789387,0.00015735772,0.0002814935,0.00028930625],"category_scores_gemma":[0.00009877208,0.0003571064,0.00040197477,0.00026597214,0.0016512766,0.00009288589,0.00015241269,0.0004171925,0.000007717934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06663579,0.002108204,0.872039,0.0003575724,0.0011245557,0.00008136962,0.00017727661,0.000007279036,0.00008023918,0.00001308311,0.0020653924,0.055310205],"study_design_scores_gemma":[0.032761954,0.045696627,0.88545567,0.0015453866,0.0005619123,0.000006352509,0.000022035872,0.000077701654,0.009269935,0.00005051371,0.024068782,0.00048313473],"about_ca_topic_score_codex":0.00019999701,"about_ca_topic_score_gemma":0.00009154726,"teacher_disagreement_score":0.05482707,"about_ca_system_score_codex":0.0004939326,"about_ca_system_score_gemma":0.0005105135,"threshold_uncertainty_score":0.99988806},"labels":[],"label_agreement":null},{"id":"W2897938485","doi":"10.1016/j.clgc.2018.10.007","title":"Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer","year":2018,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Fundação para a Ciência e a Tecnologia","keywords":"Medicine; Testicular cancer; Cancer; Oncology; Disease; Precision medicine; Biomarker; Germ cell tumors; Internal medicine; Prostate cancer; Genitourinary system; Clinical trial; Narrative review; Intensive care medicine; Pathology; Chemotherapy","score_opus":0.16430088471697618,"score_gpt":0.5135315118760754,"score_spread":0.3492306271590992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897938485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011852174,0.98900855,0.000035205958,0.000494814,0.002406385,0.005536375,0.0010235027,0.00013085529,0.00017910654],"genre_scores_gemma":[0.000198051,0.9817169,0.0011222608,0.0005055213,0.0068339584,0.007813983,0.00051132025,0.0002734255,0.0010246318],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934684,0.00036132775,0.0025359099,0.001916494,0.000714083,0.0010037591],"domain_scores_gemma":[0.9941432,0.0019898268,0.001071205,0.0012683185,0.0005576382,0.00096981914],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007295732,0.0011712544,0.0044053127,0.0004188242,0.00015345604,0.00003422338,0.0005058194,0.0010186078,0.0011640283],"category_scores_gemma":[0.0024932593,0.00080648565,0.001748808,0.00095477834,0.00058872445,0.000099845325,0.00026042634,0.0007590694,0.000088183515],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005818993,0.001410782,0.012035028,0.012278972,0.0025652002,0.000854482,0.000022353797,0.000007492611,0.0000023019359,0.0000024585447,0.016965684,0.95327336],"study_design_scores_gemma":[0.005612942,0.001923211,0.0067586317,0.0774382,0.015825903,0.00008668586,0.000017217502,0.00027150256,0.0000017983358,0.00013700798,0.8911138,0.00081309717],"about_ca_topic_score_codex":0.0013424472,"about_ca_topic_score_gemma":0.00017951474,"teacher_disagreement_score":0.9524602,"about_ca_system_score_codex":0.001039759,"about_ca_system_score_gemma":0.0030482197,"threshold_uncertainty_score":0.99974906},"labels":[],"label_agreement":null},{"id":"W2901812877","doi":"10.1016/j.clgc.2018.11.003","title":"More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Hazard ratio; Propensity score matching; Proportional hazards model; Urology; Bladder cancer; Lymph node; Dissection (medical); Internal medicine; Overall survival; Surgery; Oncology; Cancer; Confidence interval","score_opus":0.04512874150609205,"score_gpt":0.36884425104176705,"score_spread":0.323715509535675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901812877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513847,0.00096131186,0.00001750957,0.0007373196,0.0015943777,0.0006841688,0.00007979798,0.000026246107,0.00076077867],"genre_scores_gemma":[0.9971785,0.00015469718,0.0002193148,0.00048445354,0.0011606943,0.00008501091,0.0000051296906,0.00007159208,0.00064060895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977142,0.00017120627,0.00093583466,0.00044537496,0.00041702844,0.00031632648],"domain_scores_gemma":[0.99842066,0.00023013495,0.00030120878,0.0005756134,0.00031607307,0.00015628607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026388848,0.00024336085,0.0007674764,0.00008907092,0.000053002565,0.000005026295,0.00021187463,0.00015466605,0.0003239568],"category_scores_gemma":[0.00017820833,0.00016160695,0.00039843694,0.00036011304,0.00086665136,0.00006184453,0.000110095694,0.0002781084,0.000013288863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005862917,0.0016065908,0.96205246,0.00029172364,0.0006893185,0.00010302561,0.0006904161,0.000021045424,0.014880055,0.000033094286,0.0007287978,0.0130405715],"study_design_scores_gemma":[0.007122708,0.0012494439,0.9727146,0.00021843419,0.00051415333,0.000044633383,0.00029646605,0.00020314379,0.016886562,0.00012656896,0.00045929733,0.00016398933],"about_ca_topic_score_codex":0.0011855505,"about_ca_topic_score_gemma":0.00013122853,"teacher_disagreement_score":0.012876582,"about_ca_system_score_codex":0.00012447819,"about_ca_system_score_gemma":0.0005242255,"threshold_uncertainty_score":0.65901405},"labels":[],"label_agreement":null},{"id":"W2905972441","doi":"10.1016/j.clgc.2018.12.006","title":"How Are Patients With Prostate Cancer Managing Androgen Deprivation Therapy Side Effects?","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; University of Toronto; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia","funders":"Prostate Cancer Canada; Astellas Pharma Canada","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Psychological intervention; Erectile dysfunction; Attendance; Side effect (computer science); Sexual dysfunction; Physical therapy; Intensive care medicine; Cancer; Internal medicine; Psychiatry","score_opus":0.02916770483972373,"score_gpt":0.331082178830633,"score_spread":0.30191447399090926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905972441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893176,0.0037443833,0.000058663816,0.0032749372,0.001720178,0.0010574937,0.00003954255,0.000117169395,0.0006700325],"genre_scores_gemma":[0.9881639,0.0031546156,0.000115339666,0.003402565,0.0028514348,0.0003775024,0.000038011945,0.000074458185,0.0018221596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980791,0.00011578296,0.00034076555,0.00061534357,0.00042777814,0.00042120344],"domain_scores_gemma":[0.9983531,0.000123545,0.00026396156,0.00049130747,0.0005003535,0.0002677254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017375361,0.0002830571,0.00048426798,0.00007982252,0.0001576733,0.000058306512,0.00014848933,0.00015176677,0.000088838766],"category_scores_gemma":[0.00005581639,0.00020807568,0.0001643039,0.0003350008,0.00025858177,0.00018693805,0.00007071574,0.00034237088,0.00001757143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031405692,0.00021004911,0.74547684,0.00012130156,0.00020956995,0.000051651634,0.00023547743,0.0000026904722,0.00006084654,0.0000017077298,0.0013007001,0.24918862],"study_design_scores_gemma":[0.005585265,0.0021206732,0.9221888,0.00052924815,0.00016255939,0.0000035993721,0.0001411206,0.000036937196,0.0018254421,0.00006296845,0.06699964,0.00034375067],"about_ca_topic_score_codex":0.00029671763,"about_ca_topic_score_gemma":0.0009636133,"teacher_disagreement_score":0.24884486,"about_ca_system_score_codex":0.00016340613,"about_ca_system_score_gemma":0.00020241336,"threshold_uncertainty_score":0.848508},"labels":[],"label_agreement":null},{"id":"W2907881473","doi":"10.1016/j.clgc.2018.12.009","title":"Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Janssen Biotech; Orionin Tutkimussäätiö; Cilag; Astellas Pharma; Eisai; Sanofi; F. Hoffmann-La Roche; Roche; Novartis; British Microcirculation Society; Amgen; Pfizer; Bristol-Myers Squibb; International Parkinson and Movement Disorder Society; Bayer","keywords":"Medicine; Abiraterone; Prostate cancer; Metformin; Abiraterone acetate; Oncology; Internal medicine; Disease; Cancer; Androgen deprivation therapy; Insulin; Androgen receptor","score_opus":0.05126263416340064,"score_gpt":0.39075892055386896,"score_spread":0.3394962863904683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907881473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814664,0.014844742,0.0000058566266,0.000008185277,0.00023589403,0.0023513515,0.0010680731,0.000007492694,0.000011989357],"genre_scores_gemma":[0.9955657,0.0026651814,0.0002671928,0.000029846531,0.00016842694,0.00090399303,0.0002491131,0.000047144305,0.00010341139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748576,0.00026796878,0.00093954755,0.00062705553,0.00030232675,0.00037734758],"domain_scores_gemma":[0.9984417,0.00003661949,0.0005058918,0.0004708187,0.00029828315,0.00024667793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031992054,0.0003266035,0.00068335293,0.00010635621,0.000042414893,0.00002290345,0.00016050682,0.00004716433,0.00022533239],"category_scores_gemma":[0.000042920736,0.00023631571,0.00014197931,0.00026237647,0.00009420842,0.00003678693,0.00006395962,0.00010199284,0.0000031987224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02146535,0.01456266,0.7648575,0.0002176411,0.0008968971,0.000019390147,0.00036351976,0.0022976648,0.04318007,4.8015147e-7,0.00014585802,0.15199299],"study_design_scores_gemma":[0.017749019,0.05586702,0.9084397,0.00036298457,0.00049875496,4.4175178e-7,0.00016700677,0.000057416397,0.0153835425,0.0000063804014,0.000955523,0.0005122299],"about_ca_topic_score_codex":0.000501869,"about_ca_topic_score_gemma":0.00060854945,"teacher_disagreement_score":0.15148076,"about_ca_system_score_codex":0.00013726692,"about_ca_system_score_gemma":0.00075731816,"threshold_uncertainty_score":0.9636675},"labels":[],"label_agreement":null},{"id":"W2912199505","doi":"10.1016/j.clgc.2019.01.015","title":"COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; University of British Columbia","funders":"Janssen Biotech; National Cancer Institute; Eisai; Ipsen Biopharmaceuticals; Prometheus; North Carolina GlaxoSmithKline Foundation; Novartis; GlaxoSmithKline Australia; Exelixis; Sanofi; GlaxoSmithKline; Merck; Astellas Pharma Global Development; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; Memorial Sloan-Kettering Cancer Center; Roche; Astellas Pharma US; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Pazopanib; Medicine; Post-hoc analysis; Oncology; Renal cell carcinoma; Internal medicine; Post hoc; Sunitinib","score_opus":0.03562386660572312,"score_gpt":0.33030507837456136,"score_spread":0.2946812117688382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912199505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913148,0.0022893199,0.000012831112,0.0009905858,0.00042824223,0.0009616609,0.00005489574,0.000098529876,0.0038491127],"genre_scores_gemma":[0.99126035,0.00024375129,0.0011144023,0.0016281983,0.00059700495,0.00009997638,0.00022260078,0.00007891658,0.004754813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965892,0.00023993659,0.0009145896,0.0010440233,0.0005965795,0.0006156891],"domain_scores_gemma":[0.9973171,0.00030321343,0.00040355677,0.001097448,0.00030487374,0.0005738197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003644726,0.0004589839,0.001274108,0.0003056447,0.00009993524,0.000034771245,0.0002526013,0.00020560967,0.0007788789],"category_scores_gemma":[0.00002290391,0.00034472943,0.0006880552,0.00078492827,0.0001701303,0.00016798583,0.00012233206,0.0006636799,0.00032710255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026633857,0.0009459763,0.91982263,0.00020528314,0.0014879424,0.0018432711,0.00018554955,0.00030728345,0.042118367,0.0000045991223,0.00054255914,0.005902668],"study_design_scores_gemma":[0.007289181,0.009672205,0.9663489,0.00013047521,0.0025568986,0.00006698779,0.00033413016,0.00022784657,0.0075963987,0.0000022959666,0.0053011393,0.00047357086],"about_ca_topic_score_codex":0.000068897825,"about_ca_topic_score_gemma":0.0000338615,"teacher_disagreement_score":0.046526227,"about_ca_system_score_codex":0.00032019944,"about_ca_system_score_gemma":0.0005462854,"threshold_uncertainty_score":0.99990046},"labels":[],"label_agreement":null},{"id":"W2912754254","doi":"10.1016/j.clgc.2019.01.009","title":"Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Brigham Research Institute","keywords":"Medicine; Bladder cancer; Cancer therapy; Cancer; Oncology; Internal medicine","score_opus":0.1357726139639858,"score_gpt":0.4188765261547862,"score_spread":0.28310391219080044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912754254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732086,0.0040729265,0.000033256005,0.0012614714,0.0012288007,0.0041180123,0.0011504932,0.00013045243,0.014795969],"genre_scores_gemma":[0.9720963,0.008911753,0.00033426992,0.0047075227,0.0017592584,0.002417207,0.00022259407,0.00018542522,0.00936565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680626,0.00019212403,0.0008122213,0.0011007481,0.00041457693,0.0006740634],"domain_scores_gemma":[0.9962947,0.0016472262,0.00035781815,0.00055938377,0.0007085657,0.000432346],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026345713,0.00062909554,0.0013447496,0.00011554646,0.00016288152,0.000039258757,0.00020869548,0.00035046853,0.0018975531],"category_scores_gemma":[0.00009792023,0.00040209194,0.00048572032,0.0003634316,0.00034546855,0.00020289776,0.00006019126,0.00048458134,0.00013638427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067413665,0.002466597,0.87384325,0.00028545954,0.0055397777,0.00071921985,0.00063617574,0.000018223187,0.0013170001,0.00001872451,0.018110175,0.029631717],"study_design_scores_gemma":[0.08058147,0.035913285,0.8180184,0.0016051573,0.0014463501,0.000054344953,0.002319913,0.00008095038,0.015683385,0.00013266059,0.042499892,0.0016642273],"about_ca_topic_score_codex":0.0009683593,"about_ca_topic_score_gemma":0.00022901534,"teacher_disagreement_score":0.055824902,"about_ca_system_score_codex":0.00021625725,"about_ca_system_score_gemma":0.0031160712,"threshold_uncertainty_score":0.9998431},"labels":[],"label_agreement":null},{"id":"W2922172159","doi":"10.1016/j.clgc.2019.03.005","title":"A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; CancerCare Manitoba; BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Cancer Care Ontario; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Castration; Clinical trial; Gynecology; Hormone","score_opus":0.15472136721313998,"score_gpt":0.4811174060029069,"score_spread":0.326396038789767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922172159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98238957,0.0020951477,1.7071186e-7,0.00047907635,0.0009186902,0.013139103,0.00089131587,0.000024170411,0.00006274981],"genre_scores_gemma":[0.99352944,0.0013348123,0.000051064228,0.00012387673,0.00028062914,0.0030167638,0.00011058613,0.00006971771,0.0014830837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942837,0.0009277874,0.00202663,0.0009701857,0.0009968164,0.00079492293],"domain_scores_gemma":[0.9969977,0.00041575197,0.0006812773,0.0006678658,0.00054639083,0.00069102895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016697594,0.00046906894,0.0018929858,0.00045866228,0.00017423509,0.000034517612,0.00026790623,0.0001158273,0.0011967995],"category_scores_gemma":[0.00020504517,0.00029312476,0.00018369652,0.0009790538,0.00015063465,0.00020004867,0.00011417523,0.0007064459,0.000009389754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062934145,0.033264313,0.8377609,0.00024821342,0.0015699051,0.00052232743,0.002905403,0.00007963874,0.00008505997,5.732228e-7,0.000611015,0.06001846],"study_design_scores_gemma":[0.12695196,0.13308947,0.7317076,0.0007718299,0.0012117948,0.0000016084814,0.0043007387,0.00006109076,0.000059136302,0.000005042373,0.00139342,0.00044633314],"about_ca_topic_score_codex":0.11148261,"about_ca_topic_score_gemma":0.44081256,"teacher_disagreement_score":0.32932994,"about_ca_system_score_codex":0.0010993415,"about_ca_system_score_gemma":0.0047198324,"threshold_uncertainty_score":0.9999521},"labels":[],"label_agreement":null},{"id":"W2933596744","doi":"10.1016/j.clgc.2019.03.003","title":"Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Urology; Proportional hazards model; Cohort; Upper urinary tract; Internal medicine; Population; Oncology; Epidemiology; Chemotherapy; Urinary system","score_opus":0.04144192562534474,"score_gpt":0.38248303098953385,"score_spread":0.3410411053641891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933596744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993486,0.0020473474,0.0000032111227,0.00029377316,0.001646495,0.0014016592,0.0000747555,0.000038792114,0.0045591136],"genre_scores_gemma":[0.99638444,0.00040225362,0.00015921053,0.00035723325,0.00070427055,0.00015025641,0.000020334037,0.00006728601,0.0017546932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712354,0.0005032628,0.0009083288,0.00059613417,0.0004122587,0.0004565054],"domain_scores_gemma":[0.9982202,0.0006940646,0.00019538826,0.0005730696,0.00007305025,0.00024420972],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061773264,0.00035471108,0.001268678,0.00016126747,0.000027218648,0.000009020496,0.0001932974,0.00018002412,0.001704134],"category_scores_gemma":[0.00008451596,0.0002702492,0.00055982935,0.00028693103,0.00014036252,0.0001143854,0.00008436447,0.00055505574,0.00017478724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066841305,0.001438165,0.97893065,0.00040354047,0.0002466389,0.00058745965,0.00008614067,0.0000132318255,0.0010949033,0.0000036596307,0.00023620953,0.010275295],"study_design_scores_gemma":[0.015677119,0.012486782,0.96436864,0.00023328244,0.00046175442,0.0001296813,0.000039835002,0.000091412956,0.0029359253,0.000029796254,0.0032722154,0.00027356076],"about_ca_topic_score_codex":0.00038548996,"about_ca_topic_score_gemma":0.000008306857,"teacher_disagreement_score":0.014561992,"about_ca_system_score_codex":0.00014454298,"about_ca_system_score_gemma":0.00047095932,"threshold_uncertainty_score":0.99997497},"labels":[],"label_agreement":null},{"id":"W2936749762","doi":"10.1016/j.clgc.2019.04.009","title":"Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Hazard ratio; Oncology; Internal medicine; Population; Proportional hazards model; Urology; Prostate; Adenocarcinoma; Cancer; Surveillance, Epidemiology, and End Results; Confidence interval; Cancer registry","score_opus":0.0909769474591462,"score_gpt":0.40316706546182113,"score_spread":0.31219011800267493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936749762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161595,0.005547017,7.88976e-7,0.00035558923,0.00055673026,0.0016757369,0.00017142144,0.000020418602,0.000056332563],"genre_scores_gemma":[0.9991481,0.00023268697,0.00012733413,0.000120003235,0.00010461776,0.00008950541,0.00006664483,0.000027432492,0.00008368362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975028,0.00021290137,0.0013067999,0.000517469,0.00026098356,0.0001990223],"domain_scores_gemma":[0.9980166,0.00058749417,0.0006394368,0.00040004918,0.00017696594,0.00017944367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045120023,0.00025111344,0.0015413386,0.0000836974,0.000040769795,0.0000087972585,0.00007483771,0.00012562981,0.000036960577],"category_scores_gemma":[0.00012249431,0.00019294054,0.00015774168,0.00010652251,0.00016390109,0.00006311089,0.00010920939,0.00024713742,0.0000022655502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017309856,0.0027087608,0.99211925,0.00037686573,0.00018949897,0.0001347141,0.0002842526,0.0000027013136,0.000057935104,0.0000029113698,0.000052341675,0.0023397969],"study_design_scores_gemma":[0.00741309,0.008837956,0.98223853,0.00012545525,0.0003272109,0.0000049848168,0.0005948735,0.00013483113,0.00012319027,0.000009314444,0.000023951527,0.00016661461],"about_ca_topic_score_codex":0.00021155823,"about_ca_topic_score_gemma":0.000010019212,"teacher_disagreement_score":0.0098807085,"about_ca_system_score_codex":0.000049336046,"about_ca_system_score_gemma":0.00025592747,"threshold_uncertainty_score":0.7867887},"labels":[],"label_agreement":null},{"id":"W2942671874","doi":"10.1016/j.clgc.2019.04.015","title":"Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Seminoma; Stage (stratigraphy); Orchiectomy; Propensity score matching; Surveillance, Epidemiology, and End Results; Hazard ratio; Testicular cancer; Proportional hazards model; Internal medicine; Incidence (geometry); Epidemiology; Population; Cumulative incidence; Urology; Oncology; Chemotherapy; Confidence interval; Cancer registry; Cohort","score_opus":0.06811372294504209,"score_gpt":0.4375365370072789,"score_spread":0.3694228140622368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942671874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555635,0.0024964858,0.000013881878,0.00014402017,0.00015252744,0.0010474958,0.00035694157,0.000024322864,0.00020795687],"genre_scores_gemma":[0.99872124,0.00007964409,0.000432757,0.000050562245,0.0001319473,0.00013836948,0.0002745282,0.000026477543,0.00014449193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982061,0.00022877226,0.0006666993,0.00045499924,0.00023366913,0.00020980516],"domain_scores_gemma":[0.99816966,0.0009457484,0.00026271155,0.0003261385,0.000081593964,0.0002141603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016864491,0.00023963164,0.0009455031,0.00008256997,0.00002311018,0.000009914352,0.000050492083,0.00011256795,0.0001180223],"category_scores_gemma":[0.000069413276,0.00018723331,0.00018063719,0.0001498507,0.00007885852,0.00005330531,0.000039573042,0.00016437843,0.000004480375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009018357,0.0013926206,0.9926145,0.00015212747,0.00028647808,0.00018730627,0.000023623998,0.00012338723,0.000029315344,0.0000013842773,0.000012446997,0.004274964],"study_design_scores_gemma":[0.0076397713,0.0018363893,0.9884496,0.00019240219,0.00016062043,0.0000010081875,0.00005490648,0.0012753352,0.000063233645,0.0000069582106,0.0001499759,0.00016984393],"about_ca_topic_score_codex":0.0011564344,"about_ca_topic_score_gemma":0.00008216506,"teacher_disagreement_score":0.006737936,"about_ca_system_score_codex":0.00021728654,"about_ca_system_score_gemma":0.00052096363,"threshold_uncertainty_score":0.7635153},"labels":[],"label_agreement":null},{"id":"W2945029662","doi":"10.1016/j.clgc.2019.05.015","title":"Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Cancer; Incidence (geometry); Oncology; Prostate; Internal medicine; Gynecology; Family history","score_opus":0.10185653789288218,"score_gpt":0.3954380661042507,"score_spread":0.2935815282113685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945029662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96220577,0.027895568,5.0106166e-7,0.0035671468,0.0024087043,0.0032679993,0.0004078703,0.000027406299,0.00021903405],"genre_scores_gemma":[0.9742043,0.018496282,0.000081118065,0.002396778,0.0005669281,0.0019071213,0.000029541347,0.000039153594,0.002278775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971552,0.00020369726,0.0010690644,0.000761936,0.00041844015,0.0003916691],"domain_scores_gemma":[0.99774706,0.000908648,0.00032219526,0.00058109435,0.00017011278,0.0002708699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006885005,0.00028447152,0.0007988102,0.00007899325,0.000052033083,0.000015314505,0.0001921005,0.00017073228,0.00025912223],"category_scores_gemma":[0.0002389682,0.00020635917,0.00017601124,0.00028175252,0.00026112655,0.00015398455,0.00016800992,0.00055225496,0.000020310159],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013458872,0.0003479314,0.96719545,0.000107980515,0.00016750103,0.000045582936,0.0017216759,0.0001190333,0.00026399302,0.000010545345,0.0075647626,0.008996699],"study_design_scores_gemma":[0.018973926,0.0012382994,0.96331877,0.0008765598,0.00024513394,9.660274e-7,0.00016993438,0.000052294876,0.00014275982,0.00013664548,0.014618688,0.00022603254],"about_ca_topic_score_codex":0.01376692,"about_ca_topic_score_gemma":0.002339632,"teacher_disagreement_score":0.011998531,"about_ca_system_score_codex":0.0013149676,"about_ca_system_score_gemma":0.0017866658,"threshold_uncertainty_score":0.9928005},"labels":[],"label_agreement":null},{"id":"W2945646193","doi":"10.1016/j.clgc.2019.05.019","title":"Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Cyclophosphamide; Chemotherapy; Sarcomatoid carcinoma; Urothelial carcinoma; Radiation therapy; Oncology; Disease; Histology; Internal medicine; Cancer; Carcinoma","score_opus":0.030470337433298546,"score_gpt":0.33155655983775306,"score_spread":0.30108622240445454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945646193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951252,0.0023064355,0.00003536687,0.0006125834,0.00023690466,0.00074320514,0.000108105654,0.000029267232,0.000802935],"genre_scores_gemma":[0.99403864,0.0008179516,0.0006909525,0.00043417735,0.00024704382,0.00009785127,0.000015530679,0.00003958787,0.0036182571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806595,0.00025765816,0.000581649,0.00059718295,0.00019320173,0.00030434775],"domain_scores_gemma":[0.998531,0.0003086907,0.00020420368,0.0006014485,0.00009772171,0.0002569439],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022277128,0.00027410558,0.0010496072,0.00021628772,0.00004677543,0.000007138555,0.000093366034,0.00016639431,0.0010934917],"category_scores_gemma":[0.000020039051,0.00018988141,0.00033263655,0.0003108841,0.00025517464,0.00003847667,0.000053940323,0.00015936774,0.000045229735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028885324,0.00077725225,0.95602185,0.000035378125,0.0037897974,0.0005471373,0.00021843643,0.000020510399,0.003758278,0.0000064841665,0.00012182022,0.0058177616],"study_design_scores_gemma":[0.009657444,0.008936444,0.9709898,0.000027419783,0.0038174898,0.00018261932,0.00006338828,0.00013113272,0.0011569897,0.000010938231,0.004824194,0.0002020908],"about_ca_topic_score_codex":0.0007602145,"about_ca_topic_score_gemma":0.000107554704,"teacher_disagreement_score":0.01922788,"about_ca_system_score_codex":0.00023158421,"about_ca_system_score_gemma":0.0007786941,"threshold_uncertainty_score":0.99981964},"labels":[],"label_agreement":null},{"id":"W2946472581","doi":"10.1016/j.clgc.2019.05.017","title":"Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Eisai; Fondazione Internazionale Menarini; British Microcirculation Society; M.S.I. Foundation; Ipsen Biopharmaceuticals; Pfizer; Intuitive Surgical; Takeda Pharmaceutical Company; Exelixis; Meso Scale Diagnostics; Ipsen; Olympus; Medtronic; Roche; Baxter International; Novartis Pharma; Novartis","keywords":"Medicine; Renal cell carcinoma; Real world evidence; Oncology; Internal medicine; Real world data; Data science","score_opus":0.27979379609309263,"score_gpt":0.45433514373646267,"score_spread":0.17454134764337004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946472581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866173,0.0024329766,3.8050717e-7,0.0021140908,0.00078364724,0.004059645,0.0000459278,0.000043319294,0.003902696],"genre_scores_gemma":[0.9715674,0.0019172439,0.0001368857,0.00038810275,0.000678716,0.00038470296,0.000052130334,0.00006222375,0.0248126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953091,0.00091724447,0.0012253905,0.0013388103,0.0006690454,0.00054037303],"domain_scores_gemma":[0.9927623,0.0029885874,0.00032383623,0.0035368155,0.000087981425,0.0003004622],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013950424,0.0004595519,0.0010288884,0.00018158913,0.000089748646,0.000033157965,0.00067273533,0.000101975354,0.00050698966],"category_scores_gemma":[0.0002343627,0.00026937327,0.00027173548,0.0005857816,0.00013115554,0.00015631763,0.00040063052,0.0007292606,0.00060212106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035366158,0.0050494606,0.9767631,0.00007255167,0.00029260296,0.0027605072,0.00025340766,0.00014853511,0.00020654607,0.0000034926509,0.0045683356,0.0063448036],"study_design_scores_gemma":[0.0086754905,0.014433868,0.9684089,0.0002912348,0.0012146406,0.00002495238,0.0005040704,0.00023362266,0.0006245245,0.000012216148,0.005286812,0.00028965922],"about_ca_topic_score_codex":0.0037142893,"about_ca_topic_score_gemma":0.0014415755,"teacher_disagreement_score":0.020909904,"about_ca_system_score_codex":0.0010298097,"about_ca_system_score_gemma":0.0008602879,"threshold_uncertainty_score":0.99997586},"labels":[],"label_agreement":null},{"id":"W2946957740","doi":"10.1016/j.clgc.2021.05.004","title":"Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia; McMaster University; Sunnybrook Health Science Centre; University of Manitoba; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta; CancerCare Manitoba; Ottawa Hospital; McGill University Health Centre; University of Ottawa","funders":"Genentech; Ipsen; Amgen Astellas Biopharma; Astellas Pharma; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Eisai; AbbVie; Exelixis; Sanofi; Roche; Karyopharm Therapeutics; Novartis; MedImmune; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cohort; Hazard ratio; Renal cell carcinoma; Internal medicine; Kidney cancer; Systemic therapy; Cancer; Cohort study; Confidence interval; Oncology; Breast cancer","score_opus":0.05802921157147152,"score_gpt":0.32756667941217094,"score_spread":0.26953746784069943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946957740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775002,0.0025614642,0.0000038753924,0.007502024,0.0012393811,0.0007067163,0.0023508677,0.000032865075,0.008102578],"genre_scores_gemma":[0.99394596,0.00042158726,0.00022499624,0.0028095178,0.0008748687,0.00022992962,0.0007041855,0.00002756662,0.0007613815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968696,0.00053074386,0.0011229254,0.00051766814,0.00044996894,0.0005090803],"domain_scores_gemma":[0.9971303,0.0006687613,0.00032381102,0.00074125396,0.00039835516,0.0007375275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005711153,0.00028552595,0.00063615997,0.000096248106,0.00017214303,0.000054544813,0.00020445364,0.00017963769,0.0002015597],"category_scores_gemma":[0.0005013029,0.0002071379,0.0002489141,0.00047749403,0.00012162916,0.00018031993,0.000089086476,0.0006990811,0.0001042873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005800596,0.00044203282,0.90189284,0.0004269143,0.0006267926,0.0065883594,0.0026406744,0.00096541404,0.0004072262,0.000018467008,0.058032524,0.022158137],"study_design_scores_gemma":[0.0068145613,0.00022915292,0.95876485,0.00029680456,0.00024450262,0.00004419073,0.0007705927,0.0005735082,0.0030438765,0.000008560276,0.028946798,0.00026263122],"about_ca_topic_score_codex":0.32363185,"about_ca_topic_score_gemma":0.2873658,"teacher_disagreement_score":0.056871958,"about_ca_system_score_codex":0.002035993,"about_ca_system_score_gemma":0.006457202,"threshold_uncertainty_score":0.99917525},"labels":[],"label_agreement":null},{"id":"W2946986050","doi":"10.1016/j.clgc.2019.05.012","title":"Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer Canada; Bristol-Myers Squibb Canada; Orionin Tutkimussäätiö; Cilag; Astellas Pharma; Ipsen; Astellas Pharma Canada; Bristol-Myers Squibb; Bayer Corporation; Janssen Canada; Meso Scale Diagnostics; Sanofi; Roche; Novartis; Amgen; Pfizer; Johnson and Johnson; Takeda Pharmaceutical Company; Active Biotech; Bayer","keywords":"Medicine; Prostate cancer; Radium-223; Oncology; Disease; Internal medicine; Radium; Castration; Urology; Cancer; Hormone; Bone metastasis","score_opus":0.06678858482934684,"score_gpt":0.420381723733961,"score_spread":0.35359313890461413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946986050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962555,0.00019322471,4.424035e-7,0.00024700552,0.00008059125,0.0027972523,0.000371878,0.00001776649,0.00003633604],"genre_scores_gemma":[0.99732274,0.0008748964,0.00015114516,0.000033098626,0.000065164924,0.00073675107,0.00050656183,0.000027041688,0.0002825987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841255,0.00010572126,0.00049020746,0.00043057516,0.0003049877,0.00025593967],"domain_scores_gemma":[0.9990457,0.000062992476,0.0001902429,0.00022062783,0.00024377665,0.00023661813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001043524,0.00020422343,0.00047771967,0.00015469347,0.000025435847,0.00004201413,0.000091904774,0.00004292216,0.000088670924],"category_scores_gemma":[0.000010915462,0.000129087,0.000041147177,0.00024380114,0.00017108949,0.0002974572,0.000030795647,0.0001591976,0.0000014854425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02918195,0.0033885452,0.94452196,0.00014697814,0.00019642117,0.00017010105,0.00015111984,0.000048570575,0.00006658785,0.0000017054647,0.000003420804,0.02212261],"study_design_scores_gemma":[0.017544279,0.009111355,0.97197545,0.00041547412,0.00014493747,9.4113506e-7,0.00003265295,0.00044583596,0.00005280681,0.000003390882,0.00012845822,0.0001444464],"about_ca_topic_score_codex":0.0011503142,"about_ca_topic_score_gemma":0.0006316497,"teacher_disagreement_score":0.027453432,"about_ca_system_score_codex":0.00041527883,"about_ca_system_score_gemma":0.00055251585,"threshold_uncertainty_score":0.52640146},"labels":[],"label_agreement":null},{"id":"W2947434657","doi":"10.1016/j.clgc.2019.05.022","title":"Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Prostate; Cancer; Cytoreductive surgery; Oncology; Internal medicine; Ovarian cancer","score_opus":0.20192312562868442,"score_gpt":0.5194030736804688,"score_spread":0.31747994805178437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947434657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788213,0.005422472,0.000056126286,0.003731525,0.002548586,0.00792784,0.0005657868,0.00005655498,0.00086984236],"genre_scores_gemma":[0.9843702,0.002076293,0.0073519577,0.00041731808,0.00046824623,0.0036471577,0.00016172027,0.00008903211,0.0014180739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965605,0.00017400712,0.0013552824,0.00089695107,0.00043254855,0.000580673],"domain_scores_gemma":[0.99686867,0.0009682589,0.0005690297,0.0005942393,0.00055335683,0.00044646967],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050331064,0.00037738206,0.0016695687,0.00009007524,0.00009083866,0.000052806983,0.00037613054,0.00015999745,0.000612834],"category_scores_gemma":[0.00023307595,0.00029637635,0.00045889578,0.00032386713,0.00038598056,0.0002103624,0.00027108323,0.0004295161,0.000033559496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061904535,0.009135778,0.7704724,0.0017293389,0.004608683,0.00010803892,0.00052307965,0.00087698916,0.002213572,0.00045444103,0.014679141,0.13329402],"study_design_scores_gemma":[0.10711253,0.03892995,0.7432777,0.0028411683,0.005330085,0.000026716807,0.0010958625,0.002762635,0.025440438,0.0007494675,0.070990264,0.0014431697],"about_ca_topic_score_codex":0.00018810968,"about_ca_topic_score_gemma":0.00003430556,"teacher_disagreement_score":0.13185084,"about_ca_system_score_codex":0.00045461644,"about_ca_system_score_gemma":0.0015526034,"threshold_uncertainty_score":0.99994886},"labels":[],"label_agreement":null},{"id":"W2950152297","doi":"10.1016/j.clgc.2019.06.003","title":"Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Hazard ratio; Seminoma; Internal medicine; Incidence (geometry); Proportional hazards model; Epidemiology; Odds ratio; Logistic regression; Germ cell tumors; Oncology; Mortality rate; Gynecology; Demography; Confidence interval; Biology; Chemotherapy","score_opus":0.029922654611996943,"score_gpt":0.3494134939490125,"score_spread":0.31949083933701555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950152297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578774,0.0025902304,0.0000011749285,0.000080263875,0.00013014025,0.00081305165,0.00003257324,0.000029287403,0.00053553487],"genre_scores_gemma":[0.99886954,0.000098954544,0.00018254241,0.00043411538,0.00008431835,0.00004533977,0.000043093853,0.00002383703,0.0002182327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986048,0.00007635451,0.00041692305,0.00044522854,0.00024650514,0.00021021061],"domain_scores_gemma":[0.99893963,0.00018439205,0.00015980564,0.000339372,0.00009836157,0.0002784134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013302316,0.00018691755,0.00044185604,0.000041399944,0.000026657084,0.000013092162,0.00006294499,0.000079234334,0.00009819529],"category_scores_gemma":[0.000100386176,0.00013248384,0.00008154984,0.00013035683,0.00012539247,0.00010023396,0.0000709424,0.00020895754,0.00003702787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062527385,0.0012055542,0.9961867,0.00012594624,0.00007276813,0.0005430739,0.000012535181,0.000011662772,0.0000099131,8.145679e-7,0.00017890659,0.0010268639],"study_design_scores_gemma":[0.006357193,0.0014774187,0.99132717,0.00026544847,0.00012891607,0.0000040898426,0.000018671084,0.00007433694,0.000036378755,0.000024284618,0.00012354569,0.00016254751],"about_ca_topic_score_codex":0.00015990726,"about_ca_topic_score_gemma":0.00000677889,"teacher_disagreement_score":0.0057319193,"about_ca_system_score_codex":0.000053298005,"about_ca_system_score_gemma":0.0003436251,"threshold_uncertainty_score":0.5402534},"labels":[],"label_agreement":null},{"id":"W2964142510","doi":"10.1016/j.clgc.2019.07.008","title":"A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Period (music); Oncology; Cancer; Prostate; Internal medicine","score_opus":0.067928409871219,"score_gpt":0.41973478168077677,"score_spread":0.35180637180955776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964142510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917137,0.004644949,0.0000024488018,0.0009140106,0.00048769082,0.0010930304,0.0003875357,0.0000335104,0.0007230976],"genre_scores_gemma":[0.9885517,0.008494224,0.00012613353,0.0008640117,0.00020938875,0.00049818336,0.000046111323,0.000039686656,0.0011705711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732935,0.00014797757,0.0010719026,0.0006787536,0.00036953515,0.00040246558],"domain_scores_gemma":[0.9983887,0.00014592236,0.00032655266,0.0007154017,0.00017610956,0.00024732394],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042706224,0.00026420786,0.0013352055,0.00024235557,0.00002502348,0.000012508413,0.00014109316,0.00017499726,0.0028105653],"category_scores_gemma":[0.000049853246,0.00021171734,0.0005941317,0.0010365368,0.00018001521,0.000082144616,0.00008807094,0.00032072995,0.00004329343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012453335,0.0012379524,0.98426265,0.0001793312,0.0049119974,0.00014215974,0.00028331793,0.000636185,0.0001713736,0.000017730168,0.00042215883,0.006489803],"study_design_scores_gemma":[0.005990366,0.0008955007,0.9800414,0.00031101404,0.0036305843,0.0000014549875,0.00013395325,0.00082811125,0.00049396645,0.000025274772,0.0074143177,0.00023404244],"about_ca_topic_score_codex":0.0020351328,"about_ca_topic_score_gemma":0.0008223876,"teacher_disagreement_score":0.006992159,"about_ca_system_score_codex":0.0003276288,"about_ca_system_score_gemma":0.0005429701,"threshold_uncertainty_score":0.998101},"labels":[],"label_agreement":null},{"id":"W2965386530","doi":"10.1016/j.clgc.2019.07.016","title":"Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval; Centre hospitalier universitaire de Québec","funders":"Janssen Pharmaceuticals; Janssen Biotech; Fonds de Recherche du Québec - Santé; Amgen; AbbVie Canada; AstraZeneca; Innocrin Pharmaceuticals; Ferring Pharmaceuticals; Astellas Pharma Canada; Bayer; Merck; MedImmune; Roche; Sanofi","keywords":"Medicine; Cystectomy; 5 Alpha-Reductase Inhibitor; Bladder cancer; Receipt; Alpha (finance); Oncology; Internal medicine; Urology; Cancer; Finasteride; Surgery; World Wide Web","score_opus":0.035415946778967325,"score_gpt":0.3493478301064011,"score_spread":0.31393188332743377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965386530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860853,0.004728127,0.0000025272489,0.0022374664,0.0030647086,0.0012145694,0.00021676092,0.00011298735,0.002337578],"genre_scores_gemma":[0.99059075,0.001300348,0.00040576214,0.00079081015,0.0030591015,0.0001535444,0.00007940017,0.00012161427,0.0034986422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587125,0.00030756075,0.0013905187,0.000997258,0.0007666634,0.0006667809],"domain_scores_gemma":[0.99709815,0.00023453793,0.00071788375,0.0011024742,0.00024005097,0.00060688064],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004281865,0.00051031436,0.0013577986,0.00017651891,0.00010097035,0.000022417264,0.00035988155,0.000477772,0.0013956615],"category_scores_gemma":[0.00017609505,0.00038972255,0.0006396696,0.0003535232,0.0005021221,0.00015098148,0.00019144439,0.0009374112,0.00015535354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010838377,0.0062895217,0.73889846,0.0011672422,0.0038158186,0.0028942819,0.0016913294,0.00009337288,0.007715293,0.0002675867,0.059858337,0.16647038],"study_design_scores_gemma":[0.06854444,0.022087969,0.7695288,0.0073196916,0.004204011,0.0012212535,0.0024339969,0.00009905227,0.054366868,0.0045688865,0.06274582,0.0028792336],"about_ca_topic_score_codex":0.00052632944,"about_ca_topic_score_gemma":0.000042555814,"teacher_disagreement_score":0.16359115,"about_ca_system_score_codex":0.00025053445,"about_ca_system_score_gemma":0.0010055556,"threshold_uncertainty_score":0.99985546},"labels":[],"label_agreement":null},{"id":"W2969581577","doi":"10.1016/j.clgc.2019.08.004","title":"Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Pfizer Canada; Ipsen Biopharmaceuticals; Novartis; Pfizer","keywords":"Medicine; Renal cell carcinoma; Clinical trial; Oncology; Clinical decision making; Intensive care medicine; Genitourinary system; Kidney cancer; Internal medicine; Overall survival","score_opus":0.2945977963045506,"score_gpt":0.483884615773327,"score_spread":0.1892868194687764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969581577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889578,0.0018060273,0.000076647404,0.0014272345,0.0023847609,0.0031776323,0.000046793382,0.000028991099,0.00209411],"genre_scores_gemma":[0.99181694,0.00018016856,0.004255612,0.0022276903,0.00093688373,0.00010119059,0.000055799188,0.000056517245,0.00036920945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99121875,0.0006429857,0.0054502035,0.0011024675,0.0010263064,0.00055929756],"domain_scores_gemma":[0.9896824,0.004354527,0.0021689425,0.0029848912,0.00044611705,0.00036315207],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004504848,0.0004022381,0.0018042865,0.00021137306,0.00007413501,0.000048007452,0.0010387931,0.000240378,0.00039655963],"category_scores_gemma":[0.00291837,0.00025071646,0.00065095036,0.00078274944,0.00024315418,0.00021811416,0.0010577342,0.0010663004,0.000080525104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13035011,0.0035155283,0.5974616,0.00040109106,0.00086054293,0.0017983598,0.00059584045,0.0009342903,0.0005180047,0.00004166641,0.0076633324,0.25585967],"study_design_scores_gemma":[0.03972178,0.007750677,0.93446237,0.00041841887,0.00077919016,0.00008932226,0.0004449389,0.0017767521,0.0002884455,0.00024457806,0.013660654,0.0003628493],"about_ca_topic_score_codex":0.00021419248,"about_ca_topic_score_gemma":0.00003918679,"teacher_disagreement_score":0.33700082,"about_ca_system_score_codex":0.00022510457,"about_ca_system_score_gemma":0.001864779,"threshold_uncertainty_score":0.9999945},"labels":[],"label_agreement":null},{"id":"W2969582517","doi":"10.1016/j.clgc.2019.08.009","title":"Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Orchiectomy; Propensity score matching; Retroperitoneal lymph node dissection; Surveillance, Epidemiology, and End Results; Hazard ratio; Proportional hazards model; Testicular cancer; Population; Stage (stratigraphy); Germ cell tumors; Cumulative incidence; Relative survival; Internal medicine; Epidemiology; Surgery; Gynecology; Oncology; Chemotherapy; Confidence interval; Cancer registry; Cohort","score_opus":0.03828911427823522,"score_gpt":0.38667993397473727,"score_spread":0.34839081969650204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969582517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99730307,0.00041671694,0.0000033215215,0.000035769728,0.00012856728,0.0013774788,0.00064453145,0.000009494132,0.000081074286],"genre_scores_gemma":[0.9994408,0.00001032075,0.00010276858,0.00003237144,0.00006366914,0.00008396659,0.00020057923,0.000023990684,0.000041531166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830335,0.0002566105,0.0006345858,0.000343229,0.00029302566,0.00016917266],"domain_scores_gemma":[0.99815065,0.00073770946,0.00051206106,0.00034889005,0.00012130475,0.00012937572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105003746,0.00022027617,0.00075755233,0.000054926022,0.000024416255,0.0000066835437,0.00007220056,0.00006562498,0.000052151994],"category_scores_gemma":[0.000037606187,0.0001354784,0.00013855456,0.0001362927,0.00013345882,0.00005027875,0.000049141363,0.00014960377,0.0000011075858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002691058,0.0026039528,0.9922604,0.00019625359,0.00021086574,0.0000587708,0.000022778428,0.000043345433,0.0000070059295,1.4558698e-7,0.0000027647302,0.0019026635],"study_design_scores_gemma":[0.012177254,0.0032154643,0.9837103,0.00031417186,0.00018170629,3.9198116e-7,0.000017711212,0.00007677672,0.00016837787,8.9311266e-7,0.000003720689,0.00013326023],"about_ca_topic_score_codex":0.0005540734,"about_ca_topic_score_gemma":0.00009942719,"teacher_disagreement_score":0.009486196,"about_ca_system_score_codex":0.00013821895,"about_ca_system_score_gemma":0.00062082574,"threshold_uncertainty_score":0.5524649},"labels":[],"label_agreement":null},{"id":"W2975223270","doi":"10.1016/j.clgc.2019.09.004","title":"Impact of Patients’ Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis","year":2019,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"Medizinische Universität Wien","keywords":"Medicine; Meta-analysis; Internal medicine; Hazard ratio; Kidney cancer; Oncology; Confidence interval; Cancer; Immunotherapy; Randomized controlled trial; Cochrane Library; Systematic review; MEDLINE","score_opus":0.1967646823354452,"score_gpt":0.4571831977062537,"score_spread":0.2604185153708085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975223270","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014021599,0.9753046,7.206291e-7,0.000016916445,0.00006426387,0.009384803,0.0011611464,0.000008404706,0.000037526468],"genre_scores_gemma":[0.004398587,0.9934476,0.00007778584,0.00026271536,0.0000261614,0.0010984562,0.0003874196,0.00010395083,0.00019733142],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9929878,0.0012848724,0.0036755505,0.0008883113,0.0008015305,0.00036194135],"domain_scores_gemma":[0.9934439,0.0010655092,0.0031552264,0.0015409095,0.00046012813,0.0003343498],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00069950457,0.0008895381,0.019341,0.0005470508,0.000019171242,0.000008030211,0.00028948876,0.00022584699,0.0007031414],"category_scores_gemma":[0.00027914043,0.000446784,0.006276752,0.0011584241,0.00015086324,0.00005120386,0.000080130194,0.0005605762,0.000010597922],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006287771,0.0025663876,0.026910163,0.629107,0.33505273,0.000016959128,0.000022733351,0.0000118306325,1.25305055e-8,2.767089e-7,0.00013323198,0.0055499026],"study_design_scores_gemma":[0.0040082247,0.0042903936,0.05815204,0.07225934,0.86037713,0.0000017336504,0.0000013485511,0.0000010512922,1.5652954e-7,4.909104e-7,0.0005509709,0.00035712947],"about_ca_topic_score_codex":0.000199506,"about_ca_topic_score_gemma":0.0000045325073,"teacher_disagreement_score":0.55684763,"about_ca_system_score_codex":0.00055892154,"about_ca_system_score_gemma":0.0012089314,"threshold_uncertainty_score":0.9997984},"labels":[],"label_agreement":null},{"id":"W2975300000","doi":"10.1016/j.clgc.2019.09.008","title":"Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Urology; Hazard ratio; Stage (stratigraphy); Proportional hazards model; Dissection (medical); Lymph node; Bladder cancer; Logistic regression; Cohort; Internal medicine; Surgery; Confidence interval; Cancer","score_opus":0.02686335273150627,"score_gpt":0.33224553994996825,"score_spread":0.305382187218462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975300000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629396,0.0002664615,0.0000892426,0.00025662297,0.00070575526,0.001274967,0.0005818009,0.000046767538,0.0004844077],"genre_scores_gemma":[0.9949475,0.000053384225,0.0007471072,0.00016578023,0.000443004,0.0002758391,0.00014361125,0.00009185234,0.0031319277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754053,0.0001237033,0.00070707314,0.000707101,0.00048110326,0.000440511],"domain_scores_gemma":[0.99841887,0.0002603151,0.00033943274,0.00048610408,0.00020115709,0.00029414266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018730963,0.0004165951,0.0010498416,0.00014348656,0.000094406074,0.000019179646,0.00011856734,0.00014706393,0.00030308808],"category_scores_gemma":[0.000025243837,0.0002754623,0.0002442125,0.00022570125,0.00023831053,0.00015854773,0.00006262617,0.00021423212,0.00000809909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01606726,0.0017659903,0.9745518,0.000370603,0.00073986663,0.000062260435,0.00010818697,0.000026185537,0.000033714965,0.0000056152453,0.00006244937,0.006206096],"study_design_scores_gemma":[0.029096719,0.011952739,0.95617086,0.00013006142,0.0008120621,0.00001847015,0.00012228586,0.00015195625,0.00014230321,0.0000048452853,0.0010659547,0.00033172173],"about_ca_topic_score_codex":0.00032373538,"about_ca_topic_score_gemma":0.00005601965,"teacher_disagreement_score":0.01838089,"about_ca_system_score_codex":0.00010668852,"about_ca_system_score_gemma":0.00039864928,"threshold_uncertainty_score":0.9999698},"labels":[],"label_agreement":null},{"id":"W2976600478","doi":"10.1016/j.clgc.2019.09.007","title":"Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Hazard ratio; Biochemical recurrence; Proportional hazards model; Prostate cancer; Internal medicine; Confidence interval; Oncology; Cancer; Urology; Surgery","score_opus":0.050618921630573264,"score_gpt":0.4138482882475533,"score_spread":0.3632293666169801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976600478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931969,0.0004150871,0.000016931206,0.00028657724,0.000297336,0.0041149906,0.0016293137,0.0000119578945,0.000030910363],"genre_scores_gemma":[0.99275815,0.0018656458,0.003729068,0.000026270998,0.00007320178,0.0012307458,0.00019424815,0.000026684182,0.00009598594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808466,0.00009727357,0.0008287824,0.00050011784,0.00019115739,0.00029803003],"domain_scores_gemma":[0.9981516,0.0005066484,0.0003946224,0.0004215237,0.0002809183,0.00024470492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018965677,0.00023414538,0.0008166127,0.00011457773,0.000029954068,0.0000037815878,0.000100241996,0.00009143432,0.00018106919],"category_scores_gemma":[0.000091562644,0.00014959423,0.00027990647,0.00028324625,0.00010654966,0.00007233637,0.000058042617,0.00015786263,0.000009104394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068451636,0.0045486116,0.88501215,0.00010495001,0.00031813,0.0000068594495,0.00020396513,0.00024006014,0.000026203144,0.0000027787432,0.000295754,0.10239535],"study_design_scores_gemma":[0.014414901,0.04956965,0.93374175,0.0008043603,0.00021278538,8.029721e-7,0.000037239384,0.00007797297,0.000646008,0.000045222914,0.0002957497,0.00015353967],"about_ca_topic_score_codex":0.0011136843,"about_ca_topic_score_gemma":0.00010831116,"teacher_disagreement_score":0.102241814,"about_ca_system_score_codex":0.00047657543,"about_ca_system_score_gemma":0.0006569079,"threshold_uncertainty_score":0.61002755},"labels":[],"label_agreement":null},{"id":"W2981079561","doi":"10.1016/j.clgc.2019.10.012","title":"Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Urology; Hazard ratio; Bladder cancer; Proportional hazards model; Perioperative; Confidence interval; Population; Internal medicine; Oncology; Cancer; Surgery","score_opus":0.036086200905455966,"score_gpt":0.34745412947923465,"score_spread":0.3113679285737787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981079561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493635,0.0004419575,0.000008385032,0.00060857314,0.00012501347,0.002197627,0.00013447057,0.000040556446,0.0015070509],"genre_scores_gemma":[0.99619603,0.00041339197,0.00044129396,0.0004730051,0.0002727917,0.00036363536,0.000035465073,0.000107586224,0.0016968237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745935,0.0002941088,0.00061352196,0.00068631675,0.00047883496,0.00046785036],"domain_scores_gemma":[0.99831814,0.000285805,0.00043695557,0.000369242,0.000381086,0.0002087802],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034747954,0.00042359918,0.0011081379,0.000095791445,0.000066506705,0.000025970588,0.00013599875,0.00018428886,0.0005409333],"category_scores_gemma":[0.000055511395,0.0002572493,0.000101201425,0.00041236507,0.00030813634,0.00017843685,0.0000391859,0.00050638086,0.000004679487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03193379,0.0010951471,0.95785105,0.00012140556,0.0011107621,0.00012622116,0.00080359983,0.00012848312,0.0052584964,0.0000017870962,0.000034386747,0.0015348973],"study_design_scores_gemma":[0.032187164,0.010646892,0.94611037,0.0018129456,0.00040483024,0.00002530838,0.0015128714,0.0005213349,0.006254515,0.0000037879913,0.00009288776,0.0004270726],"about_ca_topic_score_codex":0.0020949934,"about_ca_topic_score_gemma":0.0016738707,"teacher_disagreement_score":0.011740633,"about_ca_system_score_codex":0.00031111957,"about_ca_system_score_gemma":0.0015384256,"threshold_uncertainty_score":0.99998796},"labels":[],"label_agreement":null},{"id":"W2981238229","doi":"10.1016/j.clgc.2019.10.016","title":"Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Urothelial carcinoma; Urothelial cancer; Histology; Oncology; Urology; Population; Internal medicine; Cancer","score_opus":0.04974038611521558,"score_gpt":0.3695354914271372,"score_spread":0.3197951053119216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981238229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899243,0.0008297634,0.0001792215,0.0008924474,0.0029067611,0.0045269886,0.0003411472,0.00009860987,0.000300751],"genre_scores_gemma":[0.99053985,0.000016923494,0.00036340632,0.0012928111,0.0022938638,0.0035411406,0.00007523958,0.000107876964,0.0017688726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968925,0.00025430997,0.00083507993,0.0009762304,0.00044384846,0.0005980095],"domain_scores_gemma":[0.9981026,0.00033807484,0.0002444535,0.00068969623,0.00028347582,0.00034167475],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027009443,0.00043605067,0.0011393294,0.00010436261,0.00011756928,0.000024092664,0.00018113563,0.00022335876,0.0019220589],"category_scores_gemma":[0.000033100976,0.00032907212,0.0003467673,0.00020080211,0.00010225662,0.00007875968,0.000052005773,0.00036825327,0.00005603717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025886152,0.002110175,0.968606,0.00012792689,0.0007894353,0.00035771434,0.00014394686,0.00024548956,0.000042822492,0.0000039581996,0.00042646166,0.0012599019],"study_design_scores_gemma":[0.032385692,0.006414116,0.95110726,0.000094097326,0.0015027283,0.000019464795,0.000113657254,0.0006823179,0.00007516956,0.000012138882,0.0071385475,0.00045481877],"about_ca_topic_score_codex":0.0030909234,"about_ca_topic_score_gemma":0.0015142102,"teacher_disagreement_score":0.017498765,"about_ca_system_score_codex":0.0003594293,"about_ca_system_score_gemma":0.0011307355,"threshold_uncertainty_score":0.99991614},"labels":[],"label_agreement":null},{"id":"W2985526546","doi":"10.1016/j.clgc.2019.10.024","title":"Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"AbbVie Canada; Elekta; Varian Medical Systems; Roche; Eisai; AbbVie; Merck; Ipsen; Novartis; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Interquartile range; Systemic therapy; Renal cell carcinoma; Cohort; Internal medicine; Retrospective cohort study; Cancer; Oncology; Surgery; Breast cancer","score_opus":0.026376206283059863,"score_gpt":0.34590948857936804,"score_spread":0.3195332822963082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985526546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98613566,0.011684238,0.000015281672,0.00009141232,0.0001199559,0.0016340527,0.00020572913,0.000017217231,0.000096424636],"genre_scores_gemma":[0.9975352,0.0009436806,0.000850668,0.00017494913,0.00007572415,0.000093690825,0.00009342705,0.000051033254,0.00018160923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975084,0.00040467884,0.0008194276,0.0005690859,0.00031729572,0.00038108532],"domain_scores_gemma":[0.998102,0.0005810997,0.00035588915,0.00055848964,0.00015004593,0.0002524546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050564617,0.00034863982,0.0012161733,0.00016280223,0.000029633507,0.000012294313,0.00010594363,0.00008069347,0.00033757064],"category_scores_gemma":[0.000044959404,0.000215379,0.0003492943,0.00026140528,0.00015191184,0.00010264987,0.000057445337,0.00027661538,0.000013995647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029339006,0.0026458907,0.96847516,0.00028195034,0.0009331799,0.00022294134,0.00011531754,0.00023019507,0.00038686147,0.0000022041766,0.0002466409,0.023525773],"study_design_scores_gemma":[0.019188367,0.017945966,0.9611946,0.00025545864,0.00053527794,0.000059143684,0.00008391899,0.00008548256,0.00027333005,0.0000081676235,0.00012452844,0.00024576182],"about_ca_topic_score_codex":0.00063617446,"about_ca_topic_score_gemma":0.000020933781,"teacher_disagreement_score":0.023280011,"about_ca_system_score_codex":0.00019703289,"about_ca_system_score_gemma":0.0005219096,"threshold_uncertainty_score":0.87829006},"labels":[],"label_agreement":null},{"id":"W2992439077","doi":"10.1016/j.clgc.2019.11.010","title":"A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; McGill University Health Centre; Université de Montréal; Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Renal cell carcinoma; Nivolumab; Kidney cancer; Internal medicine; Oncology; Nephrectomy; Ipilimumab; Pembrolizumab; Cancer; Adjuvant therapy; Immunotherapy; Kidney","score_opus":0.18648242834762796,"score_gpt":0.4384022978983788,"score_spread":0.25191986955075085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992439077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97522175,0.010698313,0.003418551,0.000297909,0.002408403,0.00750365,0.00035711165,0.000064088934,0.000030206078],"genre_scores_gemma":[0.9783899,0.0033334529,0.010793976,0.00018901602,0.0020828166,0.0047156564,0.000109552384,0.00011816708,0.00026744886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505407,0.0005259588,0.0021140005,0.0011540733,0.0003991889,0.00075273594],"domain_scores_gemma":[0.9962451,0.0017188387,0.0007859661,0.0005245373,0.00032102948,0.0004045274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002008696,0.0004923323,0.0019776195,0.0002903842,0.00013321481,0.00004448198,0.0002208058,0.00020293091,0.00030787577],"category_scores_gemma":[0.0003311997,0.0004144107,0.0008360402,0.00046365752,0.000050284707,0.00012481536,0.00007030627,0.00052608666,0.000020389663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031742267,0.0023118118,0.6760288,0.00089782634,0.0007854726,0.00005433418,0.00066869403,0.0060269544,0.07418278,0.000011270249,0.0037511778,0.20353863],"study_design_scores_gemma":[0.04971531,0.012496265,0.85488534,0.00083715486,0.0015592524,0.000014492239,0.0007080357,0.0038583216,0.064663626,0.00018120746,0.00985276,0.0012282261],"about_ca_topic_score_codex":0.0009007913,"about_ca_topic_score_gemma":0.00013641719,"teacher_disagreement_score":0.2023104,"about_ca_system_score_codex":0.0011379255,"about_ca_system_score_gemma":0.0007257975,"threshold_uncertainty_score":0.9998308},"labels":[],"label_agreement":null},{"id":"W2995419061","doi":"10.1016/j.clgc.2019.12.002","title":"Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis","year":2019,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Hazard ratio; Meta-analysis; Oncology; Subgroup analysis; Cancer; Cochrane Library; Confidence interval","score_opus":0.2286906265936641,"score_gpt":0.496953248459781,"score_spread":0.26826262186611693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995419061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016182858,0.9819675,0.0000016928514,0.00055010687,0.00010098882,0.015928112,0.0011863027,0.000026245962,0.0000772356],"genre_scores_gemma":[0.00018207851,0.98812604,0.00015513432,0.00039823062,0.000076426964,0.0062540085,0.00023277753,0.00009951924,0.004475765],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9918685,0.0018967071,0.0036058535,0.0012544565,0.0007271599,0.0006473504],"domain_scores_gemma":[0.99449736,0.001877147,0.001719681,0.0010869473,0.000431642,0.00038723156],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0020467096,0.00088588294,0.021535376,0.00063436123,0.000045352197,0.000025059775,0.0003012805,0.00032030515,0.00016732392],"category_scores_gemma":[0.0005936368,0.0005210424,0.004604962,0.0021754447,0.00035337682,0.00009505562,0.00026955505,0.001090623,0.000036349436],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016228209,0.0003617085,0.00013137385,0.7787763,0.21438576,0.0005015437,0.000044075943,0.0000040167242,1.487244e-7,0.000002876144,0.00028749384,0.005342398],"study_design_scores_gemma":[0.0010093373,0.00068579015,0.00012295287,0.1002503,0.8920697,0.00006181916,0.00002768702,0.000026328114,8.4879144e-7,0.000006524569,0.0053114705,0.00042725704],"about_ca_topic_score_codex":0.00025977494,"about_ca_topic_score_gemma":0.000036411835,"teacher_disagreement_score":0.67852604,"about_ca_system_score_codex":0.0004281786,"about_ca_system_score_gemma":0.0021384743,"threshold_uncertainty_score":0.9997241},"labels":[],"label_agreement":null},{"id":"W2996164021","doi":"10.1016/j.clgc.2019.12.007","title":"Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Manitoba; University of Calgary","funders":"Mailman School of Public Health, Columbia University; Foundation Medicine; Genentech; Ipsen; Bayer; Calithera Biosciences; Bristol-Myers Squibb Canada; Eisai; Eli Lilly and Company; National Comprehensive Cancer Network; F. Hoffmann-La Roche; Pfizer Canada; Alexion Pharmaceuticals; Dana-Farber Cancer Institute; Roche; Novartis; Exelixis; Sanofi; Merck; GlaxoSmithKline; Instituto de Salud Carlos III; Amgen; Pfizer; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Sunitinib; Hazard ratio; Discontinuation; Renal cell carcinoma; Internal medicine; Odds ratio; Oncology; Confidence interval; Retrospective cohort study; Kidney cancer","score_opus":0.03917808895234826,"score_gpt":0.3492407280194261,"score_spread":0.31006263906707787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996164021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371123,0.001148206,0.0000042738156,0.00056041725,0.0010384519,0.0018550989,0.00010021591,0.000031728083,0.0015503698],"genre_scores_gemma":[0.9960182,0.00031750268,0.0008803986,0.00043403628,0.00023568893,0.00013132878,0.00023560098,0.0000694133,0.0016778413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99458903,0.000525117,0.0027832245,0.0008645142,0.0006345614,0.0006035371],"domain_scores_gemma":[0.9960199,0.0013978772,0.0009036384,0.00091160985,0.0003384447,0.0004285046],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010461904,0.0004902597,0.002147424,0.00018725298,0.000044221462,0.000008807878,0.00027653066,0.00034232778,0.000546972],"category_scores_gemma":[0.00022435759,0.00034972056,0.00077621086,0.00035830514,0.00036338478,0.00010621283,0.0002090516,0.00085846806,0.000050569222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067443047,0.006180661,0.97998416,0.00019548468,0.00039040705,0.0002886829,0.00009146362,0.000027253547,0.00021053004,6.2819294e-7,0.0020203849,0.00386604],"study_design_scores_gemma":[0.030748023,0.017739633,0.94420445,0.0001659966,0.0006046803,0.000007145024,0.00011478042,0.000029270144,0.0020719767,0.000007024664,0.003960397,0.00034660543],"about_ca_topic_score_codex":0.00033809754,"about_ca_topic_score_gemma":0.00010994419,"teacher_disagreement_score":0.035779692,"about_ca_system_score_codex":0.00040628333,"about_ca_system_score_gemma":0.0006338574,"threshold_uncertainty_score":0.99989545},"labels":[],"label_agreement":null},{"id":"W2996730987","doi":"10.1016/j.clgc.2019.12.001","title":"Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Université de Montréal","funders":"","keywords":"Medicine; Chemotherapy; Cystectomy; Bladder cancer; Internal medicine; Oncology; Hazard ratio; Transitional cell carcinoma; Cancer; Urology; Surgery; Confidence interval","score_opus":0.07390756539667452,"score_gpt":0.3492164704109788,"score_spread":0.2753089050143043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996730987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907235,0.0007495506,0.000032080156,0.00011184285,0.0007378357,0.0018877115,0.0003604241,0.000018430814,0.005378628],"genre_scores_gemma":[0.9963262,0.00013626063,0.000628723,0.0002011405,0.0002674731,0.00015950747,0.00005609752,0.00006388013,0.002160691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976815,0.00014088287,0.0008817611,0.00055406505,0.00041223937,0.00032956983],"domain_scores_gemma":[0.99808294,0.00031680605,0.00039324284,0.0005693599,0.00033737524,0.00030025348],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001504291,0.00036284782,0.0011770083,0.00014318048,0.000036356367,0.0000069673447,0.00018382554,0.00008715974,0.00019046493],"category_scores_gemma":[0.000019887375,0.00026245276,0.00030989092,0.00021596334,0.0001422889,0.00009665435,0.00011284019,0.0001714523,0.000027999662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072954716,0.0039118715,0.9832443,0.00033725667,0.00082821766,0.000107861575,0.00059427804,0.00010306058,0.00023894568,0.0000037440236,0.00012773086,0.0032072717],"study_design_scores_gemma":[0.024489742,0.037534274,0.9251204,0.00040760572,0.0006818725,0.000006185074,0.0016095453,0.00008340605,0.009229474,0.000026469612,0.00042414828,0.0003868418],"about_ca_topic_score_codex":0.0012695116,"about_ca_topic_score_gemma":0.000014724102,"teacher_disagreement_score":0.058123853,"about_ca_system_score_codex":0.00017708766,"about_ca_system_score_gemma":0.00079814636,"threshold_uncertainty_score":0.9999828},"labels":[],"label_agreement":null},{"id":"W2999047517","doi":"10.1016/j.clgc.2019.12.019","title":"Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Janssen Pharmaceuticals; Bristol-Myers Squibb Canada; EMD Serono; Ipsen; Ferring Pharmaceuticals; Sanofi Genzyme; Merck Sharp and Dohme; Ferring; AstraZeneca; Invitae; Innocrin Pharmaceuticals; Astellas Pharma US; Flatiron Health; Dendreon Pharmaceuticals; Bayer Fund; Astellas Pharma Canada; F. Hoffmann-La Roche; Exelixis; Sanofi; Celgene; Novartis; Merck; Roche; American Association for Cancer Research; Amgen; Janssen Biotech; Johnson and Johnson; AcelRx Pharmaceuticals; Myovant Sciences; Pfizer; Bristol-Myers Squibb; Bayer; Calithera Biosciences; Constellation Energy Group","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Docetaxel; Prednisone; Abiraterone acetate; Internal medicine; Oncology; Confidence interval; Abiraterone; Clinical trial; Androgen deprivation therapy; Cancer","score_opus":0.10347877718998197,"score_gpt":0.4589470104597338,"score_spread":0.35546823326975185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999047517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96939874,0.00048696643,8.98575e-7,0.027547276,0.0000909753,0.0021372633,0.00023019064,0.000019919036,0.000087753746],"genre_scores_gemma":[0.9854743,0.010359081,0.0003262871,0.0026542386,0.00014581427,0.0006238457,0.00019234554,0.000035896403,0.00018822409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637693,0.0008501863,0.0012006742,0.0006321368,0.0004558575,0.0004841964],"domain_scores_gemma":[0.99715334,0.0018961391,0.00026954315,0.00026699645,0.00015597299,0.0002580275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007834283,0.0002998337,0.00074989063,0.00019936913,0.00006334959,0.00004828914,0.00012334327,0.00007378314,0.000044748518],"category_scores_gemma":[0.00032142168,0.00016795134,0.00009414362,0.00079530885,0.00018596646,0.00018446123,0.00006270688,0.00069576903,0.0000031955847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009588482,0.0019740085,0.9696417,0.00012684982,0.00025206953,0.0015909312,0.002360158,0.00021633324,0.0000021329715,0.0000026272428,0.0001090533,0.01413565],"study_design_scores_gemma":[0.017293796,0.0040709744,0.97366923,0.00026709985,0.0002072847,0.0000024998035,0.0019496523,0.00061182096,0.0000066763673,0.000010407375,0.0017249722,0.00018559073],"about_ca_topic_score_codex":0.010166742,"about_ca_topic_score_gemma":0.013759393,"teacher_disagreement_score":0.024893036,"about_ca_system_score_codex":0.0003689203,"about_ca_system_score_gemma":0.000617012,"threshold_uncertainty_score":0.9964246},"labels":[],"label_agreement":null},{"id":"W3000018687","doi":"10.1016/j.clgc.2019.12.018","title":"Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pfizer Canada; EMD Serono; Eisai; Bayer Canada; Bayer; Ipsen Biopharmaceuticals; Astellas Pharma Canada; AstraZeneca Canada; Janssen Canada; Sanofi; Bristol-Myers Squibb; AstraZeneca; Pfizer; Janssen Biotech; Canadian Institutes of Health Research; ESSA Pharma; BC Cancer Foundation; Roche; Astellas Pharma US","keywords":"Renal cell carcinoma; Medicine; BAP1; Somatic cell; Liquid biopsy; Cell-free fetal DNA; Germline; Oncology; Concordance; Germline mutation; Cancer research; Cancer; Internal medicine; Gene; Mutation; Biology; Genetics","score_opus":0.042431672381923524,"score_gpt":0.3125762196046652,"score_spread":0.27014454722274167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000018687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954232,0.0028368095,0.000057901805,0.0006839686,0.00023505974,0.000180865,0.00007923598,0.000007816487,0.00049515744],"genre_scores_gemma":[0.9951711,0.00055752863,0.0009234163,0.002100303,0.0010868807,0.000042228115,0.00003280945,0.00003120055,0.000054504384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847347,0.00008273747,0.00051983853,0.00053422694,0.00011208638,0.00027761864],"domain_scores_gemma":[0.9992377,0.00013012344,0.00013655596,0.00019535384,0.000043639415,0.000256637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017665463,0.00018485537,0.0003067024,0.00002555409,0.000054954275,0.000025273475,0.00015643435,0.00008951663,0.000051631167],"category_scores_gemma":[0.00021268823,0.00019140977,0.00012827611,0.00010035592,0.00011148473,0.000004571865,0.00024196888,0.00020487484,0.000008008132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020718074,0.000717563,0.5122612,0.0006327577,0.00022894675,0.0015082866,0.00060387276,0.0030079358,0.43749696,0.00008783769,0.021751102,0.01963175],"study_design_scores_gemma":[0.021371737,0.0067040944,0.42848727,0.00021643264,0.0005836067,0.00031269185,0.0012487872,0.016101489,0.3751632,0.0007344578,0.1455907,0.0034855509],"about_ca_topic_score_codex":0.000047936228,"about_ca_topic_score_gemma":0.000054673557,"teacher_disagreement_score":0.12383959,"about_ca_system_score_codex":0.00002196773,"about_ca_system_score_gemma":0.00026245267,"threshold_uncertainty_score":0.78054637},"labels":[],"label_agreement":null},{"id":"W3000024629","doi":"10.1016/j.clgc.2019.12.020","title":"A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806)","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Impact; Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre","funders":"Sanofi","keywords":"Medicine; Brachytherapy; Prostate cancer; External beam radiotherapy; Dose fractionation; Radiation therapy; Randomized controlled trial; Prostate; Androgen deprivation therapy; Urology; Oncology; Nuclear medicine; Internal medicine; Cancer","score_opus":0.04768839545873921,"score_gpt":0.39801358100444806,"score_spread":0.35032518554570885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000024629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9634347,0.009772897,0.00037116473,0.012155932,0.0014155192,0.012548322,0.00019608907,0.00006546816,0.000039910694],"genre_scores_gemma":[0.9191794,0.06394057,0.0007406986,0.0035668858,0.0032880588,0.008162492,0.00015605566,0.00011323963,0.0008525956],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952517,0.0006409856,0.0019791808,0.0008370765,0.0008235897,0.0004674676],"domain_scores_gemma":[0.996407,0.0011488397,0.0013475902,0.00039346504,0.0003622447,0.00034086563],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010484974,0.00048154235,0.0016613458,0.0001446496,0.00019361934,0.000051338542,0.00021444971,0.00018747778,0.00067553425],"category_scores_gemma":[0.00030641604,0.00029237717,0.00053601776,0.0005862801,0.00042465035,0.0003718165,0.00004122995,0.0006453145,0.0000035973187],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94004375,0.005203616,0.004123285,0.000136145,0.0012282247,0.00014784983,0.0008095854,0.0010894364,0.0005058032,0.0000113152155,0.0010155315,0.045685455],"study_design_scores_gemma":[0.94234025,0.03677109,0.0035120733,0.00046200166,0.000563773,0.000019150804,0.00007738007,0.004558854,0.00056417036,0.00003497123,0.010757169,0.0003391139],"about_ca_topic_score_codex":0.00020610436,"about_ca_topic_score_gemma":0.00004410992,"teacher_disagreement_score":0.054167673,"about_ca_system_score_codex":0.0007820676,"about_ca_system_score_gemma":0.002382444,"threshold_uncertainty_score":0.99995285},"labels":[],"label_agreement":null},{"id":"W3004761772","doi":"10.1016/j.clgc.2020.02.001","title":"Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; University of Ottawa; Surgical Specialties (Canada); McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Chromophobe cell; Renal cell carcinoma; Logistic regression; Nephrectomy; Internal medicine; Carcinoma; Clear cell; Gastroenterology; Urology; Pathology; Oncology; Kidney","score_opus":0.09900866393972269,"score_gpt":0.3375998677825703,"score_spread":0.2385912038428476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004761772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98229915,0.011297228,0.0000027965727,0.0041034324,0.00019921157,0.0014703338,0.00012484932,0.000042374522,0.00046064038],"genre_scores_gemma":[0.9969594,0.0003900023,0.0005414152,0.0012938594,0.00040740348,0.00019806005,0.000017220724,0.0000356971,0.00015693918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966873,0.00056707044,0.0011453861,0.00079519,0.00036843447,0.00043660484],"domain_scores_gemma":[0.99722135,0.0011840782,0.00043724402,0.0005696505,0.00014854259,0.0004391532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055982545,0.00035826594,0.0010516957,0.00004638289,0.00007842052,0.000013420614,0.0002739644,0.000108107466,0.00019605471],"category_scores_gemma":[0.00081348314,0.00023246488,0.00028715012,0.00036380638,0.00066541653,0.00006420291,0.00022561521,0.00067910005,0.000007806767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038571684,0.0012971524,0.98226,0.0008109583,0.00013207634,0.0029474336,0.00038641278,0.00010787716,0.0036235163,0.0000062466556,0.0026872256,0.001883938],"study_design_scores_gemma":[0.004102013,0.0048047057,0.9767588,0.000078803016,0.0005400059,0.00017082102,0.00017328892,0.00023040596,0.0111381635,0.00007969108,0.0016658215,0.00025752292],"about_ca_topic_score_codex":0.0006292568,"about_ca_topic_score_gemma":0.00016877828,"teacher_disagreement_score":0.014660269,"about_ca_system_score_codex":0.00026336813,"about_ca_system_score_gemma":0.00092929933,"threshold_uncertainty_score":0.9479643},"labels":[],"label_agreement":null},{"id":"W3004971171","doi":"10.1016/j.clgc.2020.01.007","title":"Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Cystectomy; Bladder cancer; Hazard ratio; Oncology; Internal medicine; Odds ratio; Proportional hazards model; Chemotherapy; Cancer; Adenocarcinoma; Neoadjuvant therapy; Urology; Population; Gastroenterology; Confidence interval","score_opus":0.038623644687281564,"score_gpt":0.32093572236471685,"score_spread":0.28231207767743527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004971171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98453027,0.010730872,0.00004443587,0.0018921322,0.0005007806,0.0018806728,0.00023731754,0.000055109653,0.00012839679],"genre_scores_gemma":[0.9923326,0.0031820037,0.00033826602,0.0022242356,0.0009356408,0.0006631669,0.000017034337,0.000072389674,0.0002346981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971512,0.0001564357,0.0006725659,0.0010350815,0.00049460196,0.0004901471],"domain_scores_gemma":[0.99870384,0.000119488504,0.00014166207,0.0002830805,0.00013754863,0.00061437476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017481546,0.00046292273,0.00091361447,0.000077388766,0.0001328521,0.000041640673,0.00012482876,0.00019918136,0.00060263945],"category_scores_gemma":[0.00002034525,0.00033440633,0.000103855884,0.00032242085,0.00038120753,0.0001473378,0.00010544211,0.00061830535,0.000008624474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012273432,0.0033201217,0.9662266,0.00012631314,0.00029252385,0.00072040677,0.0009080798,0.000058155707,0.00002764491,0.0000011406124,0.00036175505,0.015683841],"study_design_scores_gemma":[0.0510969,0.0035620704,0.93706495,0.00013182669,0.000311814,0.00000838526,0.00016558084,0.00021266997,0.000041719464,0.0000029835867,0.0069962675,0.0004048233],"about_ca_topic_score_codex":0.0011031087,"about_ca_topic_score_gemma":0.0005328843,"teacher_disagreement_score":0.03882347,"about_ca_system_score_codex":0.00021368326,"about_ca_system_score_gemma":0.00064318546,"threshold_uncertainty_score":0.9999108},"labels":[],"label_agreement":null},{"id":"W3009221479","doi":"10.1016/j.clgc.2020.02.011","title":"Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Biochemical recurrence; Prostate cancer; Meta-analysis; Hazard ratio; Surgical margin; Confidence interval; Oncology; Radiation therapy; Internal medicine; Systematic review; MEDLINE; Urology; Cancer","score_opus":0.14183398920565934,"score_gpt":0.4451487956099993,"score_spread":0.30331480640433994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009221479","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031739144,0.9824457,2.8803774e-7,0.0018404777,0.00010668339,0.01312456,0.0020761185,0.000030742576,0.000058017446],"genre_scores_gemma":[0.00020547785,0.9858522,0.00007941908,0.0006545986,0.00015981807,0.011932941,0.00034274053,0.00009767931,0.0006751137],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99245465,0.001394819,0.0036157642,0.0014424123,0.0005751621,0.0005171852],"domain_scores_gemma":[0.99481064,0.0016734283,0.0018931524,0.00079695677,0.0002474719,0.00057832507],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0009071759,0.00094689295,0.02023564,0.00026508834,0.0000551694,0.00002112941,0.00026022783,0.0003434251,0.00046520645],"category_scores_gemma":[0.00036000262,0.00059084257,0.0050982744,0.0015903127,0.00026776278,0.00006284164,0.0003585303,0.000816301,0.000022409175],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001622617,0.0005521089,0.0039283745,0.8129268,0.16744627,0.0023496714,0.000035773584,0.000002881935,1.9454768e-8,0.0000066679045,0.00038706593,0.012202054],"study_design_scores_gemma":[0.0008261552,0.00077183935,0.00045874983,0.18484442,0.7705765,0.0001297533,0.000004916329,0.000007637069,6.531705e-7,0.0000033230876,0.041970495,0.00040558845],"about_ca_topic_score_codex":0.00023580028,"about_ca_topic_score_gemma":0.00007424444,"teacher_disagreement_score":0.62808245,"about_ca_system_score_codex":0.0008398439,"about_ca_system_score_gemma":0.0011378215,"threshold_uncertainty_score":0.9996543},"labels":[],"label_agreement":null},{"id":"W3009812442","doi":"10.1016/j.clgc.2020.02.005","title":"A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer","year":2020,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Health Sciences Centre; Mount Sinai Hospital; University of Calgary","funders":"Janssen Biotech; Astellas Pharma Canada; Bayer","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Meta-analysis; Oncology; Enzalutamide; Subgroup analysis; Androgen deprivation therapy; Randomized controlled trial; Placebo; Confidence interval; Androgen receptor; Cancer; Pathology","score_opus":0.22681532087135517,"score_gpt":0.4784924576525275,"score_spread":0.2516771367811723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009812442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000781845,0.9883421,0.0000022077704,0.0008151241,0.0001978651,0.00895414,0.0015518045,0.000021227594,0.000037349866],"genre_scores_gemma":[0.00004749933,0.99153835,0.00036893936,0.00038774617,0.00031427536,0.0058436636,0.00037628834,0.000092632006,0.00103061],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9926461,0.00079244183,0.004201865,0.001121787,0.00065771246,0.0005800747],"domain_scores_gemma":[0.99560404,0.0010245453,0.0017951044,0.00074692105,0.00031711772,0.0005122954],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0016622758,0.00078365015,0.016149325,0.0004057043,0.00007075431,0.000033518412,0.00027944922,0.00029209052,0.00041420216],"category_scores_gemma":[0.0003507953,0.000487111,0.003775382,0.0031393992,0.00027383922,0.00009015411,0.00019621465,0.0009423351,0.000011047019],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019116083,0.00040958956,0.00012267285,0.7640802,0.2204892,0.00026921052,0.00006167257,0.000019407069,0.0000015883957,0.0000013233481,0.001635878,0.012718087],"study_design_scores_gemma":[0.0011673248,0.00052837736,0.00003086915,0.16650225,0.78654313,0.000016594859,0.000024562994,0.000051859937,0.0000010146457,0.0000016348788,0.044709228,0.00042318078],"about_ca_topic_score_codex":0.00021290864,"about_ca_topic_score_gemma":0.00017552837,"teacher_disagreement_score":0.5975779,"about_ca_system_score_codex":0.00037843714,"about_ca_system_score_gemma":0.001973422,"threshold_uncertainty_score":0.99975806},"labels":[],"label_agreement":null},{"id":"W3024665518","doi":"10.1016/j.clgc.2020.05.004","title":"Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Eisai; Astellas Pharma; British Microcirculation Society; Merck Sharp and Dohme; Janssen Biotech; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Ipsen; Pharmacyclics; Astellas Pharma Canada; Sanofi España; Sanofi; GlaxoSmithKline Japan; Boehringer Ingelheim; Roche; Novartis; Bayer; University of Bristol; Merck; Novartis Farmacéutica; Ipsen Biopharmaceuticals; Bristol-Myers Squibb; AstraZeneca; Pfizer; Takeda Pharmaceutical Company","keywords":"Medicine; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Chemotherapy; Oncology; Internal medicine; Urothelial cancer; Overall survival; Cancer; Bladder cancer","score_opus":0.08429556182043416,"score_gpt":0.40567108539705654,"score_spread":0.32137552357662236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024665518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928056,0.0011295516,0.000017446739,0.0026781287,0.0007996688,0.0014775533,0.00062210136,0.000028557155,0.0004413682],"genre_scores_gemma":[0.99603635,0.0005699479,0.0000681427,0.0016045626,0.0008536961,0.0002929521,0.000044529337,0.00005755897,0.00047228465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969485,0.00019995146,0.0010727098,0.00079530216,0.0005229993,0.00046058305],"domain_scores_gemma":[0.99824166,0.00020012638,0.00031611163,0.00066106045,0.00027330688,0.0003077342],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016727974,0.00039907556,0.0012417543,0.00011612563,0.000073442156,0.000011822424,0.00032726588,0.00015927496,0.0010444502],"category_scores_gemma":[0.00014572077,0.00028958818,0.00076140754,0.0009445415,0.00023500617,0.00009044628,0.00015932298,0.0005434301,0.000012268661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066160455,0.0031097447,0.9146055,0.00010924406,0.0016752294,0.00052352337,0.0021423446,0.00053410913,0.00017224663,0.0000013869898,0.00016437947,0.010801856],"study_design_scores_gemma":[0.059427254,0.011071705,0.9205159,0.00010301974,0.0031060805,0.0000018846556,0.0011620496,0.00041564938,0.00052728585,0.0000041017865,0.003344179,0.00032088507],"about_ca_topic_score_codex":0.0005113893,"about_ca_topic_score_gemma":0.0016484067,"teacher_disagreement_score":0.010480971,"about_ca_system_score_codex":0.00027044557,"about_ca_system_score_gemma":0.0005673624,"threshold_uncertainty_score":0.99995565},"labels":[],"label_agreement":null},{"id":"W3024966661","doi":"10.1016/j.clgc.2020.05.006","title":"Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Bristol-Myers Squibb Canada; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Daiichi-Sankyo; Pfizer; Moderna; Five Prime Therapeutics; Mirati Therapeutics; Clovis Oncology; Roche; Karyopharm Therapeutics; Novartis; AbbVie; Sanofi; MedImmune; Merck; GlaxoSmithKline; British Microcirculation Society; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Chromophobe cell; Nivolumab; Internal medicine; Renal cell carcinoma; Adverse effect; Regimen; Gastroenterology; Clinical endpoint; Phases of clinical research; Rash; Clear cell; Urology; Surgery; Oncology; Chemotherapy; Cancer; Clinical trial; Immunotherapy","score_opus":0.03434760163426389,"score_gpt":0.31876612176908636,"score_spread":0.2844185201348225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024966661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952948,0.00088877865,0.0000041273383,0.0005950772,0.0001405041,0.0021196362,0.00027607413,0.000025685169,0.0006553133],"genre_scores_gemma":[0.99836123,0.00021517224,0.00030740854,0.0003497112,0.00036418895,0.000039055223,0.00010790185,0.000056797544,0.00019855639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671316,0.00027774464,0.0012655617,0.0008871574,0.000494686,0.00036170718],"domain_scores_gemma":[0.9976601,0.0006394422,0.00045320712,0.00070248195,0.00015525077,0.0003894974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029995784,0.0003549968,0.0009041327,0.000042367632,0.00008449611,0.000012376214,0.00023851114,0.0001271347,0.00006174479],"category_scores_gemma":[0.00013660346,0.00023022978,0.00016408424,0.0003048501,0.00021280338,0.00007828994,0.00022033087,0.00061910454,0.00001558638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14701468,0.009069576,0.8290372,0.000090018526,0.00016008323,0.00056438026,0.0024057315,0.000206674,0.00094501517,7.039892e-8,0.0006639077,0.009842693],"study_design_scores_gemma":[0.11071464,0.021517564,0.8639756,0.00009436046,0.00042142524,8.1541646e-7,0.00048647478,0.00020202532,0.0019023572,7.3633913e-7,0.00046681153,0.00021721453],"about_ca_topic_score_codex":0.00041113698,"about_ca_topic_score_gemma":0.000040607298,"teacher_disagreement_score":0.036300045,"about_ca_system_score_codex":0.00012774272,"about_ca_system_score_gemma":0.0002541585,"threshold_uncertainty_score":0.93884975},"labels":[],"label_agreement":null},{"id":"W3026350312","doi":"10.1016/j.clgc.2020.05.009","title":"Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Université de Montréal","funders":"","keywords":"Medicine; Propensity score matching; Renal cell carcinoma; Hazard ratio; Cohort; Nephrectomy; Internal medicine; Proportional hazards model; Clinical endpoint; Urology; Oncology; Population; Surgery; Randomized controlled trial; Kidney; Confidence interval","score_opus":0.1313542326888146,"score_gpt":0.3565032904072205,"score_spread":0.2251490577184059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026350312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749737,0.00748741,0.000012166156,0.0035402228,0.00054787216,0.0014581407,0.00006943653,0.000091046015,0.011820031],"genre_scores_gemma":[0.9928206,0.0003005609,0.0013492901,0.0019465368,0.0016013436,0.00022052704,0.000067356574,0.000102312566,0.0015914434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961168,0.00038455153,0.0012825847,0.0010817666,0.0005499611,0.0005843315],"domain_scores_gemma":[0.99761105,0.00050202495,0.0003396532,0.0005166988,0.00018311903,0.00084743643],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004139731,0.000492362,0.0012327434,0.00012493017,0.00007442238,0.000031362633,0.00027599526,0.00019775322,0.00036025848],"category_scores_gemma":[0.0001284098,0.000421265,0.00053250795,0.00047788268,0.00026028926,0.00018464625,0.00020860281,0.00096529874,0.00018106372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02000561,0.0038599526,0.91144365,0.0011449725,0.00041274654,0.011570247,0.0015507693,0.0002840188,0.014793452,0.000009965127,0.027573522,0.0073510953],"study_design_scores_gemma":[0.031202428,0.01872208,0.8494801,0.00030629255,0.001117562,0.00010005644,0.0024870168,0.0011912226,0.057363186,0.0001594225,0.036368657,0.0015019616],"about_ca_topic_score_codex":0.000415713,"about_ca_topic_score_gemma":0.000024745923,"teacher_disagreement_score":0.061963536,"about_ca_system_score_codex":0.00032936202,"about_ca_system_score_gemma":0.0011165556,"threshold_uncertainty_score":0.9998239},"labels":[],"label_agreement":null},{"id":"W3029830108","doi":"10.1016/j.clgc.2020.05.013","title":"A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Astellas Pharma; Bayer Fund; Parker Institute for Cancer Immunotherapy; Sanofi; Exelixis; Genentech; Valeant Pharmaceuticals International; Merck; Astellas Pharma US; Society for Immunotherapy of Cancer; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Sunitinib; Dasatinib; Prostate cancer; Hazard ratio; Internal medicine; Oncology; Abiraterone acetate; Clinical endpoint; Randomized controlled trial; Androgen deprivation therapy; Urology; Docetaxel; Confidence interval; Cancer; Tyrosine kinase","score_opus":0.12002647259925224,"score_gpt":0.45093749650814924,"score_spread":0.330911023908897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029830108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903813,0.000577254,0.00006678809,0.00367768,0.00009988642,0.0038676814,0.0010888615,0.000020239771,0.00022032799],"genre_scores_gemma":[0.9945616,0.0015821684,0.00062899635,0.00032649233,0.0002761435,0.0012725677,0.0003996551,0.000038538106,0.00091381924],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974081,0.00028488087,0.00115333,0.0004084049,0.0004644105,0.00028089923],"domain_scores_gemma":[0.9984649,0.00033770417,0.0003749894,0.00020052152,0.00030876556,0.00031315547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043310574,0.00020973948,0.0009001006,0.00010919682,0.00003801729,0.0000116178035,0.00010073175,0.00007515295,0.0006481741],"category_scores_gemma":[0.00028864504,0.0001394545,0.00012137366,0.0006547881,0.00016415825,0.00012005376,0.00003431267,0.00022559575,0.0000031609607],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93022174,0.0028794473,0.001815418,0.0004690816,0.00043736646,0.0002208743,0.0010225385,0.0001768125,0.04169658,0.0000018593362,0.009802399,0.011255891],"study_design_scores_gemma":[0.8900099,0.04993065,0.0020217565,0.00094190467,0.00074478844,0.0000044488293,0.000910258,0.00082711637,0.051305678,0.000011347424,0.0029404373,0.00035175958],"about_ca_topic_score_codex":0.00028169563,"about_ca_topic_score_gemma":0.00018078819,"teacher_disagreement_score":0.047051203,"about_ca_system_score_codex":0.000115212635,"about_ca_system_score_gemma":0.0011447085,"threshold_uncertainty_score":0.7097052},"labels":[],"label_agreement":null},{"id":"W3036074908","doi":"10.1016/j.clgc.2020.06.005","title":"Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Interquartile range; Hazard ratio; Bladder cancer; Internal medicine; Chemoradiotherapy; Cancer; Urology; Surgery; Confidence interval","score_opus":0.09806510995669171,"score_gpt":0.4090351033570236,"score_spread":0.3109699934003319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036074908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501604,0.00068235624,0.000015736305,0.00020710852,0.00022315005,0.0021479535,0.0013430523,0.000044461813,0.0003201361],"genre_scores_gemma":[0.9915096,0.0066983146,0.00015821005,0.00023242527,0.000291729,0.0007532123,0.00007750481,0.00007710096,0.00020187674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978175,0.00008144425,0.0007787595,0.0006180094,0.0003208462,0.000383452],"domain_scores_gemma":[0.9983215,0.00030499112,0.0004274707,0.000300355,0.00030365144,0.00034205825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000059181057,0.0004567449,0.0013387982,0.00006366004,0.0000579661,0.000006058673,0.00012348166,0.00013235911,0.00023157703],"category_scores_gemma":[0.000024339428,0.00028894714,0.0007231917,0.00020906125,0.00017257666,0.00005085766,0.00003279869,0.00014978067,0.0000031532484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011616948,0.0024773495,0.93713146,0.00034097987,0.0071934094,0.00007398448,0.00036075985,0.00015424308,0.0001747537,0.0000034915263,0.00011129235,0.04036131],"study_design_scores_gemma":[0.033928975,0.026853599,0.9340738,0.0004529972,0.0016683133,0.0000018459363,0.0001161152,0.000031794156,0.0023793466,0.0000035005191,0.00019719619,0.00029251294],"about_ca_topic_score_codex":0.000433272,"about_ca_topic_score_gemma":0.000035165587,"teacher_disagreement_score":0.040068798,"about_ca_system_score_codex":0.0006557428,"about_ca_system_score_gemma":0.0004939271,"threshold_uncertainty_score":0.99995625},"labels":[],"label_agreement":null},{"id":"W3043096196","doi":"10.1016/j.clgc.2020.07.011","title":"Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Stage (stratigraphy); Cystectomy; Bladder cancer; Oncology; Internal medicine; Cancer; Hazard ratio; Urinary bladder; Carcinoma; Adenocarcinoma; Urology; Confidence interval","score_opus":0.14080938582434996,"score_gpt":0.42606383480198334,"score_spread":0.2852544489776334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043096196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97520685,0.008687601,0.00006043669,0.012467214,0.0006384255,0.0011369764,0.0012869494,0.00009874403,0.0004167898],"genre_scores_gemma":[0.9824757,0.0068249134,0.00032782226,0.004336492,0.00424111,0.000391014,0.0000484027,0.00008720045,0.001267322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969052,0.00018935656,0.0009045646,0.0010224164,0.0002917445,0.00068671594],"domain_scores_gemma":[0.99816257,0.00028193244,0.0002268663,0.0003589667,0.00010002304,0.000869647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001570064,0.0005337975,0.0014352966,0.00004763291,0.00021395853,0.00005187528,0.00015289079,0.00034192018,0.00030287218],"category_scores_gemma":[0.000045605175,0.00043186237,0.0002470004,0.00011605599,0.0006046391,0.000105876745,0.00019219037,0.00044985057,0.00002070463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035070449,0.00047348687,0.90662074,0.00017363025,0.0014142463,0.00056030374,0.0042791916,0.000012345387,0.00039933313,0.000010484967,0.00338165,0.07916754],"study_design_scores_gemma":[0.02344909,0.012033063,0.82379436,0.000118649994,0.002456267,0.000102408194,0.00086351327,0.00069388474,0.00164206,0.00008111221,0.1338968,0.0008688089],"about_ca_topic_score_codex":0.0036573883,"about_ca_topic_score_gemma":0.00026558904,"teacher_disagreement_score":0.13051514,"about_ca_system_score_codex":0.00025368083,"about_ca_system_score_gemma":0.0006163669,"threshold_uncertainty_score":0.9998133},"labels":[],"label_agreement":null},{"id":"W3093155264","doi":"10.1016/j.clgc.2020.10.001","title":"Neoadjuvant Versus Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Microsimulation Model","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chemotherapy; Adverse effect; Bladder cancer; Perioperative; Gemcitabine; Internal medicine; Oncology; Urology; Cancer; Surgery","score_opus":0.13380061401930163,"score_gpt":0.4132333197204557,"score_spread":0.2794327057011541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093155264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790876,0.0026887287,0.002202652,0.011325853,0.001311365,0.001936072,0.00042163412,0.00015165699,0.0008744439],"genre_scores_gemma":[0.98169136,0.00076467404,0.0028875675,0.009342242,0.0040069474,0.0002987079,0.000098203345,0.00010588202,0.00080444047],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9978668,0.00004793803,0.00068054383,0.00069964485,0.00026917973,0.00043589546],"domain_scores_gemma":[0.9986539,0.00020328064,0.00015453213,0.0003308239,0.00016491523,0.00049256085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013054954,0.00033068814,0.000693593,0.000041723575,0.0001187702,0.000021093574,0.00015787125,0.00024885757,0.0002611513],"category_scores_gemma":[0.00009503076,0.00028077475,0.00063083426,0.00013330892,0.00013373556,0.0001061138,0.00004076433,0.00033663659,0.00004376449],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19975083,0.006615119,0.23873729,0.00096609397,0.0021086195,0.00044428487,0.004095761,0.007971691,0.03504854,0.000082969826,0.08535096,0.41882783],"study_design_scores_gemma":[0.21564585,0.028023275,0.17705487,0.00032453585,0.0034889737,0.00005397887,0.00041294083,0.33065864,0.021840652,0.00048200638,0.21975511,0.0022591746],"about_ca_topic_score_codex":0.000036703732,"about_ca_topic_score_gemma":0.000003271837,"teacher_disagreement_score":0.41656867,"about_ca_system_score_codex":0.00015057968,"about_ca_system_score_gemma":0.0006780453,"threshold_uncertainty_score":0.9999644},"labels":[],"label_agreement":null},{"id":"W3098898455","doi":"10.1016/j.clgc.2020.11.003","title":"Improving the Stratification of Patients With Intermediate-risk Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Risk stratification; Prostate cancer; Stratification (seeds); Prostate; Cancer; Oncology; Internal medicine","score_opus":0.035170907386635294,"score_gpt":0.33033798943828435,"score_spread":0.29516708205164904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3098898455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223363,0.0020495285,0.000025275776,0.003850635,0.00030250588,0.0011224995,0.00031056686,0.00003250529,0.00007285125],"genre_scores_gemma":[0.99205726,0.005102742,0.00016406718,0.0015201877,0.0005501324,0.00045486906,0.00005696837,0.000030023868,0.00006376267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984225,0.000082745675,0.0006194931,0.00039421904,0.0002689077,0.00021210448],"domain_scores_gemma":[0.9985306,0.0001824008,0.00049447716,0.00030431812,0.00027441495,0.00021378239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014525525,0.00017451355,0.00036562348,0.000018386241,0.00007323544,0.000014255658,0.00012659932,0.000066349116,0.00015310876],"category_scores_gemma":[0.00014170508,0.000096911346,0.0001305562,0.0001827041,0.00022243349,0.000080083424,0.00006132749,0.00032277146,0.0000087183835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016944727,0.0003906582,0.8424582,0.00012329995,0.00022460728,0.000009905102,0.00036067463,0.00005788871,0.00006526921,0.0000024880305,0.0016582306,0.1529543],"study_design_scores_gemma":[0.0036456876,0.003038975,0.9869887,0.00014305046,0.00047875667,3.2490027e-7,0.00012361578,0.0002966525,0.0016349498,0.0000101838095,0.0035041817,0.00013490905],"about_ca_topic_score_codex":0.00017818,"about_ca_topic_score_gemma":0.00003738286,"teacher_disagreement_score":0.15281938,"about_ca_system_score_codex":0.000085036045,"about_ca_system_score_gemma":0.00040071845,"threshold_uncertainty_score":0.395193},"labels":[],"label_agreement":null},{"id":"W3100270977","doi":"10.1016/j.clgc.2020.10.008","title":"Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Incidence (geometry); Obesity; Life expectancy; Population; Kidney cancer; Artificial neural network; Renal cell carcinoma; Demography; Environmental health; Internal medicine; Machine learning; Computer science; Mathematics","score_opus":0.07402055290459694,"score_gpt":0.373951521271211,"score_spread":0.29993096836661404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100270977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90379477,0.0018505777,0.00003299176,0.09191672,0.0010463899,0.0010564771,0.000051629457,0.00007006354,0.00018041098],"genre_scores_gemma":[0.9105896,0.0019005846,0.00008116228,0.078380935,0.008346968,0.00040123865,0.000112473186,0.000043172324,0.00014386959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704283,0.00039123342,0.0008421414,0.0006706208,0.0005121492,0.0005409999],"domain_scores_gemma":[0.9979223,0.00037341137,0.0001450007,0.00046567546,0.00014793065,0.00094566133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039998302,0.0003235479,0.0005637266,0.00009005287,0.00011142335,0.000041076695,0.00038484612,0.00021540908,0.00047827588],"category_scores_gemma":[0.00034625808,0.00021206259,0.0002476414,0.0010635266,0.00014272971,0.00007327595,0.00016721124,0.0010386002,0.00006702133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01289935,0.0011087684,0.633583,0.00022480248,0.0003984544,0.0071138847,0.004810655,0.048380006,0.00037258296,0.000025022453,0.2097282,0.08135529],"study_design_scores_gemma":[0.0038115524,0.008642738,0.7313279,0.00048383354,0.0007563943,0.00013873138,0.002186136,0.09693626,0.00054207747,0.00010982836,0.1542363,0.0008282641],"about_ca_topic_score_codex":0.0012529466,"about_ca_topic_score_gemma":0.00021241778,"teacher_disagreement_score":0.09774488,"about_ca_system_score_codex":0.00019412122,"about_ca_system_score_gemma":0.00035261182,"threshold_uncertainty_score":0.8647661},"labels":[],"label_agreement":null},{"id":"W3108115906","doi":"10.1016/j.clgc.2020.11.004","title":"Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Stage (stratigraphy); Urology; Upper urinary tract; Adenocarcinoma; Internal medicine; Odds ratio; Oncology; Cancer; Urinary system","score_opus":0.10736175486310746,"score_gpt":0.38198908150011895,"score_spread":0.2746273266370115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108115906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96210974,0.0046388926,0.000052642208,0.015242241,0.0032315315,0.00082932296,0.00014883172,0.00022144761,0.0135253295],"genre_scores_gemma":[0.98179567,0.00067538605,0.00055333093,0.00840777,0.0068089846,0.00016273922,0.000037616475,0.000091560534,0.0014669292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713874,0.0001962199,0.00084268505,0.00089080987,0.00035273546,0.0005788097],"domain_scores_gemma":[0.9980921,0.00025555448,0.0001783094,0.0005042066,0.0001159291,0.000853915],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015270621,0.00039419264,0.00089209166,0.00006338776,0.00012964985,0.000017075912,0.0002688494,0.00030616662,0.002913031],"category_scores_gemma":[0.00019077475,0.00033997063,0.00056230585,0.00022867792,0.00027080285,0.000109363085,0.00014077878,0.00076376554,0.00054670376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0691299,0.008852509,0.750284,0.000509782,0.0015797883,0.036010087,0.0012001148,0.000034287477,0.0015210347,0.000168468,0.0677348,0.062975235],"study_design_scores_gemma":[0.03376152,0.028941296,0.6381056,0.0001355613,0.0015060751,0.0013069938,0.00020522943,0.00039826267,0.0007164795,0.000096272284,0.29389575,0.00093095435],"about_ca_topic_score_codex":0.00015434356,"about_ca_topic_score_gemma":0.0000025048464,"teacher_disagreement_score":0.22616096,"about_ca_system_score_codex":0.0002192676,"about_ca_system_score_gemma":0.0010500131,"threshold_uncertainty_score":0.9999052},"labels":[],"label_agreement":null},{"id":"W3120326425","doi":"10.1016/j.clgc.2020.12.001","title":"Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Cumulative incidence; Cancer; Incidence (geometry); Adenocarcinoma; Epidemiology; Proportional hazards model; Disease; Cancer registry; Oncology; Gynecology; Cohort","score_opus":0.061875441818343604,"score_gpt":0.3911019798275126,"score_spread":0.329226538009169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120326425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834358,0.009888405,0.0000014134711,0.001690901,0.0019832547,0.0003349265,0.00013524998,0.00004406204,0.0024859486],"genre_scores_gemma":[0.9804559,0.008023994,0.00007701641,0.0010816453,0.00042337022,0.00012923758,0.00004769578,0.000034341287,0.009726839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768174,0.00027921324,0.00070790533,0.000656563,0.00028006439,0.00039454564],"domain_scores_gemma":[0.9989244,0.00022389487,0.00013613011,0.00027846155,0.00014967531,0.00028746773],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001876345,0.00025918515,0.0007841017,0.00007025461,0.00008609182,0.000014926755,0.00010222085,0.00030061151,0.0011745832],"category_scores_gemma":[0.00012373723,0.00021937615,0.00014474384,0.00024191978,0.00028502595,0.000076057426,0.00017858623,0.0005873522,0.000012748347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004898013,0.0010038553,0.9710552,0.00007173714,0.000242281,0.00040238825,0.0002636323,0.000003300814,0.00006950552,0.000011830836,0.0008256047,0.02556085],"study_design_scores_gemma":[0.0072974297,0.0006836091,0.98500943,0.00014265171,0.00018770232,0.0000094817415,0.00013814769,0.000042891203,0.00020085268,0.0001438964,0.005908089,0.00023581229],"about_ca_topic_score_codex":0.00096222723,"about_ca_topic_score_gemma":0.0009584621,"teacher_disagreement_score":0.025325038,"about_ca_system_score_codex":0.00022454464,"about_ca_system_score_gemma":0.00067099946,"threshold_uncertainty_score":0.99973845},"labels":[],"label_agreement":null},{"id":"W3126428342","doi":"10.1016/j.clgc.2021.01.007","title":"The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; McGill University Health Centre; Ministère de la Santé et des Services sociaux; McGill University","keywords":"Medicine; Bladder cancer; Cystectomy; Hazard ratio; Proportional hazards model; Propensity score matching; Internal medicine; Retrospective cohort study; Confidence interval; Surgery; Cancer; Oncology; Urology","score_opus":0.05813035974551425,"score_gpt":0.36739308850707963,"score_spread":0.3092627287615654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126428342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853886,0.0025436555,0.0000024100063,0.0070644026,0.003259254,0.0012020954,0.00050028536,0.000013488474,0.000025848884],"genre_scores_gemma":[0.98692125,0.0045548356,0.00036783467,0.002201101,0.0010094641,0.00038779282,0.00003562681,0.00006163406,0.004460453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957803,0.0003495779,0.0020382812,0.00080424343,0.000436477,0.0005911111],"domain_scores_gemma":[0.99607253,0.0024467343,0.0003672784,0.00050849526,0.0002170356,0.00038792746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048582978,0.00033817661,0.0009880877,0.000073353454,0.00011664542,0.00003617615,0.00015843262,0.00029949858,0.00009263154],"category_scores_gemma":[0.0012017043,0.00022902891,0.00030171007,0.0002584636,0.00045536456,0.00014209817,0.00016534173,0.0006772144,8.2584916e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028294886,0.0007847787,0.9442349,0.00018255805,0.0003606386,0.00030389894,0.000079443795,0.000015521018,0.00016654286,0.0000031272639,0.007277607,0.04376147],"study_design_scores_gemma":[0.030771567,0.0012430251,0.9018296,0.00071583234,0.000631642,0.000016195418,0.00053874735,0.0002823927,0.0040457207,0.00004093789,0.05926473,0.0006195829],"about_ca_topic_score_codex":0.31074193,"about_ca_topic_score_gemma":0.8746017,"teacher_disagreement_score":0.56385976,"about_ca_system_score_codex":0.0005916292,"about_ca_system_score_gemma":0.004474598,"threshold_uncertainty_score":0.9339528},"labels":[],"label_agreement":null},{"id":"W3136768966","doi":"10.1016/j.clgc.2021.03.006","title":"Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University of Calgary","funders":"Mailman School of Public Health, Columbia University; Pfizer Canada; Genentech; Astellas Pharma; Bristol-Myers Squibb Canada; Eisai; Ipsen; Astellas Pharma Canada; Roche; EMD Serono; Novartis; AstraZeneca; Amgen; Pfizer; Exelixis; Meso Scale Diagnostics; Sanofi; MedImmune; Merck; GlaxoSmithKline","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Oncology; Internal medicine; Clinical Oncology; Kidney cancer; Cancer","score_opus":0.0731584245030044,"score_gpt":0.40543841801258984,"score_spread":0.3322799935095854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136768966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933753,0.0016552829,0.000003904448,0.000054297474,0.0008046653,0.002256285,0.0000385362,0.000028650718,0.001783097],"genre_scores_gemma":[0.99736154,0.00032547372,0.0006479533,0.0001757011,0.00029693078,0.0003113688,0.00012451064,0.000082104285,0.00067440246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924249,0.0034348562,0.0020752405,0.0009842278,0.00056332786,0.0005174535],"domain_scores_gemma":[0.9945268,0.0031823704,0.0005386118,0.00092294323,0.0005018841,0.00032741012],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024016395,0.00044031814,0.002212445,0.00021981023,0.00006766666,0.000012098252,0.00021671841,0.0001837361,0.00035575012],"category_scores_gemma":[0.000177463,0.00033334875,0.00069940824,0.0007591431,0.00022854182,0.0000959922,0.00018294241,0.0008735637,0.000009788732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017688423,0.019260626,0.9462171,0.00022153603,0.0009796487,0.005079681,0.00018435995,0.000027883167,0.00068388873,0.0000010446527,0.000053327094,0.009602474],"study_design_scores_gemma":[0.04680541,0.029225938,0.91828203,0.00024988333,0.000759115,0.000010675721,0.00028268772,0.0000075369967,0.003787118,0.000013839008,0.00029404505,0.00028172944],"about_ca_topic_score_codex":0.0003773406,"about_ca_topic_score_gemma":0.0008604332,"teacher_disagreement_score":0.029116988,"about_ca_system_score_codex":0.00043042575,"about_ca_system_score_gemma":0.0017048492,"threshold_uncertainty_score":0.99991184},"labels":[],"label_agreement":null},{"id":"W3138725098","doi":"10.1016/j.clgc.2021.03.015","title":"Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Interquartile range; Prostate cancer; Prostatectomy; Stage (stratigraphy); Epidemiology; Proportional hazards model; Surveillance, Epidemiology, and End Results; Internal medicine; Cancer; Oncology; Urology; Cancer registry","score_opus":0.052553990776346114,"score_gpt":0.39787147044985366,"score_spread":0.34531747967350757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138725098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616797,0.020927126,0.000021221893,0.012658167,0.0018858897,0.00081952545,0.0016480093,0.00012895591,0.0002314337],"genre_scores_gemma":[0.87017226,0.1135456,0.0006894569,0.0039322763,0.0029611825,0.0008446322,0.00047692418,0.000116556825,0.007261101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99646664,0.00025333965,0.0010408583,0.0010441861,0.00044430076,0.0007506733],"domain_scores_gemma":[0.9974586,0.00045573208,0.000284305,0.0006151347,0.00049852725,0.0006877461],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000681323,0.00043423465,0.0010838095,0.00003643821,0.00023385212,0.000101443395,0.00011044752,0.00026213104,0.00051775423],"category_scores_gemma":[0.0004744102,0.0003617588,0.00027058137,0.00031198066,0.0006486435,0.00013853853,0.00027364702,0.00069365057,0.000026278627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001960218,0.001109802,0.8234667,0.0005114759,0.000579946,0.0038665575,0.0003199569,0.0000049265673,0.0005033454,0.000025340974,0.009777111,0.1578746],"study_design_scores_gemma":[0.0074159424,0.0009001039,0.72195816,0.0007434214,0.000492634,0.00013698373,0.00025410188,0.00011942839,0.0039434396,0.00007302236,0.26342118,0.0005415988],"about_ca_topic_score_codex":0.00012230322,"about_ca_topic_score_gemma":0.0000899169,"teacher_disagreement_score":0.25364408,"about_ca_system_score_codex":0.00027397307,"about_ca_system_score_gemma":0.0012887852,"threshold_uncertainty_score":0.9998834},"labels":[],"label_agreement":null},{"id":"W3146689657","doi":"10.1016/j.clgc.2021.03.010","title":"Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched Analysis","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Urology; Lymph node; Hazard ratio; Chemotherapy; Proportional hazards model; Internal medicine; Stage (stratigraphy); Dissection (medical); Surgery; Cancer; Confidence interval","score_opus":0.0627656918527785,"score_gpt":0.4133542788830282,"score_spread":0.35058858703024975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146689657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878086,0.0042921063,0.000079172016,0.0044110892,0.0006932956,0.0008110623,0.0002550254,0.000111322646,0.00056609017],"genre_scores_gemma":[0.9898303,0.0019570815,0.0011724407,0.0025209496,0.0011332879,0.0008003813,0.00041073273,0.000058060417,0.00211676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617964,0.00044398452,0.001195237,0.0010938674,0.00049943663,0.0005878402],"domain_scores_gemma":[0.99783695,0.00038363482,0.00021134502,0.00084931887,0.0001830285,0.0005357455],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026715963,0.00044763385,0.0015756416,0.00023776515,0.00011471389,0.000036328172,0.00014673494,0.00037147265,0.0028594218],"category_scores_gemma":[0.00012371798,0.00037561462,0.0010666633,0.0013220541,0.00015556836,0.00008073664,0.00006343337,0.00044865152,0.000038857706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017244406,0.0027010269,0.96644145,0.0000761857,0.0028722475,0.0025691083,0.000117028,0.0017177043,0.000073041185,0.0000027458752,0.00036654362,0.021338446],"study_design_scores_gemma":[0.012044256,0.00067505654,0.97361094,0.00012374102,0.0037692739,0.000013900612,0.00005354394,0.0027596103,0.0005280603,0.00004448451,0.0059983633,0.00037875873],"about_ca_topic_score_codex":0.01671092,"about_ca_topic_score_gemma":0.0092213405,"teacher_disagreement_score":0.020959688,"about_ca_system_score_codex":0.0011863641,"about_ca_system_score_gemma":0.0017680426,"threshold_uncertainty_score":0.9998696},"labels":[],"label_agreement":null},{"id":"W3152739953","doi":"10.1016/j.clgc.2021.04.008","title":"Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Janssen Pharmaceuticals; EMD Serono; Genentech; National Institutes of Health; Bavarian Nordic; Bayer Schering; Astellas Pharma; Eisai; Cancer Research UK; GlaxoSmithKline; Virginia Marine Resources Commission; Advanced Accelerator Applications; Bayer Fund; Clovis Oncology; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Jounce Therapeutics; Merck Sharp and Dohme; Genzyme; National Institute on Handicapped Research; Exelixis; Sanofi; Novartis; Merck; Heron Therapeutics; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Nivolumab; Internal medicine; Pembrolizumab; Durvalumab; Oncology; Atezolizumab; Metastatic Urothelial Carcinoma; Carboplatin; Cisplatin; Response Evaluation Criteria in Solid Tumors; Retrospective cohort study; Urology; Bladder cancer; Urothelial carcinoma; Cancer; Chemotherapy; Progressive disease; Immunotherapy","score_opus":0.03517358340460927,"score_gpt":0.3511806430000108,"score_spread":0.31600705959540154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152739953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947761,0.0007846003,0.000028596955,0.0006634106,0.000739531,0.0010200832,0.00029993177,0.00009340243,0.0015943298],"genre_scores_gemma":[0.9923544,0.00097425474,0.0016873353,0.0009448576,0.0009896711,0.00016314336,0.00017311946,0.00011569385,0.0025975374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960758,0.00017903034,0.0015560457,0.0009780913,0.00067379774,0.00053721084],"domain_scores_gemma":[0.99674636,0.0006035767,0.00048919575,0.0008586812,0.00078479387,0.0005174037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019816645,0.0005199944,0.001579781,0.0000933121,0.00012198476,0.00001669787,0.00017864072,0.00031118217,0.00050464785],"category_scores_gemma":[0.00023981139,0.00034146287,0.0005079704,0.00050342386,0.00040506394,0.00014053588,0.00011683376,0.00057552505,0.000029745734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009544162,0.0033787466,0.9659949,0.00013739878,0.0009622189,0.0004737128,0.000047297977,0.00007007566,0.000027280545,0.0000020655057,0.0011294329,0.018232714],"study_design_scores_gemma":[0.03051779,0.008256713,0.95243293,0.00040192247,0.0009858726,0.000020279438,0.00004286557,0.000015972091,0.001815108,0.0000132806235,0.0050961166,0.00040114872],"about_ca_topic_score_codex":0.00021502093,"about_ca_topic_score_gemma":0.00027147765,"teacher_disagreement_score":0.020973628,"about_ca_system_score_codex":0.00013071482,"about_ca_system_score_gemma":0.0012604281,"threshold_uncertainty_score":0.99990374},"labels":[],"label_agreement":null},{"id":"W3154739493","doi":"10.1016/j.clgc.2021.04.002","title":"Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"National Cancer Institute; EMD Serono; Exelixis; Boehringer Ingelheim; Gilead Sciences; Sanofi; Roche; Janssen Pharmaceuticals; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Blockade; Odds ratio; Internal medicine; Oncology; Confidence interval; Logistic regression; Cancer; Angiotensin receptor; Angiotensin II; Receptor","score_opus":0.07895815771233301,"score_gpt":0.3820731702178508,"score_spread":0.3031150125055178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154739493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821528,0.007854229,0.000010546833,0.00768197,0.0012380282,0.0005754929,0.000033183132,0.000030703082,0.00042304717],"genre_scores_gemma":[0.9957822,0.00055081776,0.0005372646,0.00041243603,0.001441676,0.000046919322,0.000004436756,0.000045360917,0.0011788884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969892,0.00056737807,0.0010199975,0.00056341157,0.00044939507,0.0004106092],"domain_scores_gemma":[0.99753165,0.0008912228,0.0003057892,0.000736247,0.00038083908,0.00015425026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068385655,0.00028111352,0.001118243,0.00009428103,0.00008398919,0.000013296495,0.00015281049,0.00016324586,0.000074829266],"category_scores_gemma":[0.00077431015,0.0001943315,0.00056711293,0.00056346215,0.0004151973,0.000061821964,0.00024403106,0.0005582967,0.000018533967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001092973,0.00091562676,0.92981917,0.00011471789,0.00072599045,0.0017942053,0.00057143666,0.00019285918,0.037685294,0.0000067662527,0.007038962,0.02004201],"study_design_scores_gemma":[0.0024460931,0.00041303464,0.951818,0.0003081302,0.00041517292,0.00015480179,0.00015582002,0.0004745499,0.040411986,0.00005917785,0.0031241728,0.00021909853],"about_ca_topic_score_codex":0.00042562524,"about_ca_topic_score_gemma":0.00014785411,"teacher_disagreement_score":0.021998802,"about_ca_system_score_codex":0.00011530394,"about_ca_system_score_gemma":0.0006183332,"threshold_uncertainty_score":0.79246086},"labels":[],"label_agreement":null},{"id":"W3155835287","doi":"10.1016/j.clgc.2021.04.004","title":"Apparent Diffusion Coefficient and Other Preoperative Magnetic Resonance Imaging Features for the Prediction of Positive Surgical Margins in Prostate Cancer Patients Undergoing Radical Prostatectomy","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"Ministero della Salute","keywords":"Medicine; Prostatectomy; Prostate cancer; Magnetic resonance imaging; Effective diffusion coefficient; Confidence interval; Logistic regression; Prostate; Univariate analysis; Urology; Radiology; Nuclear medicine; Youden's J statistic; Cancer; Receiver operating characteristic; Internal medicine; Multivariate analysis","score_opus":0.020981356460879,"score_gpt":0.3276683650322122,"score_spread":0.3066870085713332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155835287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92798567,0.06575748,0.0000144307505,0.002159544,0.0004692924,0.002503313,0.0009858755,0.0000177319,0.00010663719],"genre_scores_gemma":[0.9738003,0.023173401,0.00014556167,0.0005690813,0.00026879561,0.0015118052,0.00007407221,0.000036391666,0.00042060617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979177,0.00016392865,0.0006504706,0.00061357324,0.00030231668,0.00035200178],"domain_scores_gemma":[0.99835044,0.00081326277,0.00016364004,0.000222545,0.00029702502,0.00015305841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022010322,0.0002374604,0.00048203085,0.000052716176,0.00013984827,0.000027852444,0.00006841126,0.00008022972,0.000067074645],"category_scores_gemma":[0.00012238002,0.000157958,0.00015035381,0.00022763383,0.0003378258,0.00006157616,0.0001246492,0.00030252826,4.7217233e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026915981,0.0017039466,0.9306214,0.00017810965,0.00007799174,0.00012770022,0.00072377705,0.00012534866,0.00008428031,0.000027995915,0.0008514655,0.06278642],"study_design_scores_gemma":[0.012308716,0.0016556088,0.9705831,0.0014695368,0.0002211468,0.000023616221,0.0003127546,0.0014404536,0.0019140341,0.000032646905,0.009879569,0.0001588587],"about_ca_topic_score_codex":0.00014758937,"about_ca_topic_score_gemma":0.00015665824,"teacher_disagreement_score":0.06262757,"about_ca_system_score_codex":0.00029135344,"about_ca_system_score_gemma":0.00050364784,"threshold_uncertainty_score":0.64413404},"labels":[],"label_agreement":null},{"id":"W3196657023","doi":"10.1016/j.clgc.2021.08.003","title":"Radical Cystectomy vs. Radiotherapy in Urothelial Bladder Cancer in Elderly and Very Elderly Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Cohort; Urology; Chemotherapy; Radiation therapy; Internal medicine; Confidence interval; Concomitant; Urothelial carcinoma; Oncology; Cancer","score_opus":0.027970536787984952,"score_gpt":0.35711583299522026,"score_spread":0.3291452962072353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196657023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97837704,0.015633294,0.000010132885,0.002761731,0.001385307,0.0007978133,0.000110066256,0.000047546986,0.0008770694],"genre_scores_gemma":[0.97244036,0.020089671,0.00036763842,0.0034899642,0.0016228093,0.00039906517,0.000029865745,0.00008949137,0.0014711395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996709,0.00031260456,0.0009904613,0.00093073584,0.0004326776,0.00062454847],"domain_scores_gemma":[0.9986446,0.00024190698,0.0001316396,0.00044227202,0.00014016873,0.0003994003],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002575371,0.00038832478,0.0009774147,0.0001740908,0.000066133594,0.000036376736,0.0001465282,0.00040129886,0.0015113392],"category_scores_gemma":[0.00010801517,0.0003513273,0.00024050935,0.00047811551,0.0002648333,0.00015317928,0.000084204905,0.00082396896,0.000016728789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031484633,0.0016444668,0.8049292,0.00010800067,0.00027106714,0.0011724124,0.0002540241,0.000018618104,0.00034740573,0.000004575953,0.0020645962,0.18603718],"study_design_scores_gemma":[0.029647019,0.0029634936,0.92570907,0.0005135858,0.00017641153,0.00005009728,0.00006626933,0.00011507357,0.0005779667,0.000089455345,0.039623033,0.00046852033],"about_ca_topic_score_codex":0.0009059408,"about_ca_topic_score_gemma":0.0009802171,"teacher_disagreement_score":0.18556866,"about_ca_system_score_codex":0.0003960682,"about_ca_system_score_gemma":0.0011932012,"threshold_uncertainty_score":0.99989384},"labels":[],"label_agreement":null},{"id":"W3199482111","doi":"10.1016/j.clgc.2021.08.009","title":"Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Prostate cancer; Castration; Oncology; Hormone; Internal medicine; Hormonal therapy; Cancer","score_opus":0.4711515689813758,"score_gpt":0.5250952329655744,"score_spread":0.05394366398419859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199482111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786587,0.016934136,0.000045908007,0.00064796413,0.0003850509,0.00095502473,0.0016513146,0.000017531873,0.0007043919],"genre_scores_gemma":[0.97107136,0.021659471,0.004115313,0.00013717574,0.0004732727,0.00011940657,0.0006470314,0.00004152153,0.0017354592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658495,0.0003097773,0.0011183396,0.00081091374,0.0007137496,0.00046225256],"domain_scores_gemma":[0.99775714,0.0002720761,0.00025188268,0.0009979815,0.00045943502,0.000261459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085217267,0.00026178412,0.0012636639,0.0001509812,0.00009332737,0.000021324377,0.000246749,0.00006583565,0.00021402618],"category_scores_gemma":[0.00008475453,0.00021935267,0.00033584904,0.00090140884,0.00039186355,0.00018968634,0.00032310296,0.00048401073,0.0000037311372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02597424,0.008563667,0.8331399,0.0019518494,0.017238954,0.009087508,0.0015592003,0.020291792,0.03545009,0.000062927684,0.0054501127,0.04122976],"study_design_scores_gemma":[0.0167563,0.000651651,0.9447523,0.0012119499,0.0019304351,0.00004712268,0.000795757,0.013852874,0.005536751,0.00002733641,0.013928808,0.00050874415],"about_ca_topic_score_codex":0.0041210996,"about_ca_topic_score_gemma":0.004105918,"teacher_disagreement_score":0.11161237,"about_ca_system_score_codex":0.0004793771,"about_ca_system_score_gemma":0.0031056316,"threshold_uncertainty_score":0.89449424},"labels":[],"label_agreement":null},{"id":"W3202899348","doi":"10.1016/j.clgc.2021.09.004","title":"The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments","year":2021,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Prostate cancer; Androgen deprivation therapy; Dose fractionation; Cyberknife; Prostate; Oncology; Cancer; Radiology; Internal medicine; Radiosurgery","score_opus":0.07510440788300249,"score_gpt":0.4424829346515171,"score_spread":0.3673785267685146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202899348","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042280894,0.9486994,0.000014348046,0.0011880124,0.0021050575,0.004885329,0.00075401785,0.000036464327,0.00003648387],"genre_scores_gemma":[0.0018493342,0.9899869,0.00039804645,0.00029749548,0.0016835663,0.0033649995,0.00051442016,0.00016282812,0.0017423865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933249,0.0011637296,0.0029803389,0.0011582887,0.00070719805,0.0006655701],"domain_scores_gemma":[0.99466246,0.0016441896,0.001917725,0.0009353135,0.00035394565,0.0004863384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010043336,0.0008211142,0.0031815444,0.0002925688,0.00023015657,0.0000916553,0.00030095517,0.0005056148,0.0005099887],"category_scores_gemma":[0.00020157601,0.00055278395,0.0013266786,0.00088172377,0.00021911082,0.00016001341,0.000088900924,0.0009683266,0.000018531195],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014682775,0.0020418572,0.06551655,0.0016182229,0.0038136067,0.00022840386,0.00013549531,0.000085703556,0.0000033392344,0.000015066957,0.002541546,0.92253196],"study_design_scores_gemma":[0.0113758575,0.0030712187,0.12586363,0.016109819,0.0035260648,0.000048389564,0.000026624948,0.00010059151,0.000012464255,0.00003600295,0.8392074,0.0006219153],"about_ca_topic_score_codex":0.00075552694,"about_ca_topic_score_gemma":0.0001713149,"teacher_disagreement_score":0.92191,"about_ca_system_score_codex":0.0031793432,"about_ca_system_score_gemma":0.0025039632,"threshold_uncertainty_score":0.9996924},"labels":[],"label_agreement":null},{"id":"W3207290793","doi":"10.1016/j.clgc.2021.10.002","title":"Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"European Association of Urology; Uehara Memorial Foundation","keywords":"Medicine; Urothelial carcinoma; Pathological; Grading (engineering); Urothelial cancer; Oncology; Carcinoma; Internal medicine; Bladder cancer; Cancer","score_opus":0.10614644549365204,"score_gpt":0.4237975035817943,"score_spread":0.31765105808814226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207290793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900435,0.0061496007,0.000031373173,0.002149183,0.0005796642,0.00035323369,0.00007403512,0.000039154704,0.0005802395],"genre_scores_gemma":[0.9889982,0.005996421,0.00095264293,0.0013601173,0.002045425,0.000055888064,0.000020823638,0.000038898535,0.0005316313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971411,0.00036223428,0.0009602607,0.00088684773,0.00022092003,0.0004286352],"domain_scores_gemma":[0.9984852,0.00057562726,0.00011266825,0.0003276152,0.000063407635,0.0004354678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057812646,0.00027137698,0.00090558524,0.00006179955,0.00009643831,0.000035916386,0.00008389135,0.00025985306,0.00012129849],"category_scores_gemma":[0.00026667182,0.00022230213,0.00021644749,0.00017998877,0.000423792,0.00011799715,0.00017522076,0.00084151485,0.000006822351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036730437,0.0004246062,0.9182423,0.00005914097,0.00006390867,0.0021274306,0.00010232291,4.076674e-7,0.0001125837,0.000012769094,0.00013614801,0.07835108],"study_design_scores_gemma":[0.0053936355,0.0008490208,0.98977023,0.00017269929,0.00022202427,0.00015595464,0.00015173417,0.000035575482,0.00016363744,0.00032436242,0.002522621,0.00023851202],"about_ca_topic_score_codex":0.00006693902,"about_ca_topic_score_gemma":0.000020743519,"teacher_disagreement_score":0.07811257,"about_ca_system_score_codex":0.000057787594,"about_ca_system_score_gemma":0.0003624866,"threshold_uncertainty_score":0.9065218},"labels":[],"label_agreement":null},{"id":"W3213383090","doi":"10.1016/j.clgc.2021.10.010","title":"Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Lymph node; Bladder cancer; Stage (stratigraphy); Urology; Dissection (medical); Urinary bladder; Carcinoma; Proportional hazards model; Hazard ratio; Adenocarcinoma; Internal medicine; Oncology; Cancer; Surgery; Confidence interval","score_opus":0.050856143172672355,"score_gpt":0.35134109118836987,"score_spread":0.30048494801569753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213383090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346525,0.011684174,0.000026844498,0.002145146,0.00086173345,0.00042569448,0.00017631217,0.000015859334,0.0011989945],"genre_scores_gemma":[0.99562216,0.00053600525,0.00022747701,0.00041341575,0.00058842846,0.000089004476,0.00002488963,0.0000348644,0.0024637496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818915,0.00020763343,0.0006940268,0.00049956643,0.0001901587,0.00021945602],"domain_scores_gemma":[0.9985743,0.00046628955,0.00023854873,0.00040736824,0.0001278152,0.00018566556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017556448,0.00021117208,0.00070893246,0.00006527925,0.000112015616,0.0000045208812,0.000090366586,0.00022675861,0.00017027499],"category_scores_gemma":[0.00013661537,0.0001515048,0.000310877,0.00017242278,0.0006037501,0.000039199538,0.00017204563,0.00018394088,7.5730594e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011952258,0.0021195482,0.9503702,0.0006122513,0.00087055034,0.00046609264,0.00035876688,0.0000034615164,0.006854245,0.000045464447,0.003976112,0.022371076],"study_design_scores_gemma":[0.015759068,0.0015693747,0.9702366,0.00013716098,0.0006601828,0.0009773817,0.000052861207,0.000093794464,0.003385918,0.000046333585,0.006925222,0.00015609048],"about_ca_topic_score_codex":0.00012432635,"about_ca_topic_score_gemma":0.000011627914,"teacher_disagreement_score":0.022214986,"about_ca_system_score_codex":0.0001007655,"about_ca_system_score_gemma":0.0006157275,"threshold_uncertainty_score":0.6178187},"labels":[],"label_agreement":null},{"id":"W4200262376","doi":"10.1016/j.clgc.2021.12.003","title":"Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; University of Ottawa; Centre Hospitalier de l’Université de Montréal; CancerCare Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Foothills Medical Centre; University of British Columbia; Juravinski Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre; Alberta Cancer Foundation; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Ipilimumab; Nivolumab; Medicine; Discontinuation; Renal cell carcinoma; Internal medicine; Cohort; Oncology; Kidney cancer; Adverse effect; Expanded access; Cancer; Surgery; Immunotherapy","score_opus":0.07943066627634919,"score_gpt":0.3662064179276324,"score_spread":0.2867757516512832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200262376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921693,0.0029224486,0.000011879281,0.000077318655,0.00020022805,0.0006516254,0.0000648199,0.000010012281,0.0038923423],"genre_scores_gemma":[0.99450487,0.003027885,0.00077905314,0.00006874445,0.00008938957,0.000043431966,0.00012525487,0.000028676357,0.0013326887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973756,0.0002762082,0.0012579222,0.00047744185,0.0003782887,0.00023454452],"domain_scores_gemma":[0.99834645,0.00031294662,0.00035592282,0.00043531766,0.00036503386,0.0001843289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031657532,0.000198086,0.00089626276,0.00014568729,0.000027056476,0.000003847556,0.000073249816,0.000090828114,0.00020917755],"category_scores_gemma":[0.00012171767,0.00017897473,0.00019780498,0.00044366595,0.000183774,0.000056872068,0.00012328521,0.00023358094,0.0000026864184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027745573,0.001230599,0.98425895,0.0005076739,0.00012203287,0.0003219779,0.00013854152,0.000056111858,0.00054094644,0.000007036935,0.0002620916,0.009779453],"study_design_scores_gemma":[0.009577626,0.0012811226,0.97503996,0.00021745922,0.0004714035,0.000009515131,0.000082009516,0.0003083897,0.012554868,0.000028922996,0.0002971921,0.00013152356],"about_ca_topic_score_codex":0.0006495464,"about_ca_topic_score_gemma":0.00041483113,"teacher_disagreement_score":0.012013922,"about_ca_system_score_codex":0.0002972783,"about_ca_system_score_gemma":0.0007370424,"threshold_uncertainty_score":0.7298378},"labels":[],"label_agreement":null},{"id":"W4205349880","doi":"10.1016/j.clgc.2022.01.003","title":"Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Prostate Cancer Canada","keywords":"Medicine; Capra; Cohort; Nomogram; Biochemical recurrence; Prostate cancer; Oncology; Internal medicine; Cancer; Metastasis; Prostatectomy; Retrospective cohort study","score_opus":0.025291342321551374,"score_gpt":0.34153732938166614,"score_spread":0.31624598706011475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205349880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98767495,0.006921106,3.9153352e-7,0.0029525256,0.00045854313,0.0016470412,0.00019397006,0.000021590198,0.00012986251],"genre_scores_gemma":[0.9932394,0.0019677782,0.000106234416,0.00079971546,0.0001573966,0.0034898398,0.00008500318,0.000028759983,0.00012586138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980429,0.0001501896,0.0006050401,0.0004788066,0.00041059658,0.00031247767],"domain_scores_gemma":[0.99869007,0.00030837904,0.000355472,0.0003292684,0.00019201315,0.00012478334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029922384,0.00019763819,0.000435908,0.000060909155,0.00012867732,0.000011293816,0.00018691488,0.000038515205,0.00007785607],"category_scores_gemma":[0.00013043033,0.00012638561,0.00010492866,0.00040224966,0.00027411195,0.000058165388,0.00017896763,0.00058651995,0.0000013102788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023150698,0.0022136685,0.9615306,0.00013821441,0.00013342281,0.000064016436,0.00048221168,0.000071454044,0.00042896374,0.000012777826,0.0041290354,0.028480561],"study_design_scores_gemma":[0.004779386,0.004283697,0.9814326,0.00044146506,0.00021655783,0.000013814976,0.00032419318,0.00007161442,0.0051557934,0.00005468457,0.0030185422,0.0002076174],"about_ca_topic_score_codex":0.00038042528,"about_ca_topic_score_gemma":0.00004915009,"teacher_disagreement_score":0.028272945,"about_ca_system_score_codex":0.00028846876,"about_ca_system_score_gemma":0.00059906475,"threshold_uncertainty_score":0.51538557},"labels":[],"label_agreement":null},{"id":"W4206405356","doi":"10.1016/j.clgc.2021.11.018","title":"Establishing metastatic prostate cancer quality indicators using a modified Delphi approach","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Princess Margaret Cancer Centre; University of Toronto","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Delphi method; Quality (philosophy); Prostate; Internal medicine; Artificial intelligence","score_opus":0.5175260287163131,"score_gpt":0.568070829747509,"score_spread":0.05054480103119585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206405356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037762786,0.98683333,0.000027334323,0.0001294666,0.0016665778,0.004737222,0.0012209076,0.0001689761,0.0014399244],"genre_scores_gemma":[0.00015328458,0.98662233,0.0012371897,0.00028019169,0.0019559315,0.004742106,0.0010349225,0.00030258985,0.0036714734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99016833,0.00205939,0.0029857492,0.0019532747,0.0015091237,0.0013241088],"domain_scores_gemma":[0.9944871,0.0014879102,0.0015703687,0.0013035979,0.000172487,0.0009785133],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029462199,0.0010795309,0.004969942,0.0008109879,0.0005465792,0.00014507909,0.0008122798,0.0005528537,0.0016663801],"category_scores_gemma":[0.00055114744,0.0008078989,0.0020559265,0.0022170113,0.00055757165,0.00027324492,0.0009086055,0.0036628917,0.000018903085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007523303,0.0013234952,0.00089659257,0.030510886,0.0031457962,0.0007785367,0.00029748637,0.000093747505,8.199946e-7,0.000009338509,0.0022478295,0.9599431],"study_design_scores_gemma":[0.003061463,0.00048173225,0.00010146832,0.0051417556,0.006524592,0.0001200642,0.00035320444,0.00023796881,0.0000011379285,0.00002732563,0.9829749,0.0009743765],"about_ca_topic_score_codex":0.0009106623,"about_ca_topic_score_gemma":0.000013180395,"teacher_disagreement_score":0.9807271,"about_ca_system_score_codex":0.001997011,"about_ca_system_score_gemma":0.008587887,"threshold_uncertainty_score":0.9994372},"labels":[],"label_agreement":null},{"id":"W4206793550","doi":"10.1016/j.clgc.2022.01.004","title":"Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology","keywords":"Medicine; Gemcitabine; Internal medicine; Chemotherapy; Oncology; Cisplatin; Vinblastine; Hazard ratio; Proportional hazards model; Cancer; Cohort; Urology; Confidence interval","score_opus":0.04488737502863818,"score_gpt":0.3753688852645977,"score_spread":0.3304815102359595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206793550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919394,0.0008280305,0.0000020904258,0.0020157713,0.0014411514,0.0028425269,0.0005230069,0.00007672935,0.0003312542],"genre_scores_gemma":[0.99041533,0.00038173655,0.00016912262,0.0052004065,0.0006394336,0.002030212,0.000071726245,0.000088092405,0.0010039393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996663,0.00036710894,0.00086067675,0.0008869166,0.0007035061,0.0005188048],"domain_scores_gemma":[0.9985893,0.00026138156,0.0002487554,0.0005393707,0.00009971214,0.00026149186],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024508184,0.00041501378,0.0010116855,0.00012072572,0.00018303555,0.000021727388,0.0002900723,0.000118759315,0.0052155987],"category_scores_gemma":[0.00003140204,0.00029700887,0.00028919656,0.00027386853,0.00010509809,0.00010389512,0.00014205372,0.00088565703,0.000021565684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009995496,0.016290225,0.89950913,0.000010760097,0.0005408672,0.00043620548,0.0008321743,0.00007007172,0.00001315811,1.5055089e-7,0.0007605606,0.07154121],"study_design_scores_gemma":[0.045847777,0.01163672,0.93004006,0.000049158894,0.00035132768,0.0000019568402,0.00060913595,0.00003452125,0.000018954539,0.000010915773,0.011075151,0.0003243002],"about_ca_topic_score_codex":0.0036387194,"about_ca_topic_score_gemma":0.0005100077,"teacher_disagreement_score":0.07121691,"about_ca_system_score_codex":0.00068001787,"about_ca_system_score_gemma":0.0005993104,"threshold_uncertainty_score":0.9999482},"labels":[],"label_agreement":null},{"id":"W4210695409","doi":"10.1016/j.clgc.2022.01.011","title":"Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Chemotherapy; Cystectomy; Proportional hazards model; Perioperative; Bladder cancer; Urothelial carcinoma; Urology; Oncology; Carcinoma; Cancer; Database; Internal medicine; Surgery","score_opus":0.07033369076109303,"score_gpt":0.4018111346463198,"score_spread":0.33147744388522676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210695409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352986,0.00055887416,0.000029364668,0.0028505346,0.00040488155,0.0008016313,0.0014619919,0.000012177336,0.0003507009],"genre_scores_gemma":[0.99579537,0.0004673601,0.00013621668,0.0008976747,0.0011508565,0.0004991556,0.00020459275,0.000025720323,0.0008230603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977323,0.00047214385,0.00052956486,0.00043561836,0.00061270426,0.00021771072],"domain_scores_gemma":[0.9987758,0.00055408024,0.0002334695,0.00017314943,0.00016035627,0.00010316482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001006022,0.00015014461,0.00055144535,0.00014356572,0.00024054368,0.000012344262,0.00012736047,0.00010467931,0.00030746788],"category_scores_gemma":[0.00014749657,0.00012116482,0.00023775369,0.00052488927,0.00010699854,0.000109424196,0.00009974022,0.00039862725,1.5342971e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028930514,0.0003794485,0.9913164,0.00004555769,0.0014844951,0.0000026475452,0.00044397605,0.0003681291,0.00067111343,0.000012510291,0.0004959664,0.0018867259],"study_design_scores_gemma":[0.006781512,0.0010797482,0.9870578,0.000021854032,0.0013992431,0.0000012285199,0.00026603334,0.0015062899,0.00033384276,0.000038719783,0.0013865094,0.00012718579],"about_ca_topic_score_codex":0.0010654597,"about_ca_topic_score_gemma":0.0010513763,"teacher_disagreement_score":0.0042585456,"about_ca_system_score_codex":0.0012666764,"about_ca_system_score_gemma":0.0011590105,"threshold_uncertainty_score":0.4940958},"labels":[],"label_agreement":null},{"id":"W4213176808","doi":"10.1016/j.clgc.2022.02.004","title":"Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University Health Network; Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Androgen deprivation therapy; Cohort; Cancer; Cancer research","score_opus":0.08870405857679521,"score_gpt":0.40095933957297974,"score_spread":0.31225528099618455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213176808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97076434,0.023410706,0.000010403718,0.0008062276,0.00066658034,0.002184591,0.002025148,0.000030762447,0.00010123433],"genre_scores_gemma":[0.98646194,0.009259331,0.0012918209,0.00019416021,0.00029036272,0.0007670157,0.00020777764,0.000064812535,0.0014628092],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99635905,0.00066079496,0.0012255034,0.0006572169,0.0005375607,0.0005598845],"domain_scores_gemma":[0.99785864,0.00027111598,0.00062195613,0.0004717252,0.00053181534,0.00024472992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003865925,0.00035424242,0.0012237283,0.00017574355,0.0002189162,0.000008766758,0.00016639836,0.00007463459,0.00059701107],"category_scores_gemma":[0.000019034467,0.00027600434,0.00044920036,0.00037167082,0.0004516658,0.00006452319,0.00016928987,0.00046297818,0.000004542203],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02061582,0.0026874696,0.06553061,0.001134632,0.005748986,0.0030856533,0.0014520753,0.0037343623,0.8730453,0.0000709607,0.00032011003,0.022573965],"study_design_scores_gemma":[0.048841935,0.058443457,0.57847935,0.0009796263,0.007902767,0.00040022362,0.009321437,0.0014826043,0.28690988,0.0025541224,0.002787991,0.0018965772],"about_ca_topic_score_codex":0.0015668918,"about_ca_topic_score_gemma":0.00002875502,"teacher_disagreement_score":0.58613545,"about_ca_system_score_codex":0.0009864194,"about_ca_system_score_gemma":0.0020519155,"threshold_uncertainty_score":0.9999692},"labels":[],"label_agreement":null},{"id":"W4220970449","doi":"10.1016/j.clgc.2022.03.011","title":"Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC)","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Varian Medical Systems","keywords":"Medicine; Radiofrequency ablation; Renal cell carcinoma; Cost-effectiveness analysis; Stage (stratigraphy); Cohort; Radiology; Cost effectiveness; Ablation; Oncology; Internal medicine","score_opus":0.11082511121681382,"score_gpt":0.4046624807217256,"score_spread":0.2938373695049118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220970449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906407,0.004537087,0.00044522696,0.00011321559,0.0010975968,0.0022376475,0.00039310503,0.000042610616,0.0004928174],"genre_scores_gemma":[0.99568546,0.00043681785,0.00054634357,0.00009876181,0.00051857566,0.0010990356,0.00025312707,0.00007160258,0.0012902897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964682,0.0007322891,0.0009756205,0.00077155716,0.00060760474,0.00044474727],"domain_scores_gemma":[0.9963719,0.0017621584,0.0005623012,0.0007657027,0.00024528682,0.00029264356],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00095626997,0.0003346981,0.0011955102,0.0004234797,0.00021428324,0.000016802482,0.0002368838,0.00014063739,0.0009450604],"category_scores_gemma":[0.00008137685,0.00031631824,0.0010891041,0.001034631,0.00013992349,0.00010599629,0.000087357,0.00046627258,0.000004087333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043536015,0.0022931127,0.91173,0.00046114312,0.0059752557,0.00054167345,0.00037044514,0.005406273,0.015795143,0.00001656852,0.0004729796,0.013401373],"study_design_scores_gemma":[0.016641663,0.013177274,0.94885457,0.000023628927,0.0059048855,0.000009705927,0.00009028858,0.0031088958,0.0063483315,0.000008195487,0.0054915203,0.0003410513],"about_ca_topic_score_codex":0.0005038885,"about_ca_topic_score_gemma":0.000012688434,"teacher_disagreement_score":0.03712454,"about_ca_system_score_codex":0.001504709,"about_ca_system_score_gemma":0.0005483411,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W4224301051","doi":"10.1016/j.clgc.2022.04.003","title":"Physical Activity in Patients With Kidney Cancer: A Scoping Review","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Randomized controlled trial; Quality of life (healthcare); Cochrane Library; Systematic review; MEDLINE; Cohort; Population; Cohort study; Cancer; Gerontology; Family medicine; Physical therapy; Internal medicine; Environmental health; Nursing","score_opus":0.12704742887252504,"score_gpt":0.47176413437025727,"score_spread":0.34471670549773226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224301051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019252562,0.99025846,5.2258946e-7,0.0002931603,0.0018720528,0.0045258002,0.00040940888,0.00007244651,0.00064291665],"genre_scores_gemma":[0.000054134875,0.99082404,0.000008836223,0.0019841937,0.0019476388,0.0042089596,0.00026100536,0.00015918596,0.0005520152],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954694,0.0007439674,0.0010751114,0.0012641316,0.0008319844,0.0006153989],"domain_scores_gemma":[0.9969757,0.00053031073,0.0007633126,0.0009949435,0.00011584083,0.0006198995],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004943873,0.00073032826,0.0048982645,0.00016370855,0.000102747894,0.0000176468,0.00040113463,0.00030530384,0.0020349496],"category_scores_gemma":[0.00023849767,0.00055029336,0.0012871191,0.0010768509,0.00016753693,0.000106581734,0.00036665163,0.0024312166,0.000029214661],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031424788,0.0010023771,0.005029002,0.17408298,0.00025218638,0.00011984454,0.000018926394,3.6135305e-7,5.753409e-9,3.4617577e-7,0.003127933,0.8160518],"study_design_scores_gemma":[0.0010687145,0.0005911402,0.0008292743,0.36599156,0.0018325193,0.00000440031,0.0000025591455,7.949472e-7,7.354826e-8,5.558784e-7,0.6292475,0.00043093628],"about_ca_topic_score_codex":0.0005426402,"about_ca_topic_score_gemma":0.00045274984,"teacher_disagreement_score":0.81562084,"about_ca_system_score_codex":0.0010391733,"about_ca_system_score_gemma":0.005897059,"threshold_uncertainty_score":0.99987024},"labels":[],"label_agreement":null},{"id":"W4224305740","doi":"10.1016/j.clgc.2022.04.005","title":"Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Stage (stratigraphy); Urology; Lymph node; Lymph; Biopsy; Pathological; Prostate; Cancer; Internal medicine; Gynecology; Oncology; Pathology","score_opus":0.02828518460997291,"score_gpt":0.3324095367179585,"score_spread":0.30412435210798555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224305740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983291,0.0031958416,0.0000033540164,0.0013676819,0.0008582474,0.0024606362,0.0086761555,0.000101858655,0.000045228753],"genre_scores_gemma":[0.9795564,0.007484825,0.00008170605,0.0016893646,0.00038928888,0.008866187,0.001566407,0.000061203646,0.00030461018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956476,0.00065111596,0.0012835994,0.0010660602,0.00065427355,0.0006973271],"domain_scores_gemma":[0.99816644,0.00024137423,0.00049890275,0.00046455662,0.00015307195,0.0004756618],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048832066,0.00041307166,0.00095871266,0.00010017944,0.00022454117,0.000026194737,0.00019080704,0.00008957403,0.00058066536],"category_scores_gemma":[0.00015825602,0.00033948533,0.0003050867,0.0007849264,0.00054094597,0.00012675309,0.00039123817,0.0012997526,0.000017785338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076553863,0.00401689,0.9356596,0.000067265915,0.00014782083,0.0019380486,0.00014870937,0.00023010341,0.000002826629,0.0000018975593,0.003946898,0.046184584],"study_design_scores_gemma":[0.008674925,0.005881727,0.944872,0.000060969644,0.00012811157,0.000005308649,0.00010360111,0.00007110414,0.000046113637,0.000013288531,0.039770525,0.00037230924],"about_ca_topic_score_codex":0.0019486722,"about_ca_topic_score_gemma":0.00040576988,"teacher_disagreement_score":0.045812275,"about_ca_system_score_codex":0.0012754515,"about_ca_system_score_gemma":0.00076454727,"threshold_uncertainty_score":0.9999057},"labels":[],"label_agreement":null},{"id":"W4224880568","doi":"10.1016/j.clgc.2022.04.009","title":"Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"Sanofi Genzyme; Sanofi","keywords":"Cabazitaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen deprivation therapy","score_opus":0.25056824733698807,"score_gpt":0.5262210880224615,"score_spread":0.2756528406854734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224880568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21255219,0.779298,7.260108e-8,0.0011341752,0.00033180718,0.004186672,0.0024073997,0.000025267738,0.00006439636],"genre_scores_gemma":[0.003368405,0.9831683,0.00007330066,0.00008046721,0.00018535588,0.0030547613,0.00009455472,0.0001257953,0.00984907],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99418306,0.0014574615,0.0019630485,0.0009560967,0.00064335385,0.00079700036],"domain_scores_gemma":[0.9925608,0.0050891084,0.00064103707,0.0009930208,0.00015256567,0.00056348095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001916664,0.000723603,0.003576312,0.0006123637,0.0002002756,0.000064517124,0.000409589,0.00016269743,0.0006517516],"category_scores_gemma":[0.0007426285,0.00039332925,0.0011935505,0.0013653437,0.00043468087,0.000116368035,0.0004748608,0.0014503627,0.000009801964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04533653,0.002661056,0.2132744,0.0195394,0.00755132,0.0076497803,0.0011003816,0.00020230931,0.000018785826,0.000004930529,0.0124829905,0.6901781],"study_design_scores_gemma":[0.004099923,0.0045443815,0.20695657,0.008359613,0.0023570273,0.000051118936,0.0001527507,0.000012743521,0.000002855638,0.000013442277,0.77282065,0.0006289173],"about_ca_topic_score_codex":0.017273802,"about_ca_topic_score_gemma":0.0044950997,"teacher_disagreement_score":0.76033765,"about_ca_system_score_codex":0.0018118205,"about_ca_system_score_gemma":0.005317294,"threshold_uncertainty_score":0.9998519},"labels":[],"label_agreement":null},{"id":"W4249692483","doi":"10.1016/j.clgc.2020.06.002","title":"Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Guardant Health; Janssen Pharmaceuticals; Janssen Biotech; Bristol-Myers Squibb Canada; EMD Serono; Genentech; Astellas Pharma; Eisai; Daiichi-Sankyo; Aileron Therapeutics; CTI Biopharma; ImmunoGen; Mirati Therapeutics; Bayer Fund; Five Prime Therapeutics; Acceleron; Clovis Oncology; TG Therapeutics; AstraZeneca; Novocure; Sanofi Genzyme; Takeda Pharmaceuticals U.S.A.; Immunocore; AbbVie; Karyopharm Therapeutics; Exelixis; MedImmune; Sanofi; Celgene; Novartis; Merck; GlaxoSmithKline; Roche; Foundation Medicine; Astellas Pharma US; American Society of Clinical Oncology; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Boston Biomedical; Pfizer; Amgen; Boehringer Ingelheim; Calithera Biosciences; Bayer; Sarah Cannon Research Institute","keywords":"Medicine; Internal medicine; Nivolumab; Renal cell carcinoma; Rash; Clinical endpoint; Regimen; Clear cell renal cell carcinoma; Progression-free survival; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cancer; Toxicity; Chemotherapy; Clinical trial; Immunotherapy","score_opus":0.038017893248143676,"score_gpt":0.32126363076328307,"score_spread":0.2832457375151394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249692483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511844,0.0011989052,0.0000030623482,0.0006703564,0.0001353522,0.0019627435,0.00028785606,0.000028571496,0.0005947354],"genre_scores_gemma":[0.9983886,0.00024980897,0.00028656542,0.00036261015,0.00036551987,0.0000344164,0.000108368266,0.000053555377,0.00015056983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99672675,0.00033027137,0.0012499504,0.0008596306,0.00048645056,0.00034697336],"domain_scores_gemma":[0.99767435,0.0006822796,0.00044155336,0.0006757908,0.00015023927,0.0003757834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031221742,0.00033779757,0.0008637258,0.000039736526,0.00008213537,0.000011876888,0.00022638516,0.00012264974,0.00006371921],"category_scores_gemma":[0.00015481935,0.00021789107,0.00015853156,0.00029142,0.00021706682,0.00007579164,0.00020957763,0.000606196,0.0000141134715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18858816,0.0100279795,0.78322303,0.00009120591,0.00017106022,0.0005775624,0.0025544523,0.00025058846,0.0006813582,1.3553736e-7,0.0007517854,0.013082646],"study_design_scores_gemma":[0.10916356,0.021710219,0.86561316,0.00008430656,0.00040988697,9.348509e-7,0.00048808343,0.0001226974,0.0014528083,0.000001056063,0.00074521615,0.00020803852],"about_ca_topic_score_codex":0.0003599888,"about_ca_topic_score_gemma":0.00004075464,"teacher_disagreement_score":0.08239013,"about_ca_system_score_codex":0.00012432827,"about_ca_system_score_gemma":0.00023532126,"threshold_uncertainty_score":0.88853395},"labels":[],"label_agreement":null},{"id":"W4286510751","doi":"10.1016/j.clgc.2022.07.008","title":"CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary; Alberta Cancer Foundation","funders":"Ipsen; Ipsen Biopharmaceuticals","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Refractory (planetary science); Oncology; Internal medicine; Carcinoma; Clear cell; Urology","score_opus":0.040498504198724965,"score_gpt":0.3156316967992041,"score_spread":0.27513319260047914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286510751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896395,0.0019320877,0.000004898646,0.0005275503,0.0008621219,0.002202702,0.0036211545,0.000021427124,0.0011885281],"genre_scores_gemma":[0.9957039,0.00014545287,0.00029338925,0.00028580683,0.0003256053,0.000722126,0.0018590626,0.00006788635,0.0005967862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942073,0.0018744352,0.0013403792,0.0010281394,0.0010652554,0.00048447348],"domain_scores_gemma":[0.9933016,0.004069498,0.0007708913,0.0013613676,0.00027259407,0.0002241014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013318856,0.00048434982,0.0008977653,0.00012147287,0.0002398049,0.000019640123,0.0005994361,0.00007693594,0.0002581272],"category_scores_gemma":[0.00018324854,0.00027548816,0.00035614084,0.00038343592,0.00037931994,0.00012077746,0.0004331424,0.0008572198,0.000009842386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08063659,0.0066696024,0.90015817,0.000104219194,0.0004362575,0.0013936122,0.0006124624,0.0018728988,0.0038455543,0.000004300886,0.0014488179,0.0028174843],"study_design_scores_gemma":[0.03639565,0.0072329743,0.93567365,0.00010600798,0.0007442751,0.0000137290135,0.0004621768,0.000105478815,0.014270751,0.000011584168,0.0046896175,0.00029410675],"about_ca_topic_score_codex":0.0032353846,"about_ca_topic_score_gemma":0.00022508405,"teacher_disagreement_score":0.044240944,"about_ca_system_score_codex":0.0009365807,"about_ca_system_score_gemma":0.0011148043,"threshold_uncertainty_score":0.9999697},"labels":[],"label_agreement":null},{"id":"W4293217252","doi":"10.1016/j.clgc.2022.08.010","title":"Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Université de Montréal","funders":"","keywords":"Medicine; Proportional hazards model; Internal medicine; Renal cell carcinoma; Concomitant; Cohort; Epidemiology; Nephrectomy; Gastroenterology; Surgery; Urology; Kidney","score_opus":0.17532934324454227,"score_gpt":0.42396707200482325,"score_spread":0.24863772876028098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293217252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920174,0.0016532803,0.000008456803,0.0007502148,0.00078095734,0.0015022951,0.00005666573,0.000050137493,0.0031806203],"genre_scores_gemma":[0.992345,0.000096453376,0.00082872336,0.00072468567,0.0005759838,0.0013437793,0.000033697983,0.000056782326,0.0039949026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966034,0.0005118299,0.0009852926,0.00082995626,0.00049965596,0.0005698482],"domain_scores_gemma":[0.9982715,0.00040934558,0.00019502398,0.0006064797,0.000065034816,0.00045256614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007068861,0.00032903883,0.000856175,0.00024447928,0.00025823453,0.00001899245,0.00018072376,0.000053688655,0.0007433394],"category_scores_gemma":[0.00009308908,0.0002917136,0.00041840045,0.0007748546,0.000052401316,0.000052507025,0.00029662886,0.00050182804,0.000038693586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017279974,0.002338762,0.9684382,0.00007478289,0.00021303984,0.0061196918,0.00048725982,0.0020300094,0.0033170618,0.0000018752775,0.001303737,0.013947547],"study_design_scores_gemma":[0.009160028,0.009740882,0.95551574,0.000052273936,0.00087635353,0.00023770912,0.0023919363,0.0006588223,0.009919193,0.000047176003,0.0108430805,0.00055680814],"about_ca_topic_score_codex":0.0018015453,"about_ca_topic_score_gemma":0.0001690968,"teacher_disagreement_score":0.013390739,"about_ca_system_score_codex":0.0022500092,"about_ca_system_score_gemma":0.00092001876,"threshold_uncertainty_score":0.9999535},"labels":[],"label_agreement":null},{"id":"W4295942277","doi":"10.1016/j.clgc.2022.09.004","title":"Multi-Institution Evaluation of Sequential Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin Naïve Patients with Non-Muscle Invasive Bladder Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Docetaxel; Gemcitabine; Bladder cancer; Urology; Bacillus (shape); Oncology; Internal medicine; Cancer; Microbiology","score_opus":0.08438223880145321,"score_gpt":0.38274343369118446,"score_spread":0.29836119488973123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295942277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952102,0.0016039376,0.000018257704,0.00039014927,0.0004089445,0.0018722543,0.00033804958,0.00000635106,0.0001519],"genre_scores_gemma":[0.9964607,0.0016280814,0.00022250073,0.00021221866,0.0002683608,0.0010498915,0.000076843084,0.000021088346,0.000060337177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756587,0.00035946694,0.0006412733,0.0004214141,0.0007750905,0.00023686564],"domain_scores_gemma":[0.9988793,0.00014965989,0.00026101695,0.0003190476,0.0002864014,0.000104566374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043131455,0.00022454369,0.000537787,0.00010002481,0.000107976164,0.000006139687,0.00011106638,0.000082780454,0.00044602837],"category_scores_gemma":[0.00005163649,0.00014594683,0.00014000239,0.00029913895,0.0003073704,0.00007830108,0.000056975394,0.0002321783,0.000001388552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050814026,0.010773097,0.72995913,0.00013366362,0.0009982858,0.00009523138,0.0032464152,0.0021008393,0.0014454139,0.0000058519836,0.00020155769,0.24595909],"study_design_scores_gemma":[0.024496587,0.007744027,0.96306807,0.000077627614,0.0012447509,0.00000850693,0.00041195878,0.0009181342,0.00096431514,0.000014527126,0.0008822331,0.00016925832],"about_ca_topic_score_codex":0.0016008046,"about_ca_topic_score_gemma":0.00065099564,"teacher_disagreement_score":0.24578984,"about_ca_system_score_codex":0.0005064834,"about_ca_system_score_gemma":0.00093519496,"threshold_uncertainty_score":0.5951539},"labels":[],"label_agreement":null},{"id":"W4304891956","doi":"10.1016/j.clgc.2022.10.003","title":"Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Population; Hazard ratio; Prostate cancer; Proportional hazards model; Cancer; Urology","score_opus":0.05194096266369281,"score_gpt":0.39466579880682723,"score_spread":0.3427248361431344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304891956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96149224,0.03588325,0.0000035010025,0.00085256377,0.00054747134,0.000734909,0.00035810145,0.000025304424,0.00010263578],"genre_scores_gemma":[0.98308504,0.003480675,0.00032509913,0.00028856384,0.00012457749,0.0005327679,0.000110849294,0.000025773748,0.01202663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976288,0.00025567602,0.000698215,0.0005339118,0.00055064895,0.00033272375],"domain_scores_gemma":[0.9986535,0.00026183753,0.00031527027,0.00036640072,0.00017743371,0.00022556435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052504364,0.00019468684,0.0006386785,0.00027684605,0.00013120253,0.000007669242,0.00013587506,0.000041005034,0.0009125065],"category_scores_gemma":[0.000054985485,0.00016328639,0.00030415188,0.00059931446,0.00024805532,0.00006459656,0.0001183461,0.00050415477,0.0000012108509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005515896,0.00048483288,0.98007345,0.000814641,0.0011894731,0.00036576303,0.00023691452,0.0012252482,0.0011857336,0.0000015021183,0.0016391315,0.0072673955],"study_design_scores_gemma":[0.0034692339,0.0014569064,0.9828084,0.00011875641,0.0020638348,0.0000069512143,0.000097246026,0.007138248,0.00011251515,0.000015199961,0.0025082608,0.00020445125],"about_ca_topic_score_codex":0.0016515052,"about_ca_topic_score_gemma":0.00014077961,"teacher_disagreement_score":0.03240258,"about_ca_system_score_codex":0.0010961546,"about_ca_system_score_gemma":0.0017401113,"threshold_uncertainty_score":0.9991306},"labels":[],"label_agreement":null},{"id":"W4304892112","doi":"10.1016/j.clgc.2022.10.002","title":"Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Clinical trial; Expanded access; Intensive care medicine; Cabozantinib; Cancer; Urothelial carcinoma; Disease; Clinical Practice; Oncology; Bladder cancer; Internal medicine; Family medicine","score_opus":0.05980277892417523,"score_gpt":0.38068527785311157,"score_spread":0.32088249892893633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304892112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99166965,0.0035486058,0.0000015999449,0.0023988509,0.00029617694,0.0015463632,0.00023703177,0.00004569684,0.00025604828],"genre_scores_gemma":[0.99433565,0.001385728,0.00006132966,0.0020573724,0.00032517305,0.0014870835,0.000021316124,0.00005566241,0.000270685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766487,0.0001477984,0.0006952636,0.0005719863,0.00044897522,0.00047112288],"domain_scores_gemma":[0.9990685,0.00016122976,0.00019616143,0.00029323302,0.000078033445,0.0002028357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028383225,0.00029425896,0.0006774182,0.00026391656,0.00020253586,0.000088538814,0.00035505666,0.00008123879,0.00013792279],"category_scores_gemma":[0.00003624323,0.00022971466,0.000072584124,0.0005861701,0.00014750884,0.0003984485,0.0005013695,0.00058355456,0.0000011535318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00370943,0.0021655497,0.98527104,0.00024221641,0.000100002035,0.00010059965,0.0011128187,0.00036259147,0.000020827336,0.000003246422,0.00020338489,0.006708312],"study_design_scores_gemma":[0.0071741324,0.0028179807,0.98642194,0.0006033831,0.00007802571,0.000034800007,0.0006526989,0.000027101876,0.00001542298,0.00001810995,0.001876678,0.00027973854],"about_ca_topic_score_codex":0.0070186006,"about_ca_topic_score_gemma":0.00047882838,"teacher_disagreement_score":0.0065397723,"about_ca_system_score_codex":0.00044560258,"about_ca_system_score_gemma":0.00040193793,"threshold_uncertainty_score":0.99959373},"labels":[],"label_agreement":null},{"id":"W4309341654","doi":"10.1016/j.clgc.2022.11.005","title":"Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Internal medicine; Quartile; Disease; Prospective cohort study; Proportional hazards model; Gene expression profiling; Biomarker; DNA repair; Bioinformatics; Gene; Cancer; Gene expression; Genetics; Confidence interval; Biology","score_opus":0.07357477446378567,"score_gpt":0.3947500217146571,"score_spread":0.32117524725087143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309341654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886774,0.005693955,0.0000050626936,0.0016755492,0.00065057655,0.0014719818,0.0011372889,0.00013680436,0.00055139686],"genre_scores_gemma":[0.98156637,0.005463656,0.0003331011,0.00014441895,0.0004400253,0.0013952962,0.00007709561,0.00006364143,0.010516413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669856,0.00038088328,0.00078536203,0.00074553076,0.0008170045,0.0005726845],"domain_scores_gemma":[0.9979522,0.00033241944,0.0004987843,0.0006126982,0.00026237045,0.0003414911],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000803957,0.00031782436,0.0008407286,0.00011661595,0.00039660415,0.000010787807,0.00021949054,0.00008942743,0.0016747132],"category_scores_gemma":[0.00015857453,0.00021954584,0.00039830199,0.00052102044,0.00042650194,0.0000967879,0.00044644828,0.00093192025,0.0000110654755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012921807,0.0015181584,0.9589877,0.0003807147,0.0007545364,0.00043601284,0.00014173241,0.00012764904,0.00050234963,0.000004336839,0.0041859923,0.020039022],"study_design_scores_gemma":[0.0059423028,0.0050242036,0.96123725,0.00013353564,0.0006696615,0.000024672267,0.0001873889,0.00024452579,0.0028551412,0.00003317265,0.023299465,0.0003487053],"about_ca_topic_score_codex":0.0014776959,"about_ca_topic_score_gemma":0.00019979093,"teacher_disagreement_score":0.019690316,"about_ca_system_score_codex":0.00049564487,"about_ca_system_score_gemma":0.001208033,"threshold_uncertainty_score":0.9992379},"labels":[],"label_agreement":null},{"id":"W4310353441","doi":"10.1016/j.clgc.2022.11.020","title":"Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Health Authority; Juravinski Cancer Centre; University of Calgary; St. Michael's Hospital; Princess Margaret Cancer Centre; Dalhousie University; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Pandemic; Prostate cancer; Oncology; Internal medicine; Androgen deprivation therapy; Cabazitaxel; Cancer; Family medicine; Gynecology; Disease; Coronavirus disease 2019 (COVID-19)","score_opus":0.22629383110741824,"score_gpt":0.5035467576751977,"score_spread":0.2772529265677795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310353441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789114,0.015660176,4.73673e-7,0.0025808848,0.00029957958,0.0011563102,0.0013000795,0.000012066412,0.000079054436],"genre_scores_gemma":[0.98940283,0.006619112,0.000012835451,0.00023850486,0.00014749222,0.0013583886,0.00010969564,0.000026345437,0.0020848166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960839,0.0009635291,0.00081416697,0.0004283483,0.0012694248,0.000440586],"domain_scores_gemma":[0.9983165,0.0003991755,0.00034937065,0.00037269955,0.00032975015,0.00023248617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001823075,0.00020924456,0.00066989695,0.000094053525,0.00019103177,0.000004879024,0.00012922961,0.00004292698,0.0005000467],"category_scores_gemma":[0.00012689651,0.00014085304,0.00019815694,0.0007036238,0.00029210703,0.000043251002,0.00012689338,0.00032281713,4.3589665e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015107406,0.0020114218,0.72349,0.00021625317,0.0020209246,0.000942929,0.008661954,0.020364514,0.004041161,0.0000011429727,0.0018782642,0.22126403],"study_design_scores_gemma":[0.030503416,0.003719866,0.9409259,0.000055902598,0.0013913151,0.000120143195,0.00627359,0.0021460818,0.002593754,0.000040135586,0.011918522,0.000311368],"about_ca_topic_score_codex":0.30071232,"about_ca_topic_score_gemma":0.25797507,"teacher_disagreement_score":0.22095266,"about_ca_system_score_codex":0.0050808056,"about_ca_system_score_gemma":0.005484164,"threshold_uncertainty_score":0.9987385},"labels":[],"label_agreement":null},{"id":"W4312143504","doi":"10.1016/j.clgc.2022.12.006","title":"Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Internal medicine; Meta-analysis; Relative risk; Diabetes mellitus; Confidence interval; Metabolic syndrome; Oncology; Random effects model; Cancer; Endocrinology; Obesity","score_opus":0.19316705373262885,"score_gpt":0.4690140193793063,"score_spread":0.27584696564667743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312143504","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029192764,0.96561635,5.414636e-7,0.00025877918,0.0001511075,0.003048801,0.0016627703,0.000033337496,0.000035543726],"genre_scores_gemma":[0.0012380836,0.9863861,0.000042259333,0.0001517534,0.00021069098,0.003917359,0.0056699878,0.000090648595,0.0022930996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99472994,0.0012553155,0.0015915617,0.00095461844,0.0010019108,0.00046663274],"domain_scores_gemma":[0.9968622,0.00029041685,0.0013451477,0.0007198938,0.00040090547,0.00038144147],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009777026,0.0005225838,0.0045591695,0.000644824,0.0000916439,0.000025132891,0.00028732128,0.00022255655,0.0034867048],"category_scores_gemma":[0.00008023219,0.00032333136,0.0021951103,0.0025455873,0.00010163414,0.00018484477,0.000114463975,0.0008304062,0.0000041588264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026393055,0.0033049772,0.36354962,0.0014236494,0.22347656,0.00014222109,0.00008729043,0.0001057369,1.4943672e-7,0.000001044722,0.00060116954,0.4046683],"study_design_scores_gemma":[0.0029429644,0.0008447,0.020168468,0.00015881596,0.27477214,4.5755803e-7,0.000009365025,0.00001975216,0.000002729868,0.0000061969167,0.7007466,0.0003278381],"about_ca_topic_score_codex":0.0005042297,"about_ca_topic_score_gemma":0.00016895514,"teacher_disagreement_score":0.7001454,"about_ca_system_score_codex":0.0007502661,"about_ca_system_score_gemma":0.002433048,"threshold_uncertainty_score":0.99992186},"labels":[],"label_agreement":null},{"id":"W4313216173","doi":"10.1016/j.clgc.2022.12.005","title":"The Importance of Repeat Imaging Prior to Treatment Decision-making in Testicular Cancer: Commentary From the Inaugural Global Society of Rare Genitourinary Tumors Summit","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Summit; Testicular cancer; Genitourinary system; Cancer; Prostate cancer; Gynecology; Internal medicine","score_opus":0.07201843192627884,"score_gpt":0.44156567897869503,"score_spread":0.3695472470524162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313216173","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.077782884,0.9149317,0.0000041232097,0.0013554535,0.0007623631,0.0026870074,0.0024153807,0.000032889628,0.000028152985],"genre_scores_gemma":[0.008953168,0.98609287,0.0010587943,0.0012206116,0.0009344319,0.0013381512,0.00027337176,0.00009153468,0.000037073427],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99456,0.00053877087,0.002472722,0.0010407879,0.00077471574,0.0006130293],"domain_scores_gemma":[0.99201137,0.004599618,0.001344022,0.0015943304,0.00012953751,0.00032112584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004934476,0.0007578436,0.0026110632,0.000053674656,0.00035135105,0.0000291234,0.00080399,0.00018148775,0.00034488586],"category_scores_gemma":[0.00047398117,0.0004322873,0.0024022711,0.00078424637,0.00037041484,0.00006346752,0.00083131343,0.00066543923,0.0000047710655],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043780616,0.00077976077,0.3597745,0.00065443164,0.0010520167,0.0009953738,0.000045343644,0.000028384457,9.660992e-8,7.446335e-7,0.0053104595,0.63092107],"study_design_scores_gemma":[0.0034087603,0.001386236,0.20028667,0.02749741,0.007951162,0.00010755227,0.0006981282,0.00010278996,0.0000010123432,0.00014998997,0.75774485,0.0006654494],"about_ca_topic_score_codex":0.0022363262,"about_ca_topic_score_gemma":0.00046656156,"teacher_disagreement_score":0.7524344,"about_ca_system_score_codex":0.0022435165,"about_ca_system_score_gemma":0.0018891195,"threshold_uncertainty_score":0.9998129},"labels":[],"label_agreement":null},{"id":"W4313627518","doi":"10.1016/j.clgc.2023.01.001","title":"Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Foundation Medicine; Ipsen; National Institute for Health and Care Research; Astellas Pharma; F. Hoffmann-La Roche; Sanofi; Pfizer; Genentech; Medical Research Council; PharmaMar; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Discontinuation; Placebo; Prostate cancer; Internal medicine; Prednisone; Rash; Adverse effect; Prednisolone; Gastroenterology; Cancer; Oncology; Urology; Pathology","score_opus":0.1045101810834043,"score_gpt":0.4297782096430927,"score_spread":0.3252680285596884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313627518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98709947,0.0039256113,0.0000060652014,0.003423666,0.0007480797,0.0028189914,0.0014394375,0.00012561903,0.00041304424],"genre_scores_gemma":[0.96972215,0.011506708,0.00036455208,0.0002892153,0.0005116776,0.0018686355,0.0007644138,0.00010192069,0.0148707125],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9955262,0.00034919125,0.0016439701,0.00083983765,0.0007159861,0.0009248084],"domain_scores_gemma":[0.9979223,0.00037903275,0.00034999568,0.00061443076,0.0003059015,0.00042832404],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010727429,0.00041609915,0.001210867,0.00032942154,0.00013680589,0.000031423006,0.0002544637,0.00019181163,0.0010322108],"category_scores_gemma":[0.00014365074,0.00032681003,0.00024303499,0.0011307921,0.00044622234,0.00021178379,0.00019561133,0.0006720566,0.00016701565],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3560484,0.0047115525,0.3196518,0.009586946,0.00404204,0.0150868725,0.006219559,0.014866488,0.10295712,0.00007684953,0.07634987,0.0904025],"study_design_scores_gemma":[0.087233074,0.008888867,0.82814264,0.0033639383,0.0010823351,0.000053716896,0.0020532683,0.010334171,0.040125713,0.00021897025,0.016956566,0.0015467235],"about_ca_topic_score_codex":0.0015607931,"about_ca_topic_score_gemma":0.0010427238,"teacher_disagreement_score":0.50849086,"about_ca_system_score_codex":0.00089440006,"about_ca_system_score_gemma":0.0028284108,"threshold_uncertainty_score":0.9999184},"labels":[],"label_agreement":null},{"id":"W4318064951","doi":"10.1016/j.clgc.2023.01.009","title":"Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Niagara Health System; Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Health Science Centre","funders":"Joseph and Silvana Melara Cancer Research Fund","keywords":"Medicine; Prostate cancer; Sarcopenia; Castration; Internal medicine; Oncology; Cancer; Urology; Hormone","score_opus":0.13355121096114417,"score_gpt":0.4533313267624982,"score_spread":0.319780115801354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318064951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771969,0.0053814105,0.000007806353,0.014265932,0.0003923457,0.0014837381,0.0000523732,0.0001389705,0.0010805556],"genre_scores_gemma":[0.954412,0.034933433,0.0011048476,0.00223766,0.0006741138,0.0008421425,0.00004744077,0.00007779614,0.005670598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972359,0.00022041074,0.0009884668,0.0005561032,0.00040285918,0.0005962412],"domain_scores_gemma":[0.99851716,0.00044307223,0.00023159695,0.00033434154,0.00014292556,0.00033092912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009108562,0.00024831263,0.0006763924,0.00021409194,0.00016252129,0.000032578097,0.000112753485,0.000092656424,0.0005308542],"category_scores_gemma":[0.00006776278,0.00018852358,0.0001232323,0.0007420662,0.00015921578,0.00012514512,0.00004924214,0.0005352662,0.00010081929],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048464775,0.0037223857,0.65458965,0.003611513,0.000998792,0.01294889,0.003528289,0.0011614179,0.020026494,0.00017720141,0.102862775,0.14790782],"study_design_scores_gemma":[0.05562375,0.004365825,0.85558164,0.0047902726,0.0002855868,0.00014379412,0.0027728574,0.0035254702,0.0021027364,0.00086658954,0.06889346,0.0010480183],"about_ca_topic_score_codex":0.0005749798,"about_ca_topic_score_gemma":0.0014900761,"teacher_disagreement_score":0.200992,"about_ca_system_score_codex":0.0002606761,"about_ca_system_score_gemma":0.0013401955,"threshold_uncertainty_score":0.76877683},"labels":[],"label_agreement":null},{"id":"W4318065001","doi":"10.1016/j.clgc.2023.01.008","title":"Predictive and Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Muscle Invasive Bladder Cancer Treated With Neoadjuvant Chemotherapy and Radical Cystectomy","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Receiver operating characteristic; Oncology; Internal medicine; Youden's J statistic; Urology; Area under the curve; Neoadjuvant therapy; Proportional hazards model; Logistic regression; Retrospective cohort study; Cancer; Gastroenterology","score_opus":0.017831391182377688,"score_gpt":0.30661674822825696,"score_spread":0.28878535704587927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318065001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331194,0.0026161908,0.0000016670839,0.0017996378,0.00013177795,0.0018908742,0.00007376888,0.00006768918,0.000106466665],"genre_scores_gemma":[0.99492955,0.0029282055,0.00009256793,0.00077782245,0.00031140394,0.0007961372,0.0000075376124,0.00005008294,0.000106687745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980116,0.00019422875,0.00055753725,0.00057536457,0.00031345818,0.00034782302],"domain_scores_gemma":[0.99864006,0.00040150233,0.00017103313,0.00035272492,0.00012999288,0.00030468433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002716032,0.0002501662,0.00053007377,0.00013865768,0.000083972576,0.000014588764,0.00014091772,0.00017718821,0.00005529257],"category_scores_gemma":[0.00020595618,0.00016506601,0.00010146563,0.0006920696,0.0006407071,0.00006886715,0.00016225608,0.0002803795,0.0000033653653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004166784,0.00021798686,0.966783,0.0001609212,0.00035422956,0.00019342272,0.000490475,0.00008779861,0.004421494,0.0000023816278,0.00048325828,0.02263829],"study_design_scores_gemma":[0.0063220076,0.000964703,0.98558235,0.0007489112,0.00028081925,0.000021675989,0.0002798245,0.001312958,0.0035586176,0.00002931262,0.00070970866,0.00018911168],"about_ca_topic_score_codex":0.00016591189,"about_ca_topic_score_gemma":0.00010961203,"teacher_disagreement_score":0.022449177,"about_ca_system_score_codex":0.00012996054,"about_ca_system_score_gemma":0.0006894892,"threshold_uncertainty_score":0.67311966},"labels":[],"label_agreement":null},{"id":"W4327692917","doi":"10.1016/j.clgc.2023.03.005","title":"Identifying the Needs of Health Care Providers in Advanced First-Line Renal Cell Carcinoma: A Mixed-Methods Research","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Psychological intervention; Nursing; Health care; Family medicine","score_opus":0.19710779382864,"score_gpt":0.510845723783789,"score_spread":0.31373792995514904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327692917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96598166,0.024754858,0.00005573578,0.0058039157,0.00082883507,0.0016705198,0.00002190737,0.00006257065,0.00082002126],"genre_scores_gemma":[0.99175,0.0030730653,0.002120615,0.00025768072,0.0005575201,0.00047905144,0.000047121834,0.00006710492,0.0016478302],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99451023,0.0017943196,0.0015025468,0.00058117916,0.00073786627,0.0008738798],"domain_scores_gemma":[0.9959156,0.0021152773,0.00032824118,0.0009528633,0.00038584913,0.00030217454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046680286,0.00027586927,0.0008948525,0.0005729103,0.0002592467,0.000022037837,0.00037769967,0.00019670145,0.000060210594],"category_scores_gemma":[0.0005176179,0.00019694427,0.00039708536,0.0022735375,0.00042345354,0.00009380604,0.00041651845,0.0011956664,0.000043975706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041363356,0.0014215444,0.39953285,0.0045731408,0.00021337846,0.0012646625,0.016104031,0.0018060879,0.0046614725,0.000018640792,0.024080303,0.5421876],"study_design_scores_gemma":[0.008770964,0.0063069924,0.92194253,0.00090797653,0.00015931253,0.00003548126,0.028630262,0.00038380863,0.015899286,0.00023641087,0.016327666,0.0003992833],"about_ca_topic_score_codex":0.0011171344,"about_ca_topic_score_gemma":0.00034114573,"teacher_disagreement_score":0.5417883,"about_ca_system_score_codex":0.00067953026,"about_ca_system_score_gemma":0.0013929639,"threshold_uncertainty_score":0.8031154},"labels":[],"label_agreement":null},{"id":"W4360874540","doi":"10.1016/j.clgc.2023.03.009","title":"Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Myovant Sciences","keywords":"Medicine; Enzalutamide; Docetaxel; Concomitant; Prostate cancer; Urology; Testosterone (patch); Internal medicine; Oncology; Prostate; Adverse effect; Cancer; Androgen receptor","score_opus":0.06496777092265317,"score_gpt":0.45894922739006777,"score_spread":0.3939814564674146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360874540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98694617,0.0056997784,4.0071106e-7,0.0033388585,0.00024299056,0.002161565,0.00054399314,0.00005574246,0.0010105128],"genre_scores_gemma":[0.9025129,0.09423971,0.00006740541,0.0000528104,0.00019912019,0.0008668502,0.00007210165,0.000057488167,0.0019316087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970694,0.00015468642,0.0009858701,0.00063795573,0.00055182504,0.00060025405],"domain_scores_gemma":[0.99761426,0.00078870024,0.00039456147,0.0004867755,0.000331503,0.00038419597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005218294,0.00031756217,0.0009485906,0.00027986558,0.00008085251,0.000007915749,0.00016755161,0.00015891033,0.00015854603],"category_scores_gemma":[0.00017602356,0.00021045192,0.00017401091,0.0010110898,0.0007028369,0.000110937355,0.00011633404,0.0005690355,0.0000065694903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11958092,0.00095849234,0.7839369,0.00048048317,0.0014243912,0.0002859994,0.0013394082,0.0027382243,0.0028144706,0.000012239502,0.0027407063,0.083687745],"study_design_scores_gemma":[0.038507447,0.0076557198,0.9477957,0.0017298012,0.00029151165,0.000004617793,0.00031756455,0.0004121851,0.0017785378,0.000026284848,0.0012116202,0.00026900152],"about_ca_topic_score_codex":0.0012159027,"about_ca_topic_score_gemma":0.0003004501,"teacher_disagreement_score":0.16385879,"about_ca_system_score_codex":0.00052696717,"about_ca_system_score_gemma":0.0021255056,"threshold_uncertainty_score":0.858198},"labels":[],"label_agreement":null},{"id":"W4361228771","doi":"10.1016/j.clgc.2023.03.012","title":"Toward Precision Medicine: Development and Validation of A Machine Learning Based Decision Support System for Optimal Sequencing in Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Research Foundation of Korea","keywords":"Medicine; Prostate cancer; Precision medicine; Decision support system; Oncology; Cancer; Internal medicine; Machine learning; Artificial intelligence; Pathology; Computer science","score_opus":0.1484363886325666,"score_gpt":0.4358126648759478,"score_spread":0.28737627624338113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361228771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544173,0.0015465129,0.00030152377,0.00077831873,0.00034784232,0.00140273,0.000060566537,0.00006361304,0.000057181096],"genre_scores_gemma":[0.9923803,0.0020875295,0.0035785362,0.000036819933,0.00023202649,0.00066685735,0.00025031273,0.000035339894,0.0007322503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975615,0.00011486832,0.0010173916,0.00048046984,0.00047719188,0.00034853665],"domain_scores_gemma":[0.99837184,0.0007451968,0.00023412493,0.0001609829,0.00029347301,0.00019438469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001574548,0.00019285179,0.0005510698,0.00029931936,0.00011482165,0.0000135959845,0.0000821313,0.0001347216,0.00005824362],"category_scores_gemma":[0.00032896246,0.00014281648,0.00008598224,0.00046958463,0.000120914614,0.00008969843,0.00006666996,0.0002739659,0.000003712457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037657846,0.00037812156,0.4483916,0.0059951385,0.00044511672,0.0012504249,0.0054916115,0.032982174,0.048268914,0.000011802556,0.0018902905,0.41723698],"study_design_scores_gemma":[0.07491468,0.016540872,0.41530663,0.019878453,0.00090086134,0.00008667691,0.0079942765,0.20733365,0.23052645,0.000097904944,0.024909077,0.0015104742],"about_ca_topic_score_codex":0.00024394381,"about_ca_topic_score_gemma":0.000065873915,"teacher_disagreement_score":0.4157265,"about_ca_system_score_codex":0.0006940553,"about_ca_system_score_gemma":0.0016977603,"threshold_uncertainty_score":0.5823887},"labels":[],"label_agreement":null},{"id":"W4366754119","doi":"10.1016/j.clgc.2023.04.007","title":"Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs","year":2023,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Hypokalemia; Cardiotoxicity; Internal medicine; Prostate cancer; Randomized controlled trial; Placebo; Abiraterone acetate; Odds ratio; Meta-analysis; Cancer; Gastroenterology; Androgen deprivation therapy; Chemotherapy; Pathology","score_opus":0.36135703015794335,"score_gpt":0.5240024488816203,"score_spread":0.16264541872367694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366754119","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05038734,0.93231666,0.00013550036,0.00117113,0.0002620751,0.009814934,0.0058404505,0.000067696186,0.0000042305282],"genre_scores_gemma":[0.00094277173,0.9771315,0.0018830969,0.000068537665,0.00024394326,0.010612768,0.0036032952,0.00012885303,0.005385251],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99494296,0.000860493,0.0020170973,0.0010988425,0.00047504605,0.0006055776],"domain_scores_gemma":[0.9911095,0.004658941,0.0024253663,0.00046691805,0.0008223725,0.0005169026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019062153,0.0005557398,0.0058739022,0.00055540167,0.00013883995,0.000029477967,0.00018213675,0.00047571817,0.00003228364],"category_scores_gemma":[0.0019267999,0.00036043694,0.0020783332,0.0012827738,0.00018801542,0.00015158109,0.000109548404,0.00046395688,0.0000016037116],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003074296,0.00049393356,0.06954593,0.020345787,0.3586547,0.000013909301,0.00011888625,0.000060447837,0.000004597874,0.000001907729,0.00064288767,0.54704267],"study_design_scores_gemma":[0.00697487,0.0027887928,0.038215872,0.0020986882,0.90008587,4.9334545e-7,0.000013758168,0.000077652316,0.000013962119,0.00011941055,0.049032893,0.0005777181],"about_ca_topic_score_codex":0.00006676909,"about_ca_topic_score_gemma":0.00010102155,"teacher_disagreement_score":0.546465,"about_ca_system_score_codex":0.00062007544,"about_ca_system_score_gemma":0.0013146538,"threshold_uncertainty_score":0.9998848},"labels":[],"label_agreement":null},{"id":"W4366814658","doi":"10.1016/j.clgc.2023.04.008","title":"Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Chemotherapy; Internal medicine; Oncology; Taxane; Cancer; Breast cancer","score_opus":0.10718751538685452,"score_gpt":0.4346031280357007,"score_spread":0.3274156126488462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366814658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465483,0.0016682815,0.0000013534171,0.0011300276,0.00020394972,0.0019657488,0.00032070623,0.000042624484,0.00001245525],"genre_scores_gemma":[0.98927283,0.006668261,0.00019524677,0.000121196965,0.00007506357,0.00078002317,0.00006939703,0.000032129352,0.00278584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981083,0.00014584814,0.0005762664,0.0004377102,0.00031650515,0.00041535345],"domain_scores_gemma":[0.99911124,0.00017468979,0.00012356573,0.00023939555,0.00014390133,0.00020720807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017952993,0.0002616878,0.0006970298,0.00020291728,0.00007823701,0.000009198006,0.00007844047,0.000026175876,0.00015591407],"category_scores_gemma":[0.00004787515,0.00015256043,0.0000994267,0.0004599143,0.00025086096,0.00008217476,0.00007840641,0.00020170235,0.000004011132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004361321,0.0044566677,0.96018267,0.00010410146,0.001032398,0.00090932386,0.0005409834,0.00014078009,0.000055002536,0.0000010366629,0.00006322742,0.028152486],"study_design_scores_gemma":[0.02851667,0.0059695463,0.9637524,0.00007664919,0.00023917125,0.00000576021,0.00045182716,0.00017105439,0.00013675127,0.0000068065283,0.00053735095,0.0001360078],"about_ca_topic_score_codex":0.00043653543,"about_ca_topic_score_gemma":0.001278845,"teacher_disagreement_score":0.02801648,"about_ca_system_score_codex":0.00020574649,"about_ca_system_score_gemma":0.00060957106,"threshold_uncertainty_score":0.62212336},"labels":[],"label_agreement":null},{"id":"W4377023748","doi":"10.1016/j.clgc.2023.05.010","title":"Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Lymph node; Lymph; Proportional hazards model; Dissection (medical); Internal medicine; Urology; Subgroup analysis; Oncology; Cancer; Surveillance, Epidemiology, and End Results; Surgery; Pathology; Cancer registry; Confidence interval","score_opus":0.12734387318785548,"score_gpt":0.39714999251112304,"score_spread":0.2698061193232676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377023748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915519,0.0012171741,0.0000043972327,0.002899969,0.0019051793,0.0016394329,0.00019500447,0.00016750851,0.00041944586],"genre_scores_gemma":[0.98073876,0.01462441,0.0001261689,0.0012803837,0.001085536,0.0016039427,0.00012617737,0.000057588462,0.0003570151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963247,0.00015768375,0.001121309,0.0010498458,0.00058783626,0.000758598],"domain_scores_gemma":[0.99813396,0.0003489266,0.00019551201,0.0005509092,0.00015688599,0.0006137791],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043744675,0.0003872978,0.00096599356,0.00025728476,0.00012411573,0.00004558035,0.0002426069,0.00020755017,0.0004653701],"category_scores_gemma":[0.00015663773,0.00031324942,0.00025878457,0.0010163586,0.00017174995,0.00011769953,0.00026651417,0.00039668378,0.00021666243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010054142,0.0010651201,0.93859935,0.00010902856,0.00014685231,0.0003802168,0.00012110048,0.000033019456,0.00025763415,0.0000075411203,0.004239211,0.05403552],"study_design_scores_gemma":[0.006471312,0.0006815281,0.9842343,0.00076007424,0.00008953101,0.0000015836833,0.00012486072,0.00008911157,0.0009121094,0.000079620324,0.0062139393,0.0003420571],"about_ca_topic_score_codex":0.00071746495,"about_ca_topic_score_gemma":0.000118653836,"teacher_disagreement_score":0.053693462,"about_ca_system_score_codex":0.0007568253,"about_ca_system_score_gemma":0.0004767221,"threshold_uncertainty_score":0.99993193},"labels":[],"label_agreement":null},{"id":"W4377826791","doi":"10.1016/j.clgc.2023.05.012","title":"Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; National Institutes of Health; Breast Cancer Research Foundation","keywords":"Medicine; Prostate cancer; Germline; Gene; DNA repair; Cancer; Oncology; Genetics; Internal medicine; Cancer research; Biology","score_opus":0.034704448532788965,"score_gpt":0.3476029334437013,"score_spread":0.3128984849109123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377826791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98982227,0.0041078147,0.0000015660701,0.0017076739,0.0012551674,0.0016837994,0.0006257998,0.0005199315,0.00027596622],"genre_scores_gemma":[0.96280956,0.027617235,0.00027979308,0.001269822,0.0015217622,0.0020823912,0.00039178363,0.00014410735,0.0038835153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996464,0.00013962676,0.0009323967,0.0010716928,0.0005843659,0.00080792006],"domain_scores_gemma":[0.99767375,0.00017969549,0.00033456745,0.0007725042,0.0003969629,0.00064254645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003648933,0.00045599678,0.0008530495,0.00014831,0.00019947438,0.000029206765,0.00017529601,0.00020716831,0.0005133239],"category_scores_gemma":[0.000059653365,0.00032771533,0.00043589776,0.0007727464,0.00039091325,0.00016834204,0.0001797184,0.00040440715,0.00012432328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018790246,0.0010518917,0.9273993,0.0001628416,0.0008271759,0.0007898881,0.00011397245,0.00009260284,0.00006483829,0.0000030184262,0.011796195,0.055819273],"study_design_scores_gemma":[0.0064090816,0.002120815,0.97303337,0.00052263687,0.00064945465,0.000004939401,0.00004520437,0.00019729078,0.00024712476,0.000031629104,0.016324151,0.00041431948],"about_ca_topic_score_codex":0.00029558904,"about_ca_topic_score_gemma":0.00021774546,"teacher_disagreement_score":0.055404954,"about_ca_system_score_codex":0.0003245625,"about_ca_system_score_gemma":0.00068082416,"threshold_uncertainty_score":0.9999175},"labels":[],"label_agreement":null},{"id":"W4380318667","doi":"10.1016/j.clgc.2023.06.003","title":"Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Hazard ratio; Proportional hazards model; Propensity score matching; Confidence interval; Internal medicine; Nephrectomy; Urology; Surveillance, Epidemiology, and End Results; Oncology; Incidence (geometry); Cancer; Surgery; Cancer registry; Kidney","score_opus":0.10840050343005263,"score_gpt":0.3723783414142304,"score_spread":0.26397783798417773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380318667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955215,0.0005505076,0.000017825165,0.0008969573,0.0010637732,0.0008666394,0.00004838321,0.00006842138,0.0009660042],"genre_scores_gemma":[0.9964424,0.0002876234,0.0009278091,0.00017420725,0.0010659619,0.00019182704,0.00002860694,0.000060921666,0.0008206907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961539,0.00049682107,0.0012033253,0.00081401033,0.00064474484,0.0006872333],"domain_scores_gemma":[0.99766177,0.0008667057,0.00024579972,0.00050634186,0.00012421235,0.0005951653],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007300791,0.00036430018,0.0012656964,0.0003410055,0.00006694549,0.000017194481,0.00028184944,0.00016811013,0.00023083937],"category_scores_gemma":[0.00018876922,0.00030168128,0.00043883527,0.000954421,0.00027596072,0.000084092535,0.00026132845,0.0006073271,0.00016568972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007487479,0.0013858208,0.96887064,0.00031854238,0.00015583343,0.0021612681,0.00065841334,0.00014104044,0.012396694,0.000008602172,0.002328741,0.0040869396],"study_design_scores_gemma":[0.005723113,0.005331219,0.94108456,0.00016186768,0.00041365402,0.000018747412,0.0013807478,0.0004322006,0.043894857,0.000052028783,0.0011137384,0.0003932844],"about_ca_topic_score_codex":0.00038895686,"about_ca_topic_score_gemma":0.000031841508,"teacher_disagreement_score":0.031498164,"about_ca_system_score_codex":0.00025002143,"about_ca_system_score_gemma":0.00068988884,"threshold_uncertainty_score":0.99994355},"labels":[],"label_agreement":null},{"id":"W4385454243","doi":"10.1016/j.clgc.2023.07.013","title":"Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Concordance; Hazard ratio; Biopsy; Internal medicine; Oncology; Proportional hazards model; Lymphovascular invasion; Biochemical recurrence; Cancer; Prostatectomy; Confidence interval; Metastasis","score_opus":0.1461759309016695,"score_gpt":0.41726883086174177,"score_spread":0.27109289996007224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385454243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623704,0.0011331857,0.000012004208,0.0005729705,0.00023961863,0.0011663989,0.0005315078,0.00005024996,0.000057011945],"genre_scores_gemma":[0.9931825,0.0045220894,0.001460814,0.000040964616,0.00029351984,0.00024870443,0.0001354621,0.000023987348,0.000091986694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784166,0.00006760969,0.0010743105,0.0005396394,0.0002102814,0.00026650567],"domain_scores_gemma":[0.99825615,0.0002804219,0.00073072105,0.00031031616,0.00015594893,0.00026645014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041761695,0.00018728629,0.00043373392,0.00009110673,0.00011367168,0.00003272173,0.000039795825,0.00008798967,0.000027879894],"category_scores_gemma":[0.0005849892,0.00015461216,0.0000852981,0.00026252057,0.0001483028,0.00015268583,0.00008288729,0.00016250678,0.0000028362188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004953779,0.00029515498,0.8393506,0.00023706834,0.00019296841,0.00027015732,0.000819895,0.00012311988,0.0036391257,0.000013794365,0.00050225196,0.15406048],"study_design_scores_gemma":[0.0013328298,0.0018606437,0.9860955,0.0003902308,0.0003630854,0.00008950458,0.0005195393,0.00184916,0.0069397413,0.00014144993,0.00024117854,0.00017715964],"about_ca_topic_score_codex":0.00040527922,"about_ca_topic_score_gemma":0.000022612341,"teacher_disagreement_score":0.15388332,"about_ca_system_score_codex":0.00013082997,"about_ca_system_score_gemma":0.0002162656,"threshold_uncertainty_score":0.6304901},"labels":[],"label_agreement":null},{"id":"W4385752997","doi":"10.1016/j.clgc.2023.08.004","title":"Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Concomitant; Lung; Lymph node; Prostate cancer; Lymph; Internal medicine; Prostate; Proportional hazards model; Oncology; Gastroenterology; Cancer; Pathology","score_opus":0.13186869164170348,"score_gpt":0.45688983475261163,"score_spread":0.32502114311090813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385752997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949022,0.0015199014,0.000015951666,0.0011345149,0.0006884825,0.0013133092,0.0002472502,0.00005403263,0.00012438542],"genre_scores_gemma":[0.9928488,0.0031819332,0.0004086069,0.00019406788,0.00024351635,0.00034633485,0.0001735218,0.000051505038,0.0025516895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715227,0.00020232744,0.0010243752,0.0004685566,0.00067125284,0.00048124042],"domain_scores_gemma":[0.9976319,0.00046022708,0.00031368082,0.00034878912,0.0009319578,0.0003134575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006265723,0.00023738814,0.0008533553,0.00028675425,0.00006506868,0.000012359282,0.0001771739,0.000059698297,0.00017771438],"category_scores_gemma":[0.00043969654,0.00018517056,0.00022553724,0.0012533442,0.00017904514,0.00013252006,0.00018438952,0.00025099632,0.00004847539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038425701,0.0011223943,0.95788884,0.0015909107,0.0009390044,0.00007725735,0.0005647435,0.0009742046,0.005328197,0.000013660787,0.004152823,0.023505382],"study_design_scores_gemma":[0.009892268,0.0041305586,0.96977985,0.0011013373,0.0008037057,0.0000021236601,0.0006274553,0.0010670844,0.010582138,0.00022147462,0.0014021731,0.0003898426],"about_ca_topic_score_codex":0.0003361531,"about_ca_topic_score_gemma":0.000044344968,"teacher_disagreement_score":0.02311554,"about_ca_system_score_codex":0.00017457615,"about_ca_system_score_gemma":0.00071791175,"threshold_uncertainty_score":0.75510365},"labels":[],"label_agreement":null},{"id":"W4388099416","doi":"10.1016/j.clgc.2023.10.007","title":"Prognostic Significance of Radiographic Lymph Node Invasion in Contemporary Metastatic Renal Cell Carcinoma Patients","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Proportional hazards model; Stage (stratigraphy); Lymph node; Radiography; Internal medicine; Cohort; Nephrectomy; Oncology; Cancer; Metastasis; Histology; Clear cell; Radiology; Kidney","score_opus":0.11458592131447154,"score_gpt":0.35041434628872703,"score_spread":0.2358284249742555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388099416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934839,0.0029136685,0.0000055791133,0.00025990984,0.0004674019,0.0014754618,0.000070413116,0.00007040126,0.0012532711],"genre_scores_gemma":[0.99738723,0.0006831866,0.00038866416,0.00023102868,0.0002078813,0.00036928058,0.00017373529,0.00006121981,0.00049778423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649125,0.000394244,0.0013751828,0.0007033934,0.000571451,0.00046450496],"domain_scores_gemma":[0.99766695,0.0008051109,0.0003972579,0.0005829911,0.00020764918,0.00034006173],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060774287,0.0003230865,0.0009304202,0.00047158505,0.000048437516,0.000008643761,0.00021135346,0.0001516472,0.00008093019],"category_scores_gemma":[0.00024347485,0.0002711111,0.0004381575,0.0012678006,0.0002679057,0.00009505596,0.00013209095,0.0003602491,0.0000689387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013193599,0.0015596852,0.9869686,0.00057078083,0.00009376559,0.0012584489,0.00009925064,0.00008963105,0.002832597,0.0000010424283,0.0027758635,0.0024309838],"study_design_scores_gemma":[0.007260995,0.0016508517,0.98451954,0.00033026966,0.00022401806,0.000007419728,0.000079053025,0.00024731865,0.005097516,0.00005352908,0.00029304533,0.00023646365],"about_ca_topic_score_codex":0.0003105963,"about_ca_topic_score_gemma":0.000009784311,"teacher_disagreement_score":0.005941635,"about_ca_system_score_codex":0.00017128456,"about_ca_system_score_gemma":0.0007220441,"threshold_uncertainty_score":0.99997413},"labels":[],"label_agreement":null},{"id":"W4388210755","doi":"10.1016/j.clgc.2023.10.011","title":"Other-Cause Mortality, According to Partial vs. Radical Nephrectomy: Age and Stage Analyses","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Nephrectomy; Medicine; Renal cell carcinoma; Stage (stratigraphy); Incidence (geometry); Surgery; Urology; Internal medicine; Kidney","score_opus":0.3514332743406447,"score_gpt":0.5119868355715679,"score_spread":0.16055356123092318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388210755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501663,0.0006636213,0.000032575637,0.0019102877,0.0006405805,0.00062888913,0.000054272314,0.00023535592,0.0008177882],"genre_scores_gemma":[0.990205,0.00096944836,0.0005045146,0.0024267226,0.0021425737,0.00017023513,0.000030641422,0.00006805038,0.0034828112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973055,0.00020430333,0.0007394515,0.0007493294,0.0004503697,0.0005510592],"domain_scores_gemma":[0.9979724,0.0004162553,0.00011947074,0.00060121506,0.000057288078,0.0008333664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053797365,0.00029942094,0.0007970627,0.00018539767,0.000116001036,0.000049963768,0.00015623833,0.00018847191,0.00036723382],"category_scores_gemma":[0.0002712656,0.00024146067,0.00032127532,0.0005934133,0.0002297415,0.00007857737,0.00030765802,0.00039861258,0.00026050917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014462541,0.0003498047,0.96063846,0.0001284223,0.0010910948,0.009559894,0.00014069767,0.00010863006,0.0038893898,0.000016462523,0.009017475,0.013613428],"study_design_scores_gemma":[0.003430148,0.001945153,0.9103709,0.00016923905,0.0011928786,0.00004243973,0.00021539241,0.00054245366,0.0031868515,0.000069742455,0.07840471,0.00043012158],"about_ca_topic_score_codex":0.000483388,"about_ca_topic_score_gemma":0.00009492523,"teacher_disagreement_score":0.069387235,"about_ca_system_score_codex":0.0001417679,"about_ca_system_score_gemma":0.00023276955,"threshold_uncertainty_score":0.98464805},"labels":[],"label_agreement":null},{"id":"W4388498795","doi":"10.1016/j.clgc.2023.11.001","title":"Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence","year":2023,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ipsen; Ipsen Fund","keywords":"Cabozantinib; Medicine; Tolerability; Renal cell carcinoma; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Kidney cancer; Adverse effect; Systematic review; MEDLINE","score_opus":0.2021130837119291,"score_gpt":0.46081948946590984,"score_spread":0.25870640575398074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388498795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005534229,0.9885711,5.519489e-7,0.0001836154,0.00043840575,0.007763953,0.00010044244,0.000027540955,0.0023609484],"genre_scores_gemma":[0.0009884534,0.99077255,0.00015421797,0.00017423529,0.00054658076,0.0017543776,0.00012477404,0.00010315968,0.005381654],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99040544,0.0020287575,0.00510915,0.00091943896,0.0010607127,0.00047647502],"domain_scores_gemma":[0.99240595,0.0024484498,0.0025347546,0.0021221347,0.00030640975,0.0001822817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039579696,0.0007403431,0.006446837,0.00040758812,0.000035196306,0.00001556827,0.0008864031,0.00034068656,0.00006663399],"category_scores_gemma":[0.00027117328,0.0004132225,0.0022526577,0.0027233677,0.00018374436,0.00005888636,0.00035634657,0.0012001292,0.000050894705],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010755135,0.0004799258,0.00042066447,0.97584236,0.0004679729,0.004746804,0.00006144687,5.317332e-7,2.725241e-7,0.00001647321,0.0031780729,0.014677949],"study_design_scores_gemma":[0.00078426435,0.0006880632,0.0021181179,0.9575304,0.012476411,0.00013039501,0.00003604666,0.000001996378,0.0000031174004,0.000003457413,0.025937697,0.0002900795],"about_ca_topic_score_codex":0.000098597586,"about_ca_topic_score_gemma":0.00002312492,"teacher_disagreement_score":0.022759624,"about_ca_system_score_codex":0.00031278827,"about_ca_system_score_gemma":0.00071717927,"threshold_uncertainty_score":0.999832},"labels":[],"label_agreement":null},{"id":"W4388752480","doi":"10.1016/j.clgc.2023.11.006","title":"The Prognostic Role of Preoperative PSMA PET/CT in cN0M0 pN+ Prostate Cancer: A Multicenter Study","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Lymph node; Biochemical recurrence; Radiology; PET-CT; Proportional hazards model; Nuclear medicine; Positron emission tomography; Internal medicine; Cancer","score_opus":0.046225874543025944,"score_gpt":0.39990364442914156,"score_spread":0.3536777698861156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388752480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98577535,0.007034117,7.7451126e-8,0.0021727174,0.00067364064,0.003950769,0.000119532255,0.00007056975,0.0002032168],"genre_scores_gemma":[0.9749529,0.018372491,0.000025898607,0.00020916697,0.00033492,0.004654064,0.000020059872,0.000047576967,0.0013829661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720454,0.00028446398,0.0009957467,0.0006067094,0.0003768246,0.0005317057],"domain_scores_gemma":[0.9980052,0.0008316968,0.00024060224,0.000490603,0.00022591512,0.00020594559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062468316,0.00027780674,0.00064786815,0.00009496519,0.00013716587,0.000028112687,0.00020023588,0.000024135019,0.00008813429],"category_scores_gemma":[0.00026154972,0.00017623395,0.0002138373,0.0005719445,0.00023454327,0.000085507505,0.00019786601,0.00042214722,0.00005323194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013966967,0.0024992505,0.9618994,0.000086090295,0.00042305025,0.0015610318,0.0012677542,0.00015741966,0.0000488298,0.0000030453011,0.0014035893,0.029253831],"study_design_scores_gemma":[0.0061403066,0.00296234,0.98134375,0.00045944247,0.00029135527,0.000011919369,0.0033005609,0.0007602818,0.0005042652,0.000051710296,0.0039863167,0.00018772778],"about_ca_topic_score_codex":0.0008507011,"about_ca_topic_score_gemma":0.001156725,"teacher_disagreement_score":0.029066104,"about_ca_system_score_codex":0.00025020493,"about_ca_system_score_gemma":0.00056294154,"threshold_uncertainty_score":0.7186612},"labels":[],"label_agreement":null},{"id":"W4389751876","doi":"10.1016/j.clgc.2023.12.004","title":"Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guérin","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université Laval","funders":"Fonds de Recherche du Québec - Santé; University of British Columbia; Centre Hospitalier Universitaire de Québec","keywords":"Medicine; Internal medicine; Bacillus (shape); Oncology; Immunology; Microbiology","score_opus":0.1080198090621359,"score_gpt":0.44221844007046646,"score_spread":0.3341986310083306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389751876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98349243,0.000453972,0.000080184785,0.010630206,0.0013148001,0.0022991071,0.00016336207,0.0002699909,0.001295923],"genre_scores_gemma":[0.976723,0.00016125114,0.0010619634,0.005268736,0.0023725631,0.001792435,0.000046098336,0.000104771876,0.012469196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973241,0.00021633305,0.0007074549,0.00074037776,0.00036885703,0.00064286625],"domain_scores_gemma":[0.99700457,0.0015685273,0.00010294987,0.0005185869,0.00019966638,0.00060567964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010333896,0.00028511696,0.00058890757,0.0001761893,0.00016756913,0.000027046326,0.00016208779,0.00020518247,0.0005002039],"category_scores_gemma":[0.002254563,0.00024875262,0.00041801162,0.0006289665,0.00008596577,0.00005974532,0.0001331427,0.00028681688,0.00075901195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059862986,0.0013819103,0.5303009,0.0006489923,0.001559887,0.0054283333,0.0006965608,0.00031371054,0.010620563,0.000021834468,0.086421676,0.30274266],"study_design_scores_gemma":[0.008365972,0.0060149445,0.8331525,0.00044082216,0.00054072455,0.00013633978,0.0001401892,0.0005811749,0.0005162531,0.00040046373,0.14920102,0.00050959183],"about_ca_topic_score_codex":0.000069523354,"about_ca_topic_score_gemma":0.000009449365,"teacher_disagreement_score":0.30285162,"about_ca_system_score_codex":0.00019826443,"about_ca_system_score_gemma":0.0007049663,"threshold_uncertainty_score":0.9999965},"labels":[],"label_agreement":null},{"id":"W4390024431","doi":"10.1016/j.clgc.2023.12.010","title":"Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Incorporated; Eisai Canada","keywords":"Medicine; Lenvatinib; Adverse effect; Pembrolizumab; Sunitinib; Internal medicine; Rash; Renal cell carcinoma; Oncology; Intensive care medicine; Cancer; Thyroid cancer; Immunotherapy","score_opus":0.03796370185734156,"score_gpt":0.34374328476668353,"score_spread":0.305779582909342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390024431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922971,0.0001701928,0.0000018856995,0.0005002433,0.00044440053,0.0014425723,0.00010712669,0.000091499416,0.0049449923],"genre_scores_gemma":[0.98647964,0.0011505446,0.00026989484,0.00008563057,0.00014091868,0.00072597014,0.00015117097,0.000049265385,0.010946957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979145,0.000055436452,0.0007466873,0.0005623491,0.0003665031,0.00035453113],"domain_scores_gemma":[0.99858767,0.00012016245,0.00022906135,0.0005652482,0.00014541425,0.00035247553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105278275,0.00026158523,0.0005482133,0.00015681545,0.00009070197,0.0000041755893,0.00009101948,0.00010986172,0.00032982102],"category_scores_gemma":[0.000008743406,0.00019449252,0.00027998077,0.00059882214,0.000106536005,0.000056636945,0.000090019756,0.00015887756,0.00013316036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030217445,0.0023326746,0.9692373,0.00016783348,0.00073200907,0.00080575,0.0002181314,0.001171024,0.000014203355,0.000011325638,0.004206095,0.01808186],"study_design_scores_gemma":[0.0143853035,0.0052098376,0.9694315,0.00032926415,0.00076263584,0.000002632689,0.00016249921,0.00005458044,0.00037966517,0.0000066803605,0.009086455,0.00018894812],"about_ca_topic_score_codex":0.00048185044,"about_ca_topic_score_gemma":0.000060588965,"teacher_disagreement_score":0.017892912,"about_ca_system_score_codex":0.0006318794,"about_ca_system_score_gemma":0.00020934327,"threshold_uncertainty_score":0.79311746},"labels":[],"label_agreement":null},{"id":"W4390246136","doi":"10.1016/j.clgc.2023.12.013","title":"The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Clear cell renal cell carcinoma; Internal medicine","score_opus":0.10167405571182835,"score_gpt":0.3936564586000451,"score_spread":0.29198240288821675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390246136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963197,0.0004547929,7.5840575e-7,0.00020812094,0.00043244148,0.0013924593,0.00004655232,0.00003976647,0.0011054215],"genre_scores_gemma":[0.9971753,0.00059200544,0.000021073283,0.00009947006,0.00018416489,0.00033070074,0.00006231215,0.000046461995,0.001488517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972232,0.00061231246,0.0009110297,0.0005106977,0.0003717155,0.00037103426],"domain_scores_gemma":[0.99726886,0.0013462193,0.00030376908,0.0007773604,0.000113580565,0.00019021948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006959034,0.00029164564,0.00064245315,0.0001209123,0.00007812253,0.000010804453,0.00014789723,0.000103329425,0.000041163614],"category_scores_gemma":[0.0001518871,0.00017035495,0.00037616104,0.00038519624,0.00017693716,0.000033165845,0.000059483616,0.0002788162,0.0001661922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041332785,0.0010781966,0.97938794,0.00014618738,0.00021357763,0.00022423407,0.00012707147,0.0001659538,0.0010078086,0.0000014825205,0.0010442646,0.01246999],"study_design_scores_gemma":[0.006924204,0.020093756,0.9369027,0.000071664595,0.0006091406,0.0000018593328,0.00006136029,0.00035297152,0.033833556,0.000012942812,0.0009946349,0.00014122401],"about_ca_topic_score_codex":0.00044467492,"about_ca_topic_score_gemma":0.000072553295,"teacher_disagreement_score":0.04248527,"about_ca_system_score_codex":0.00051698927,"about_ca_system_score_gemma":0.00017143047,"threshold_uncertainty_score":0.69468737},"labels":[],"label_agreement":null},{"id":"W4391234973","doi":"10.1016/j.clgc.2023.12.006","title":"Corrigendum","year":2024,"lang":"en","type":"erratum","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine","score_opus":0.15522069340825687,"score_gpt":0.4697687129662767,"score_spread":0.3145480195580198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391234973","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002079915,0.2854688,0.0000028777786,0.010137062,0.34964302,0.001497765,0.0006689929,0.00045481644,0.35004675],"genre_scores_gemma":[0.00042316594,0.11702592,0.0000688783,0.0013158136,0.03664708,0.00031976023,0.00095213903,0.00018262622,0.8430646],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996346,0.00011502145,0.0009125964,0.0011439102,0.0007349778,0.0007474743],"domain_scores_gemma":[0.9979399,0.000094569004,0.00016361692,0.0008654237,0.00026041633,0.0006761172],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.000373584,0.00054082746,0.0012153113,0.00024104038,0.0001051694,0.000067274195,0.00031205456,0.0013244217,0.003877982],"category_scores_gemma":[0.00010690147,0.00039231998,0.0010149103,0.00039899486,0.0003943665,0.000050434668,0.0003471121,0.004518363,0.0029353371],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063091563,0.00034867125,0.0018678984,0.0012310072,0.0010567545,0.005657826,0.000027369933,1.6348953e-7,0.000010453337,0.0000060554908,0.95042807,0.038734797],"study_design_scores_gemma":[0.0012777387,0.0011629667,0.003254807,0.0017282263,0.0010132109,0.00007866421,0.00002387636,0.00006900488,0.000029826993,0.00016505929,0.9907985,0.00039812477],"about_ca_topic_score_codex":0.00006865327,"about_ca_topic_score_gemma":0.000021068547,"teacher_disagreement_score":0.49301788,"about_ca_system_score_codex":0.00052257604,"about_ca_system_score_gemma":0.0041751857,"threshold_uncertainty_score":0.99997205},"labels":[],"label_agreement":null},{"id":"W4391431106","doi":"10.1016/j.clgc.2024.01.016","title":"Married Status Affects Rates of Treatment and Mortality in Male and Female Renal Cell Carcinoma Patients Across all Stages","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Demography; Proportional hazards model; Logistic regression; Marital status; Internal medicine; Performance status; Stage (stratigraphy); Epidemiology; Cancer; Kidney; Population; Biology","score_opus":0.06728784782878564,"score_gpt":0.41100857975809013,"score_spread":0.3437207319293045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391431106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834447,0.014631443,6.717336e-7,0.000080820915,0.00060091115,0.00043589922,0.00036980095,0.0000196843,0.00041608972],"genre_scores_gemma":[0.9933907,0.004828132,0.00002190236,0.00011397266,0.0002473338,0.00007223335,0.0000482783,0.000024753781,0.0012527324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985323,0.00011596186,0.0004033662,0.00047542242,0.0001395713,0.00033337463],"domain_scores_gemma":[0.99913645,0.0002526461,0.000070768685,0.00023114265,0.000049951726,0.000259052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022332736,0.00019614071,0.00047846555,0.000049323306,0.000029600033,0.000023972518,0.000041335516,0.00013277044,0.00011203703],"category_scores_gemma":[0.000025386711,0.00015678495,0.00011343678,0.00012973772,0.00020048083,0.000068350906,0.00008965255,0.00020491188,0.0000020686875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005991785,0.00027360616,0.97819364,0.00065915246,0.00008270879,0.000224421,0.0013564073,0.0000028857182,0.000429849,0.000001440279,0.00023703957,0.017939672],"study_design_scores_gemma":[0.0025918144,0.0024292895,0.9862627,0.00016302538,0.00014619404,0.000004911704,0.00043367894,0.000051901334,0.0025610968,0.000011274437,0.0051899333,0.00015421277],"about_ca_topic_score_codex":0.0025674973,"about_ca_topic_score_gemma":0.0031408947,"teacher_disagreement_score":0.017785458,"about_ca_system_score_codex":0.00016372638,"about_ca_system_score_gemma":0.00023079496,"threshold_uncertainty_score":0.6393505},"labels":[],"label_agreement":null},{"id":"W4391743861","doi":"10.1016/j.clgc.2024.02.003","title":"Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; University of Toronto; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; CHEK2; Genetic testing; Germline mutation; Prostate cancer; PMS2; Oncology; Germline; Internal medicine; Cancer; Malignancy; Gynecology; Mutation; DNA mismatch repair; Genetics; Gene; Colorectal cancer; Biology","score_opus":0.09665042977454873,"score_gpt":0.4267790101597776,"score_spread":0.33012858038522885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391743861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93158907,0.059000876,0.00009867688,0.0033832705,0.0010797874,0.0019438615,0.002306474,0.00015052155,0.00044745026],"genre_scores_gemma":[0.9174687,0.026226409,0.0034905996,0.00092312874,0.002450918,0.002172655,0.00011851003,0.00018210997,0.04696694],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99694574,0.00006476764,0.0008830711,0.00083844614,0.00040877907,0.0008592173],"domain_scores_gemma":[0.9982141,0.0004259751,0.0001539023,0.00040492482,0.00038395944,0.00041712815],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033052795,0.0003455088,0.0006564358,0.00014001117,0.00015762859,0.000028327962,0.00018111308,0.00022434325,0.0004521667],"category_scores_gemma":[0.00010570019,0.00026083284,0.0004287949,0.00037948432,0.00024028645,0.00009796755,0.00022258809,0.00042419368,0.00001847996],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026646273,0.00074298104,0.7437101,0.0031860743,0.0010001863,0.00038839597,0.00047020227,0.0020022998,0.009254837,0.000010128391,0.032512564,0.20405763],"study_design_scores_gemma":[0.022315513,0.0034802642,0.20709153,0.009784155,0.0034837017,0.00007571305,0.00031570034,0.6196493,0.020358587,0.0008220045,0.110903434,0.0017201188],"about_ca_topic_score_codex":0.00027328174,"about_ca_topic_score_gemma":0.00023451292,"teacher_disagreement_score":0.617647,"about_ca_system_score_codex":0.000557193,"about_ca_system_score_gemma":0.0019913123,"threshold_uncertainty_score":0.9999844},"labels":[],"label_agreement":null},{"id":"W4392126042","doi":"10.1016/j.clgc.2024.02.011","title":"Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal; Centre hospitalier de l'Université Laval; University of Calgary; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; CancerCare Manitoba; University Health Network; McMaster University Medical Centre; Hôtel-Dieu de Québec; McGill University; University of Ottawa; University of Alberta; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Toxicity; Tyrosine-kinase inhibitor; Kidney cancer; Oncology; Drug; Cancer; Internal medicine; Clinical trial; Tyrosine kinase; Pharmacology; Receptor","score_opus":0.059389763356065835,"score_gpt":0.36273070475990254,"score_spread":0.3033409414038367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392126042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870321,0.0010890667,0.00004625964,0.0036868867,0.00202407,0.0022365095,0.0030771396,0.000048562426,0.00075936085],"genre_scores_gemma":[0.9961736,0.00023346725,0.00050559535,0.00033631903,0.0011732783,0.00070895476,0.00040501513,0.000037159436,0.00042660063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99613345,0.0007294559,0.0016827752,0.000549573,0.00046935922,0.0004354139],"domain_scores_gemma":[0.9950402,0.003000469,0.000517366,0.0005054671,0.00045719268,0.00047933825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00266041,0.0002830726,0.0008172408,0.00018263927,0.00015795643,0.000059480102,0.00018015392,0.0002828065,0.000034362187],"category_scores_gemma":[0.0008713373,0.00018827447,0.00039754433,0.00054262066,0.00015355089,0.0002358361,0.00004232337,0.0007009454,0.00001736485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01793658,0.00078218017,0.91600597,0.0024529346,0.0021201165,0.00046220567,0.001457764,0.0014962662,0.000617277,0.00005990203,0.04016031,0.016448488],"study_design_scores_gemma":[0.009926167,0.001650971,0.9625926,0.0016895434,0.0018599126,0.000019065326,0.00040107805,0.0023625104,0.003239389,0.0000192276,0.01595998,0.00027957757],"about_ca_topic_score_codex":0.11413131,"about_ca_topic_score_gemma":0.06529331,"teacher_disagreement_score":0.048838,"about_ca_system_score_codex":0.001991184,"about_ca_system_score_gemma":0.0049440335,"threshold_uncertainty_score":0.9517627},"labels":[],"label_agreement":null},{"id":"W4394008881","doi":"10.1016/j.clgc.2024.102087","title":"Honing the Hunt: A Comprehensive Review of Cell-free Tumor DNA to Predict Neoadjuvant Therapy Efficacy in Bladder Cancer","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Bladder cancer; Honing; Oncology; Cancer; Neoadjuvant therapy; Internal medicine; Breast cancer","score_opus":0.13661444070638556,"score_gpt":0.46326579593080336,"score_spread":0.3266513552244178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394008881","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000887459,0.9866072,8.05336e-7,0.0016988897,0.00252331,0.006369858,0.0007764812,0.00008040732,0.0010555735],"genre_scores_gemma":[0.00007698937,0.9853424,0.000092382186,0.0066717607,0.003167701,0.0029395611,0.00007272201,0.00023638865,0.0014001137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937773,0.00065891363,0.0027535025,0.0013151648,0.0007682941,0.00072685716],"domain_scores_gemma":[0.99575895,0.00092111353,0.00073409884,0.0018492105,0.00028715405,0.0004494438],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006118911,0.001019051,0.004829008,0.00025879336,0.000084186475,0.000030082414,0.0010066937,0.000396115,0.0009065635],"category_scores_gemma":[0.00020312834,0.000582033,0.0020764102,0.0012396872,0.00028843057,0.000053604246,0.0005452572,0.0018797135,0.0001645685],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003796948,0.00096201827,0.00013493006,0.087632984,0.0017071129,0.0006289002,0.00014334076,0.0000031211596,0.000004066621,0.0000015728153,0.07627746,0.83212477],"study_design_scores_gemma":[0.002353043,0.0011128159,0.00059763284,0.20395027,0.0048247147,0.000057863665,0.00002144015,0.0000022124202,0.000011226144,0.000007777228,0.7866345,0.00042649152],"about_ca_topic_score_codex":0.00038839536,"about_ca_topic_score_gemma":0.00004167865,"teacher_disagreement_score":0.8316983,"about_ca_system_score_codex":0.0004602936,"about_ca_system_score_gemma":0.0033735267,"threshold_uncertainty_score":0.9996631},"labels":[],"label_agreement":null},{"id":"W4395070926","doi":"10.1016/j.clgc.2024.102105","title":"Unmarried Status Effect on Stage at Presentation and Treatment Patterns in Non-Metastatic Upper Tract Urothelial Carcinoma Patients","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Urothelial carcinoma; Oncology; Urothelial cancer; Presentation (obstetrics); Metastatic Urothelial Carcinoma; Internal medicine; Cancer; Bladder cancer; Surgery","score_opus":0.04021238607358731,"score_gpt":0.38709177310232806,"score_spread":0.34687938702874077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395070926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441135,0.00099612,0.0000034496381,0.00023458323,0.0011314868,0.0017869791,0.00068261195,0.00005137657,0.00070202263],"genre_scores_gemma":[0.9934743,0.0014982146,0.000027724293,0.00035158283,0.00056368497,0.00051728275,0.0002084185,0.00006952621,0.0032892518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774075,0.00022317399,0.0005625159,0.0007080203,0.00032332726,0.00044221195],"domain_scores_gemma":[0.9987498,0.00050350063,0.0000723434,0.00029770224,0.000034799046,0.0003418736],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015083812,0.0003547685,0.00056903943,0.00016246461,0.000067948145,0.000038853967,0.00005428381,0.000118224416,0.0005111061],"category_scores_gemma":[0.00004273287,0.00025457825,0.00022847879,0.00015252712,0.00008016176,0.00010510441,0.000047474987,0.00027772124,0.00007232874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033479203,0.0010744892,0.88400704,0.0002578555,0.00021281352,0.00077268766,0.00041895075,0.00001321477,0.00009947887,0.0000010671029,0.00029628832,0.10949818],"study_design_scores_gemma":[0.011647999,0.013018128,0.96791345,0.00028853476,0.00038368462,0.000008927136,0.000041615855,0.0003032166,0.0011266937,0.0000071411177,0.0050402414,0.0002203586],"about_ca_topic_score_codex":0.0011108267,"about_ca_topic_score_gemma":0.00018517025,"teacher_disagreement_score":0.10927782,"about_ca_system_score_codex":0.0007664321,"about_ca_system_score_gemma":0.000250474,"threshold_uncertainty_score":0.99999064},"labels":[],"label_agreement":null},{"id":"W4396776424","doi":"10.1016/j.clgc.2024.102115","title":"A Real World Observational Study Characterizing Patients With Advanced Prostate Cancer Treated With or Without Androgen Receptor-Pathway-Inhibitor Therapies in Alberta, Canada","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; AstraZeneca (Canada); University of Alberta; University of Calgary","funders":"AstraZeneca","keywords":"Medicine; Prostate cancer; Androgen receptor; Observational study; Oncology; Management of prostate cancer; Internal medicine; Androgen; Cancer; Androgen Receptor Antagonists; Hormone","score_opus":0.07166703167350277,"score_gpt":0.3801032690257118,"score_spread":0.30843623735220904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396776424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927654,0.0011728753,1.6877487e-7,0.002005766,0.00041943684,0.003059443,0.00027128716,0.000080379046,0.00022520278],"genre_scores_gemma":[0.9750109,0.0017095747,0.0001407626,0.00032930833,0.0006144105,0.0019929158,0.00028873034,0.00011244838,0.019800998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682534,0.00017003277,0.00071362354,0.00090817723,0.00075279234,0.0006300374],"domain_scores_gemma":[0.9985118,0.00032688532,0.00015097843,0.00035015028,0.00032406359,0.00033615273],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021208862,0.0004386267,0.00078948896,0.00017990005,0.00013420459,0.000065868255,0.00014538727,0.00008813796,0.0003946594],"category_scores_gemma":[0.000026448583,0.00024962708,0.00007955756,0.00097532436,0.00016580385,0.00028954176,0.000064582,0.00060143135,0.0000068138024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024734493,0.0010363049,0.95026475,0.00018634756,0.0007664204,0.0007412339,0.0006954005,0.00001600597,0.00016276939,9.958806e-7,0.00081423565,0.020581031],"study_design_scores_gemma":[0.012140028,0.0049330983,0.9597851,0.001627338,0.00018578274,0.000004608588,0.00040627876,0.000095843054,0.0006331355,0.0000017727108,0.019745132,0.0004418953],"about_ca_topic_score_codex":0.22694048,"about_ca_topic_score_gemma":0.73550475,"teacher_disagreement_score":0.50856423,"about_ca_system_score_codex":0.0011096974,"about_ca_system_score_gemma":0.0049963533,"threshold_uncertainty_score":0.9999956},"labels":[],"label_agreement":null},{"id":"W4396809848","doi":"10.1016/j.clgc.2024.102119","title":"Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Bladder cancer; Urothelial carcinoma; Urology; Urothelial cancer; Metastatic Urothelial Carcinoma; Cancer; Oncology; Urinary bladder; Internal medicine","score_opus":0.07550536402370836,"score_gpt":0.37294869773629125,"score_spread":0.2974433337125829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396809848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731046,0.022948332,0.0000034386806,0.0013440213,0.00058954506,0.0007934913,0.00034706225,0.00005020607,0.0008193289],"genre_scores_gemma":[0.9874397,0.009587486,0.000070681504,0.0003459844,0.00077642855,0.00034155225,0.000020820073,0.000073932366,0.0013434382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973882,0.00025957372,0.0007829573,0.0007561989,0.00041868503,0.00039440795],"domain_scores_gemma":[0.9987508,0.00024588837,0.00015479099,0.0005500632,0.00008291134,0.00021556758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024845428,0.00039303914,0.00078976445,0.00018339409,0.000078878686,0.000028101775,0.00018212204,0.00017454947,0.0005555031],"category_scores_gemma":[0.000013713938,0.00023188964,0.0003236287,0.0007625449,0.00055303704,0.000117763535,0.000075502816,0.0005908092,0.0000042097367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00262126,0.0009686284,0.8891478,0.00017231646,0.00066881464,0.0008725886,0.00039006426,0.000015970803,0.00062247575,0.00000803388,0.0007243273,0.103787675],"study_design_scores_gemma":[0.0068421806,0.0028248068,0.9825792,0.0004317637,0.00042712165,0.00006937085,0.00010864482,0.00009193547,0.0015605266,0.00004800787,0.0047586565,0.00025782775],"about_ca_topic_score_codex":0.0025695725,"about_ca_topic_score_gemma":0.00040727702,"teacher_disagreement_score":0.10352985,"about_ca_system_score_codex":0.00018010593,"about_ca_system_score_gemma":0.0010947172,"threshold_uncertainty_score":0.9456185},"labels":[],"label_agreement":null},{"id":"W4396887599","doi":"10.1016/j.clgc.2024.102120","title":"Hydronephrosis as a Prognostic Factor in Primary Bladder Adenocarcinoma: Insights from a 15-Year Tertiary Center Experience","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Urinary and Genital Oncology Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Hydronephrosis; Oncology; Adenocarcinoma; Bladder cancer; Center (category theory); Internal medicine; Urology; Cancer; Urinary system","score_opus":0.044912572032890875,"score_gpt":0.3677872979111405,"score_spread":0.3228747258782496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396887599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9512666,0.041033886,0.000004897313,0.0020242855,0.0017433056,0.00074418064,0.000075652024,0.00017339656,0.002933782],"genre_scores_gemma":[0.98807144,0.0034875318,0.00026413056,0.0034241416,0.0018312408,0.00047058976,0.00005188165,0.00005756119,0.0023414574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708396,0.00018701104,0.000887591,0.0010073542,0.00033617328,0.00049790106],"domain_scores_gemma":[0.998397,0.00070361106,0.00008234047,0.00043965993,0.00006312052,0.0003142898],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009181935,0.0003811793,0.00073818135,0.00017359547,0.00010147582,0.000036025893,0.00022302728,0.00034880044,0.0007819368],"category_scores_gemma":[0.00014126717,0.0003050068,0.0003459147,0.00035881074,0.0004591996,0.00027369751,0.0003498495,0.00092275476,0.0005710831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011164183,0.0015170178,0.9741491,0.00013263793,0.00050248584,0.006103403,0.0022797808,0.0000012723572,0.0011368403,0.0000056681693,0.0055509857,0.007504387],"study_design_scores_gemma":[0.0022065842,0.0015719362,0.96996486,0.0005233763,0.00024108747,0.000090625326,0.00040206622,0.000067137626,0.00028594607,0.00020342498,0.024084201,0.0003587511],"about_ca_topic_score_codex":0.00012831196,"about_ca_topic_score_gemma":0.00006276595,"teacher_disagreement_score":0.037546355,"about_ca_system_score_codex":0.00024669795,"about_ca_system_score_gemma":0.00044920787,"threshold_uncertainty_score":0.9999402},"labels":[],"label_agreement":null},{"id":"W4399240896","doi":"10.1016/j.clgc.2024.102132","title":"Neoadjuvant Versus Adjuvant Chemotherapy in Non-Metastatic Locally-Advanced Stage Radical Cystectomy Candidates","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Stage (stratigraphy); Incidence (geometry); Cumulative incidence; Internal medicine; Adjuvant; Chemotherapy; Overall survival; Urology; Oncology; Gastroenterology; Surgery; Bladder cancer; Cohort; Cancer","score_opus":0.04327223786571829,"score_gpt":0.4050090018454212,"score_spread":0.36173676397970295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399240896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968336,0.02058256,0.00019122295,0.0027699242,0.0037125512,0.0013507114,0.00016784572,0.00021413574,0.0026750818],"genre_scores_gemma":[0.9829928,0.008131769,0.00096453435,0.001461423,0.0012672314,0.00039572082,0.00005717244,0.000118631535,0.0046107],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969134,0.0001239018,0.0009616724,0.0008983856,0.00045031053,0.00065234373],"domain_scores_gemma":[0.99840236,0.0004546727,0.0000924441,0.0005199976,0.00006730038,0.00046322987],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036364957,0.00042619545,0.0009516615,0.00019298447,0.000064682456,0.000045132434,0.00020950711,0.00019778467,0.0014139586],"category_scores_gemma":[0.00008020359,0.0003361986,0.000387094,0.00052244746,0.00034246995,0.0001591232,0.00007707259,0.00084227446,0.00025517636],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030882956,0.0026009753,0.043793622,0.001346862,0.0019221846,0.015122342,0.0008931884,0.00030270993,0.0023500242,0.000043628883,0.013207666,0.88753384],"study_design_scores_gemma":[0.14554729,0.020478174,0.19836932,0.006292955,0.0018275827,0.00032990327,0.0011539563,0.01679058,0.006847109,0.00042434217,0.59934,0.0025987609],"about_ca_topic_score_codex":0.00037547795,"about_ca_topic_score_gemma":0.00017772752,"teacher_disagreement_score":0.8849351,"about_ca_system_score_codex":0.00045894255,"about_ca_system_score_gemma":0.0010432057,"threshold_uncertainty_score":0.999909},"labels":[],"label_agreement":null},{"id":"W4399361696","doi":"10.1016/j.clgc.2024.102133","title":"Preoperative Plasma Insulin-Like Growth Factor-I and Its Binding Proteins-Based Risk Stratification of Patients Treated With Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Urothelial carcinoma; Medicine; Urology; Insulin-like growth factor; Insulin-like growth factor-binding protein; Internal medicine; Oncology; Risk stratification; Insulin; Growth factor; Endocrinology; Cancer; Receptor; Bladder cancer","score_opus":0.040373999970872654,"score_gpt":0.3333764279400442,"score_spread":0.29300242796917153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399361696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99298817,0.0011229739,0.00011540446,0.00023081759,0.00039117486,0.0032265526,0.0017521457,0.00008063279,0.000092107504],"genre_scores_gemma":[0.99677545,0.0003551739,0.0007660434,0.00010948166,0.0006460792,0.0007890066,0.00022811754,0.00007538814,0.0002552481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978218,0.00018637726,0.0006660447,0.00069461385,0.0003230003,0.00030812997],"domain_scores_gemma":[0.99860895,0.0004244177,0.00018870269,0.00021503938,0.00029570045,0.00026720844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001593583,0.00034287566,0.0005806969,0.00014128424,0.00012399183,0.00004239149,0.00009433872,0.0002440642,0.00012114613],"category_scores_gemma":[0.00011534805,0.00023838025,0.00022208266,0.00023783308,0.00018680055,0.00017217577,0.000020151565,0.00040908816,0.000006072395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01068175,0.0014426816,0.9670487,0.0007246918,0.00065397366,0.000058679074,0.0003839351,0.000007832302,0.00147948,0.00001530056,0.0003004865,0.017202461],"study_design_scores_gemma":[0.016572228,0.014279468,0.9265975,0.0006120302,0.0012469532,0.0000133306585,0.000044906657,0.0032582588,0.035186548,0.000018388237,0.001723659,0.00044674295],"about_ca_topic_score_codex":0.000101911864,"about_ca_topic_score_gemma":0.000012774601,"teacher_disagreement_score":0.040451244,"about_ca_system_score_codex":0.00015480752,"about_ca_system_score_gemma":0.00076959096,"threshold_uncertainty_score":0.9720865},"labels":[],"label_agreement":null},{"id":"W4399556172","doi":"10.1016/j.clgc.2024.102137","title":"Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Surrogate endpoint; Oncology; Internal medicine; Clinical trial; Castration; Clinical endpoint; Cancer; Hormone","score_opus":0.3290512161179735,"score_gpt":0.5274228000287672,"score_spread":0.19837158391079368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399556172","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021741329,0.9656445,7.6436123e-7,0.00096392335,0.0033141924,0.006764221,0.0013867468,0.00009578288,0.000088534616],"genre_scores_gemma":[0.001503324,0.9810951,0.0001475789,0.0000519139,0.002611941,0.00800407,0.0006968162,0.00019236968,0.005696927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98971486,0.0022134243,0.004608693,0.001752186,0.0007155484,0.0009952881],"domain_scores_gemma":[0.99169546,0.006007328,0.00092898234,0.0006729489,0.00012065648,0.0005746049],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026166248,0.0011124244,0.007710295,0.0007210577,0.00009546133,0.00008115274,0.00027534948,0.00059717393,0.00028972345],"category_scores_gemma":[0.0012594404,0.00071119977,0.0018856172,0.0010971759,0.00015529012,0.00012478452,0.00017569982,0.0017585612,0.00010024155],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003278495,0.0021418342,0.006665601,0.027656185,0.0031452,0.016200969,0.00037147428,0.00002876151,0.000009848088,0.000001250149,0.0017968714,0.93870354],"study_design_scores_gemma":[0.016434744,0.0044145784,0.001875789,0.095117845,0.0149628725,0.00004259452,0.000048188725,0.00018959587,0.000042734886,0.0001388126,0.86566305,0.0010692173],"about_ca_topic_score_codex":0.007836732,"about_ca_topic_score_gemma":0.007747005,"teacher_disagreement_score":0.9376343,"about_ca_system_score_codex":0.010046654,"about_ca_system_score_gemma":0.004606789,"threshold_uncertainty_score":0.9995339},"labels":[],"label_agreement":null},{"id":"W4399605698","doi":"10.1016/j.clgc.2024.102139","title":"Survival of Metastatic Urothelial Carcinoma of Urinary Bladder According to Number and Location of Visceral Metastases","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Urothelial carcinoma; Urology; Urinary bladder; Metastatic Urothelial Carcinoma; Urinary system; Carcinoma; Urothelial cancer; Bladder cancer; Oncology; Internal medicine; Cancer","score_opus":0.07465514347380514,"score_gpt":0.41600303817888884,"score_spread":0.3413478947050837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399605698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916854,0.005386918,0.00021553776,0.00037162728,0.0008081702,0.00055133284,0.00024379577,0.000024108582,0.00071313523],"genre_scores_gemma":[0.9970658,0.0005585575,0.0011937836,0.000128189,0.0004650752,0.000060666513,0.000015440699,0.000043137603,0.0004693879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979744,0.00015496524,0.00090956886,0.00040701427,0.00033868678,0.00021534912],"domain_scores_gemma":[0.9986228,0.0003782844,0.00015525387,0.00031219784,0.0003331331,0.0001983667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037705855,0.00021310899,0.000814437,0.00012935683,0.000026037547,0.000008194575,0.00010227646,0.00007754901,0.0003317005],"category_scores_gemma":[0.0001518988,0.00017338678,0.00020954976,0.0005400199,0.00022273861,0.00009827413,0.000109182394,0.00018362474,0.0000118742255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006732747,0.0026080224,0.88885635,0.0052016443,0.0034868396,0.00045629864,0.0009558383,0.00014269193,0.013488695,0.0003495383,0.0024356532,0.0752857],"study_design_scores_gemma":[0.009361646,0.011619559,0.906694,0.002606989,0.006067865,0.00029923778,0.0015990733,0.0007809873,0.055341024,0.0004931372,0.0043973755,0.0007391295],"about_ca_topic_score_codex":0.00044981425,"about_ca_topic_score_gemma":0.000010354518,"teacher_disagreement_score":0.07454657,"about_ca_system_score_codex":0.000046753292,"about_ca_system_score_gemma":0.00067358464,"threshold_uncertainty_score":0.7070508},"labels":[],"label_agreement":null},{"id":"W4400016505","doi":"10.1016/j.clgc.2024.102143","title":"Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Medicine; Chemotherapy; Bladder cancer; Oncology; Cancer; Angiotensin-converting enzyme; Neoadjuvant therapy; Internal medicine; Urology; Pathology; Breast cancer","score_opus":0.08896954853584528,"score_gpt":0.41624653728751193,"score_spread":0.32727698875166666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400016505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827587,0.0086229155,0.00005619575,0.005503484,0.0010994067,0.0014861906,0.0002589946,0.00014393814,0.000070195434],"genre_scores_gemma":[0.9937255,0.001190001,0.00070472865,0.0013670129,0.0020138263,0.00021650227,0.000015997848,0.00011919248,0.000647233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968261,0.0002963364,0.0010646912,0.00086461985,0.000395063,0.00055316836],"domain_scores_gemma":[0.9959259,0.0023798172,0.00035010758,0.0005618133,0.00054063485,0.00024169813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093531294,0.00044744517,0.0012544828,0.00019584925,0.00011382941,0.000025737118,0.00014206575,0.00026872446,0.0001244632],"category_scores_gemma":[0.000561697,0.00028752928,0.00090086245,0.00040989093,0.0004644298,0.00007532734,0.00007697439,0.00044932007,0.000019740235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10039633,0.0014197183,0.3636377,0.000686006,0.008312844,0.00478164,0.0039828755,0.0012320514,0.22947401,0.000013091197,0.19029225,0.09577151],"study_design_scores_gemma":[0.006059591,0.014487341,0.9572511,0.0033763042,0.0006449437,0.0001589076,0.00017261259,0.00079934276,0.0076614954,0.000028682789,0.008798164,0.0005615259],"about_ca_topic_score_codex":0.00017296278,"about_ca_topic_score_gemma":0.000031473704,"teacher_disagreement_score":0.5936134,"about_ca_system_score_codex":0.00036215284,"about_ca_system_score_gemma":0.0010307792,"threshold_uncertainty_score":0.9999577},"labels":[],"label_agreement":null},{"id":"W4400624727","doi":"10.1016/j.clgc.2024.102161","title":"Regional Differences in Stage III Nonseminoma Germ Cell Tumor Patients Across SEER Registries","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Epidemiology; Proportional hazards model; Cancer registry; Internal medicine; Surveillance, Epidemiology, and End Results; Stage (stratigraphy); Oncology; Hazard ratio; Cancer; Gynecology; Confidence interval","score_opus":0.06848158676397974,"score_gpt":0.3984688936577359,"score_spread":0.32998730689375616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400624727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885952,0.008818185,0.0000053938056,0.0005728414,0.00082909706,0.00040847532,0.00028708574,0.00008648802,0.00039724927],"genre_scores_gemma":[0.99114716,0.0007589535,0.00009722555,0.0005099921,0.00053148903,0.00012186223,0.00009635625,0.000033617845,0.006703338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808407,0.000057981713,0.0005748171,0.0005717593,0.00033129615,0.00038005484],"domain_scores_gemma":[0.99889207,0.00028724648,0.00011682311,0.00032235746,0.000077396,0.00030413078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012681991,0.00023811577,0.00043444542,0.00005264393,0.00007142628,0.000050599247,0.00011939482,0.000116037714,0.00026780285],"category_scores_gemma":[0.00010304118,0.00017972705,0.0002874278,0.00020530482,0.00024252893,0.000088182365,0.0001058994,0.00034807783,0.000084509054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062224333,0.0015006129,0.98327094,0.0002751054,0.00011244771,0.0029971318,0.00016244139,0.0000037209343,0.000010967204,0.000012749012,0.0034118604,0.007619794],"study_design_scores_gemma":[0.0035612786,0.0007114122,0.9828337,0.0005324256,0.00014252102,0.0000148244535,0.000120173216,0.0000800037,0.00004928352,0.000074294476,0.011677948,0.00020212712],"about_ca_topic_score_codex":0.00025568015,"about_ca_topic_score_gemma":0.00004245388,"teacher_disagreement_score":0.008266087,"about_ca_system_score_codex":0.00019579238,"about_ca_system_score_gemma":0.00065450155,"threshold_uncertainty_score":0.7329056},"labels":[],"label_agreement":null},{"id":"W4400798284","doi":"10.1016/j.clgc.2024.102166","title":"Rates of Systemic Therapy for Metastatic Bladder Cancer Are Lower in Unmarried Males and Females","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Systemic therapy; Bladder cancer; Oncology; Internal medicine; Cancer; Breast cancer","score_opus":0.14799061125416446,"score_gpt":0.4574729877468923,"score_spread":0.30948237649272786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400798284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85867286,0.13745092,0.000020368841,0.0013647805,0.0010472683,0.0010301425,0.00026365597,0.000036704932,0.00011329625],"genre_scores_gemma":[0.9563523,0.039683305,0.00023254514,0.00058468885,0.0006988935,0.0007979107,0.000012041131,0.000055210803,0.00158313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827576,0.000092770315,0.0006960232,0.0004893067,0.00017093225,0.0002752145],"domain_scores_gemma":[0.9988899,0.000498686,0.000124011,0.0002288217,0.000114101946,0.00014445177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028762157,0.00023997275,0.00072544784,0.00011702783,0.00003532774,0.000021319553,0.00008303786,0.00012055433,0.0002890888],"category_scores_gemma":[0.00005523931,0.00017409891,0.00023729363,0.00021030384,0.00019191079,0.000080073696,0.00003199388,0.00021259226,0.0000054480906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067195334,0.0010982021,0.8749905,0.0036041124,0.0025923094,0.0005902733,0.00067459425,0.000062580075,0.0029866714,0.00006585539,0.0070184744,0.09959686],"study_design_scores_gemma":[0.02021417,0.005518959,0.9218535,0.009376562,0.0019563136,0.00016691128,0.001447145,0.0012062995,0.006704819,0.001015495,0.029599592,0.0009402792],"about_ca_topic_score_codex":0.00017711312,"about_ca_topic_score_gemma":0.00012355468,"teacher_disagreement_score":0.09865657,"about_ca_system_score_codex":0.00008810557,"about_ca_system_score_gemma":0.00050064945,"threshold_uncertainty_score":0.70995474},"labels":[],"label_agreement":null},{"id":"W4401002134","doi":"10.1016/j.clgc.2024.102176","title":"Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck KGaA","keywords":"Medicine; Cisplatin; Gemcitabine; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Oncology; Regimen; Meta-analysis; Internal medicine; Urothelial cancer; Chemotherapy; Cancer; Bladder cancer","score_opus":0.11901612622383809,"score_gpt":0.4274046873142976,"score_spread":0.30838856109045953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401002134","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004712932,0.9882849,0.000006745026,0.00015259277,0.00032048646,0.0101693515,0.00087464525,0.000056378758,0.00008778621],"genre_scores_gemma":[0.00013886362,0.9891528,0.0009295245,0.001290356,0.0004475734,0.004629548,0.00039954632,0.00019158015,0.0028202005],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99263835,0.001195459,0.0031980998,0.0016155856,0.00069092005,0.00066161284],"domain_scores_gemma":[0.9963342,0.0007251327,0.00096430746,0.0012390884,0.00024517483,0.00049210986],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00094539096,0.0012953328,0.015299457,0.00040120303,0.000073031304,0.000089252426,0.0003110834,0.00040428503,0.0004329413],"category_scores_gemma":[0.00019022025,0.0006335199,0.0035848494,0.0030508544,0.0001568344,0.00012687738,0.00019420158,0.0014741848,0.000051877436],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094870065,0.0005696798,0.0006068814,0.8008379,0.15881278,0.0020021286,0.000034115692,0.000007909709,1.3390984e-9,0.0000034244842,0.0011894911,0.034987003],"study_design_scores_gemma":[0.002446915,0.0016144766,0.00036968014,0.17761464,0.78268725,0.00008286338,0.0000036029267,0.0000077419,6.1649432e-9,0.000007683633,0.03461049,0.000554672],"about_ca_topic_score_codex":0.000027948608,"about_ca_topic_score_gemma":0.00010110879,"teacher_disagreement_score":0.6238744,"about_ca_system_score_codex":0.00028512403,"about_ca_system_score_gemma":0.0013204316,"threshold_uncertainty_score":0.99997985},"labels":[],"label_agreement":null},{"id":"W4401542816","doi":"10.1016/j.clgc.2024.102194","title":"The Incidence of Extreme Serum Prostate Specific Antigen Levels During the COVID-19 Pandemic","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Pandemic; Incidence (geometry); 2019-20 coronavirus outbreak; Prostate cancer; Prostate-specific antigen; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Betacoronavirus; Virology; Immunology; Coronavirus Infections; Internal medicine; Oncology; Cancer; Outbreak; Disease","score_opus":0.19616703783216913,"score_gpt":0.4284442812121122,"score_spread":0.23227724337994307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401542816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91224116,0.07312632,0.000015294052,0.011778576,0.0013801233,0.0009430249,0.00017774254,0.00010353086,0.00023424941],"genre_scores_gemma":[0.89766586,0.09738558,0.00004363375,0.0010141971,0.0010646243,0.00028041282,0.0000055225596,0.000037602906,0.0025025953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763745,0.00017888664,0.0008306246,0.0005430472,0.00038720132,0.00042279152],"domain_scores_gemma":[0.9974633,0.0012816193,0.0001711109,0.0006685128,0.000110748966,0.00030471405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009853643,0.00023356895,0.00040396582,0.000046756533,0.00032305223,0.00006341535,0.00028487653,0.00010765024,0.0003067551],"category_scores_gemma":[0.00019445956,0.00012054786,0.0003272417,0.0003360113,0.00055708975,0.00009315615,0.00018923674,0.00051124423,0.000055002816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009521976,0.00020831329,0.9071116,0.00046943533,0.0004901993,0.000859469,0.00057482684,0.00008150202,0.0022195657,0.000072377916,0.012027212,0.074933305],"study_design_scores_gemma":[0.0013401378,0.0005970299,0.6842326,0.00040802066,0.00013961853,0.00014346011,0.00017667554,0.00007597523,0.0013289384,0.00043469307,0.31094483,0.00017805232],"about_ca_topic_score_codex":0.00009745523,"about_ca_topic_score_gemma":0.00007273972,"teacher_disagreement_score":0.29891762,"about_ca_system_score_codex":0.0004330139,"about_ca_system_score_gemma":0.0009665678,"threshold_uncertainty_score":0.49157992},"labels":[],"label_agreement":null},{"id":"W4401833551","doi":"10.1016/j.clgc.2024.102210","title":"Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Advanced Research Projects Agency for Health; Bladder Cancer Advocacy Network; American Society of Clinical Oncology; Prostate Cancer Fight Foundation","keywords":"Medicine; Clinical trial; Clinical Oncology; Genitourinary system; Alternative medicine; Family medicine; Oncology; Medical physics; Internal medicine; Cancer; Pathology","score_opus":0.7695312986740319,"score_gpt":0.6581462062715825,"score_spread":0.11138509240244943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401833551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96650946,0.017149502,0.0000023864134,0.011683095,0.0020853893,0.001462509,0.0009496165,0.000057018675,0.000101000296],"genre_scores_gemma":[0.9810945,0.007467152,0.000046311045,0.009888813,0.00076867803,0.00030842877,0.00020488843,0.00004468412,0.00017658055],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9814145,0.013131592,0.003427081,0.0007972474,0.00038733592,0.0008422614],"domain_scores_gemma":[0.97909397,0.0188665,0.0006666126,0.0003268439,0.00017250044,0.0008735787],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012425959,0.0005101309,0.0019771531,0.0005078931,0.0002478364,0.000049730945,0.00047729586,0.0015119447,0.00041614287],"category_scores_gemma":[0.0046814927,0.00040352307,0.00016475814,0.0019585507,0.0010267444,0.00017299106,0.00016621566,0.006895236,0.0000026226937],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010019941,0.0010258446,0.8690606,0.0016606086,0.0009146032,0.0024286008,0.0034213725,0.01744519,0.0017063933,0.0005334176,0.037769962,0.05401351],"study_design_scores_gemma":[0.012525426,0.0011965837,0.18307672,0.0014083906,0.0008604482,0.0000618929,0.0038546233,0.051539816,0.0026528346,0.00072836364,0.74095654,0.0011383325],"about_ca_topic_score_codex":0.094836675,"about_ca_topic_score_gemma":0.035208587,"teacher_disagreement_score":0.7031866,"about_ca_system_score_codex":0.00039380623,"about_ca_system_score_gemma":0.0031331135,"threshold_uncertainty_score":0.9998417},"labels":[],"label_agreement":null},{"id":"W4402327929","doi":"10.1016/j.clgc.2024.102215","title":"Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Medicine; Tremelimumab; Metastatic Urothelial Carcinoma; Bone metastasis; Oncology; Urothelial carcinoma; Metastasis; Internal medicine; Carcinoma; Cancer; Immunotherapy; Bladder cancer","score_opus":0.061469192054745055,"score_gpt":0.3951481070672198,"score_spread":0.33367891501247476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402327929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382186,0.0009006052,0.0000073082833,0.00012772436,0.000071887625,0.0046302443,0.00020074999,0.000048121172,0.00019150818],"genre_scores_gemma":[0.99821234,0.000065574364,0.00023483824,0.00009871769,0.00014212266,0.0008772341,0.00004205417,0.00010432427,0.00022282441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963337,0.0005684915,0.0009529148,0.0007913599,0.0008366802,0.00051685027],"domain_scores_gemma":[0.99832606,0.00044850202,0.00019298629,0.0006499128,0.00019300531,0.00018951239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005504794,0.0005196158,0.0013127263,0.0003182152,0.000055515422,0.00004411376,0.00019824615,0.00007728739,0.00019234311],"category_scores_gemma":[0.000063264284,0.00021859763,0.00020427028,0.001354819,0.0002839949,0.0001725388,0.00004086055,0.0005846873,0.000007450103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04873643,0.006994253,0.9313157,0.00020202497,0.0016143583,0.00271001,0.0013281077,0.000089899746,0.00000486893,5.5795033e-7,0.000068756206,0.0069350046],"study_design_scores_gemma":[0.029537229,0.056897268,0.90875715,0.00068827445,0.002741625,0.0000842496,0.0008190559,0.00013666644,0.000022966564,0.0000034643583,0.00003373174,0.00027832369],"about_ca_topic_score_codex":0.0031805634,"about_ca_topic_score_gemma":0.002604367,"teacher_disagreement_score":0.049903013,"about_ca_system_score_codex":0.0003232578,"about_ca_system_score_gemma":0.0016734762,"threshold_uncertainty_score":0.8914153},"labels":[],"label_agreement":null},{"id":"W4402667368","doi":"10.1016/j.clgc.2024.102214","title":"Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Associazione Italiana per la Ricerca sul Cancro; Deutsche Forschungsgemeinschaft; Merck","keywords":"Medicine; Cystectomy; Pembrolizumab; Oncology; Internal medicine; Neoadjuvant therapy; Bladder cancer; Cancer; Immunotherapy","score_opus":0.03257032447753763,"score_gpt":0.3766893100353639,"score_spread":0.3441189855578263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402667368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98936224,0.0067393095,0.000014613556,0.000785674,0.0010927317,0.0015571499,0.00014332737,0.00006138728,0.00024354232],"genre_scores_gemma":[0.995718,0.0008291,0.00002432818,0.0007655492,0.001164436,0.0007834447,0.00003243538,0.00005654634,0.0006261643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971443,0.0004038101,0.0007592784,0.0007919603,0.000512741,0.00038795045],"domain_scores_gemma":[0.9988406,0.0002568524,0.00007325717,0.0005331056,0.000050535065,0.00024566436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040342344,0.00032131633,0.0005753881,0.00010562729,0.00009646162,0.000090857684,0.00019977185,0.00018756474,0.0003851249],"category_scores_gemma":[0.00006787824,0.00019494498,0.00020724154,0.00022277203,0.00014735309,0.00013900174,0.00019367643,0.0007757815,0.000040441406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020281416,0.0018986509,0.97620904,0.00017402475,0.00017371462,0.0027230193,0.0011592295,5.633518e-7,0.000035631463,6.4005116e-7,0.0023840128,0.013213302],"study_design_scores_gemma":[0.007503896,0.0021737306,0.9853757,0.00043096236,0.00057777815,0.00006181373,0.00019934688,0.00002679317,0.000051461677,0.000043451055,0.003339966,0.00021511882],"about_ca_topic_score_codex":0.00017738239,"about_ca_topic_score_gemma":0.00010901907,"teacher_disagreement_score":0.012998183,"about_ca_system_score_codex":0.00013748741,"about_ca_system_score_gemma":0.0001620212,"threshold_uncertainty_score":0.7949626},"labels":[],"label_agreement":null},{"id":"W4403499706","doi":"10.1016/j.clgc.2024.102237","title":"The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Concomitant; Renal cell carcinoma; Systemic therapy; Oncology; Meta-analysis; Internal medicine; Overall survival; Intensive care medicine; Cancer","score_opus":0.1818844136184329,"score_gpt":0.4447486379091504,"score_spread":0.26286422429071754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403499706","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066680936,0.9775145,0.00000416351,0.00014822163,0.000057207093,0.014091303,0.0014606607,0.000013989368,0.00004183524],"genre_scores_gemma":[0.042590305,0.94975126,0.00003840948,0.000066926485,0.000047784826,0.006153571,0.0001860127,0.00008633329,0.0010794158],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99344367,0.0017334966,0.0031646618,0.00069940876,0.0006410056,0.0003177324],"domain_scores_gemma":[0.9878401,0.007219608,0.0026423403,0.0014875589,0.00059479394,0.00021560681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017035356,0.00077047595,0.010522966,0.00017399757,0.00010202426,0.000020198118,0.00040439153,0.00015377969,0.00008566467],"category_scores_gemma":[0.00035127113,0.00023017607,0.00578957,0.0008322467,0.00031782873,0.000028101926,0.00006685586,0.00046524202,0.0000037720472],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013513243,0.00077323295,0.00018616942,0.6493495,0.3461978,0.00005599433,0.00003998617,0.000006781373,5.9189676e-7,0.000009429473,0.0006807405,0.0013484075],"study_design_scores_gemma":[0.0016958587,0.0064023673,0.00019295063,0.029053478,0.9616479,0.000029338738,0.000026076692,0.000013918281,0.0000031151612,0.0000038458575,0.00068932935,0.00024181686],"about_ca_topic_score_codex":0.000067710454,"about_ca_topic_score_gemma":0.000013159319,"teacher_disagreement_score":0.62029606,"about_ca_system_score_codex":0.00032305988,"about_ca_system_score_gemma":0.0012377676,"threshold_uncertainty_score":0.93863076},"labels":[],"label_agreement":null},{"id":"W4403727295","doi":"10.1016/j.clgc.2024.102251","title":"Central Nervous System Toxicity in Prostate Cancer Patients Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Innovációs és Technológiai Minisztérium; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; European Association of Urology","keywords":"Medicine; Meta-analysis; Prostate cancer; Androgen receptor; Oncology; Central nervous system; Toxicity; Bioinformatics; Cancer; Internal medicine; Biology","score_opus":0.11726088546034366,"score_gpt":0.3980136414811087,"score_spread":0.280752756020765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403727295","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006926803,0.9840717,0.0000056954864,0.00025201697,0.00037623005,0.012475639,0.0019146948,0.00017601639,0.00003537163],"genre_scores_gemma":[0.0019661004,0.9814572,0.00007341233,0.00049303466,0.00077791733,0.01298013,0.0006601671,0.00020413207,0.001387906],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9860981,0.002935627,0.0060152835,0.0024817577,0.0012413636,0.0012278453],"domain_scores_gemma":[0.993403,0.0010600165,0.0029841124,0.0011117179,0.0007527411,0.00068839744],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0024142812,0.0018843289,0.03402348,0.0010217032,0.00019171655,0.00011930458,0.00034305113,0.0005910097,0.0004719236],"category_scores_gemma":[0.00025506425,0.0010471363,0.016399736,0.007931036,0.00030035235,0.00014990741,0.00034756216,0.001761466,0.000030025623],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001477778,0.00025624564,0.0019783918,0.35313976,0.64183646,0.00027045514,0.00003531411,0.00010009815,1.8707404e-8,2.5589793e-7,0.001299173,0.00093606825],"study_design_scores_gemma":[0.00066386873,0.00063603907,0.00008314788,0.09794341,0.89300597,0.000021849084,0.00003435247,0.000042001513,6.671908e-7,5.091922e-7,0.006680859,0.00088730606],"about_ca_topic_score_codex":0.0006050914,"about_ca_topic_score_gemma":0.00067665376,"teacher_disagreement_score":0.25519633,"about_ca_system_score_codex":0.0014773409,"about_ca_system_score_gemma":0.0008097812,"threshold_uncertainty_score":0.99939007},"labels":[],"label_agreement":null},{"id":"W4403914498","doi":"10.1016/j.clgc.2024.102249","title":"Reevaluating the Role of Extended Pelvic Lymphadenectomy in Muscle-Invasive Bladder Cancer: Insights From SWOG S1011 and LEA AB 25-02 Trials","year":2024,"lang":"en","type":"editorial","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Bladder cancer; Lymphadenectomy; Oncology; Internal medicine; Urology; Cancer","score_opus":0.0636659490453141,"score_gpt":0.41644178006503174,"score_spread":0.35277583101971766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403914498","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25568262,0.29021633,0.000001179022,0.00079307426,0.44612333,0.002775764,0.002118059,0.0001087675,0.0021808709],"genre_scores_gemma":[0.2201386,0.100285344,0.00011245576,0.0004074937,0.675186,0.0014696926,0.00035780543,0.00025797446,0.0017846467],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99189365,0.0013640256,0.0029358866,0.0016995558,0.001470735,0.000636141],"domain_scores_gemma":[0.98826575,0.008686685,0.0011647295,0.0010729402,0.00042950918,0.0003803562],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015100224,0.00090455485,0.003276259,0.00028613763,0.00014790187,0.00007992792,0.000535319,0.0016134718,0.0008220332],"category_scores_gemma":[0.0029035693,0.0006060955,0.000944109,0.00049671356,0.0005182894,0.00013111392,0.0004164572,0.002093857,0.00004092446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057897344,0.0013609609,0.008037492,0.001192641,0.006603094,0.0010226682,0.0025778809,0.00002807452,0.001568935,0.00001266079,0.72865576,0.24315009],"study_design_scores_gemma":[0.026654782,0.0036402,0.03566396,0.008885187,0.013315114,0.0000151203885,0.001650464,0.00025179586,0.002175418,0.0054378714,0.9007038,0.001606279],"about_ca_topic_score_codex":0.009511716,"about_ca_topic_score_gemma":0.0026820817,"teacher_disagreement_score":0.24154381,"about_ca_system_score_codex":0.0006276363,"about_ca_system_score_gemma":0.0057171504,"threshold_uncertainty_score":0.99991953},"labels":[],"label_agreement":null},{"id":"W4403978554","doi":"10.1016/j.clgc.2024.102261","title":"Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Wilfrid Laurier University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Carboplatin; Pembrolizumab; Medicine; Cisplatin; Gemcitabine; Chemotherapy; Regimen; Internal medicine; Oncology; Chemotherapy regimen; Phases of clinical research; Progression-free survival; Urology; Cancer; Immunotherapy","score_opus":0.08280996112484124,"score_gpt":0.4458786824423694,"score_spread":0.36306872131752815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403978554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98167366,0.01052265,0.00012928025,0.0023970627,0.0018687047,0.0021865985,0.0007127114,0.00021244565,0.00029689886],"genre_scores_gemma":[0.9886061,0.0022815317,0.00016525702,0.0031766554,0.002815229,0.00163045,0.00008699516,0.00013018423,0.0011075839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957414,0.00042992955,0.0012699546,0.0012706748,0.0006958015,0.0005921844],"domain_scores_gemma":[0.9971538,0.0011490142,0.00019701646,0.001023528,0.00013273083,0.00034391458],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047969297,0.0005727151,0.0013357308,0.0002635623,0.00016328844,0.00008657446,0.00039223136,0.00025158437,0.0030343616],"category_scores_gemma":[0.0001066074,0.0003653739,0.00070717745,0.0017384504,0.00021713307,0.00015174018,0.00008017248,0.00095968216,0.00005263812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07746508,0.007121908,0.4842012,0.00019194307,0.010385833,0.004588512,0.0051712366,0.005554036,0.00093035545,0.0000029934588,0.0047280183,0.3996589],"study_design_scores_gemma":[0.20445503,0.0170175,0.6395741,0.0016702994,0.018995762,0.000019206418,0.0039580157,0.05617773,0.0026205622,0.0001471746,0.053008087,0.002356543],"about_ca_topic_score_codex":0.0031496645,"about_ca_topic_score_gemma":0.0042844433,"teacher_disagreement_score":0.39730236,"about_ca_system_score_codex":0.0007690001,"about_ca_system_score_gemma":0.0030284126,"threshold_uncertainty_score":0.99987984},"labels":[],"label_agreement":null},{"id":"W4404195234","doi":"10.1016/j.clgc.2024.102259","title":"Robot-Assisted Cystectomy in Patients With Previous Pelvic Irradiation: A Comprehensive Systematic Review and Single-Arm Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Medicine; Cystectomy; Meta-analysis; Bladder cancer; Urology; Surgery; General surgery; Oncology; Internal medicine; Cancer","score_opus":0.1854983916649068,"score_gpt":0.4282979106529379,"score_spread":0.24279951898803107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404195234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000051865965,0.9902678,0.00000214026,0.00019468606,0.00023745485,0.008708217,0.0003247313,0.00007561828,0.0001374599],"genre_scores_gemma":[0.00053688115,0.9929915,0.00013190601,0.0010031994,0.00021656735,0.0033818437,0.000354037,0.00013520283,0.0012488511],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99377316,0.0010310909,0.0028357957,0.0013320209,0.0006073035,0.00042064703],"domain_scores_gemma":[0.9965802,0.0005257956,0.0010796634,0.0011115379,0.00033076433,0.00037206543],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037574657,0.0009985253,0.014289754,0.00048433643,0.000059549173,0.000063801046,0.00024292043,0.00042284984,0.00034158357],"category_scores_gemma":[0.00009932066,0.0005628816,0.0036513759,0.0019102668,0.00014461234,0.000082317805,0.0001428888,0.0009302748,0.000083406114],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076321194,0.0010855965,0.0003502364,0.76643705,0.21384951,0.00028965605,0.000018439398,0.0000011117475,3.3874936e-9,4.577576e-7,0.00034581052,0.017545803],"study_design_scores_gemma":[0.0013676728,0.0014790825,0.0020843763,0.14021395,0.83080906,0.00005847501,0.0000044586777,0.000001836456,8.717972e-9,0.0000017228701,0.023520011,0.0004593388],"about_ca_topic_score_codex":0.00005635623,"about_ca_topic_score_gemma":0.000047397578,"teacher_disagreement_score":0.6262231,"about_ca_system_score_codex":0.0005099701,"about_ca_system_score_gemma":0.0006288494,"threshold_uncertainty_score":0.99968225},"labels":[],"label_agreement":null},{"id":"W4404436762","doi":"10.1016/j.clgc.2024.102269","title":"Trends and Disparities in Inpatient Palliative Care Use in Metastatic Renal Cell Carcinoma Patients Receiving Critical Care Therapy","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Palliative care; Intensive care medicine; Internal medicine; Oncology; Nursing","score_opus":0.23133950319896626,"score_gpt":0.4877354794917965,"score_spread":0.2563959762928303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404436762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9268174,0.07144676,0.000005050653,0.00026169722,0.000549322,0.0002525596,0.00016722547,0.000022828497,0.0004771638],"genre_scores_gemma":[0.98950857,0.008971479,0.0006876174,0.00024852518,0.00021308342,0.0001037937,0.00009299996,0.000035998808,0.00013795108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776363,0.0002653918,0.0007909801,0.0005365598,0.00029989457,0.0003435443],"domain_scores_gemma":[0.99795544,0.0013496816,0.000070732254,0.00021512437,0.00022909642,0.00017990972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014460791,0.00025456506,0.0006519558,0.00031985884,0.000033691445,0.00003162293,0.00008657822,0.00013984203,0.00006309298],"category_scores_gemma":[0.00037855495,0.00021090133,0.0001748356,0.00041756858,0.0002564769,0.00017585023,0.000086848115,0.0005546927,0.0000024736792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005550086,0.00028238964,0.9351176,0.0008672181,0.000035725672,0.00031944446,0.007964748,0.000012762417,0.000023506222,0.000011048608,0.00027612774,0.054534405],"study_design_scores_gemma":[0.0027184966,0.0016477033,0.9862643,0.0019799438,0.00009332529,7.055325e-7,0.0030489073,0.000128086,0.0005151374,0.00003365989,0.0033397847,0.00022994242],"about_ca_topic_score_codex":0.00084265997,"about_ca_topic_score_gemma":0.0007871016,"teacher_disagreement_score":0.06269116,"about_ca_system_score_codex":0.00024817305,"about_ca_system_score_gemma":0.0002137885,"threshold_uncertainty_score":0.86003065},"labels":[],"label_agreement":null},{"id":"W4404630453","doi":"10.1016/j.clgc.2024.102274","title":"Real-world Clinical Outcomes and Prognostic Factors in Neuroendocrine Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Cancer Foundation; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Neuroendocrine tumors; Cancer; Prostate","score_opus":0.11318034506068382,"score_gpt":0.48364685449129363,"score_spread":0.3704665094306098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404630453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97589016,0.010412122,6.768667e-7,0.008781494,0.0023389834,0.0013629016,0.00010552692,0.00019143977,0.00091666967],"genre_scores_gemma":[0.8954165,0.08050398,0.0000787254,0.00051059254,0.0010217152,0.00043264686,0.000041802406,0.00007977705,0.021914262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642766,0.00025484135,0.0012129619,0.0010028481,0.0003932719,0.0007084153],"domain_scores_gemma":[0.9973959,0.0014656809,0.000094532035,0.0003792448,0.000096965916,0.00056770403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005003681,0.00037101668,0.0009362595,0.0003089535,0.00007822493,0.00007528676,0.00014580622,0.00011144403,0.00038030103],"category_scores_gemma":[0.00029894675,0.00024894008,0.00035993822,0.00063755485,0.0004764026,0.00016679462,0.00021767947,0.0012563621,0.00003758327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086856185,0.00047065012,0.93539506,0.00038547706,0.00032452072,0.0038642657,0.000088607754,0.0000042139814,0.00003397791,0.000020026911,0.004071592,0.054473035],"study_design_scores_gemma":[0.0030689354,0.00093613594,0.96961594,0.0005990923,0.000249205,0.000020039495,0.000054260698,0.00029310174,0.00008974811,0.00013022998,0.02468814,0.00025515427],"about_ca_topic_score_codex":0.0010973407,"about_ca_topic_score_gemma":0.0008939262,"teacher_disagreement_score":0.080473684,"about_ca_system_score_codex":0.00022468201,"about_ca_system_score_gemma":0.0009476017,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W4406169109","doi":"10.1016/j.clgc.2025.102300","title":"Clinically Meaningful Upstaging and Upgrading in Favorable Intermediate-Risk Radical Prostatectomy Patients","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Stage (stratigraphy); Cancer; Internal medicine","score_opus":0.019467790870964785,"score_gpt":0.36674264614547786,"score_spread":0.3472748552745131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406169109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917281,0.0030985465,0.000031766405,0.0011443242,0.0010755934,0.0010606184,0.000044347587,0.000074005504,0.0017426646],"genre_scores_gemma":[0.98044944,0.016012253,0.00063715526,0.0017657871,0.00029452148,0.0003313124,0.000030433355,0.000034850018,0.00044424407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99692297,0.00022470497,0.0013017439,0.00079802633,0.00023693251,0.00051562453],"domain_scores_gemma":[0.9981499,0.0007600569,0.00026010894,0.00037102733,0.00012966199,0.00032928685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081434386,0.00029302013,0.0008042335,0.00020571578,0.000116926654,0.000042799962,0.00014011169,0.00021095073,0.00007167338],"category_scores_gemma":[0.00072300626,0.00024324411,0.00020799213,0.00037386853,0.0003283827,0.000121974605,0.00022773271,0.0008570853,0.000014166405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011291087,0.000984528,0.8514254,0.00013844605,0.00017689262,0.00014180048,0.00012478697,0.0000092063465,0.0000069843477,0.000026787375,0.0017217638,0.1441143],"study_design_scores_gemma":[0.011397631,0.0016312501,0.9736009,0.0013585815,0.00026621326,0.0000030338347,0.00010624277,0.00040883137,0.00014598168,0.0008665372,0.009964247,0.0002505538],"about_ca_topic_score_codex":0.00012048303,"about_ca_topic_score_gemma":0.000028769586,"teacher_disagreement_score":0.14386375,"about_ca_system_score_codex":0.00033202753,"about_ca_system_score_gemma":0.0004705169,"threshold_uncertainty_score":0.9919207},"labels":[],"label_agreement":null},{"id":"W4406771426","doi":"10.1016/j.clgc.2025.102306","title":"Nonintravesical Interventions for Preventing Intravesical Recurrence in Patients With Nonmuscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Bladder cancer; Meta-analysis; Urology; Oncology; Cancer; Internal medicine","score_opus":0.14743990973766827,"score_gpt":0.4676024706977903,"score_spread":0.3201625609601221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406771426","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035615147,0.98473734,0.000088271634,0.0003267858,0.00019866266,0.0130421,0.0014667896,0.000032676046,0.00007174011],"genre_scores_gemma":[0.00007724786,0.9843071,0.00052021595,0.00072290126,0.00020456346,0.011707144,0.00033419495,0.00007363566,0.0020529935],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99363226,0.00075608614,0.0032063988,0.0013931424,0.0004341488,0.0005779773],"domain_scores_gemma":[0.995359,0.0017312396,0.0012593326,0.0008825622,0.00040223158,0.00036562406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008182475,0.0008879729,0.013289855,0.00044697543,0.00010217887,0.0000477121,0.00035958178,0.0004460277,0.0004126536],"category_scores_gemma":[0.0007470643,0.0005537173,0.0059027784,0.0012955074,0.00020957695,0.00010489189,0.00019261004,0.000935569,0.000007689419],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010738046,0.0009812632,0.00054567755,0.8086404,0.16185626,0.000027811813,0.00001605949,6.7671465e-7,1.7344808e-9,0.000004416507,0.0003984169,0.027421618],"study_design_scores_gemma":[0.0013096242,0.0008134807,0.0006281895,0.24983054,0.7445562,0.000005065454,0.000005007527,0.0000022110867,9.802014e-8,0.000008117535,0.0024403832,0.00040108955],"about_ca_topic_score_codex":0.000060045313,"about_ca_topic_score_gemma":0.00020456777,"teacher_disagreement_score":0.58269995,"about_ca_system_score_codex":0.00033166466,"about_ca_system_score_gemma":0.0015805016,"threshold_uncertainty_score":0.9996914},"labels":[],"label_agreement":null},{"id":"W4407122004","doi":"10.1016/j.clgc.2025.102313","title":"Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Santé et de Services Sociaux de Chicoutimi; Cégep de Chicoutimi; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Merck Sharp and Dohme; EMD Serono; Astellas Pharma; Natera; Bladder Cancer Advocacy Network; American Association for Cancer Research; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Bladder cancer; Urothelial cancer; Chart; Oncology; Cancer; Internal medicine; Bacillus (shape); Urology","score_opus":0.021617643058209353,"score_gpt":0.3654198877687889,"score_spread":0.3438022447105796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407122004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98200434,0.006311336,0.000006589609,0.006848192,0.0009301981,0.002658131,0.00076819124,0.000064757434,0.0004082777],"genre_scores_gemma":[0.79018456,0.1955076,0.00012382702,0.008922354,0.00046898666,0.0014417119,0.00010409781,0.000070440066,0.0031764056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99594134,0.0003656922,0.0011969773,0.0011105572,0.0007262149,0.0006592197],"domain_scores_gemma":[0.99711275,0.0009322265,0.00032162212,0.00074747385,0.00028463016,0.0006013086],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034440224,0.0006380078,0.0017996132,0.0002525321,0.00014367848,0.000022348506,0.00021129935,0.00029012328,0.0009897714],"category_scores_gemma":[0.00032460337,0.00042941383,0.00029761967,0.00047943302,0.00029982027,0.00011148438,0.00016684427,0.00068561756,0.000024636605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020296534,0.0017298482,0.8892106,0.00058730115,0.0013341765,0.00046824518,0.000086339205,0.000003641947,0.0000011588285,0.0000024630458,0.0020417862,0.10250481],"study_design_scores_gemma":[0.020916343,0.0026464073,0.9643412,0.0049648494,0.0018023675,0.0000032780135,0.000043009015,0.000020233207,0.000041065723,0.000010439542,0.0048198644,0.00039093033],"about_ca_topic_score_codex":0.02066974,"about_ca_topic_score_gemma":0.019021895,"teacher_disagreement_score":0.19181974,"about_ca_system_score_codex":0.00082924496,"about_ca_system_score_gemma":0.0019416357,"threshold_uncertainty_score":0.99992347},"labels":[],"label_agreement":null},{"id":"W4407790476","doi":"10.1016/j.clgc.2025.102320","title":"Lymphovascular Invasion Predicts Cancer-specific Mortality in Penile Localized Squamous Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Lymphovascular invasion; Penile cancer; Oncology; Basal cell; Cancer; Internal medicine; Metastasis","score_opus":0.06391110629489691,"score_gpt":0.3895034241149258,"score_spread":0.32559231782002884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407790476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9480892,0.042215046,0.000026603722,0.00081376516,0.0019073301,0.0012197098,0.00008265982,0.00009255409,0.0055531594],"genre_scores_gemma":[0.9909142,0.0016163004,0.00011585432,0.0033907508,0.0009179699,0.00044542708,0.00006695581,0.00003849517,0.0024940502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634033,0.00029319094,0.0012802518,0.0009066407,0.00046951117,0.0007100421],"domain_scores_gemma":[0.9976064,0.00027246113,0.00016410465,0.0008974237,0.00019789029,0.00086174003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060076936,0.00033891888,0.0008436033,0.00020421688,0.0001403927,0.000019698326,0.00026183645,0.0003758997,0.00078328216],"category_scores_gemma":[0.0001866615,0.00031202688,0.0004695322,0.0006826339,0.00021898012,0.00009245374,0.00018867146,0.00058853225,0.00008289153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028945373,0.0017079937,0.9598597,0.001453743,0.000019075285,0.0009261045,0.000055630382,0.00013544096,0.0001824369,0.000008954116,0.019545943,0.0132104],"study_design_scores_gemma":[0.012769894,0.0004922005,0.95880634,0.00012367037,0.00028484486,0.00000712359,0.00010529512,0.00067838444,0.000841444,0.00013520595,0.025470382,0.00028524146],"about_ca_topic_score_codex":0.0025078529,"about_ca_topic_score_gemma":0.00037255517,"teacher_disagreement_score":0.04282502,"about_ca_system_score_codex":0.0005406781,"about_ca_system_score_gemma":0.0027039018,"threshold_uncertainty_score":0.9999332},"labels":[],"label_agreement":null},{"id":"W4409197276","doi":"10.1016/j.clgc.2025.102342","title":"Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Sunnybrook Health Science Centre; London Health Sciences Centre; Western University; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec; McMaster University; BC Cancer Agency; Alberta Health Services; University of Calgary; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; University Health Network; Dalhousie University; University of Manitoba; Juravinski Cancer Centre; McGill University; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Renal cell carcinoma; Nephrectomy; Oncology; Internal medicine; Urology; Pathology; Kidney","score_opus":0.06990687001142348,"score_gpt":0.38939416906212765,"score_spread":0.31948729905070417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409197276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912908,0.0011968365,0.000009417228,0.000094911695,0.00046190366,0.0018732388,0.00003653469,0.000036431902,0.004999892],"genre_scores_gemma":[0.99466574,0.0001915575,0.003639757,0.00010366279,0.00013684167,0.00025746977,0.000025878844,0.00004348188,0.0009356129],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963075,0.00044707212,0.001517486,0.0007383813,0.00042717904,0.0005623777],"domain_scores_gemma":[0.99782807,0.0006787102,0.0003660654,0.0005902268,0.00026571905,0.0002711975],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043955515,0.0003680244,0.0011790653,0.0005081727,0.000074510295,0.000014635025,0.00016331192,0.00008477584,0.0001410119],"category_scores_gemma":[0.00015075925,0.0003268443,0.00030534453,0.0007327737,0.00021977477,0.0001045833,0.00024928473,0.00055449596,0.000008604405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027016876,0.0047855177,0.9852021,0.00026070053,0.0003466409,0.00082114205,0.0007577702,0.00031393906,0.00062265294,0.0000035275216,0.00066084584,0.0035235311],"study_design_scores_gemma":[0.0114081865,0.0027266887,0.9753736,0.00029305537,0.00064767885,0.000004710136,0.00162874,0.00025536196,0.006993196,0.000024867988,0.0004001853,0.00024369515],"about_ca_topic_score_codex":0.0017737775,"about_ca_topic_score_gemma":0.00029933435,"teacher_disagreement_score":0.009828411,"about_ca_system_score_codex":0.00065805105,"about_ca_system_score_gemma":0.0010181343,"threshold_uncertainty_score":0.99991834},"labels":[],"label_agreement":null},{"id":"W4411275540","doi":"10.1016/j.clgc.2025.102385","title":"Comorbidity Burden and Effectiveness of Immunotherapy in Metastatic Renal Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Dana-Farber Cancer Institute","keywords":"Medicine; Discontinuation; Comorbidity; Internal medicine; Hazard ratio; Renal cell carcinoma; Nivolumab; Adverse effect; Oncology; Confidence interval; Cancer; Immunotherapy","score_opus":0.04757200492122552,"score_gpt":0.38146650259542847,"score_spread":0.33389449767420293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411275540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98170006,0.0150217265,0.00002987092,0.00029743704,0.0002636578,0.0006885813,0.000014120217,0.0000123903055,0.0019721638],"genre_scores_gemma":[0.99721557,0.001615502,0.00035022327,0.00009038369,0.00012872169,0.00010277343,0.000010025901,0.000017350172,0.000469423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815536,0.00048899045,0.00060365815,0.0003810861,0.00016081563,0.00021007996],"domain_scores_gemma":[0.99845386,0.00088501896,0.000118173,0.00036955564,0.0000739052,0.00009948933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071030215,0.00018501173,0.0007359018,0.00014186164,0.000028944485,0.0000057222837,0.00009616391,0.00009723495,0.0000661617],"category_scores_gemma":[0.00005105315,0.00015161371,0.00018649033,0.00025333025,0.00020654488,0.000035580022,0.000081921695,0.0003042412,0.000003671361],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059583755,0.00077830005,0.9320919,0.0012893314,0.00025442548,0.00062171824,0.000094357674,0.000080946156,0.023386994,0.000029944995,0.00020525,0.03520844],"study_design_scores_gemma":[0.007098683,0.0012341742,0.9571031,0.00042284568,0.00020015679,0.000014010503,0.00004390969,0.000119280354,0.032622237,0.00021329158,0.00081341807,0.00011492778],"about_ca_topic_score_codex":0.0005477768,"about_ca_topic_score_gemma":0.000019062849,"teacher_disagreement_score":0.035093512,"about_ca_system_score_codex":0.00015448293,"about_ca_system_score_gemma":0.00034004822,"threshold_uncertainty_score":0.61826277},"labels":[],"label_agreement":null},{"id":"W4414089879","doi":"10.1016/j.clgc.2025.102431","title":"CABOSEQ 3—Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Therapure Biopharma (Canada); Institute of Cancer Research; Alberta Cancer Foundation; University of Calgary","funders":"Ipsen; Ipsen Biopharmaceuticals","keywords":"Cabozantinib; Sunitinib; Ipilimumab; Renal cell carcinoma; Metastatic melanoma; Emulation; Clinical trial; Expanded access","score_opus":0.282927175586458,"score_gpt":0.4596656794035395,"score_spread":0.17673850381708145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414089879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98170227,0.0029675774,0.0016088585,0.0010645774,0.004548511,0.0031633147,0.0041032447,0.000055162767,0.00078648364],"genre_scores_gemma":[0.97449976,0.00016148856,0.01580146,0.00023530787,0.0018765361,0.00025093,0.006018089,0.000097195116,0.0010592366],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99317193,0.00067999813,0.002926488,0.0014940314,0.0010031189,0.0007244122],"domain_scores_gemma":[0.9893657,0.0061974325,0.001413587,0.0021881715,0.0005005235,0.0003346063],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016750976,0.00066835905,0.0018951303,0.00034983858,0.0003859441,0.00008427022,0.001146643,0.0001428711,0.00029245802],"category_scores_gemma":[0.0009569871,0.0005459688,0.0008777134,0.00070662954,0.00038437668,0.0003440633,0.0008191393,0.0008041058,0.000010453665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45761737,0.0118574435,0.44419536,0.0015763019,0.0062000365,0.0016225144,0.0010312065,0.007039432,0.01587902,0.00008181293,0.047375288,0.0055241887],"study_design_scores_gemma":[0.49348447,0.010871439,0.13805182,0.0013055997,0.030407295,0.000021840435,0.0026278975,0.2281887,0.06786024,0.00031210567,0.02478241,0.002086185],"about_ca_topic_score_codex":0.008154854,"about_ca_topic_score_gemma":0.0037522507,"teacher_disagreement_score":0.30614355,"about_ca_system_score_codex":0.00052238646,"about_ca_system_score_gemma":0.002219186,"threshold_uncertainty_score":0.9996992},"labels":[],"label_agreement":null},{"id":"W4414113945","doi":"10.1016/j.clgc.2025.102429","title":"Rates of Secondary Bladder and Rectal Cancers After External Beam Radiation for Prostate Cancer According to Age and D’amico Risk Groups in A Contemporary Cohort","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Prostate cancer; External beam radiation; Cohort; External beam radiotherapy; Bladder cancer; Prostate; Radiation therapy; Affect (linguistics)","score_opus":0.03408347317099797,"score_gpt":0.38332738780107994,"score_spread":0.349243914630082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414113945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9536336,0.04185302,0.000025889665,0.0008459684,0.0006247893,0.0023461648,0.0005136523,0.00001797787,0.0001389203],"genre_scores_gemma":[0.96292573,0.03170189,0.0003065435,0.0013265442,0.00030829175,0.0030534044,0.000028403478,0.000029713285,0.00031945817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811363,0.00008131157,0.00075667247,0.00062152994,0.00013028446,0.00029657627],"domain_scores_gemma":[0.9988632,0.0004003207,0.0002169909,0.00020375557,0.00010955654,0.00020618587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042533048,0.0002443378,0.00071841106,0.00017297178,0.00006284793,0.000026746524,0.000061382256,0.00013599184,0.0000332482],"category_scores_gemma":[0.000109145716,0.00021479516,0.00012766116,0.00021567123,0.00017216578,0.00013782886,0.000100541685,0.00029326446,4.847027e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043763067,0.00015898953,0.8685308,0.00030045304,0.00037986698,0.000108964516,0.0003124933,0.000031776002,0.00033614127,0.0000027896208,0.0014205804,0.124040835],"study_design_scores_gemma":[0.0062897345,0.0011238786,0.9855253,0.0010440908,0.00030652294,0.0000038565313,0.0002547971,0.00017228708,0.0021858818,0.00015812379,0.002729684,0.00020582927],"about_ca_topic_score_codex":0.0023814745,"about_ca_topic_score_gemma":0.0006298379,"teacher_disagreement_score":0.123835005,"about_ca_system_score_codex":0.00036958954,"about_ca_system_score_gemma":0.0008238611,"threshold_uncertainty_score":0.8759092},"labels":[],"label_agreement":null},{"id":"W4416397242","doi":"10.1016/j.clgc.2025.102467","title":"Transperineal versus Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2025,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Prostate cancer; Randomized controlled trial; Prostate; Urinary retention; Odds ratio; Confidence interval; Prostate biopsy; Meta-analysis; Complication","score_opus":0.24107333823660282,"score_gpt":0.5052030998858291,"score_spread":0.2641297616492263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416397242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000070603764,0.95928854,0.000008757285,0.00072010135,0.00044377707,0.03686624,0.002392948,0.000042729236,0.00022984066],"genre_scores_gemma":[0.000023460932,0.96075076,0.00011453876,0.00033835988,0.0001310685,0.03664878,0.00032354015,0.000055793575,0.001613678],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97951686,0.0072776144,0.011217249,0.0010672149,0.00053529674,0.00038577037],"domain_scores_gemma":[0.9691785,0.024861606,0.0042962553,0.0009392213,0.00037888373,0.0003455607],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.011283697,0.0011037666,0.13451122,0.0006139224,0.000056007044,0.000030455441,0.00023731282,0.00046178905,0.0008077258],"category_scores_gemma":[0.005229114,0.0005303718,0.050106205,0.0012280103,0.00038215873,0.000046152934,0.00005224757,0.0005547819,0.000004393862],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027240908,0.00028465965,7.265625e-7,0.47890228,0.48839223,0.0000683935,0.000012176163,4.18968e-7,1.3747975e-8,0.0000061121023,0.00007668186,0.005015403],"study_design_scores_gemma":[0.13402359,0.00042513193,5.306985e-7,0.09940814,0.7619477,0.000009590752,0.0000039890933,0.000005133962,2.5447363e-7,0.000002495362,0.0038888317,0.00028459312],"about_ca_topic_score_codex":0.000038750415,"about_ca_topic_score_gemma":0.000008952207,"teacher_disagreement_score":0.37949413,"about_ca_system_score_codex":0.00015910507,"about_ca_system_score_gemma":0.00133159,"threshold_uncertainty_score":0.9997148},"labels":[],"label_agreement":null},{"id":"W4417259318","doi":"10.1016/j.clgc.2025.102484","title":"Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University; Sunnybrook Health Science Centre; Alberta Cancer Foundation; Queen Elizabeth II Health Sciences Centre; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache","funders":"","keywords":"Renal cell carcinoma; First line; Attrition; First line therapy; Second line; Line (geometry); Expanded access","score_opus":0.0958034315958499,"score_gpt":0.38373461358010946,"score_spread":0.28793118198425954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417259318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974508,0.0092780655,0.00009906458,0.011495516,0.0013504539,0.0010735987,0.0009212552,0.000048454447,0.0012255869],"genre_scores_gemma":[0.98962635,0.0020238657,0.0012017033,0.0024225418,0.0007117412,0.00035679413,0.0017540314,0.000040371324,0.0018626162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966954,0.00034135027,0.0013627731,0.0008236962,0.00039435577,0.00038244986],"domain_scores_gemma":[0.9957936,0.0027512698,0.0002902633,0.00088698743,0.0001238697,0.00015405423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006115924,0.0003926112,0.0007134501,0.00017232339,0.00016220605,0.000053966465,0.0003326648,0.00013604951,0.00025448218],"category_scores_gemma":[0.00028003938,0.00027257996,0.0005937876,0.00036910686,0.000164957,0.00011044543,0.00010094418,0.00043576953,0.000040624967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03956658,0.00841569,0.87268645,0.00016283328,0.002442894,0.0067136637,0.00054448657,0.0014994347,0.016194792,0.000012682721,0.018358676,0.033401836],"study_design_scores_gemma":[0.09182139,0.0036920775,0.74957883,0.0015320659,0.0021104976,0.000019042838,0.00042116598,0.0057818666,0.07301472,0.00019319003,0.07108224,0.0007529075],"about_ca_topic_score_codex":0.0029547263,"about_ca_topic_score_gemma":0.0009210821,"teacher_disagreement_score":0.12310759,"about_ca_system_score_codex":0.0007277769,"about_ca_system_score_gemma":0.0008468765,"threshold_uncertainty_score":0.99997264},"labels":[],"label_agreement":null},{"id":"W7116661595","doi":"10.1016/j.clgc.2025.102491","title":"Efficacy and Safety of Immune Checkpoint Blockade in Locally Advanced or Metastatic Penile Cancer: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Blockade; Adverse effect; Immune checkpoint; Hazard ratio; Meta-analysis; Malignancy; Incidence (geometry); Immunotherapy; Penile cancer","score_opus":0.07886086246731193,"score_gpt":0.4474153223984749,"score_spread":0.368554459931163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116661595","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20381796,0.7865701,0.000030136018,0.0051276716,0.000079983365,0.004031799,0.00013681262,0.000023904637,0.0001816934],"genre_scores_gemma":[0.94065654,0.05148327,0.0006232719,0.0031329342,0.000027904802,0.0010380367,0.000016195921,0.000019265233,0.0030025514],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959725,0.00039691952,0.0025309327,0.0005367689,0.00024149966,0.0003213892],"domain_scores_gemma":[0.9974666,0.0008604229,0.0004909193,0.0005812854,0.00019271868,0.00040801766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011279852,0.0002825491,0.004155869,0.00021401109,0.000054884695,0.000007881349,0.00013153176,0.00008872983,0.0005235904],"category_scores_gemma":[0.0011754282,0.00018418639,0.00078197813,0.0010408114,0.0001875405,0.00005717698,0.00013062815,0.00032161182,0.0000032438056],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011992169,0.0019011078,0.0064611686,0.9252869,0.0508864,0.00036263716,0.00013556621,0.00020144836,0.00010616501,0.000017343486,0.00022317132,0.0024259423],"study_design_scores_gemma":[0.00946853,0.0010354065,0.055386323,0.007500689,0.92529213,0.000024115108,0.00016507282,0.000398642,0.00010018633,0.000060152957,0.00020833015,0.0003604414],"about_ca_topic_score_codex":0.00029114966,"about_ca_topic_score_gemma":0.0002363946,"teacher_disagreement_score":0.9177862,"about_ca_system_score_codex":0.0000788354,"about_ca_system_score_gemma":0.00080600625,"threshold_uncertainty_score":0.7510903},"labels":[],"label_agreement":null}]}